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CHAPTER 1  
Introduction to the Arizona Newborn Screening Program 
 
 
1.1 Overview 
  
For most types of genetic or metabolic disease, early diagnosis and treatment 
are critical.  Although babies born with these disorders may appear to be normal 
at birth, with time the disorder may have a devastating or lethal effect on the 
infant’s health and development.  Early screening, detection and treatment of 
these disorders can, in many cases, result in normal growth and development. 
 
Arizona has been conducting widespread newborn screening for certain 
disorders since 1979.  A laboratory in Colorado originally performed screening 
tests for Arizona newborns. 
 
In 1993, the Arizona Legislature enacted legislation requiring the Arizona 
Department of Health Services to develop and administer a formal Newborn 
Screening Program.  The Arizona Newborn Screening Program was created and 
is now housed in the Bureau of State Laboratory Services, in the Division of 
Public Health Services.  The Program has enabled the Department to enhance 
its public health role in the newborn screening process, obtain more timely 
results from screening, and promote better follow-up for suspected or confirmed 
cases. 
 
In 2006 the Newborn Screening Program expanded its panel of screened 
disorders to twenty-seven disorders (27) with the addition of tandem mass 
spectrometry testing and added follow-up for hearing screening to follow-up done 
for bloodspot disorders.  Cystic fibrosis screening was added in October, 2007, 
completing the panel of twenty-nine disorders.   
 
The panel of twenty-nine screened disorders (including hearing loss) was 
recommended by the U.S Department of Health and Human Services (HHS) 
Secretary’s Advisory Committee on Heritable Disorders in Newborns and 
Children (SACHDNC) as the original Uniform Screening Panel.  In May, 2010 the 
Secretary added severe combined immunodeficiency (SCID) to the panel but 
Arizona does not yet screen for SCID. 
 
The Advisory Committee to the Arizona Newborn Screening Program endorsed 
the original panel and Rules were written to allow the program to adopt this list of 
disorders. These disorders were selected because their detection and treatment 
in the newborn period is effective in preventing severe morbidity or mortality and 
a reliable, reasonably priced test can be used for screening.  The disorders 
currently on the screening panel are: 
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Congenital Hypothyroidism 
Endocrine Disorders (2) 
Congenital Adrenal Hyperplasia 
 
 
Sickle Cell Anemia 
Hemoglobin Disorders (3) 
Sickle Beta Thalassemia 
Sickle C Disease 
 
 
Biotinidase Deficiency 
Other Enzyme Deficiencies (2) 
Galactosemia  
 
Phenylketonuria 
Amino Acid Disorders (6) 
Maple Syrup Urine Disease 
Homocystinuria 
Citrullinemia 
Argininosuccinic Acidemia 
Tyrosinemia Type 1 
 
 
Carnitine Uptake Defect 
Fatty Acid Oxidation Disorders (5) 
Medium-chain Acyl-CoA Dehydrogenase Deficiency 
Very long-chain Acyl-CoA Dehydrogenase Deficiency 
Long-chain 3-OH Acyl-CoA Dehydrogenase Deficiency 
Trifunctional Protein Deficiency 
 
 
Isovaleric Acidemia 
Organic Acid Disorders (9) 
Glutaric Acidemia Type 1 
3-Hydroxy-3-methylglutaric Aciduria 
3-Methylcrotonyl-CoA Carboxylase Deficiency 
Multiple Carboxylase Deficiency 
Methylmalonic Acidemia - mutase 
Methylmalonic Acidemia - cobalamin defects 
Propionic Acidemia 
Beta-Ketothiolase Deficiency 
 
 
Cystic Fibrosis 
Pulmonary Disorder (1) 
 
 
Hearing Loss (screening done elsewhere but results of screening reported 
to the program and follow-up done) 
Disorder not detected by bloodspot screening (1) 
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For most of these disorders, the incidence in the population is rare, but the 
potential for devastating consequences and the high costs of treating 
undiagnosed infants who do have the disorders is thought to justify mass 
screening.  Hearing loss is the most common, occurring in approximately 2 – 4 
per 1000 births. 
 
The Arizona State Laboratory is now designated as the sole testing facility for the 
program.  Fees charged for the testing are used to support the operation of the 
Newborn Screening Program. 
 
 
1.11 Program Goals 
 
The goals of the Arizona Newborn Screening Program are: 
 
1. To identify newborns with certain, rare disorders and assist families of 
affected infants so that they receive appropriate and timely treatment to 
prevent or delay serious medical problems. 
 
2. To identify possible hearing loss before one month of age and link families 
with appropriate assessment and intervention.   
 
3. To ensure that all newborns referred for a follow-up hearing screen prior to 
discharge return for an outpatient screen and receive appropriate 
assessment by three months of age and intervention by six months of 
age.   
 
 
1.12 Key Roles 
 
The success of the Newborn Screening Program depends upon the coordinated 
efforts of many health care professionals: 
 
• Medical Home and/or other Healthcare Professionals 
 
Medical Home and/or other Healthcare Professionals are generally responsible 
for: ordering the screening tests for newborn infants in their care, informing 
parents about the screening tests, and collection and handling of newborn 
screening specimens.  Practitioners, and/or their contracted laboratories, may 
collect and send specimens for testing.  Practitioners, hospitals and laboratories 
work together to coordinate timely collection and rapid delivery of acceptable 
newborn screening specimens to the Arizona Public Health Laboratory (State 
Lab). 
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Providers are encouraged to refer to the test as Newborn Screening, not the PKU 
test.  Although PKU was the first and for a while the only disorder screened, it is 
now only one of the 29 disorders on the Arizona panel. 
 
• Screening Laboratory 
 
As per ARS §36-694, the sole screening laboratory is the Arizona Public Health 
Laboratory (State Lab).  The State Lab receives all Arizona newborn screening 
specimens for testing of twenty-eight bloodspot disorders.  Staff there review the 
specimens for acceptability, perform laboratory testing, keep records of the tests 
performed, mail results to submitters and physicians and conduct quality control 
studies of laboratory methods and practices.   
 
• Arizona Department of Health Services - Newborn Screening Program 
 
As per ARS §36-694, the Department is responsible for the overall development, 
implementation, management and evaluation of the Newborn Screening 
Program. The Office Chief for Newborn Screening is responsible for the 
administration and coordination of program operations.  In addition, the Chief 
coordinates resource networks for the specialized treatment and medical 
management of identified newborn screening disorders, as well as other program 
consultants and contractors.  The Department oversees the collection of 
revenues from the screening tests. 
 
The Office Chief also administers the Follow-up component of the Newborn 
Screening Program.  The Follow-up group has many responsibilities, including, 
but not limited to: reporting of positive bloodspot results to physicians and 
parents, tracking infants with positive results to help them get diagnostic testing 
and appropriate care, monitoring confirmatory testing, and reporting of confirmed 
cases to national newborn screening databases.  They also receive reports of 
newborn hearing screening and track infants who do not pass hospital screening 
tests in order to assist families to get further testing and early intervention 
services when a hearing loss is confirmed.  
 
• Contracted Specialists 
 
The Office of Newborn Screening works with contracted endocrinologists, 
metabolic geneticists, hematologists, pulmonologists (specializing in the 
treatment of cystic fibrosis) and audiologists.  On behalf of the Office of Newborn 
Screening, these contracted specialists provide consultation to primary care 
physicians of newborns or infants with possible disorders or hearing loss.  The 
purpose of consultation is to assure that the medical home checks on the clinical 
status of the baby, reviews signs and symptoms indicative of a possible disorder 
or hearing loss, reviews family history, recommends further testing  and, if 
necessary, makes a referral to a specialist for diagnostic evaluation. 
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When newborn screening results are highly abnormal and
 
 the attempts to contact 
a medical home are unsuccessful, the contracted specialist may contact the 
family on behalf of the Newborn Screening Office in order to explain the results to 
the baby’s parents, verify the clinical status of the baby and advise parents to 
schedule an appointment with a primary care physician immediately. 
Contracted specialists also provide consultation services to the Newborn 
Screening Program.  These services include case review, technical and program 
support, provision of technical information and recommendations regarding 
diagnostic testing methodologies, review of educational materials, and 
attendance at critical meetings where program issues are discussed. 
 
 
1.2 Key Points about Newborn Screening for Discussions with Parents 
 
1. Every baby is at risk and you can’t tell if a baby has a disorder without 
screening 
Newborn screening is important for all babies because even without a family 
history of any of the screened disorders, every baby is at risk.  Most babies 
with a disorder are born into a family with no other affected family members.  
Most affected babies look healthy at birth.   
 
2. Disorders are serious and can be life-threatening  
The screened disorders are serious and can cause severe disability or even 
death if not detected and treated early.  For some disorders, symptoms 
appear quickly and for others the baby appears fine for a while before 
symptoms appear and by that time permanent damage has been done. 
 
Newborn screening is not just a PKU test anymore but includes hearing 
screening and a panel of 28 disorders detected by bloodspot testing. 
 
3.  How the testing will be done 
A few large drops of blood are obtained by pricking the baby’s heel.  These 
blood drops are collected on a special filter paper kit, dried, and sent to the 
State Lab for analysis.   
 
Hearing screening is done when the baby is quiet or asleep by a trained 
screener using equipment that provides an automated pass or refer result – 
sound is introduced into the baby’s ear and either an otoacoustic emission is 
measured or an auditory brainstem response is measured from scalp 
electrodes.  This testing is painless and takes only a few minutes to complete.   
 
4. Testing must be timely 
The first bloodspot test should be done between 24 and 36 hours of age or 
prior to discharge from the hospital.  For some disorders, false negative 
results can occur with later testing.  The second screen should be done at the 
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first outpatient visit to the medical home or other healthcare professional or 
between 5 and 10 days of age, whichever comes first. 
 
The hearing test will be done before the baby is discharged from the hospital. 
Any rescreening should be done within two weeks and diagnostic testing 
should be done as soon as possible following a failed outpatient screen.  
Completing diagnostic testing before three months of age ensures that testing 
can be done without sedation or anesthesia and that early intervention and 
fitting of hearing aids, if appropriate, can take place before six months of age.  
Babies that are in the neonatal intensive care unit for more than five days 
should go directly to a diagnostic evaluation if they fail the inpatient screen. 
 
5. Results of screening tests are reported to the provider who ordered the 
test but parents will be contacted if there is an abnormal result 
 
Parents will not be contacted by the Newborn Screening Program if their 
baby’s results are normal.  Providers who order the screening will receive 
mailed results and providers can request copies of tests ordered by others 
when they begin care for a baby.  All newborn screening results should be 
documented in the baby’s medical record. 
 
If results are highly abnormal, parents will get a call from their baby’s doctor 
or from the Program with instructions for immediate diagnostic testing.  For 
borderline results, they will usually be contacted by their doctor and will get a 
letter from the Program.  If a specimen can’t be tested (an unsatisfactory or 
“unsat” specimen) or if results show a hemoglobin trait, parents will receive a 
letter from the Program asking them to contact their baby’s doctor for further 
information. 
 
Screening tests are not diagnostic and abnormal results will occur for babies 
that do not have a disorder (false positive results).  Further testing will be 
needed promptly.   So that parents can be notified, it is important for them to 
submit a current address and phone number on the specimen card.  It is 
recommended that a second contact phone number also be included on the 
collection card. 
 
Results of the hearing screening are recorded on the back of the baby’s 
immunization card.  If the baby does not pass, a repeat test will usually be 
scheduled at the hospital where the baby was born.  The Program does not 
start follow-up until the baby is a month of age and has not yet passed a 
hearing screening.   
 
6. Where parents can get further information 
 
Hospitals or other health care professionals should give a copy of the 
brochure, “Newborn Screening, A Guide for Parents,” to parents before the 
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first newborn screening test is ordered.  Hearing screeners should also have 
a supply of the brochure, “Universal Newborn Hearing Screening,” to share 
with parents at the time of their baby’s hearing test. 
 
Parents are encouraged to visit the Arizona Newborn Screening Program’s 
website at www.AZNewborn.com where there is more information about the 
program and links to many other sites with newborn screening information. 
 
 
1.3 Arizona Newborn Screening History 
 
1.31 Bloodspot Screening History 
 
Screening for phenylketonuria (PKU) began in Arizona in the late 60’s and early 
70’s. 
 
In 1979 a three-year federal grant from the Office of Maternal and Child Health 
was awarded to the Colorado State Laboratory to establish a regional newborn 
screening laboratory.  The testing panel was composed of six disorders. 
 
In 1989 a test for biotinidase deficiency was added to the panel of tests. 
 
In 1993 legislation was passed establishing a Newborn Screening Program in 
Arizona funded by fees collected for screening.  On November 1, 1994 the 
Arizona Public Health Laboratory began screening for the seven disorders on the 
Colorado panel and also providing follow-up for abnormal results.  A second 
screen was encouraged but not mandated. 
 
In 2001 legislation was passed that increased the screening fees and added 
congenital adrenal hyperplasia (CAH) to the newborn screening panel.  
Screening for CAH began in February, 2002.  Second screens were now 
required for all babies. 
  
In 2005 legislation again was passed that increased the screening fees and 
allowed the expansion of the panel to include the 29 disorders in the Uniform 
Screening Panel recommended by the federal Secretary’s Advisory Committee 
on Heritable Disorders in Newborns and Children (SACHDNC). 
 
Between July and September, 2006, newborn screening for 20 disorders (fatty 
acid oxidation disorders, aminoacidopathies, and organic acidemias) was started 
using tandem mass spectrometry (MS/MS) and accompanied the testing by other 
methods of seven other disorders already on the panel.  Follow-up for hearing 
loss began as well. 
 
In October, 2007, testing for cystic fibrosis began and Arizona was now 
screening and doing follow-up for the complete original Uniform Screening Panel. 
Arizona Newborn Screening Program Guidelines – August, 2010 Page 12 
 
1.32 Hearing Screening History 
 
Newborn Hearing Screening in Arizona began with the Never Too Young (NTY) 
program in 1985.  NTY supported screening children with risk factors for hearing 
loss.  By 1993 it was recognized that half of the babies born with hearing loss 
had no risk factors and the national move towards universal newborn hearing 
screening began.  New technology made it faster and easier to screen all babies 
and new research was showing that age of identification of hearing loss was a 
significant factor in development of speech and language for children with 
hearing loss.  The NTY evolved into the Arizona Early Hearing Detection and 
Intervention program (AzEHDI).   By 2000 all birthing hospitals in Arizona were 
screening for hearing loss.  In 2005 the current law was passed creating the 
follow-up program.  The goals of the program within the Department of Health 
Services were to: 
 
• Include parents and professionals on an advisory panel 
• Educate parents, health care professionals and the public about early 
hearing detection and intervention 
• Mandate reporting of screening and diagnostic testing  
• Institute a centralized system of tracking and follow up to support parents 
in connecting with screening, diagnostic services and early intervention 
 
Today 98% of all babies born in Arizona are screened for hearing loss by one 
month of age and 97% of babies are screened nationally.  The average age of 
identification of hearing loss was two years of age.  Now, with the goals of 
AzEHDI in place, the average is less than six months of age.  New generations of 
children who are Deaf and Hard of Hearing have a greater opportunity to meet 
their full potential. 
 
 
1.4 Statute and Rules 
 
1.41 Arizona Statutes and Authority 
 
The statute establishing the Newborn Screening Program, designating the State 
Lab as the only testing facility of the program and requiring hearing tests to be 
reported to the Program is found in the Appendices or in: ARS § 36-694 
  
The statute establishing the newborn screening program fund is found in:   
ARS § 36-694.01  
 
The statute regarding insurance coverage of medical foods is found in:   
ARS § 20-2327  
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1.42 Arizona Administrative Code  
 
Rules regarding the Arizona Newborn Screening Program are in the Appendices 
and also available online at the Arizona Secretary of State’s web site: 
(http://www.azsos.gov/PUBLIC_SERVICES/Title_09/9-13.htm).  
 
For a discussion of provider responsibilities under these rules, please see 
Chapter 3.1 on page 33 and Chapter 5.4 on page 66. 
 
 
1.5 Newborn Screening Advisory Committee 
 
The Newborn Screening Advisory Committee is established by statute (ARS 36-
694) to provide recommendations and advice to the Department of Health 
Services regarding tests that should be included in the Newborn Screening 
panel. 
 
In 2006 the committee recommended the 29 disorders, including hearing loss, of 
the original core panel of the Uniform Screening Panel from the HHS Secretary’s 
Advisory Committee on Heritable Disorders in Newborns and Children.       
 
Any recommendation of a test to be added to the panel must be accompanied by 
a cost-benefit analysis. 
 
The committee is chaired by the Director of the Department of Health Services 
and meets annually. 
   
The Director appoints the members of the committee to include:  
 
• Seven physicians representing the medical specialties of endocrinology, 
pediatrics, neonatology, family practice, otology and obstetrics;  
• A neonatal nurse practitioner;  
• An audiologist;  
• A representative of an agency that provides services under part C of the 
Individuals with Disabilities Education Act;  
• At least one parent of a child with a hearing loss or a congenital disorder;  
• A representative from the insurance industry familiar with health care 
reimbursement issues;  
• The Director of the Arizona Health Care Cost Containment System 
(AHCCCS) or the director's designee and  
• A representative of the hospital or health care industry. 
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1.6 Privacy and the Health Insurance Portability and Accountability Act 
(HIPAA) 
 
HIPAA became Federal law in April of 2003. Its goal is to “provide patients with 
access to their medical records and more control over how their personal health 
information is used and disclosed.” (Source: DHHS, available at 
http://www.hhs.gov/news/facts/privacy.html) 
 
The Arizona Department of Health Services (ADHS) is considered to be a “public 
health authority” as defined in the act and as such is granted access to protected 
health information (PHI) when necessary to prevent or control disease or where 
required by law (federal, tribal, state or local). 
 
Each employee at ADHS is trained in HIPAA policies and procedures and any 
information obtained will be kept confidential.  
 
As part of a HIPAA-exempt public health entity, Newborn Screening is able to 
lawfully receive or disclose confidential information used in the follow-up process 
without obtaining consent from parents.  
 
Photocopies of the HIPAA exemption may be sent to you as explanation. Please 
see the Code of Federal Regulations (45 CFR 164.512) or contact the Program 
with any questions. 
 
See http://www.cdc.gov/privacyrule/Guidance/PRPH.htm for further discussion of 
public health disclosures. 
 
 
1.7 Program Fees and Payment Procedures 
 
1.71 Testing Fees 
Arizona’s Newborn Screening test consists of two required screens.  The first 
screen is billed at $30.00 each and the second screen is billed at $40.00 each.  
Fees support the operation of the Newborn Screening Program, including follow-
up for bloodspot disorders and hearing loss. 
 
1.72 First Screen 
The first bloodspot screen is billed to and paid for by the submitter (generally a 
hospital, birthing center or midwife) who sends the first specimen for a baby. 
 
1.73 Second Screen 
The second bloodspot screen may be billed to and paid for by a hospital, 
midwife, insurance company or other responsible party (parent or guardian of a 
newborn). 
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If a baby is still a hospital inpatient at the time of collection of a second screen, 
the billing will be to the hospital.  If a midwife collects a screen from a baby five or 
more days old, it will be considered to be a second screen and will be billed at 
the second screen rate. 
 
Please submit the following insurance information (or a notation that the family 
does not have insurance) with all second screens which are not billed to a 
hospital or midwife: 
 
 Policy holder’s name (as shown on the insurance card) 
 Policy holder’s date of birth 
 Policy holder’s gender 
 Policy holder’s employer and employer’s address 
 Policy holder’s address if different from mother’s address 
 Member ID# 
 Group ID# 
 Insurance company’s name 
 Insurance company’s billing address 
 Insurance company’s phone number 
 Notation of whether the insurance is primary or secondary 
 
Please do not attach insurance information to the bloodspot card with staples.  
Place the insurance information with the cards or use paperclips, but these are 
not necessary. 
 
If this information is not received, staff from the Program will contact physicians 
and facilities to obtain the information. 
 
1.74 Recall Screen 
After the second screen, a recall test for a specific disorder may be requested in 
response to an abnormal or borderline result.  There is no fee for this test.  A 
supplementary specimen kit should be used to collect the specimen and the 
Recall box above the Baby’s Name field should be marked and the disorder 
being retested should be written on the line next to the box.  Only a test for the 
requested disorder will be reported.  Otherwise, if the specimen is not marked as 
a recall, it will be considered a billable specimen. 
 
1.75 Insurance Coverage 
Practitioners should encourage parents to add their newborns to their insurance 
as soon as possible after the birth since insurance payments cannot be made on 
behalf of infants until they are listed as insured. 
 
Complete insurance information as listed above (in Chapter 1.73) should be 
submitted with second screens.  
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1.76 Payment to the Department 
The Department will bill for first and second screens at least monthly.  Payments 
are due to the Department within 30 days of the billing date. 
 
Payments should be sent to: 
  Arizona Department of Health Services 
  Newborn Screening Program 
  PO Box 25046 
  Phoenix, AZ  85002-5046 
 
 
1.8 Program Contacts 
 
1.81 Office of Newborn Screening 
 
Main Phone: (602) 364-1409 or (800) 548-8381 within Arizona 
Fax:  (602) 364-1495 
 
Ward Jacox, Office Chief 
(602) 364-1410 
Ward.Jacox@azdhs.gov 
 
Sundin Applegate, MD, NBS Medical Director 
(602) 542-2950 
Sundin.Applegate@azdhs.gov  
 
Sondi Aponte, Quality Improvement Manager 
(602) 364-1642 
Sondi.Aponte@azdhs.gov  
 
Brigitte Dufour, Case Management Coordinator 
(602) 364-1406 
Brigitte.Dufour@azdhs.gov  
 
Wendie Jenkins, Educator 
(602) 364-1407 
Wendie.Jenkins@azdhs.gov  
 
Christopher Rogers, Laboratory Manager 
(602) 542-1184 
Christopher.Rogers@azdhs.gov  
 
Yvonne Carroll, Demographics Supervisor 
(602) 364-1468 
Yvonne.Carroll@azdhs.gov  
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Cheryl Gillman, Billing Manager 
(602) 542-2520 
Cheryl.Gillman@azdhs.gov  
 
 To obtain a submitter code (for new providers): (602) 364-1468 
 
Billing or Insurance questions: (602) 542-0897 or (602) 542-2520 
 
Requesting copies of lab results, fax to (602) 542-4099  
or call (602) 364-3190 
(Please include the baby’s name, date of birth, mother’s name and her date of 
birth with your request.) 
 
Ordering specimen cards and envelopes: 
call Lab Receiving at 542-1190 
or E-mail an order form to labreceiving@azdhs.gov 
or fax an order form to (602) 364-0758 
 
Mailing address for submitting bloodspot specimens: 
State Laboratory, Receiving 
c/o Newborn Screening 
250 N. 17th
Phoenix, AZ  85007-3231 
 Avenue 
 
1.82 Pediatric Specialists and Program Consultants 
 
Endocrinology 
Roger E. Johnsonbaugh, MD 
Arizona Pediatric Endocrinology 
(602) 274-5078 
 
  Edward I. Holland, MD 
  East Valley Pediatric Endocrinology 
  (480) 464-8600 
 
  Donnie P. Wilson, MD   
  Phoenix Children’s Hospital, Endocrinology Dept. 
  (602) 546-0935 
 
  Alvin H. Perelman, MD 
  Southwest Pediatric Endocrinology 
  (480) 323-4800 
 
  Mark D. Wheeler, MD 
  University Physicians – Angel Wing Clinic 
  (520) 626-6077
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Hematology 
  Jesse D. Cohen, MD 
  Pediatric Hematology-Oncology Associates 
  (602) 253-5993 
  
  Brenda J. Wittman, MD 
  University Medical Center 
  (520) 626-4851 
 
 Metabolic Genetics 
  Kirk A. Aleck, MD 
  R. Stephen Amato, MD, PhD 
  CHC Phoenix Genetics Program 
  St. Joseph’s Hospital and Medical Center 
  (602) 406-3611 
 
  Melanie Colville, MS, RD, Metabolic Dietitian   
  (602) 406-4383 
 
Candice Candelaria, MS, RD, Metabolic Dietitian    
  (602) 406-7346 
 
 Cystic Fibrosis Centers 
  Peggy J. Radford, MD 
  Pulmonology, Phoenix Children’s Hospital 
  (602) 546-0985 
 
  Wayne J. Morgan, MD 
  Arizona Respiratory Center, 
  University of Arizona Health Sciences Center 
  (520) 626-7780 
 
 Hearing 
Randi Winston, AuD, Audiology Consultant 
The EAR Foundation of Arizona 
 
(602) 284-1091 
Lylis Olsen, MS, MPH, Audiology Consultant 
The EAR Foundation of Arizona 
Arizona EHDI Coordinator 
(602) 690-3975 
 
Bradley F. Golner, MD  
AzEHDI Chapter Champion 
(602) 971-5121 
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CHAPTER 2   
Disorders 
 
 
2.1 Arizona’s Newborn Screening Panel of 29 Disorders 
 
These are the original core disorders of the recommended Uniform Screening 
Panel from the US Department of Health and Human Services Secretary’s 
Advisory Committee on Heritable Disorders in Newborns and Children 
(SACHDNC).   In May, 2010 the HHS Secretary endorsed this panel along with 
the addition of Severe Combined Immunodeficiency (SCID).  This panel is 
recommended for all state newborn screening programs and is also endorsed by 
the American Academy of Pediatrics and the March of Dimes.  Arizona does not 
yet screen for SCID. 
 
Early identification and lifelong treatment of these disorders can help to prevent 
many of the harmful consequences of the disorders and in many cases affected 
babies can grow and develop normally. 
 
Endocrine Disorders
Endocrine disorders occur when one or more of the body’s hormones cannot be 
produced while others are overproduced.  Hormones regulate metabolism and 
are necessary for the normal function of the body’s organs. 
 (2 disorders) 
 
Congenital hypothyroidism (CH) 
• A common*, endocrine condition resulting from deficient thyroid hormone 
secretion. It is not often an inherited condition and is most commonly caused 
by a failure of the thyroid gland to develop properly. 
• If undetected, developmental delays, poor growth and mental retardation 
develop before diagnosis is made and most of this damage is not reversible 
with treatment.   A newborn with CH may have feeding problems, lethargy, 
hypotonia, jaundice and constipation. 
• Treated with daily oral doses of thyroid hormone.  If treatment begins by two 
weeks of age a baby can develop normally. 
• Risk of this disorder is detected by an immunoassay for elevated thyroid 
stimulation hormone (TSH). 
 
Congenital adrenal hyperplasia -21-hydroxylase deficiency (CAH) 
• A relatively common*, inherited group of disorders (autosomal recessive) 
marked by deficiency or absence of one or more enzymes essential to the 
production of adrenal cortex hormones.  The enzyme involved most 
commonly is steroid 21-hydroxylase.  This results in the inability to synthesize 
cortisol, aldosterone or both and also results in an overproduction of adrenal 
androgens. 
 Arizona Newborn Screening Program Guidelines – August, 2010  Page 20 
 
 
• Symptoms include ambiguous genitalia in girls and in the salt-wasting form of 
the disorder, vomiting, dehydration, electrolyte imbalances (hyponatremia and 
hypokalemia), hypotension, shock and even death within 2 weeks of birth.  
• Treated with hormone and electrolyte replacement with possible surgery for 
virilized females.  Early treatment can prevent salt-wasting crises and growth 
and development problems. 
• Risk of this disorder is detected by an immunoassay for elevated 17α-
hydroxyprogesterone (17-OHP). 
 
 
Hemoglobin Disorders
Hemoglobinopathies are disorders of the red blood cells and in varying degrees 
affect the transport of oxygen to cells of the body. 
 (3 disorders) 
 
Sickle cell anemia (Hb SS) 
• A relatively common*, inherited red blood cell disorder (autosomal recessive) 
marked by sickling of the cells and chronic hemolytic anemia.  It is caused by 
a mutation of both copies of the gene controlling the structure of β 
hemoglobin chains. 
• Symptoms include intermittent severe pain, infection, damage to organs, 
jaundice, stroke and early death. 
• Treated with prophylactic penicillin (to prevent bacterial infections), pain 
medications, timely vaccinations, education of parents to recognize when 
their child needs prompt medical care, blood transfusions and sometimes 
bone marrow transplants.  Careful medical supervision can prevent or reduce 
the number of painful crises and subsequent organ damage. 
• Risk of this disorder is detected by a hemoglobin result of FS by isoelectric 
focusing and HPLC. 
 
Sickle beta thalassemia (Hb S/βTh) 
• Rare*, inherited red blood cell disorders in which sickle genes are inherited 
along with genes that impair the production of hemoglobin (thalassemia). In 
the most serious form, normal beta hemoglobin is completely absent.  This is 
referred to as S/β° thalassemia or S/β° thal.  When some normal β chains are 
produced but in decreased amount it is called S/β+ thalassemia (S/β+ thal) 
which can cause milder symptoms, depending on the amount of normal 
hemoglobin produced. 
• Symptoms and treatment are similar to or can be milder than those of sickle 
cell anemia and include splenomegaly. 
• Risk of this disorder is detected by a hemoglobin result of FS or FSA by 
isoelectric focusing and HPLC. 
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Sickle C disease (Hb S/C) 
• A rare*, inherited red blood cell disorder (hemolytic anemia) with hemoglobins 
S and C present in the absence of Hb A. 
• Symptoms are variable and can be much milder than for sickle cell disease 
but some individuals with SC disease can have serious symptoms. 
• Treatment of symptoms is similar to treatment of the same symptoms of 
sickle cell disease. 
• Risk of this disorder is detected by a hemoglobin result of FSC by isoelectric 
focusing and HPLC. 
 
 
Other Enzyme Deficiencies
 
 (2 disorders) 
Biotinidase deficiency (BIO) 
• A rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, biotinidase, necessary to recycle the vitamin biotin is missing or not 
working properly.  Free biotin is needed as a cofactor for carboxylase 
enzymes and if it cannot be freed from its bound form by biotinidase it is not 
available to be used as a cofactor. 
• Symptoms which usually appear in a few months of age include seizures, 
hypotonia, hair loss and skin rashes.  Untreated, developmental delays, 
speech problems, hearing loss and ataxia develop. 
• Treatment is daily supplementation with biotin. 
• Risk of this disorder is detected by a colorimetric enzyme assay for 
biotinidase activity. 
 
Galactosemia (GALT) 
• Also called galactosemia type 1 or classic galactosemia. 
• A rare*, inherited disorder (autosomal recessive) marked by the inability to 
metabolize galactose because of a deficiency of the enzyme, galactose-1-
phosphate uridyl transferase (Gal-1-PUT), which is needed to convert 
galactose to glucose. 
• Symptoms which start in the first week of life include jaundice, vomiting and 
feeding problems leading to failure to thrive or even death.  Even with 
treatment (a diet without any galactose), many affected children have some 
development delay or mental deficit, speech or language problems, cataracts 
or enlarged liver. 
• Risk of this disorder is detected by an enzyme assay for Gal-1-PUT activity. 
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Amino Acid Disorders
Amino acidopathies are disorders of amino acid metabolism that occur when 
enzymes needed to break down specific amino acids or eliminate nitrogen from 
the body are deficient or absent.  Toxic levels of amino acids or ammonia 
accumulate and cause brain damage and even death. 
 (6 disorders) 
 
Phenylketonuria (PKU) 
• A relatively common*, inherited disorder (autosomal recessive) that occurs 
when the enzyme, phenylalanine hydroxylase, necessary to break down 
phenylalanine, is missing or not working properly. 
• Without early detection and treatment, permanent mental retardation, 
behavioral problems and eczema develop after a few months.  Newborns with 
PKU seem healthy and symptoms do not appear until irreversible damage 
has been done. 
• Treatment is a low protein diet with most protein provided in a phenylalanine-
restricted formula.  If treatment is started early, babies develop normally and 
have normal IQ. 
• Risk of this disorder is detected with elevated phenylalanine by MS/MS. 
 
Maple syrup urine disease (MSUD) 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, branched chain ketoacid dehydrogenase, necessary to break down 
ketoacid derivatives of leucine, isoleucine and valine, is missing or not 
working properly. 
• Symptoms develop within the first week of life - feeding intolerance, vomiting, 
lethargy and progress to irreversible mental retardation, seizures, coma and 
death. 
• Treatment is a low protein diet with most protein provided in a formula 
restricted in branched-chain amino acids and dietary monitoring to prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated leucine by MS/MS. 
 
Homocystinuria (HCY) 
• Also called cystathionine β-synthase deficiency or CBS deficiency. 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, cystathionine β-synthase, necessary to break down methionine, is 
missing or not working properly. 
• Symptoms develop slowly and include developmental delay, mental 
retardation, skeletal abnormalities (marfanoid appearance), osteoporosis, 
blood clots and dislocated lens in the eye. 
• Treatment is a low protein diet with most protein provided in a methionine-
restricted formula.  Vitamin B6 may be given along with other vitamin 
supplements. 
• Risk of this disorder is detected with elevated methionine by MS/MS. 
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Citrullinemia (CIT 1) 
• A rare*, inherited urea cycle disorder (autosomal recessive) that occurs when 
the enzyme, argininosuccinic acid synthetase, necessary to excrete the 
nitrogen from amino acids as urea, is missing or not working properly. 
• Crisis symptoms of hyperammonemia, which can appear in the first week of 
life, start with loss of appetite, lethargy, hypotonia and vomiting and progress 
to seizures and coma.  Prolonged periods of hyperammonemia can cause 
brain damage (intellectual disability). 
• Treatment is a low protein diet and special formula, supplementary arginine 
and other medications along with avoiding going without eating for very long. 
• Risk of this disorder is detected with elevated citrulline by MS/MS. 
 
Argininosuccinic acidemia (ASA) 
• Also called argininosuccinic aciduria or argininosuccinyl-CoA lyase deficiency. 
• A rare*, inherited urea cycle disorder (autosomal recessive) that occurs when 
the enzyme, argininosuccinyl-CoA lyase, necessary to excrete the nitrogen 
from amino acids as urea, is missing or not working properly. 
• Crisis symptoms of hyperammonemia, which can appear in the first week of 
life, start with loss of appetite, lethargy, poorly controlled breathing rate or 
body temperature, hypotonia and vomiting and progress to seizures and 
coma.  Prolonged periods of hyperammonemia can cause brain damage 
(intellectual disability) and developmental delay. 
• Treatment is a low protein diet and special formula, supplementary arginine 
and other medications along with avoiding going without eating for very long. 
• Risk of this disorder is detected with elevated citrulline by MS/MS. 
 
Tyrosinemia Type 1 (TYR 1) 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, fumarylacetoacetate hydrolase, necessary to break down tyrosine, is 
missing or not working properly. 
• Symptoms develop in the first months of life but are not present immediately 
after birth.  Untreated, a baby with tyrosinemia will develop liver disease 
(enlarged liver, jaundice, cirrhosis) and kidney damage leading to death.  
Early symptoms include lethargy, vomiting, diarrhea, irritability and failure to 
thrive. 
• Treatment includes medication, a diet low in tyrosine and phenylalanine and 
possibly a liver transplant. 
• Risk of this disorder is detected with elevated tyrosine by MS/MS. 
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Fatty Acid Oxidation Disorders
Fatty acid oxidation disorders (FAODs or FODs) occur when fatty acids cannot 
be completely metabolized to produce energy because of defects in enzymes 
needed for this conversion.  When the body’s supply of glucose and glycogen are 
expended, fatty acids are broken down to supply energy during periods of fasting 
or increased energy demands (fever, stress).  Different defects in the fatty acid 
oxidation pathway prevent the complete breakdown of fatty acids to produce 
energy and a sudden crisis occurs which can leave an affected infant or child 
dead or with brain damage.  These conditions can yield false negative results if 
screening occurs after a baby is well fed. 
 (5 disorders)  
 
Carnitine Uptake Defect (CUD) 
• Also known as primary carnitine deficiency or carnitine transporter deficiency. 
• A very rare*, inherited disorder (autosomal recessive) that is caused by a 
defect in the carnitine transporter that moves carnitine across the plasma 
membrane into cells and retains carnitine in cells.  Carnitine is needed for 
acylcarnitine formation to transport fatty acids into mitochondria where they 
can be broken down. 
• Symptoms which begin in infancy or early childhood include cardiomyopathy, 
confusion, vomiting, muscle weakness and hypoketotic hypoglycemia in acute 
episodes.  Untreated these can lead to heart failure, encephalopathy, liver 
problems, coma and sudden death. 
• Treatment with supplementary carnitine, a low-fat diet and avoiding fasting 
(frequent feedings) can prevent metabolic crises. 
• Risk of this disorder is detected with lowered C0 (free carnitine) by MS/MS. 
 
Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) 
• A relatively common*, inherited disorder (autosomal recessive) that occurs 
when the enzyme, medium chain acyl-CoA dehydrogenase, necessary to 
break down fatty acids of medium chain length (4 to 12 carbons long), is 
missing or not working properly. 
• Symptoms present acutely with fasting and include hypoketotic hypoglycemia, 
vomiting, lethargy, seizures, metabolic acidosis, hyperammonemia, 
hepatomegaly and death. 
• Avoiding fasting (frequent feedings) and a low-fat diet can prevent metabolic 
crises. 
• Risk of this disorder is detected with elevated C8 by MS/MS. 
 
Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD) 
• A rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, very long chain acyl-CoA dehydrogenase, necessary to break down 
long chain fatty acids (12 to 18 carbons long), is missing or not working 
properly. 
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• Symptoms present acutely with fasting and include hypoketotic hypoglycemia, 
cardiomyopathy in many cases, vomiting, lethargy, seizures, metabolic 
acidosis, hyperammonemia, hepatomegaly and death. 
• Avoiding fasting (frequent feedings) and a low-fat diet (supplemented with 
MCT oil and cornstarch), can prevent metabolic crises. 
• Risk of this disorder is detected with elevated C14:1 by MS/MS. 
 
Long-chain 3-OH acyl-CoA dehydrogenase deficiency (LCHAD) 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, long chain L-3-hydroxyacyl-CoA dehydrogenase, necessary to break 
down certain fatty acids (between 12 and 18 carbons long), is missing or not 
working properly. 
• Symptoms include hepatomegaly, cardiomyopathy, lethargy, hypoketotic 
hypoglycemia. 
• Avoiding fasting (frequent feedings) and a low-fat diet (low in long chain fatty 
acids and supplemented with MCT oil and cornstarch), can prevent metabolic 
crises. 
• Risk of this disorder is detected with elevated C16OH by MS/MS. 
 
Trifunctional protein deficiency (TFP) 
• Also called mitochondrial trifunctional protein deficiency. 
• A very rare*, inherited disorder (autosomal recessive) that occurs when a 
protein containing three enzymes (long chain 3-hydroxyacyl-CoA 
dehydrogenase, long chain enoyl-CoA hydratase and long chain thiolase) 
necessary to break down long-chain fatty acids is missing or not working 
properly. 
• Avoiding fasting (frequent feedings) and a low-fat diet (low in long chain fatty 
acids and supplemented with MCT oil and cornstarch), can prevent metabolic 
crises. 
• Risk of this disorder is detected with elevated C16OH by MS/MS. 
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Organic Acid Disorders
Organic acidemias (OAs) are a group of inherited metabolic disorders that occur 
when certain enzymes involved in the breakdown of amino acids and other 
substances are not functioning properly.  Toxic acids build up in the blood and 
spill into the urine (metabolic acidemia).  Without treatment and prevention of 
acute episodes, these disorders can lead to coma and death during the first days 
or weeks of life. 
 (9 disorders) 
 
Isovaleric acidemia (IVA) 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, isovaleryl-CoA dehydrogenase, necessary to break down leucine, is 
missing or not working properly. 
• Symptoms include metabolic ketoacidosis, poor feeding, vomiting, 
dehydration, lethargy, rapid shallow breathing, “sweaty feet” odor, 
hyperammonemia, coma and death. 
• Avoiding fasting (frequent feedings) and a low-protein diet can prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated C5 by MS/MS. 
 
Glutaric acidemia type 1 (GA-1) 
• A relatively rare*, inherited disorder (autosomal recessive) that occurs when 
the enzyme, glutaryl-CoA dehydrogenase, necessary to break down lysine, 
hydroxylysine and tryptophan, is missing or not working properly. 
• Affected infant is usually macrocephalic with later signs of metabolic 
ketoacidosis (during periods of fasting or illness, which can progress to coma 
and death), failure to thrive, irritability, hypotonia, poor balance and 
coordination and neurological problems. 
• Avoiding fasting (frequent feedings) and a low-protein diet can prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated C5DC by MS/MS. 
 
3-Hydroxy-3-methylglutaric aciduria (HMG) 
• Also known as 3-hydroxy-3-methylglutaryl-CoA lyase deficiency or HMG-CoA 
lyase deficiency. 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, 3-hydroxy-3-methylglutaryl-CoA lyase, necessary to break down 
leucine, is missing or not working properly. 
• Symptoms usually appear during the first year of life and include vomiting, 
diarrhea, lethargy, hypotonia and metabolic acidosis (during a period of 
fasting or illness) which can lead to coma and death. 
• Treatment includes avoidance of fasting and a low protein diet to prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated C5OH by MS/MS. 
 
 
 Arizona Newborn Screening Program Guidelines – August, 2010  Page 27 
 
 
 
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC) 
• A rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, 3-methylcrotonyl-CoA carboxylase, necessary to break down leucine 
is missing or not working properly. 
• Symptoms usually appear during the first year of life and include lethargy, 
vomiting, hypotonia, seizures, developmental delay and metabolic acidosis 
(during a period of fasting or illness) which can lead to coma and death. 
• Treatment includes avoidance of fasting and a low protein diet to prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated C5OH by MS/MS. 
 
Multiple carboxylase deficiency (MCD) 
• Also known as holocarboxylase synthetase deficiency. 
• A rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, holocarboxylase synthetase, necessary to attach biotin as a co-
factor to certain carboxylase enzymes, is missing or not working properly.   
• Symptoms can appear during the first week of life and include poor feeding, 
lethargy, vomiting, hypotonia, skin rash and metabolic acidosis which can 
lead to coma and death. 
• Treatment consists of biotin supplementation. 
• Risk of this disorder is detected with elevated C3 by MS/MS. 
 
Methylmalonic acidemia - mutase deficiency (MUT) 
• Also known as methylmalonic acidemia, Vitamin B12
• A rare*, inherited disorder (autosomal recessive)  that occurs when the 
enzyme, methylmalonyl-CoA mutase, necessary to break down certain lipids, 
amino acids and cholesterol is missing or not working properly. 
 unresponsive. 
• Symptoms include lethargy, dehydration, vomiting, hypotonia, seizures and 
metabolic ketoacidosis which can lead to coma and death. 
• Treatment includes avoiding fasting and a low protein diet to prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated C3 by MS/MS. 
 
Methylmalonic acidemia - cobalamin disorders (Cbl A,B) 
• Also known as methylmalonic acidemia, Vitamin B12
• Rare*, inherited disorders (autosomal recessive) that occur with a defect in 
the synthesis of adenosylcobalamin, one of the active forms of Vitamin B
 responsive. 
12
• Symptoms include lethargy, dehydration, vomiting, hypotonia, seizures and 
metabolic ketoacidosis which can lead to coma and death 
 
which is needed as a cofactor for methylmalonyl-CoA mutase, necessary to 
break down certain lipids, amino acids and cholesterol. 
• Treatment includes Vitamin B12
• Risk of this disorder is detected with elevated C3 by MS/MS. 
 injections and a low protein diet. 
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Propionic acidemia (PROP) 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, propionyl-CoA carboxylase, necessary to break down a product of 
protein and fat metabolism is missing or not working properly. 
• Symptoms usually appear during the first week of life and include poor 
feeding, lethargy, vomiting, dehydration, hypotonia and metabolic 
ketoacidosis which can lead to coma and death. 
• Treatment includes avoidance of fasting and a protein-restricted diet to 
prevent metabolic crises. 
• Risk of this disorder is detected with elevated C3 by MS/MS. 
 
Beta-ketothiolase deficiency (BKT) 
• A very rare*, inherited disorder (autosomal recessive) that occurs when the 
enzyme, β -ketothiolase, necessary to break down isoleucine, is missing or 
not working properly.  This disorder also impairs the body’s ability to process 
ketones, which are produced during the breakdown of fats. 
• Symptoms usually appear during the first year of life and include lethargy, 
vomiting, seizures, and metabolic acidosis (during a period of fasting or 
illness) which can lead to coma and death.  Long term complications include 
developmental delay, cardiomyopathy and hypotonia. 
• Treatment includes avoidance of fasting and a low protein diet to prevent 
metabolic crises. 
• Risk of this disorder is detected with elevated C5:1 by MS/MS. 
 
 
Pulmonary Disorder
 
 (1 disorder) 
Cystic fibrosis (CF) 
• A relatively common*, inherited disorder (autosomal recessive) where a 
protein, cystic fibrosis transmembrane regulator (CFTR), is absent or does 
not work properly in the regulation of the movement of chloride ions through 
cell membranes. This causes the production of thick, sticky mucus that clogs 
lungs, pancreatic ducts and other organs. 
• Symptoms include salty sweat, failure to thrive, lung and sinus infections, 
intestinal problems (diarrhea or constipation, pain, gas). Many babies with CF 
are born with meconium ileus. 
• Treatment includes a higher-calorie diet, extra fluids, pancreatic enzyme 
supplementation, airway clearance therapy and medications (bronchodilators, 
mucus thinners and antibiotics). 
• Risk of this disorder is detected by an immunoassay for elevated 
immunoreactive trypsinogen (IRT) followed by a DNA analysis of the highest 
2.2% of the IRT samples for 46 mutations to the CFTR gene. 
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Disorder Not Detected by Bloodspot Screening
 
 (1 disorder) 
Hearing loss (HEAR) 
• A common* disorder that is both inherited and due to environmental causes. 
• Defined as hearing loss that is permanent, bilateral or unilateral, 
sensorineural or conductive, and averaging loss of 30 decibels or more in the 
frequency range important for speech recognition. 
• Although not required by statute, hearing screening is done in all birthing 
hospitals in Arizona as a standard of care.  Reporting of hearing screening 
results to the Newborn Screening Program is required and follow-up is done 
for babies who do not pass a hearing screening and do not return to the 
hospital for further testing. 
• Hearing loss is not usually diagnosed until 2 or 3 years of age without early 
screening programs.  By that time speech and language development is 
delayed or impaired.  Early detection and intervention helps affected infants 
learn speech and language. 
 
 
 
 
 
 
 
 
 
 
For further information about the disorders on the Arizona panel and other 
disorders: 
 
ACT sheets, by disorder, from the American College of Medical Genetics, with 
suggestions for immediate action after receiving abnormal results: 
http://www.acmg.net/AM/Template.cfm?Section=ACT_Sheets_and_Confirmatory
_Algorithms&Template=/CM/HTMLDisplay.cfm&ContentID=5127  
 
Disorder information from NIH, US National Library of Medicine, Genetics Home 
Reference: 
http://www.ghr.nlm.nih.gov/search?query=%22newborn+screening%22  
 
Disorder information from Screening, Technology, and Research in Genetics 
(Star-G) including fact sheets for parents: 
http://www.newbornscreening.info/disorders.html   
 
Disorder information from Genetic Alliance: http://www.geneticalliance.org    
 
∗ common: occurs in greater than 1 in 5,000 US births 
∗ relatively common: occurs in between 1 in 5,000 and 1 in 25,000 US  births 
∗ relatively rare: occurs in between 1 in 25,000 and 1 in 50,000 US births 
∗ rare: occurs in between 1 in 50,000 and 1 in 100,000 US births 
∗ very rare: occurs in less than 1 in 100,000 US births 
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2.2 Secondary Disorders and Other Findings 
 
Screening tests for core disorders do not exclusively test for these disorders 
alone.  Other disorders or even carrier states may cause abnormal results and 
these results would be reported and followed until a diagnosis is made and a 
core disorder ruled out.  Secondary target disorders are defined as disorders that 
can be detected in the differential diagnosis of a core disorder. 
 
2.21 Other Disorders and Incidental Findings 
Some of the secondary disorders that have been detected by the Arizona 
Newborn Screening Program along with incidental findings (carrier states) 
include: 
 
• Non-classical CAH 
• Hyperphenylalaninemia 
• Hypermethioninemia 
• Partial biotinidase deficiency 
• Galactosemia carrier or Duarte variant galactosemia 
• Carnitine palmitoyl transferase deficiency type II (CPT-2) 
• Cystic Fibrosis carrier 
• Other disease carriers 
• Other hemoglobin diseases 
• Hemoglobin traits 
 
2.22 Other Hemoglobin Diseases 
Other hemoglobin diseases and traits are detected because the hemoglobin 
screening is not specific to the three sickling disorders on the Arizona panel.  
These include: 
 
Sickle/Hereditary Persistence of Fetal Hemoglobin (S-HPFH) 
• A much milder form of sickle cell disease with no Hb A produced but fetal 
hemoglobin amounts that do not decline with time. 
• Risk of this disorder is detected by a hemoglobin result of FS by isoelectric 
focusing and HPLC. 
 
Hemoglobin C Disease 
• An inherited red blood cell disorder (autosomal recessive) marked by 
target cells and chronic hemolytic anemia.  It is caused by a mutation of 
both copies of the gene controlling the structure of β hemoglobin chains. 
• It occurs most often in individuals of African descent and is characterized 
especially by splenomegaly, arthralgias, abdominal pain and the presence 
of target cells and hemoglobin C in the blood. 
• Risk of this disorder is detected by a hemoglobin result of FC by 
isoelectric focusing and HPLC. 
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Alpha Thalassemia 
• A hereditary hemolytic anemia marked by a decreased rate of synthesis of 
the α globin chains of hemoglobin. 
• Four gene deletions produce alpha thalassemia major which is 
incompatible with life.  Affected infants are stillborn or born with severe 
hydrops fetalis (abnormal accumulation of fluid in the entire body of the 
infant) and die quickly.  If transfusions are given prenatally and continued 
throughout life, a baby can survive. 
• Three gene deletions produce Hemoglobin H disease, two produce alpha 
thalassemia trait, and one the “silent carrier.” 
 
Hemoglobin H Disease 
• An inherited red blood cell disorder (autosomal recessive) marked by 
chronic hemolytic anemia.  It results from only one working copy of the 
gene controlling alpha globin synthesis (3 gene deletions or two gene 
deletion and one non-deletional mutation). 
• It is marked by hypochromic red blood cells with inclusions that cause 
them to resemble golf balls (Hemoglobin H is unstable and cannot be 
quantified by laboratory methods). 
• Risk of this disorder is detected by a hemoglobin result of FA plus Barts 
(in a concentration of at least 15% of total hemoglobin) by isoelectric 
focusing and HPLC. 
 
Hemoglobin H – Constant Spring Disease 
• A chronic inherited hemolytic anemia resulting from only one working copy 
of the gene for alpha globin synthesis and a structural defect called 
Constant Spring in one of the non-working copies of the gene.  It is a more 
severe form of Hemoglobin H disease with variable consequences up to 
transfusion dependency. 
• Risk of this disorder is detected by a hemoglobin result of FA + Barts (in a 
concentration of at least 15% of total hemoglobin) by isoelectric focusing 
and HPLC. 
 
Beta Thalassemia (β thal) 
• A hereditary hemolytic anemia marked by a decreased rate of synthesis of 
the β globin chains of hemoglobin.  
• The homozygous form (Cooley’s, Mediterranean or erythroblastic anemia) 
in which β globin is completely absent is also referred to as β° thalassemia 
or β° thal).  The NBS hemoglobin result would be F only. 
• When some beta chains are present but in decreased amount it is called 
β+ thalassemia or β+ thal).  The NBS hemoglobin result would be FA or 
possibly F only).    In an older individual, there would be increased 
amounts of Hb A2. 
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2.23 Hemoglobin Traits 
 
Sickle Cell Trait 
• A condition in which one sickle gene mutation is inherited along with a 
normal gene for β globin chain structure. 
• This trait is usually a very mild condition and most people with sickle cell 
trait never even know that they have it.  However, in rare cases a person 
with sickle cell trait can have problems at high altitude or when exercising 
hard in hot weather when not drinking enough water. 
• Risk of this trait is detected by a hemoglobin result of FAS by isoelectric 
focusing and HPLC. 
 
Alpha Thalassemia Trait 
• A condition in which an individual inherits only two working genes for 
alpha globin chain synthesis.  Individuals with this condition will have a 
mild microcytic, hypochromic anemia.  This decrease in alpha globin chain 
production does not lead to health problems. 
• Asians with alpha thalassemia trait usually, but not always, have the two 
non-working genes on the same chromosome (cis-type) making it possible 
to have a child with hydrops fetalis.  African Americans with alpha 
thalassemia trait usually, but not always, have the two non-working genes 
on different chromosomes (trans-type) and therefore can only transmit one 
non-working gene to their offspring. 
• Risk of this trait is detected by a hemoglobin result of FA plus Barts (in a 
concentration of at least 10% of total hemoglobin) by isoelectric focusing 
and HPLC. 
• See the Appendices for the Arizona Hemoglobin Barts Fact Sheet for 
Health Care Providers. 
 
Other Traits 
• Other traits like Hemoglobin C Trait, Hemoglobin D or G trait, Hemoglobin 
E trait or Unidentified Traits can be identified.  These do not usually have 
any health problems other than a mild anemia that is not responsive to 
iron therapy. 
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CHAPTER 3   
Bloodspot Screening 
 
 
3.1 Provider Responsibilities 
 
Providers are responsible for timely collection of properly identified and 
acceptable newborn screening specimens, rapid transfer of specimens to the 
State Lab and follow-up on abnormal results. 
 
1. Order a newborn screening test for each newborn and provide parents 
with information about newborn screening at the time the test is ordered.  
The brochure, “Newborn Screening, A Guide for Parents,” is included in 
the Appendices and copies can be ordered at no charge for distribution to 
parents using the brochure order form in the Appendices. 
 
If parents refuse to have their newborn tested, the provider ordering the 
screen is responsible for documenting the refusal and submitting a 
collection kit with identifying information but no blood to the State Lab. A 
sample refusal form is included in the Appendices. 
 
2. Fill out each specimen card completely.  See the Appendices for sample 
specimen cards.  Instructions for completing the demographic information 
on the card are in Chapter 4.4 on page 50. 
 
3. Collect an acceptable blood sample following the instructions in Chapter 
4.2 on page 48. 
Posters showing acceptable and unsatifactory specimens and specimen 
collection steps are available on our website, www.AZNewborn.com  
 
4. Collect a timely specimen following instructions in Chapter 4.6 on page 57. 
• First specimens must be collected, according to whichever of the 
following occurs first: 
o 24 to 72 hours of age (closer to 24 hours is recommended)  
o Before a transfusion  
o Before discharge from the hospital 
• See Chapter 4.7 and 4.8 on page 59 for special considerations for sick, 
low birth weight or preterm infants. 
• Second specimens should be collected: 
o Between 5 to 10 days of age, or  
o At the first visit to the medical home or other health care 
professional (even if this visit is before 5 days of age) 
o Unless you verified that another provider collected the 2nd 
specimen. 
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• Arizona requires healthcare providers to order a second newborn 
screening test for babies who enter their care and are not yet one year 
of age unless previous test results are verified. 
 
• Submitters of second screens must also submit payer information so 
that responsible parties (parents or insurance carriers) can be billed for 
screening. 
 
5. Promptly send specimens to the State Lab.  Submitters should send each 
specimen to the State Lab no later than 24 hours or the next working day 
after the blood sample is collected.  See Chapter 4.6 on page 57 for more 
information about timely handling of specimens. 
 
6. Receive a copy of the newborn screening test results and document them 
in the baby’s medical record. 
 
7. Follow-up on positive newborn screening results, order appropriate 
additional testing and refer the baby to a specialist, if needed. 
 
8. Send copies of results from subsequent tests performed at labs other than 
the State Lab in response to an abnormal screening test to the Newborn 
Screening Program.  Our fax number is 602-364-1495. 
 
Please refer to the Arizona Administrative Code (Public Services, Title 9, 
Section 9-13) for the Newborn Screening rules.  See the Appendices for a full 
copy of the rules. 
 
 
3.2 Obtaining a Submitter Code 
 
Each entity that sends specimens to the State Lab or receives test results from 
the State Lab must have a unique identification code.  This code is assigned by 
the Demographics unit of the Newborn Screening Program and must appear on 
each newborn screening specimen collection kit submitted to the State Lab.   
 
If you are a new provider you will need to obtain a submitter code.  Please call 
the Demographics unit at 602-364-1468.  You will need to provide complete 
contact information including practice name (if applicable), mailing address, 
telephone and fax numbers.   
 
This information needs to be updated if anything changes since it is the 
information used to mail results and contact submitters when specimens are 
unsatisfactory or abnormal. 
 
 
 
 Arizona Newborn Screening Program Guidelines – August, 2010  Page 35 
 
 
3.3 Ordering NBS Supplies and Education Materials 
 
3.31 Collection Kits and Envelopes 
 
Newborn screening collection kits and other supplies can be ordered by 
submitters at no charge to them. 
 
Remember that kits expire and cannot be tested past the expiration date (found 
above the circles for blood on the filter paper portion of the kit).  Please do not 
order more specimen cards than can be used promptly.  Always check to be sure 
that the kits have not expired before using.  Store kits on end, not stacked flat so 
that the filter paper is not compressed by the weight of kits on top of them. 
 
Linked kits and pink envelopes are sent to hospitals only.   
 
The first specimen is collected on the top kit marked 1 and the bottom kit 
marked 2 is placed in the pink envelope and sent home with the baby.  
Parents should be instructed to bring this kit to their first doctor’s 
appointment. 
 
Supplemental kits are single kits which can be used for any screen.  Above the 
baby’s name field in the top left part of the form are check boxes to indicate what 
type of screen is being submitted.  Please be sure to mark this area when using 
a supplemental kit.  There are some supplemental kits circulating without the 
check boxes.  Please note the type of specimen submitted on these forms and 
the disorder to be tested if it is a recall screen. 
 
White envelopes are used for mailing specimens to the State Lab.  Up to 4 kits 
can be sent in each envelope.  Submitters who use a courier or FedEx will not 
need these envelopes. 
 
Hospitals can arrange for FedEx pickups paid for by the Program by 
calling the State Lab Receiving Dept. at 602-542-1190 or E-mail to 
labreceiving@azdhs.gov.   
 
 
 Fill out the order form in the Appendices and fax it to State Lab Receiving at 
(602)364-0758 or go online to www.aznewborn.com to obtain an electronic copy 
which can be completed and attached to an E-mail to labreceiving@azdhs.gov.   
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3.32 Brochures 
 
Newborn screening parent brochures can also be ordered by submitters at no 
charge to them. 
 
Fill out the brochure order form in the Appendices and fax it to the Newborn 
Screening Program at (602) 364-1495 or go online to www.aznewborn.com to 
obtain an electronic copy which can be completed and attached to an E-mail to 
nbs@azdhs.gov 
 
 
3.4 Results and Follow-up 
 
3.41 Results and Reference Ranges 
 
Printed reports of newborn screening results are mailed to submitters and health 
care professionals listed on the specimen collection kit.  Each mailer has a 
disclaimer reminding providers that these results are from screening tests and 
are not diagnostic of any condition nor can they rule out the possibility of any 
screened disorder.   
 
Normal results are reported by disorder group and do not show actual values.  
Abnormal results are given for a disorder listed within a disorder group with a 
footnote requesting appropriate action.  If a result in a group is not specified as 
abnormal, it is normal.  For example, there are six amino acid disorders in that 
group and if the phenylalanine result is shown, it is an abnormal test for PKU.  
The other five disorders are not shown and they are normal. Please see the 
Appendices for sample mailers. 
 
Reference ranges are listed on the back of the mailer.  Further information about 
analytes, assays and reference ranges by disorder are shown in table form: 
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Arizona Newborn Screening Program: Analytes, Assays and Reference Ranges by Disorder 
Disorder Analyte Assay Reference Range Abnormal Result 
Endocrine Disorders 
CH TSH 
 
PerkinElmer AutoDelphia® 
time resolved fluoro-
immunoassay for TSH  
1st
 
 screen: < 30 μU/mL 
2nd
abnormal : ≥ 60 μU/mL 
 screen: < 20 μU/mL 
borderline:  
1st
2
 screen: 30 - 59.9 U/mL 
nd screen: 20 - 59.9 μU/mL 
CAH 17-OHP 
 
PerkinElmer AutoDelphia® 
time resolved fluoro-
immunoassay for 17-OHP 
by birth weight: 
<1250 g: < 135 ng/mL 
1250-1749 g: < 90 ng/mL 
1750-2499 g: < 65 ng/mL 
≥2500 g: < 50 ng/mL 
by birth weight: 
<1250 g: ≥160 ng/mL 
1250-1749 g: ≥ 135 ng/mL 
1750-2499 g:  ≥110 ng/mL 
≥2500 g: ≥ 90 ng/mL 
 
borderline, by birth weight: 
   <1250 g: 135 - 159.99 ng/mL 
   1250-1749 g: 90 - 134.99 ng/mL 
   1750-2499 g:  65 - 109.99 ng/mL 
   ≥ 2500 g: 50 - 89.99 ng/mL 
Hemoglobin Disorders 
Hb SS 
Hb S/β thal 
Hb SC 
hemoglobin 
 
Hb IEF & HPLC Normal Hb present (FA) F only, Fx, FAx where x is a variant 
Hb (S, C, D, E, G, U, Barts) 
Other Enzyme Deficiencies 
BIOT biotinidase colorimetric enzyme assay color change equal to control - 
enzyme activity present 
enzyme activity absent 
pale - reduced enzyme activity 
GALT Gal-1-PUT 
 
Bio-Rad fluorometric 
enzyme assay 
≥ 1.1 U/g Hb ≤ 0.7 U/g Hb 
equivocal: 0.8 - 1.0 U/g Hb 
Amino Acid Disorders 
PKU phenylalanine tandem mass spectrometry < 3.0 mg/dL ≥ 3.0 mg/dL 
MSUD leucine 
 
tandem mass spectrometry 1st
2
 screen: < 4.0 mg/dL 
nd
1
 screen: < 6.0 mg/dL 
st
2
 screen:  ≥4.0 mg/dL 
nd screen: ≥ 6.0 mg/dL 
HCY methionine tandem mass spectrometry < 2.0 mg/dL ≥ 2.0 mg/dL 
CIT-1 citrulline 
 
tandem mass spectrometry 1st
2
 screen: < 1.6 mg/dL 
nd
1
 screen: < 2.6 mg/dL 
st
2
 screen: ≥ 1.6 mg/dL 
nd screen: ≥ 2.6 mg/dL ASA 
TYR-1 tyrosine tandem mass spectrometry < 10.0mg/dL ≥ 10.0mg/dL 
Fatty Acid Oxidation Disorders 
CUD C0 tandem mass spectrometry > 8.00 μmol/L ≤ 8.00 μmol/L 
MCAD C8 tandem mass spectrometry < 0.60 μmol/L ≥ 0.60 μmol/L 
VLCAD C14:1 tandem mass spectrometry < 0.60 μmol/L ≥ 0.60 μmol/L 
LCHAD C16OH tandem mass spectrometry < 0.60 μmol/L ≥ 0.60 μmol/L 
TFP 
Organic Acid Disorders 
IVA C5 
 
tandem mass spectrometry 1st
2
 screen: < 0.78 μmol/L 
nd
1
 screen: < 0.92 μmol/L 
st
2
 screen: ≥ 0.78 μmol/L 
nd screen: ≥ 0.92 μmol/L 
GA-1 C5DC tandem mass spectrometry < 0.40 μmol/L ≥ 0.40 μmol/L 
HMG C5OH 
 
tandem mass spectrometry 1st
2
 screen: < 1.15 μmol/L 
nd
1
 screen: < 1.03 μmol/L 
st
2
 screen: ≥ 1.15 μmol/L 
nd screen: ≥ 1.03 μmol/L 3MCC 
MCD C3 
 
tandem mass spectrometry 1st
2
 screen: < 10.0 μmol/L 
nd
1
 screen: <  7.0 μmol/L 
st
2
 screen: ≥ 10.0 μmol/L 
nd screen: ≥  7.0 μmol/L MUT 
Cbl A, B 
PROP 
BKT C5:1 tandem mass spectrometry < 0.25 μmol/L ≥ 0.25 μmol/L 
Pulmonary Disorder 
CF IRT 
 
DNA 
 
 
PerkinElmer 
AutoDelphia® time 
resolved fluoro-
immunoassay for IRT/ 
Third Wave CFTR 
mutation assay 
IRT in lower 97.8% of batch or 
< 65 ng/mL: CF not indicated 
by IRT or 
IRT in upper 2.2% of batch and 
no mutations found 
One mutation detected 
Two mutations detected 
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3.42 Follow-up on Abnormal Results 
 
The Follow-up Section is responsible to contact primary care providers to ensure 
infants will receive medical evaluation, further testing and/or proper treatment.  It 
is the Program’s goal that no infant will be lost to follow-up. 
 
Abnormal results are communicated to the Follow-up Section by the Laboratory 
Section.  From there, follow-up staff will take appropriate actions to locate the 
infant’s primary care provider in a timely manner.  The follow-up specialist 
assigned to the case will contact the primary care provider to ensure the infant 
will receive medical evaluation, further testing and/or proper treatment.  
Abnormal results are communicated to the primary care provider (and/or the 
designated nurse practitioner or medical assistant) by phone, by fax and by mail. 
 
Follow-up specialists work closely with pediatric endocrinologists, metabolic 
geneticists, hematologists and cystic fibrosis specialists.  These contracted 
specialists provide guidance to the Follow-up case management team until 
resolution is reached.  The contact information for these specialists is listed in 
Chapter 1.81 on page 16 of this document; primary care providers are strongly 
encouraged to consult these specialists on specific cases.  
 
Follow-up specialists monitor progress made and only close the case when 
normal results are received or it is verified that the baby is receiving appropriate 
care.  It is important that physicians communicate results of testing performed at 
other labs, and the final diagnosis to the follow-up specialist.  If the follow-up 
specialist is not informed of normal confirmatory results, unnecessary phone calls 
and faxes may be made to the physician or the parents.   
 
Providers may request assistance from the Program’s Follow-up staff if they are 
having problems locating parents or obtaining repeat tests for infants. If the infant 
is no longer under their care, providers should notify the follow-up specialist 
immediately. 
 
If the follow-up specialist is unable to locate the primary care provider; he or she 
will contact the parent in order to obtain the name of the physician taking care of 
the baby.  At that time, parents are advised to contact their primary care provider 
for further testing.  Lab results are not communicated to the parents, only the fact 
that the newborn screening results are not normal and further testing is required. 
 
When the attempts to contact the parents are unsuccessful, the follow-up staff 
will coordinate efforts with submitters and other agencies in order to locate 
parents as soon as possible. 
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3.43 Follow-up on Hemoglobin Traits 
 
Letters are sent to the provider of record and the parents to notify of probable 
hemoglobin carrier status.  There is no further follow-up beyond this notification.  
Parents are encouraged to talk to their primary care provider about the fact that 
the results indicate that the baby has a hemoglobin trait.  The parent notification 
letter in English and Spanish directs them to contact the Office for Children with 
Special Health Care Needs or the Quest to Cure Foundation for more information 
and resources.  Contact information for these organizations is in Chapter 6.3 on 
page 73.  
 
A chart of hemoglobin result mnemonics with descriptions of the probable results 
is in the Appendices.  
 
 
3.44 Follow-up on Unsatisfactory Specimens 
 
Submitters and health care providers are notified of unsatisfactory specimens by 
fax and by mail.  Unsatisfactory specimens are not tested by the State 
Laboratory.  The submitter (birth hospital or provider who ordered the screen) is 
responsible to contact the parents in order to make arrangement for the 
collection of another specimen as soon as possible. 
 
The Follow-Up staff monitors unsatisfactory specimens to ensure that a 
subsequent valid specimen is received.  If a valid specimen is not received within 
two weeks, the infant’s medical home or provider who ordered the screen and 
parents will be notified by mail that a valid specimen has not been received and 
will urge them to make arrangements for the collection of another specimen as 
soon as possible.  A reminder letter will be sent if a valid specimen is not 
received thirty days after the date the first letter was mailed. 
 
Follow up will be discontinued once a valid specimen indicating normal results 
are received, or thirty days following the issuance of the reminder letter. 
 
 
3.45 Referral to Children’s Rehabilitative Services (CRS) 
 
The Children’s Rehabilitative Services (CRS) Program provides medical 
treatment, rehabilitation and related support services as a carveout to Medicaid 
recipients with qualifying chronic and disabling conditions under age 21.  Care is 
provided to more than 26,000 children and youth with special health care needs 
(CSHCN) through four family-centered, multi-specialty interdisciplinary clinics. 
CRS covers over 350 chronic and disabling health conditions including cerebral 
palsy, cleft lip/cleft palate, spina bifida, cystic fibrosis, sickle cell anemia, 
metabolic and endocrine disorders, and many congenital anomalies. Many CRS 
recipients are medically fragile and require complex care from multiple pediatric 
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physician subspecialists that are frequently in short supply.  CRS manages a 
statewide network of specialists to provide timely access to CSHCN throughout 
the state.  Strategies to ensure access include the use of field clinics in which 
specialists travel to remote areas of the state, as well as using innovative 
techniques such as telemedicine to minimize travel for both families and 
physicians. 
 
The CRS Program is administered by the Arizona Health Care Cost Containment 
System through a contract with Arizona Physicians IPA. 
 
Arizona Physicians IPA-Children’s Rehabilitative Services (APIPA-CRS) does not 
determine eligibility based on income. To be eligible for APIPA-CRS services a 
child must: 
 
• Have certain medical conditions, 
• Be under age 21, 
• Be an U.S. citizen or qualified alien, and 
• Live in Arizona. 
 
APIPA-CRS recipients must be members of an AHCCCS acute care health plan 
or an Arizona Long Term Care System (ALTCS) plan, and some recipients may 
have private insurance as well.  APIPA-CRS will coordinate care with the 
recipient’s acute care health plan, ALTCS or private insurance providers. 
 
To apply for services, anyone can fill out an application including a family 
member, doctor, or health plan representative. Along with a completed 
referral/application, medical records that document the child’s CRS eligible 
condition must be submitted.  When someone other than a parent/guardian or a 
family member completes an application, this is called a referral.  
 
Referrals/applications to the CRS Program are initiated by submitting a CRS 
Referral/Application Form. The CRS Referral/Application Form can be obtained 
from many sources, including physicians’ offices,  
 
and the APIPA-CRS website at: 
http://www.myapipa.com/en/members/refer_child.jsp?xlang=en&xrole=me
mbers&xstate=az&xplan=uhcaz&xproduct=CRS 
 
If you need help completing the APIPA-CRS referral/application or getting 
information to send in with the application packet, ask APIPA-CRS Member 
Services for help.  
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Completed applications can be mailed or faxed to: 
 
APIPA-CRS 
Attn: Eligibility and Enrollment 
PO Box 33320 
Phoenix, AZ 85067-3320 
Fax Number: 1-866-623-1692 
 
The APIPA-CRS Referral/Application Form shall contain the following: 
a. The name, address, and phone number of the referral source; 
b. The relationship of the person completing the referral/application form 
to the applicant; 
c. The applicant’s name, date of birth, social security number, gender, 
home address and contact information, race, citizenship, and preferred 
language; 
d. If the applicant is a child, the name of at least one parent/guardian of 
the applicant; 
e. If known to the referral source: 
i. The applicant's diagnosis; 
ii. The applicant’s list of allergies if applicable; 
iii. The applicant's primary care physician or, if the applicant does 
not have a primary care physician, the name of a health care 
organization at which the applicant receives medical care; 
iv. Whether the applicant is enrolled in AHCCCS (Title XIX or Title 
XXI) or has other health insurance; 
v. Whether the applicant has ever received CRS services before; 
vi. Whether the applicant is a U.S. citizen or qualified alien; and 
vii. If a physician has not evaluated the applicant, the reason the 
referral source believes the applicant may be eligible for CRS. 
 
Documentation to accompany the referral/application form for applicants who 
have been evaluated by a physician: 
 a. Documentation from a physician who has evaluated the applicant that 
supports the medical diagnosis; 
 b. Diagnostic test results that support the medical diagnosis. 
 
Within fourteen (14) calendar days of receipt of a referral/application, APIPA-
CRS will determine whether an applicant is eligible for CRS.  The applicant’s 
parent/guardian and referral source will be notified in writing of the decision.   
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3.5 Flow Chart of the Newborn Screening Process  
 
See the Appendices for a summary of the follow-up processes for bloodspot and 
hearing shown in flow charts. 
 
 
3.6 Specimen Retention 
 
Newborn screening bloodspot specimens and attached information submitted to 
the Arizona Department of Health Services (ADHS) are the property of the 
ADHS. 
 
Access to specimens and submitted information is restricted to ADHS employees 
and contractors approved by the Newborn Screening Program Manager as 
necessary to meet specific program needs.  All applicable laws, regulations and 
policies safeguarding the privacy and confidentiality of medical information are 
followed by those with access to these specimens and attached information. 
 
Specimens are stored at room temperature for 90 days and then autoclaved and 
discarded. Specimens of interest (confirmed cases) may be frozen and retained 
for quality assurance purposes.  
 
During the storage period and after the newborn screening tests are complete, 
residual dried blood may be used for lab methodology development or validation 
or other quality assurance testing. 
 
Specimens may be released to others under certain circumstances including: 
1. Written request from a provider, at the request of a parent or guardian.  
Bloodspot specimens will not be returned directly to a newborn’s parent or 
guardian. 
2. Written request from the Office of the Medical Examiner. 
3. To named persons in a court order or subpoena. 
 
 
3.7 Frequently Asked Questions 
 
What is the chance that an infant will have a disorder detected by newborn 
screening? The combined risk of having one of the 29 disorders on the panel is 
greater than 1 in 500. 
 
What if an infant has a family history of a disorder detected by newborn 
screening?  This family should arrange for diagnostic testing with an appropriate 
specialist and not wait on a newborn screening result.  The possibility of this 
disorder should be considered by any provider of care to the baby. 
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What about false positive results?  In any screening tests there will be some 
false positives.  Repeat testing should show that the baby is not affected.  
Parents should be told that screening tests are not diagnostic and further testing 
is needed.  
 
How likely is a false negative result?  False negatives can occur for some 
disorders when specimens are collected late or early.  Early collection (prior to 12 
– 24 hours of age) can cause false negative results for amino acid and organic 
acid disorders because the specific amino acid or organic acid may not have 
accumulated in sufficient quantity to reach the abnormal range in the first day of 
life.  Collection after 24 hours of age should yield a valid result for these 
disorders. 
Late collection of a first screen (after 48 hours of age) can cause a false negative 
result for fatty acid oxidation disorders because by this time the baby has been 
fed and the fatty acid oxidation pathway is not being used as it is when glucose 
sources have been exhausted.  Even with affected babies, a second screen can 
be normal after an abnormal first screen and this second normal screen does not 
rule out the possibility of the disorder.  Further diagnostic testing is required. 
 
Although rare, a false negative is possible for CF if the IRT is not sufficiently 
elevated in an affected baby and mutation testing is not done.   
 
 
 
Timing of Specimen Collection 
A baby who is only 3 days old has come for her first doctor’s appointment?  
Isn’t this too early to collect a 2nd
 
 screen?  No, the second screen should be 
collected at this appointment.  Improved testing methodology makes earlier 
testing results valid and reliable.  False negatives for some disorders are more 
likely when testing is delayed.  Also, many disorders on the expanded panel can 
cause damage very quickly if not detected early.  There is no longer any 
advantage to delaying testing. 
How long should we wait before collecting a second screen for a baby in 
the NICU? If a baby is still in the hospital at 5 days of age, a second screen 
should be collected no later than 10 days of age, or prior to discharge, whichever 
comes first.   
 
A baby missed getting a 2nd
 
 screen – is 3 months too old for a second?  No, 
the State Lab will accept specimens from babies up to a year of age.  However, 
earlier testing is recommended as some disorders will show more false negatives 
when testing is delayed beyond the newborn period.  Some other disorders 
would have already shown symptoms by 3 months of age. 
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Submitting Specimens for Testing 
A baby’s first screen was unsatisfactory for testing.  Do we need to order 
two more screens for this baby?  No, assuming that the repeat test has normal 
results.  Further testing would only be necessary if a result came back abnormal.  
Be sure to check to see that a CF test was added to the repeat screen. 
 
What about screening infants from outside Arizona?  For a baby that moves 
to Arizona, if results of newborn screening from another state are not recorded in 
the medical record or cannot be verified, a newborn screen should be collected.  
If a baby is born in Arizona or receives health care in Arizona, a newborn 
screening specimen should be collected, no matter whether the family lives in 
another state. 
  
What if an infant is adopted?  Whose demographic information should be 
listed in the Mother’s Information section?  Note that this is an adoption and 
enter information about whoever has custody of the baby - the adoptive mother, if 
the baby is with her or the adoption caseworker or agency if they have not yet 
placed the baby in the adoptive home.  The contact information under Mother’s 
Information needs to show a responsible person who could be contacted about 
the baby if there were abnormal results. 
 
What if an infant is in foster care?  Whose demographic information should 
be listed in the Mother’s Information section?  Enter the CPS caseworker’s 
contact information and note that this is foster care.  If the caseworker’s contact 
information is not available, enter the foster mother’s name, address and phone 
number and note that she is the foster mother.  The contact information under 
Mother’s Information needs to show a responsible person who could be 
contacted about the baby if there were abnormal results.   Entering “foster care” 
without contact information is not acceptable. 
 
Can blood from other than a heelstick be used for newborn screening?  
Yes, blood obtained by venipuncture is acceptable, although not the method of 
choice.  Indicate on the collection card that blood was obtained by venipuncture.  
Blood should not be drawn from an extremity or line used for infusion of IV fluids 
(including blood) without appropriate precautions.  Umbilical cord blood is not 
acceptable. 
 
 
Obtaining Results 
What is the turnaround time for NBS reports?  Once a specimen has been 
received at the State Lab, testing is usually finished within 3 working days.  
Reports are mailed the next day and should be received within about 10 days 
from the date of specimen collection (if it was sent promptly to the State Lab).  
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How do I obtain a copy of newborn screening results?  Results will be mailed 
to the provider listed on the specimen collection kit.  If you need another copy, 
please call the Demographics unit and provide them with identifying information 
about baby and mom.  Results will be sent to a new medical home for the baby 
upon request. 
 
The results have arrived but the infant’s demographic information is 
incorrect.  What should I do?  You can call or fax the NBS Demographics unit 
and they will correct the information and issue an updated mailer. 
 
It has been several weeks since I sent in a NBS sample and I have not 
received a report.  What should I do?  Call the NBS Demographics unit and 
request another copy of the report. 
 
 
Cystic Fibrosis Testing 
What kind of DNA testing is done by the Newborn Screening Program? The 
only DNA testing done by the Arizona Newborn Screening Program is to detect 
46 mutations to the CFTR gene.  Only those samples that have an elevated 
immunoreactive trypsinogen (IRT) level will be tested for mutations so for the 
great majority of babies screened, no DNA testing is done. 
 
What does a negative test for CF mean?  A negative newborn screening test 
for CF indicates a much reduced probability that a baby has CF but it doesn’t 
completely rule out the possibility of disease. 
 
The first test for CF is a test for elevated immunoreactive trypsinogen (IRT).  For 
specimens in the lower 97.8% of the batch the result would be reported as “CF 
not indicated by IRT.”  This means that IRT was not elevated and no mutation 
testing was done  
 
If the IRT was elevated (IRT in the upper 2.2% of the batch), the sample would 
be tested for 46 common CF mutations.  If none of these 46 mutations were 
detected, the result would be reported as “No Mutations Detected.”   Since there 
are over 1000 mutations to the CFTR gene, not every mutation would be picked 
up by our testing panel and cannot be considered “normal.” 
 
Why is there no CF test on most 2nd
 
 screens?  CF testing is only done once 
for each baby.  Usually the first screen is tested and the second is not.  However, 
if a first screen is not submitted or is unsatisfactory for testing, a CF test is added 
to the second screen.  IRT testing is most accurate when done early since IRT 
falls as a baby gets older, even if the baby has CF.   
It would be confusing if a first screen test was positive and a mutation was 
detected and then a second showed “CF not indicated by IRT” because the IRT 
value had fallen into the range where mutation testing was not done.  In this case 
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the first screen results are accurate and indicate the possibility of CF or CF 
carrier.  The second (although reporting IRT values accurately) is misleading 
because there is a CF mutation present.  
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CHAPTER 4 
Specimen Collection 
 
 
 
4.1 A message from the NBS Office Chief 
 
Dear Health Care Professional: 
 
Newborn Screening is one of the most important things that can happen to a 
newly born child.  The Arizona Newborn Screening Program is working diligently 
to make sure every newborn is screened properly, in a timely manner, and 
affected children have the best outcomes possible.   
 
Recently, data have shown that many specimens across the state are being 
collected improperly and are not being sent in a timely manner.  These delays 
create extreme risk for a child who is affected with a disease.  Earlier collection of 
properly obtained specimens, with prompt transport to the State Lab can prevent 
tragic outcomes for Arizona families. 
 
The Arizona Newborn Screening program quality measures are as follows: 
 
1.  Submitters should have less than a 1% rejection rate for collected specimens. 
 
2.  Specimens should be collected within the recommended screening windows. 
• for 1st
• for 2
 screens:  24 - 36 hours of age  
nd
  
 screens:  5 - 10 days of age or earlier (at the first outpatient visit to 
the doctor) 
3.  Specimens should be shipped promptly to the State Lab  
 (no more than 24 hours between collection and shipment to the State Lab) 
 
Please review the instructions for specimen collection and handling in this 
chapter with particular attention to Chapter 4.6.   Please share these instructions 
with all staff that collect and handle Newborn Screening specimens and 
emphasize the importance and urgency of proper specimen collection and 
handling.  
 
If you need further information or assistance with training, please do not hesitate 
to contact us directly at 602-364-1409 or visit our website, 
http://www.aznewborn.com.   
 
With your help, babies can be saved from disability or even death.  Your 
continued efforts are greatly appreciated. 
 
Sincerely, 
 
 Ward Jacox, Chief 
Office of Newborn Screening 
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4.2 Newborn Screening Specimen Collection Instructions 
 
1. Use the specimen collection kit supplied by ADHS.   Store the kits on end 
so that the filter paper is not compressed by the weight of kits stacked on top.  
To order kits and envelopes (US Mail and FedEx), call 602-542-1190 or use 
the order form in the Appendices or on the website, www.AZNewborn.com   
 
2. Check the kit’s expiration date (on the top left of the filter paper strip above 
the blood spot circles).  Make sure the kit has not expired since expired kits 
will be considered unsatisfactory by the lab and will not be tested.   
 
3. Check the filter paper for damage (scratched, abraded, torn or creased, 
detached or partially detached from the rest of the card) and discard the kit if 
it is not in good condition. 
 
4. Fill out the form completely, printing legibly in dark ink (preferably black) 
and pressing hard enough so that it is possible to read the bottom copy.  
Record all requested information and attach insurance information to second 
screens.  Do not use a printer or imprint card.  Complete this step before 
collecting the blood to avoid contamination or smearing of the blood and to 
ensure the baby is properly identified. 
 
5. Gather supplies, wash hands and put on powder-free gloves (preferred 
since powder can contaminate the sample).  Wash hands and change gloves 
between babies.  Observe universal precautions for handling of blood 
samples. 
 
6. Recheck the identity of the infant and mother.  Make sure that the infant 
being tested is the one described on the form. 
 
7. Position the infant with the heel lower than the heart.  Swaddling with 
one foot exposed can help to keep the infant comfortable.  Warm the heel 
with a warming device or a cloth moistened with water no hotter than 42° C 
(107° F). 
 
8. Choose a collection site on the sides of the plantar surface of the heel 
(the walking surface), avoiding the center curvature of the heel.  See the 
illustration on the back of the collection kit. 
 
9. Wipe the collection site with 70% isopropyl alcohol or other non-iodine 
containing disinfectant and allow to air dry. 
 
10. Use a sterile lancet to puncture the skin to a depth of no more than 2 
mm. 
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11. Wipe off the first drop of blood with sterile gauze.  This drop contains 
tissue fluids that can dilute the sample. 
 
12. Allow a large drop of blood to form. Apply gentle pressure to the heel 
(away from the puncture site) and release as drops of blood form.  Do not 
squeeze or “milk” the collection site (this can cause hemolysis and addition of 
tissue fluids to the sample). 
 
13. Touch the drop of blood to a filter paper circle and allow it to fill the 
circle.  Do not apply multiple drops to the same circle.  Apply blood to one 
side of the filter paper only.  Collect 5 large drops of blood to fill the 5 circles 
on the filter paper. Fold the protective biohazard flap away from the 
bloodspots so that it doesn’t touch the specimen until it is dry.  Do not touch 
the filter paper with anything but blood drops. 
 
 Do not write or put stickers on the filter paper. Cord blood is not acceptable.  
If blood is obtained by venipuncture, do not use tubes with EDTA. 
 
14. Dispose of lancets and other supplies in approved biohazard 
containers. 
 
15. Air-dry the blood spots on a level horizontal surface. Protect the 
specimen from heat, direct sunlight or contamination while drying.  Do not 
stack until dry (and the biohazard flaps are in place).   
 
16. Send the specimen to the State Lab as soon as it is dry but no later than 
24 hours after collection.  Specimens will not be tested if they are received 
more than 14 days after collection.   Do not send specimens in sealed plastic 
containers, even when completely dry, unless desiccants are included. 
 
Hospitals should send a courier or FedEx envelope each weekday so that 
the State Lab receives specimens each week day.  Hospital labs should 
know when the FedEx pickup is for their facility and ensure that a package is 
sent out daily.   
 
Include insurance information (see section 1.73) with second screens but do 
not staple paperwork to the collection card. 
 
17. Keep a record of specimens sent.  The kit number (or AZ number, found 
under the bar code and above the blood circles) can be used to track 
specimens.  Use this record to ensure that all results have been received.   
 
Call the Newborn Screening Program at 602-364-3190 or fax a request for 
results to 602-542-4099 (include the baby’s name and date of birth and 
either the mother’s name and date of birth or the kit number in your request). 
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18. If you have questions about specimen collection, please call 602-364-
1409 or 800-548-8381 (within Arizona) or send an E-mail to the Newborn 
Screening Educator at NBS@azdhs.gov. 
 
 
4.3 Sample Collection Kits 
 
Please see the Appendices for sample collection kits with fields numbered 
to correspond with the instructions for entering demographic information 
in the section below (Chapter 4.4). 
 
 
4.4  Collection Kit Demographics 
 
INSTRUCTIONS FOR COMPLETING INFORMATION ON THE NEWBORN 
SCREENING SPECIMEN    COLLECTION KIT 
 
Refer to the numbered fields on the sample collection kits found in the 
Appendices: 
 
When using the linked (double) kits, collect the first specimen with the top 
kit marked “1” and place the bottom kit marked “2” in the bright pink 
envelope and give it to the mother to take with her to the first doctor’s 
appointment after discharge.  Collect the second specimen with the kit 
marked “2”. 
 
When using the supplemental (single) kit, please mark the type of 
specimen in the appropriate box above the Baby’s Name fields.  If the 
specimen being collected is a repeat (after an abnormal result on a second 
screen), check the box marked “recall” and write in which disorder is being 
retested.  These repeat specimens will test only the disorder(s) marked on 
the form.  
 
Field #      Field Name                 Instructions 
1 Baby’s Name  
(Last, First) 
 
Enter the last name of the infant.  This may 
not always be the same as the last name of 
the mother (or the father).  Use the birth 
record or birth certificate name, if known.  
Enter the baby’s first name, if known.  If the 
first name is not known, enter Boy or Girl.  
In the case of multiple births, please enter 
name and birth order designation (e.g. Boy 
Twin A, Mary Trip B, John Quad C, etc.) 
 
2 Date of Birth Enter the infant’s date of birth, in 
“mm/dd/yy” format.  For example, June 13, 
2009 should be entered as “06/13/09.” 
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Field #      Field Name                 Instructions 
 
3 Time of Birth Enter the infant’s time of birth, using military 
time or noting am/pm.  For example, if the 
time of birth is 7:25 am, it would be entered 
as “0725” or “7:25” with am circled.   If the 
time of birth is 8:15 pm it would be entered 
as “2015” or “8:15” with pm circled. 
 
4 Birth Weight Enter the infant’s birth weight in grams.  If 
the birth weight cannot be obtained in 
grams, you may provide pounds and 
ounces, but clearly mark the form by circling 
“Lb/oz”. 
 
5 Date of Collection Enter the calendar date on which the 
specimen was taken, in “mm/dd/yy” format.   
 
6 Time of Collection Enter the time at which the specimen was 
collected, using military time or noting 
am/pm.   
 
7 Current Weight Enter the infant’s weight in grams.  If the 
current weight cannot be obtained in grams, 
you may provide pounds and ounces, but 
clearly mark the form by circling “Lb/oz”. 
 
8 Sex Mark the appropriate box to indicate the 
infant’s gender. 
 
9 Method of Collection Mark the box that states how the specimen 
was collected. 
 
10 Baby’s AHCCCS # Enter the baby’s AHCCCS ID number if it is 
known.  If the infant’s AHCCCS ID # is not 
known, leave this space blank, but enter the 
mother’s ID # (if she is enrolled in 
AHCCCS) in the Mom’s AHCCCS # field 
under Mother’s Information. 
 
11 Medical Record # 
 
Enter the infant’s medical record number. 
 
12 Single or 
Multiple Birth 
Mark the appropriate box, and circle the 
appropriate birth order (A, B, C, D) or enter 
the appropriate letter for multiple births.  
Write which multiple (twin, trip, quad, etc.). 
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Field #      Field Name                 Instructions 
 
13 Race Mark the box that identifies the infant’s 
racial group.  If unknown, mark the box that 
identifies the mother’s racial group. 
 
14 Hispanic Mark the box that indicates whether the 
infant is of Hispanic origin. 
 
15 Food Source Mark the box that identifies the infant’s 
source of nutrition (breast milk only, milk 
formula only, soy formula only, breast milk 
supplemented with milk-based formula, 
breast milk supplemented with soy-based 
formula, total parenteral nutrition (TPN) or 
no enteral feeding (NPO). 
 
16 Status Mark the box that best represents the status 
of the infant at the time of collection for 
each situation or condition listed. 
 
17 Date Last  
Transfused 
If the infant was transfused, enter the date 
of the latest transfusion.  This information is 
needed to determine if the tests for some 
disorders are valid. 
 
18 Accession Number FOR LAB USE ONLY.  DO NOT WRITE 
OR PLACE STICKERS IN THIS AREA. 
 
19 
 
 
 
 
Submitter Name/ID Enter the name of the agency/entity 
submitting the specimen for testing and the 
unique submitter ID code for that submitter.  
(If you do not have a submitter ID, call the 
Newborn Screening Demographic Entry 
Section at (602) 364-1468) 
 
20 Submitter Address Enter the mailing address of the submitter 
(can be omitted if the submitter ID is 
entered above). 
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21 Physician’s Name  
(Last, First) 
Enter the physician’s last name and first 
name.  This physician or other health care 
professional should be the provider 
responsible for the management of medical 
services provided to the infant.  Also, enter 
the physician’s NBS ID.  If the infant’s 
medical home is not known, or if the parent 
has not chosen a pediatrician for the infant 
yet, enter the attending practitioner of 
record.  This is the physician who will 
receive information about test results.  (If 
the practitioner does not have an ID, please 
contact the Newborn Screening Data Entry 
Section at (602) 542-1187.) 
 
22 Phone  Enter the physician’s phone number, 
including area code.  
 
23 Physician’s Address Enter the street address of the physician 
named above.  This is the mailing address 
where a copy of the test results will be 
mailed. 
 
24 City, State, Zip 
 
Please see #23 above. Enter the city, state 
and zip code of the physician. 
 
25 Mom’s Name  
(Last, First) 
Enter the mother’s last and first names from 
the medical record.  If the mother does not 
have physical custody of the infant, enter 
the name of the person who has custody.  
See the note below*.  
 
26 Mom’s Date of Birth Enter the mother’s birth date in “mm/dd/yy” 
format. 
 
27 Maiden Name Enter the mother’s maiden name (name 
before her first marriage). 
 
28 Street Address Enter the mother’s address (or mailing 
address).  If the mother does not have 
physical custody of the infant, enter the 
address of the person who has custody.  
See the note below*.  
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29 City, State, Zip Enter the city, state and zip code of the 
mother’s address, even if the mother does 
not reside in Arizona.  If the mother does 
not have physical custody of the infant, 
enter the city, state and zip code of the 
person who has custody.  See the note 
below*.  
 
30 Phone Enter the mother’s telephone number, 
including the area code.  If the mother does 
not have physical custody of the infant, 
enter the phone number of the person who 
has custody.  See the note below*.  
 
31 Message Phone Enter a number where the mother can be 
reached if not at her own phone.  Or if the 
mother does not have a working phone 
number of her own, enter a number where 
the mother can be contacted (friend, 
relative, neighbor, etc.). This is important so 
the mother can be reached if there are 
abnormal results. 
   
32 Mom’s AHCCCS # Enter the mother’s AHCCCS # if the mother 
is enrolled in AHCCCS. 
 
33 Parent Refused  
Testing 
Mark the box if the parent refuses to have 
the infant screened.  Parents should have 
been informed about the consequences of 
not screening their infant and their refusal 
should be documented in the infant’s 
medical record.  Most providers will have 
the parents sign a refusal form that is 
retained in the infant’s medical record.  For 
a sample form, see the Appendices.  The 
completed newborn screening kit without 
blood should be submitted to the State Lab. 
 
 
*If the infant’s mother does not have physical custody of the infant, enter the 
name, address and phone number of the person who has custody.   
 
In the case of a baby in foster care, enter the CPS caseworker’s contact 
information and note that this is foster care. If the caseworker’s contact 
information is not available, enter the foster mother’s name, address and phone 
number and note that this is foster care. 
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In cases of adoption, enter the information for the adoptive mother if the baby 
has been placed in her care.  Otherwise, enter the adoption agency caseworker 
information and note that this is an adoption.  It is extremely important to list 
contact information for someone who can be reached and who will be able to 
assume responsibility for follow-up, if necessary. 
 
 
4.5 Reasons for Specimen Rejection (UNSATS) 
(With codes for Arizona unsats) 
 
Problems with the family or baby 
UPR Parent refusal 
Make sure that parents are aware of the consequences of refusing the 
test.  Document the refusal in the medical record, fill out demographic 
information on the collection card, check the “parent refused testing” box 
in the lower right corner of the card and submit the card to Arizona State 
Lab without blood. 
 
UIO Infant too old (> 1 year of age) 
Newborn screening reference ranges apply only to newborn infants and 
most accurately indicate risk of disease when specimens are collected 
early.  Serious symptoms of these diseases appear and irreversible 
damage is done if treatment is not started early. 
 
Problems with the card 
UCE expired collection card 
CLIA regulations state that valid results cannot be reported if the card has 
expired. 
 
UNI no identifying information 
 Results cannot be reported if the infant cannot be identified. 
 
UNO no blood 
  Tests cannot be performed without blood. 
 
Problems with collection of the blood  
UCC clotted or caked blood  
This happens when a large enough drop of blood is not taken and blood 
begins to clot before being applied to the filter paper. 
Uniform amounts of blood cannot be taken from samples with extra clotted 
blood in some areas of the spot. 
 
UIS insufficient specimen 
 The baby didn’t bleed well. 
Not enough blood was submitted to complete the whole panel of tests. 
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UMA multiple specimen applications 
Blood may have been applied to both sides of the filter paper or with 
overlapping drops of blood instead of one big drop in each circle.  
Uniform amounts of blood cannot be taken for testing. 
 
UNS uneven saturation 
With areas more saturated with blood than other areas of the spot instead 
of one big drop in each circle, uniform amounts of blood cannot be taken 
for testing. 
 
UTS torn or scratched 
This usually happens when capillary tubes are used to collect the blood 
and then it is spotted onto the filter paper.  The rough edges of the tubes 
can easily abrade the filter paper if they are dragged along the surface.  
With areas where filter paper is missing or bunched up, uniform amounts 
of blood cannot be taken for testing. 
 
UST serum or tissue fluid separation 
This can happen if the first drop of blood is not wiped away, if a liquid 
contaminant is allowed to come in contact with the blood spots, if the area 
around the puncture site is squeezed excessively (“milking”), or if the 
specimen is dried vertically so that gravity can separate blood components 
before complete drying. 
 
Problems in handling and shipping  
 UTO specimen too old (>14 days from collection date) 
Blood components degrade with age and exposure to heat and light and 
cannot be accurately measured. 
  
USD specimen detached from form 
  Results cannot be reported if the infant may be incorrectly identified. 
  
USC contaminated 
Filter paper has come in contact with gloved or ungloved hands or 
substances such as alcohol, formula, antiseptic solutions, water, hand 
lotion or powder, etc. before or after specimen collection.  Contaminated 
specimens yield unreliable results. 
 
Problem in the lab 
URS results inconsistent 
Repeat testing of the same sample gives results that are greatly different 
from one another.  This could indicate that the sample was unevenly 
saturated or damaged in some way. 
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A one-page summary of these reasons for specimen rejection is found in the 
Appendices. 
 
 
4.6 Specimen Collection and Handling 
 
4.61 Collection and Handling of First Screens 
 
You can collect a perfect specimen but if it wasn’t collected during the 
recommended screening window, or if it was delayed in transport to the State 
Lab, a baby could suffer. 
 
When is the best time to collect a first specimen?  24 to 36 hours of age – 
earlier is now better. 
 
1. 
Each disorder has a “best screening window” where the test is most likely to 
detect affected infants while minimizing false positive results.  These windows 
are much earlier than those recommended in the past because the disorders 
detected by tandem mass spectrometry can be accurately detected by 24 
hours of age and some of them can harm babies in the first few days of life 
(so earlier screening is needed). 
Best screening window 
  
2. 
The Arizona Administrative Code R9-13-204 states that a first specimen must 
be collected between 24 and 72 hours of age, but collection closer to 24 
hours is recommended.  For all disorders except homocystinuria, ideal 
screening windows include the time between 24 and 48 hours of age. Waiting 
until 72 hours is already past the best window for many disorders.  
Arizona Rules 
 
3. 
Sick, preterm and low birth weight babies have their own complications for 
screening and even earlier collection is recommended to avoid interference 
from therapies like transfusion, parenteral nutrition or treatment with steroids 
and some antibiotics. 
Special Considerations 
 
How can delays in transport to the State Lab be prevented? 
 
1. 
The Arizona Administrative Code R9-13-203 A. 4 states that specimens must 
be sent to the State Lab within 24 hours of collection or the next business 
day.   
Prompt Mailing 
 
2. 
Each hospital should identify someone with the responsibility to ensure that 
samples move quickly from the nursery to the lab and shipping area so that 
Hospitals using FedEx (State paid), Courier or US Mail 
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the whole process from collection to shipping takes 24 hours or less.  The 
practice of “batching”, where a facility delays sample shipment until a 
predetermined number of samples is collected, seriously increases the risk of 
irreversible harm or death for those infants born earliest in the batch.   
Therefore, any hospital with at least one birth a day should send a shipment 
of samples to the State Lab each weekday, including Friday.   
 
3. 
For those providers who don’t attend at least one birth a day, the requirement 
is still to ship as promptly as possible.  A single specimen sent alone is 
acceptable and shouldn’t be held to be sent with others collected on a later 
date.  
Other Providers 
 
4.62 Collection and Handling of Second Screens 
 
1. When is the best time to collect a second specimen?  5 to 10 days of age 
or at the first outpatient visit to the doctor.   
 
Since babies often see their primary care physicians prior to 5 days of age, 
second screens should be collected at that visit, even though the baby is not 
yet 5 days old.  
 
Second specimens can be collected after 10 days of age (and will be tested if 
collected up to a year of age).  However, later-collected specimens may miss 
cases of certain metabolic disorders (e.g., VLCAD, MCADD, GA-1) or cystic 
fibrosis because false negatives are more likely in older babies.  For disorders 
where symptoms are not apparent until irreversible damage has been done 
(PKU, congenital hypothyroidism) later detection would mean a poorer 
outcome for an affected infant. 
 
2. For providers who collect their own second screens:   
 
Collect the specimen at the baby’s first visit and send it to the State Lab as 
soon as it is dry.  A single specimen is acceptable and shouldn’t be held to be 
sent with others collected on a later date.    
 
Protect specimens from heat and sunlight.  Don’t put them in metal collection 
boxes on outside doors during the summer or drop them in an outside 
mailbox in the sun. 
 
3. For providers who send patients to an outside lab:   
 
Please direct your patients to get the second screen collected as soon as 
possible.   
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We have heard that some labs are turning families away if the baby is 
younger than 2 weeks of age.  This should not happen since earlier collection 
is now recommended.  The Newborn Screening program will be working with 
the large contract labs to ensure that all of their drawing stations have the 
latest guidelines.  Please let us know if you hear of any parents that have 
been turned away. 
 
The bottom line is that early collection, with no delays in handling or 
shipping, gives the best chance for a disorder to be detected and treated 
before an infant is permanently harmed.  
 
 
4.7 Special Considerations  
 
For a baby in the NICU a first bloodspot specimen should be collected prior to 
transfusion, parenteral nutrition and other therapies, even if it means that the 
specimen will have to be collected prior to 24 hours of age.   
 
The CLSI Guideline for preterm, low birth weight and sick newborns recommends 
collection of the first screen on admission to the NICU so that it can be obtained 
prior to any intervention.  This guideline recommends a second screen between 
48 and 72 hours of age and a third on day 28 or prior to discharge, whichever 
comes first. 
 
Arizona rules do not have modified requirements for NICU collection.  However, 
they do require the hospital to collect the second screen between five and 10 
days of age and before discharge if a baby is still hospitalized at 5 days of age. 
 
If a baby is transferred to another hospital prior to 48 hours of age, the receiving 
hospital is required to collect a first screen, unless the first screen has been 
collected by the sending hospital. 
 
 
4.8 Factors Which Affect Test Results or Interpretation 
 
1. Transfusions 
 
According to the Arizona Administrative Code (R9-13-204A), the first newborn 
screening test should be collected prior to any transfusion, unless specified 
otherwise by a physician.  This is necessary to avoid false negative results for 
many disorders. 
 
Any transfusion of red blood cells (whole blood, packed RBCs or ECMO) can 
cause false negative results for galactosemia and hemoglobinopathies and 
this effect lasts until the donor red blood cells have been replaced (3 – 4 
months after the last transfusion).  Rescreening then would be necessary 
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unless a previous screen had been collected prior to transfusion. For both of 
the above disorder groups a specimen collected prior to 24 hours of age is 
valid and yields reliable results. 
 
Transfusions of whole blood or ECMO (or plasma, for biotinidase deficiency 
screening) can cause false negative results for all screened disorders for 4 – 
72 hours after the transfusion (except for galactosemia and 
hemoglobinopathies where the effect lasts for 3 – 4 months).    
 
2. Parenteral Nutrition (PN) 
 
Parenteral nutrition can cause false positives for amino acids and fatty acids.  
Multiple amino acid abnormal results can be an indication of excess free 
amino acids from the parenteral nutrition solution or liver problems (immature 
enzymes or illness so that liver enzymes can’t handle the amino acids fast 
enough to prevent a rise in amino acid concentration in the blood).  Medium 
chain fatty acids are also added to parenteral nutrition solutions and can be 
present in higher amounts in the blood.  Prolonged PN can lead to carnitine 
depletion.  A false positive result for IVA (elevated C5) is also possible. 
 
A repeat screen should be collected 24 – 72 hours after PN is stopped, if a 
previous screen had abnormal results. 
 
3. Maternal Conditions 
 
A mother with hyperthyroidism treated with PTU can deliver a baby with 
transient hypothyroidism (elevated TSH on the newborn screen).  Positive 
results will occur until the drug clears the newborn’s system - between 7-14 
days after birth.  A repeat screen or other thyroid testing should be done 
around two weeks of age. 
 
A mother with CAH can deliver a baby with a false positive result for 17-OHP.  
The newborn should be rescreened between 3 and 7 days after birth. 
 
Transient hyperphenylalaninemia in the newborn is a result of a mother with 
uncontrolled PKU (high phenylalanine levels).  This effect will normalize within 
12 – 24 hours, unless the baby also has PKU. 
 
A mother treated with steroids during pregnancy can deliver a baby with a 
false negative result for CAH since steroids can suppress fetal adrenal 
function.  The length of the effect depends on the class of steroid and the 
dose and is unknown but estimated at 1 – 2 weeks after birth.  A repeat 
screen done later than 2 weeks of age would be needed. 
 
Maternal carnitine or Vitamin B12 deficiencies can cause false positive results 
for C0 (carnitine) and C3 (Vitamin B12).  The effects can last several days 
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depending on the nutrition provided to the newborn (for B12
 
 deficiency) – the 
duration of the effect of carnitine deficiency is unknown). 
Carnitine supplementation can cause false negative results for C0 (Carnitine 
uptake defect) during supplementation and for some weeks afterwards.  It can 
also cause false positives for other acylcarnitines.  This effect lasts 
approximately 4 days. 
 
A mother with 3MCC can have an unaffected baby with elevated C5OH.  The 
duration of this false positive effect is unknown. 
 
4. Sick or stressed infant 
 
A sick or stressed newborn can have elevated 17-OHP and IRT (false 
positives for CAH and CF) until recovered. 
 
Liver disease and jaundice can cause false positives for many disorders 
(tyrosinemia, homocystinuria, PKU, CF, biotinidase deficiency) 
 
5. Preterm or low birth weight infant 
 
Elevated tyrosine and 17-OHP and low biotinidase are common results for 
preterm or low birth weight babies (false positives for tyrosinemia, CAH and 
biotinidase deficiency). 
 
False positives for amino acids disorders are a result of immature liver 
enzymes.  
 
A false negative result for hypothyroidism caused by an immature 
hypothalamic/ pituitary/thyroid axis where TSH does not rise in response to 
low T4 levels can last for more than a month after birth.  Since the newborn 
screen now measures only TSH, this possibility should be considered for all 
preterm and low birth weight babies, even though the hypothyroidism is 
usually transient.  
 
6. Steroid or antibiotic treatment 
 
Dopamine therapy suppresses TSH and can cause false negative results for 
hypothyroidism until the drug is discontinued. 
 
Steroid therapy (including dexamethasone) suppresses TSH and can cause 
false negative results for hypothyroidism as well as false negative results for 
CAH. This effect can last for 1 to 2 weeks after therapy has been stopped. 
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Antibiotics conjugated with pivalic acid (for example, pivampicillin) can elevate 
C5 (false positives for IVA). This effect lasts until the drug clears the baby’s 
system (at least 24 hours after discontinuing therapy). 
 
7. Early collection (prior to 24 hours of age) 
 
False positives for hypothyroidism and CAH are possible because of the 
normal hormone surge after birth.    
 
False negatives for amino acidopathies and organic acid disorders are 
possible with early collection but specimens collected shortly after 24 hours of 
age are reliable.  
 
8. Late collection 
 
Collection of a first screen after 48 hours of age can show false negative 
results for fatty acid oxidation disorders.  A well fed state can mask 
indications of a FAOD so it is important that a first screen be collected 
between 24 and 36 hours if at all possible.  
 
If a baby has an abnormal result for any FAOD on a first screen and then has 
a normal result on the second, that second result cannot be taken to mean 
that the baby had a false positive on the first screen.  All babies with 
abnormal results on first screens should have diagnostic testing done to 
confirm or rule out the possibility of a disorder even though their second 
screen is “normal.”  Very few false positive results for fatty acid oxidation 
disorders ever occur. 
 
Late collection is also not helpful in identifying disorders that have early crises 
since results will not be available when symptoms start to appear.  Disorders 
which can have serious consequences if not diagnosed early include 
galactosemia, MSUD, salt-wasting CAH, urea cycle disorders, organic acid 
disorders and some fatty acid oxidation disorders. 
 
Please see a table in the Appendices summarizing the factors which affect 
screening results, including timing of the specimen collection.  
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4.9 Parent Refusal of Screening 
 
It is important to convince parents of the value of newborn screening so that they 
get their babies screened during the best window of time to detect the disorders.   
 
Providers are required to order newborn screening tests but parents may refuse 
testing.  If after explaining the benefits of newborn screening and the risks 
involved in refusing testing, and parents still wish to refuse, they should sign a 
waiver in which they accept responsibility for adverse consequences.   
 
You should check to see that the waiver you ask parents to sign has been 
reviewed and approved by your legal counsel (See the Appendices for a sample 
form available as a template for preparing a customized form for your use).   
 
This refusal should be fully documented in the baby’s medical record.  The 
demographic information on a newborn screening kit should be fully filled out and 
submitted to the State Lab with no blood and the “Parent Refused Testing” box in 
the lower right hand corner of the form checked. 
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CHAPTER 5 
Hearing Screening and EHDI 
 
 
5.1 Hearing Screening 
 
In Arizona approximately 98% of all infants are screened for hearing loss prior to 
initial hospital discharge. Both Otoacoustic Emissions (OAE) and Automated 
Auditory Brainstem Response (AABR) screening technologies are used, 
sometimes in combination.  Nearly all neonatal intensive care units screen with 
AABR because of the increased risk of auditory neuropathy in this population.   
 
In Arizona 3% of infants do not pass the inpatient screen.  Those infants in the 
well baby nursery who do not pass the newborn screen should also receive one 
outpatient screen within the first week or two post-discharge.  Because of the 
tenfold increased incidence of hearing loss in neonatal intensive care graduates, 
this population should NOT receive an outpatient screen but should go directly to 
a pediatric audiologist for a diagnostic evaluation. 
 
 
5.2 Arizona Early Hearing Detection and Intervention (AzEHDI) Program Goals 
 
The goals of the Arizona Early Hearing Detection and Intervention (AzEHDI) 
program are: 
• screening all babies for hearing loss by one month of age 
• completing diagnostic testing by a pediatric audiologist before three 
months of age for babies who fail the newborn hearing screen 
• enrollment in early intervention services as soon as possible (prior to six 
months of age) after diagnosis of hearing loss 
 
AzEHDI is a collaborative program with all agencies, organizations, providers 
and parents involved in the early hearing detection and intervention efforts in 
Arizona.  Various aspects of the program are funded through federal grants, 
foundation grants, state funding and donations.  The AzEHDI efforts are 
coordinated through the Arizona Department of Health Services, Newborn 
Screening Program.   
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5.3 A message from the NBS Program Manager 
 
 Dear Health Care Professional, 
 
This notification is a reminder of the Arizona reporting requirements for newborn 
hearing screening and subsequent tests.  Arizona Revised Statute §36-694, 
passed in 2005, mandates the reporting of all hearing screening and diagnostic 
results for both newborns and infants to Arizona Department of Health Services, 
Office of Newborn Screening. 
 
As prescribed by A.A.C. R9-13-207 (E), all screening and diagnostic hearing 
evaluations shall be submitted within on e week following the hearing test, even 
if the results are normal.  You can report this information by: 
 
  Fax (the fastest way): (602) 364-1495 
  Mail: 
   Arizona Department of Health Services 
   Office of Newborn Screening 
   250 N 17th Ave, 1st
   Phoenix, AZ  85007-3242 
 Floor 
 
Both screening and diagnostic reporting forms are available on the Office of 
Newborn Screening website, www.aznewborn.com .  Please review the 
instructions to determine the proper reporting format.  We request a copy of the 
supporting narrative report for any diagnostic evaluation.  If you have any 
questions about the reporting forms or need assistance to determine if a report 
should be made, please contact us at 602-364-1409 or toll-free at 1-800-548-
8381. 
 
Our goal is to ensure that infants who fail their hearing screens receive 
prescribed treatment of intervention services in a timely manner.  Your role in the 
Early Hearing Detection and Intervention process is fundamental to reducing the 
number of babies who are lost to follow-up or lost to documentation. 
 
Sincerely, 
 
 Ward Jacox, Chief 
Office of Newborn Screening 
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5.4 Provider Responsibilities - Mandatory Reporting 
 
• Results of all hearing screening and subsequent tests for hearing loss performed 
on newborns and infants must be reported to the Newborn Screening Program, 
along with identifying information for the baby and the facility performing the test.  
Please see the Appendices for the complete reporting requirements in Rules 
(R9-13-207). 
 
• Results from each hearing screening or diagnostic test performed must be sent 
to the Newborn Screening Program within one week of the test date. 
 
• All tests, even if normal, should be reported.  Normal results help the Newborn 
Screening Follow-up team know when the child no longer needs active follow-up. 
 
 
5.41 Screening Forms 
 
To report any out-patient hearing screening, please submit the Hearing Out-
Patient Screening (HOPS) form or the Community Health Center Out-Patient 
Screening Clinic Form found in the Appendices. 
 
• Use for reporting screening only (not diagnostic results) 
• Multiple infants can be reported on the same form  
• Include the mother’s identifying information  
• Report the results of either the Otoacoustic Emissions (OAE) screening or the 
Automated Auditory Brainstem Response (AABR) screening 
 
 
5.42 Diagnostic Testing Forms 
Use the referral forms customized by region (Phoenix, Flagstaff, Tucson and 
Yuma) when referring a baby for a diagnostic test.  These forms are found in the 
Appendices. 
 
• Refer a child who has been diagnosed with bilateral permanent hearing loss 
to Early Intervention Services.   
• Report diagnostic test results to the state Newborn Screening Program  
• Results to be reported include: 
o Unilateral hearing loss 
o Transient hearing loss  
o Hearing loss in children from birth to three years of age and  
o NORMAL results ruling out a hearing loss  
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5.5 Statewide Testing Locations 
 
Lists of screening and diagnostic testing facilities with phone numbers are 
available in the Appendices. 
 
A map of these screening and diagnostic testing locations in Arizona is found on 
our website, www.AZNewborn.com  
 
 
5.6 Hearing Screening and Follow-up 
 
The Arizona Early Hearing Detection and Intervention Program (EHDI) includes 
Newborn Hearing Screening Follow-up under the Newborn Screening Program.  
Follow-up is conducted to meet the goals of: 
 
• Screening all infants for hearing loss by one month of age 
• Completing diagnostic testing before three months of age for children who fail 
the newborn hearing screen 
• Enrollment in Early Intervention services as soon as possible (prior to 6 
months of age) after diagnosis of hearing loss 
 
In order for the Program to know where infants are in the process of early 
identification and to provide appropriate follow up, it is critical that providers know 
when and how to report screening and diagnostic results. 
 
Screening 
If infants do not pass their newborn hearing screen in the hospital, it is important 
that the babies are screened again as soon as possible (no later than 1 month of 
age).  Most can return to the birthing hospital for an outpatient rescreen within 
the first week or two after discharge.  If it is not possible or convenient (or for 
insurance coverage), the provider can refer the infant to another screening 
location (for a list of resources, please see the Appendices or visit our website at 
www.AZNewborn.com).   
 
If the infant was screened with the AABR, it is best if AABR is used for the 
rescreening.   
 
NICU graduates (more than 5-day stay) or infants with risk indicators for hearing 
loss: 
 
• Do not rescreen 
• Refer to a pediatric audiologist for diagnostic testing 
• Older infants may need sedation/anesthesia 
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Diagnostic testing 
Refer to a pediatric audiologist if the infant fails an outpatient screen or is a NICU 
graduate that failed the inpatient screen.  Infants may need a referral from the 
primary care provider. 
 
5.61 Late Onset and Progressive Hearing Losses 
Between the newborn period and school age the prevalence of significant 
hearing loss doubles.  This increase in hearing loss is due to: 
• Late onset losses  
• Progressive losses 
• False negative screens 
• Missed newborn screens or loss to follow-up 
Although some children present with hearing loss and have no risk factors, there 
are conditions known to cause hearing loss.   The Joint Committee on Infant 
Hearing recommends that these children who pass their hearing screening but 
have risk factors receive, at minimum, a diagnostic assessment by 24 to 30 
months of age.  Risk indicators that are marked with an asterisk are of greater 
concern 
• Caregiver concern regarding
for delayed-onset hearing loss and should receive earlier and/or more 
frequent assessment. 
 hearing, speech, language, or developmental 
• Family
delay. 
 
• Neonatal
history* of permanent childhood hearing loss. 
 intensive care of more than 5 days or any of the following regardless 
of length of stay: ECMO*, assisted ventilation, exposure to ototoxic 
medications (gentimycin and tobramycin) or loop diuretics (furosemide/Lasix), 
and hyperbilirubinemia that requires 
• In utero infections, such as CMV*, herpes, rubella, syphilis, or toxoplasmosis. 
exchange transfusion. 
• Craniofacial anomalies, including those that involve the pinna, ear canal, ear 
tags, 
• Physical findings,
ear pits, and temporal bone anomalies. 
 such as white forelock, that are associated with a syndrome 
known to include a sensorineural or permanent conductive hearing 
• Syndromes associated with hearing loss or progressive
loss. 
 or late-onset hearing 
loss*, such as neurofibromatosis, osteopetrosis, and Usher syndrome.  Other 
frequently identified syndromes include 
• Neurodegenerative disorders*, such as Hunter syndrome, or sensory
Waardenburg, Alport, Pendred, and 
Jervell and Lange-Nielson. 
 motor 
neuropathies, such as Friedreich ataxia and Charcot-Marie-Tooth syndrome.
• Culture-positive postnatal infections associated
  
 with sensorineural hearing 
loss*, including confirmed bacterial and viral (especially herpes viruses and 
varicella) meningitis. 
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• Head trauma, especially basal skull/temporal bone fractures* that 
• Chemotherapy*. 
requires 
hospitalization. 
 
5.7 Hearing Screening Guidelines 
 
The following guidelines are found in the Appendices: 
 
• Newborn Screening Diagnosis and Intervention Guidelines for Medical Home 
Providers, 2010 
• Joint Committee on Infant Hearing, AAP, Year 2007 Position Statement: 
Principles and Guidelines for Early Hearing Detection and Intervention 
Programs 
 
The Arizona Pediatric Audiology Guidelines (last published in 2000) are currently 
under revision. 
 
 
5.8 Family Checklists – Infant Hearing Guides 
 
Family Checklists have been developed as a type of “roadmap” for parents and 
providers of children who have failed their newborn hearing screening tests.  The 
checklists include developmental milestones, a timeline for when various 
assessments should be completed and the appropriate next steps.   
 
These checklists may be given to families at the hospital and are included with 
letters to parents sent from the Office of Newborn Screening – Follow-up: 
o A Family’s Checklist – Infant Hearing (intended for well babies) 
o Family Checklist for Babies at High Risk for Hearing Loss (intended for 
NICU graduates or at higher risk for hearing loss) 
 
Both checklists are found in the Appendices. 
 
 
5.9 Provider Resources 
 
• The Newborn Hearing Screening Training Curriculum – Streaming Video (a 
competency-based training for new hearing screeners) is available from 
NCHAM at: http://www.infanthearing.org/nhstc_dvd/streaming.html 
 
• NCHAM Newborn Hearing Screening Training Curriculum Scripts from the 
above curriculum are found in the Appendices.  
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• CDC Early Hearing Detection & Intervention (EHDI) Program website is found 
at http://www.cdc.gov/ncbddd/ehdi/default.htm  
 
• Early Hearing Detection and Intervention – AAP Medical Home 
Implementation is found at 
http://www.medicalhomeinfo.org/how/clinical_care/hearing_screening  
 
• National Center for Hearing Assessment and Management (NCHAM) – Utah 
State University website is found at http://www.infanthearing.org  
 
• Loss & Found – What to do if your baby didn’t pass the newborn hearing 
screening - a DVD from Hands & Voices in both English and Spanish with 
subtitles for the Deaf/Hard of Hearing.  Call the Newborn Screening Program 
at (602) 364-1409 to receive a free copy to show to parents. 
 
 
5.91 Family-Friendly Resources 
 
• Universal Newborn Hearing Screening Brochure from ADHS, Office of 
Newborn Screening is available at no charge.  A copy of it and the brochure 
order form are found in the Appendices. 
 
• Frequently Asked Questions Parents May Ask (in English and Spanish) from 
the NCHAM curriculum can be found in the Appendices. 
 
• A checklist “How does your child hear and talk” from the NCHAM curriculum 
can be found in the Appendices. 
 
• A copy of the Hands & Voices brochure with contact information is found in 
the Appendices. 
 
• The Guide By Your Side brochure provides information for parents on a 
program of the Arizona Chapter of Hands & Voices. GBYS is a program of 
trained experienced parents who can mentor new parents through the 
screening and diagnostic process.  A copy is in the Appendices.  
 
• The Guide By Your Side rescreen reminder card is a small pink postcard 
sized reminder that an infant who failed the hearing screen needs to be 
rescreened as an outpatient within two weeks.  The pink card has information 
in English on one side and Spanish on the other that indicates that a Parent 
Guide will be contacting the family and how to opt out if they prefer not to be 
contacted.  A copy is in the Appendices.  
 
• The EAR Foundation website is at http://www.earfoundationaz.com  
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• A copy of “Hearing Aids – Resources for Parents” is found in the Appendices. 
 
• A copy of the HEAR for Kids: Loaner Hearing Aids, Vouchers and Permanent 
Hearing Aid Application is found in the Appendices. 
 
• The Hear and Now website is at http://www.hearandnow.org  
 
• My Baby’s Hearing website from the Boys Town National Research Hospital 
and NIDCD is at http://www.babyhearing.org/Audiologists/index.asp   
 
• AzEHDI is on Facebook at  http://www.facebook.com/pages/Glendale-
AZ/AZEHDI/162338672816  
 
• Arizona Health Care Cost Containment System (AHCCCS): Arizona’s 
Medicaid agency that provides health care to Arizonans that meet income and 
other eligibility requirements. 
http://www.azahcccs.gov  
 
Children’s Rehabilitative Services (CRS) is a program administered by 
AHCCCS through a contract with Arizona Physicians IPA.  CRS provides 
medical treatment, rehabilitation and related support services for children 
under age 21 with qualifying chronic and disabling conditions. 
 
http://www.myapipa.com/en/members/refer_child.jsp?xlang=en&xrole=me
mbers&xstate=az&xplan=uhcaz&xproduct=CRS 
 
• Arizona Early Intervention Program (AzEIP): a statewide system of support 
and services for families of children, birth to 3, with disabilities or 
developmental delays.  
https://egov.azdes.gov/CMSInternet/main.aspx?menu=98&id=3026  
 
• Arizona State Schools for the Deaf and the Blind (ASDB): provide education 
for children with hearing or vision loss. 
http://www.asdb.state.az.us  
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CHAPTER 6 
Resources and Education 
 
 
6.1 Brochures and Fact Sheets 
 
Copies of the brochures and fact sheets published by the Office of Newborn 
Screening are found in the Appendices.  These can be ordered by providers at 
no cost using the order form in the Appendices. 
 
 
6.2 Specimen Collection Resources 
 
Review the section of the website, www.AZNewborn.com, Bloodspot Screening – 
Specimen Collection Helps for color copies of posters describing proper 
specimen collection and common collection mistakes.  Black and white versions 
are in the Appendices. 
 
A one page description of common collection mistakes entitled, Specimen 
Rejection Quick Reference is found in the Appendices.  
 
6.21 Bloodspot Collection Training DVD 
 
The Clinical and Laboratory Standards Institute (CLSI) publishes a guideline for 
specimen collection (LA4-A5, Vol. 27 No. 20:  Blood Collection on Filter Paper for 
Newborn Screening Programs; Approved Standard - Fifth Edition).   
 
It is accompanied by a DVD entitled, “Making a Difference Through Newborn 
Screening:  Blood Collection on Filter Paper.”   Copies of this DVD are available 
for loan to submitters for staff training.  Check with your hospital education 
department to see if a copy is available. 
 
The first 2 minutes are an introduction to the history and importance of Newborn 
Screening and the disorders screened.  Note that Arizona does not screen for 
toxoplasmosis. 
 
The instructions on proper specimen collection and handling are about 23 
minutes long.  This is followed by a family’s story of a son born with 
homocystinuria (approximately 5 minutes long). 
 
If you would like to borrow a copy, please contact the Arizona Newborn 
Screening Program: 
 
Wendie Jenkins, Newborn Screening Educator 
jenkinw@azdhs.gov  or (602) 364-1407  
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6.3 Links to Additional Resources 
 
Below are lists of links to websites for other organizations with information about 
newborn screening, specific disorders, support groups and other resources for 
providers and parents. 
 
• Newborn Screening and Genetics 
 
National Newborn Screening & Genetics Resource Center
  
 (NNSGRC): a 
cooperative agreement between the Maternal and Child Health Bureau (MCHB), 
Genetics Services Branch and the University of Texas Health Science Center at 
San Antonio, Department of Pediatrics that provides information and resources in 
the area of newborn screening and genetics. 
http://genes-r-us.uthscsa.edu  
 
American College of Medical Geneticists (ACMG): the professional organization 
for biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic 
counselors and other health care professionals committed to the practice of 
medical genetics.  ACMG provides education, resources and a voice for the 
medical genetics profession: 
http://www.acmg.net  
 
ACT sheets and confirmatory algorithms for professionals: 
http://www.acmg.net/AM/Template.cfm?Section=ACT_Sheets_and_Confir
matory_Algorithms&Template=/CM/HTMLDisplay.cfm&ContentID=5127  
 
Genetics Home Reference: a website offering a guide to understanding genetic 
conditions from the U.S. National Library of Medicine within NIH, HHS: 
http://www.ghr.nlm.nih.gov/search?query=%22newborn+screening%22  
 
March of Dimes: a non-profit organization advocating pregnancy and baby health 
(preventing birth defects, premature birth and infant mortality) and universal 
newborn screening: 
http://www.marchofdimes.com/professionals/24279.asp  
 
National Center on Birth Defects and Developmental Disabilities
 
 (CDC) – Infant 
topics discuss newborn screening and EHDI, sickle cell disease and thalassemia. 
http://www.cdc.gov/ncbddd/index.html  
 
Gene Tests: a publicly funded medical genetics information resource hosted at 
NCBI: 
http://www.genetests.org  
 
Human Genetics and Medical Research – an on-line exhibit for families from the 
Museum of Medical Research: 
http://history.nih.gov/exhibits/genetics  
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HealthFinder.gov:  a quick guide to healthy living provided by the US Dept. of 
Health & Human Services with information for parents about newborn screening: 
http://www.healthfinder.gov/prevention/ViewTopic.aspx?topicID=57  
(includes a toll-free number to call to get services if you don’t have 
insurance) 
 
• Disorder Information 
 
Screening, Technology, and Research in Genetics (Star-G):  a multi-state project 
to improve information about the financial, ethical, legal, and social issues 
surrounding expanded newborn screening and genetic testing.  Fact sheets for 
parents about screened disorders are available on their website: 
http://www.newbornscreening.info   
 
Genetic Alliance
  
: a nonprofit health advocacy organization committed to 
transforming health through genetics.  Their network includes more than 1,000 
disease-specific advocacy organizations as well as universities, private 
companies, government agencies and public policy organizations.  Their 
resource repository contains information on newborn screening as well as other 
topics in the area of genetics: 
http://www.geneticalliance.org  
  Resource Repository at http://resourcerepository.org  
 
Genetics Home Reference:  a website offering a guide to understanding genetic 
conditions from the U.S. National Library of Medicine within NIH, HHS.  Newborn 
screening disorder information is available at: 
http://www.ghr.nlm.nih.gov/search?query=%22newborn+screening%22  
 
GeT-EQuIP (Genetic Testing Electronic Quality Information Portal):  from the 
Division of Laboratory Systems of CDC that provides a resource to facilitate 
information searches about genetic diseases detected through newborn 
screening: 
http://wwwn.cdc.gov/dls/genetics/getequip/portal.aspx  
 
MedlinePlus
  
: a service of the US National Library of Medicine and the National 
Institutes of Health that provides health information on a wide range of topics and 
in multiple languages: 
http://www.nlm.nih.gov/medlineplus  
http://medlineplus.gov 
http://www.nlm.nih.gov/medlineplus/newbornscreening.html  
 
Family Village: an on-line resource for parents of children with disabilities or 
chronic health conditions: 
http://www.familyvillage.wisc.edu/library.htm  
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Medical Home Portal: a service of the University of Utah and part of a Medical 
Home implementation project to improve care of children with chronic conditions: 
http://www.medicalhomeportal.org/newborn  
 
PerkinElmer Genetics:  a service of PerkinElmer®, provider of newborn 
screening testing kits, instruments and reagent: 
http://www.perkinelmergenetics.com/DisordersScreened.htm  
 
March of Dimes: a non-profit organization advocating pregnancy and baby health 
(preventing birth defects, premature birth and infant mortality) and universal 
newborn screening: 
http://www.marchofdimes.com/professionals/14332_15455.asp 
 
National Organization for Rare Disorders (NORD): maintains a database of rare 
diseases which can be accessed at: 
http://www.rarediseases.org/search/rdblist.html  
  http://www.rarediseases.org  
 
Online Mendelian Inheritance in Man® (OMIM): a database of the Johns Hopkins 
University housed on the NCBI website that provides information on human 
genes and genetic phenotypes along with links to other genetics resources: 
http://www.ncbi.nlm.nih.gov/omim  
 
 
• Support Groups and Disorder Information by Disorder 
 
Endocrine Disorders 
 
American Thyroid Association: a professional society of physicians and scientists 
who specialize in the research and treatment of thyroid diseases: 
http://www.thyroid.org 
 
The Magic Foundation (Major Aspects of Growth In Children): a non-profit 
organization that provides support services for the families of children with 
disorders that affect a child’s growth (including hypothyroidism and CAH): 
http://www.magicfoundation.org  
 
Cares Foundation:   Congenital Adrenal Hyperplasia Research Education and 
Support - a foundation providing information, advocacy and support for 
individuals with CAH: 
www.caresfoundation.org  
 
CAH Education and Support Network: includes message boards and support 
groups for people with CAH: 
http://www.congenitaladrenalhyperplasia.org   
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National Adrenal Diseases Foundation (NADF): a non-profit organization 
providing support, information and education to individuals with diseases of the 
adrenal glands (including CAH): 
http://www.nadf.us/diseases/cah.htm  
  
 
Hemoglobinopathies 
 
Sickling Disorders 
 
Sickle Cell Information Center: housed in Atlanta, GA, the Center provides sickle 
cell patient and professional education, news, research updates and resources: 
http://www.scinfo.org  
 
Sickle Cell Thalassemia Patients Network: a New York-based support 
organization for people with sickle cell disease, thalassemia and other 
hemoglobin disorders: 
http://sctpn.org  
 
Information Center for Sickle Cell and Thalassemic Disorders:
 
  a website from 
Harvard University that provides current information on sickle cell disease, 
thalassemia and disorders of iron metabolism: 
http://sickle.bwh.harvard.edu/index.html  
 
Sickle Cell Disease Association of America: An advocacy organization promoting 
a search for a cure for sickle cell disease and an improvement in the quality of 
health, life and services for those affected by sickle cell disease and related 
conditions: 
http://www.sicklecelldisease.org  
 
American Sickle Cell Anemia Association: a United Way Agency of Cleveland, 
Ohio that provides services to individuals and families at risk for sickle cell 
disease: 
http://www.ascaa.org  
 
National Coordinating and Evaluation Center for the Sickle Cell and Newborn 
Screening Program:  SCDAA serves as the National Coordinating and Evaluation 
Center (NCEC) for the projects of the Newborn Screening Sickle Cell Disease 
initiative of HRSA/MCHB with goals of increasing knowledge about sickle cell 
disease, strengthening partnerships between HRSA funded community programs 
and partners, including state newborn screening programs and improving the 
quality of follow-up activities of HRSA funded projects: 
http://sicklecelldisease.net  
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Thalassemias 
 
Cooley’s Anemia Foundation: a support organization for people with various 
forms of thalassemia, including Cooley’s anemia or thalassemia major: 
http://www.cooleysanemia.org 
 
 
Metabolic Disorders 
 
Biotinidase Deficiency 
 
Biotinidase Deficiency Family Support Group:
 
  a non-profit, volunteer 
organization that supports those affected by biotinidase deficiency by providing a 
forum to exchange information among affected individuals and with medical 
professionals: 
http://www.biotinidasedeficiency.20m.com 
 
Galactosemia 
 
Parents of Galactosemic Children, Inc. (PGC): a national, non-profit, volunteer 
organization providing information, support and networking opportunities to 
families affected by galactosemia: 
http://www.galactosemia.org 
 
PKU 
 
National PKU Alliance: provides research, support, education and advocacy 
while seeking a cure for PKU: 
http://www.npkua.org  
 
Children’s PKU Network
 
: a non-profit organization promoting public awareness, 
education and direct assistance to help people with PKU and other metabolic 
disorders reach their full potential: 
http://www.pkunetwork.org  
 
National PKU News: a non-profit organization providing up-to-date, accurate 
news and information to families and professionals dealing with phenylketonuria: 
http://www.pkunews.org  
 
PKU Online Community: an online resource learn about PKU, managing diet, 
medication and other resources as well as a forum to share in chats, blogs and 
other programs: 
http://www.pku.com 
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PKU Toolkit: a guide for teens or young adults with PKU: 
http://www.newenglandconsortium.org/toolkit 
 
  MSUD 
 
The MSUD Family Support Group:  provides support and personal contact for 
those with MSUD, distributes information and raises public awareness of MSUD, 
supports newborn screening and research for MSUD: 
http://www.msud-support.org  
 
Fatty Acid Oxidation Disorders 
 
FOD Family Support Group: provides emotional support, information about living 
with these disorders and medical updates on new developments in screening, 
diagnosis, research and treatment: 
http://www.fodsupport.org  
 
United Mitochondrial Disease Foundation:  promotes and funds research and 
education for the diagnosis, treatment and cure of mitochondrial disorders and 
provides support to affected individuals and families: 
http://www.umdf.org  
 
Organic Acid Disorders 
 
Organic Acidemia Association (OAA): a source for organic acidemia metabolic 
disorder support and information: 
http://www.oaanews.org  
 
International Organization of Glutaric Aciduria
 
 (IOGA):  an international non-profit 
organization engaged in patient advocacy and support for individuals with GA-1: 
http://helpioga.org 
 
Propionic Acidemia Foundation
 
: a non-profit organization funding research and 
providing information and support for families and medical professionals dealing 
with propionic acidemia: 
http://www.pafoundation.com  
 
Isovaleric Acidemia Research: a division of the Organic Acidemia Association 
that provides research and information for Isovaleric Acidemia families: 
http://www.ivasupport.org  
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Urea Cycle Disorders 
 
National Urea Cycle Disorders Foundation: a non-profit organization providing 
information and support for families of children with UCDs (including citrullinemia 
and argininosuccinic acidemia): 
http://www.nucdf.org  
 
 
Cystic Fibrosis 
 
Cystic Fibrosis Foundation: the leading organization in the US devoted to cystic 
fibrosis. It is a nonprofit donor-supported organization that funds and accredits 
CF care centers, advocates for CF research and provides families with 
information and resources: 
http://www.cff.org  
Living with Cystic Fibrosis: http://www.cff.org/LivingWithCF   
 
Internet community for CF patients and families: http://www.cysticfibrosis.com  
 
 
Hearing Loss 
 
National Center for Hearing Assessment and Management (NCHAM), Utah State 
University: the national resource center for the implementation and improvement 
of EHDI systems and the developer of the Hi*Track data management system: 
http://www.infanthearing.org  
 
Hear and Now: from NCHAM, a resource for parents: 
http://www.hearandnow.org 
 
Hands & Voic
  
es: a support organization for families of children who are deaf or 
hard of hearing: 
http://www.handsandvoices.org 
  http://www.handsandvoices.org/chapters/az.htm  
 
Guide-By-Your-Side
 
 (GBYS) – a Hands & Voices program that provides 
emotional support and specialized knowledge from trained parents of children 
who are deaf or hard of hearing: 
http://www.handsandvoices.org/services/guide.htm  
 
Joint Commission on Infant Hearing (JCIH): composed of representatives from 
the American Academy of Pediatrics, the American Academy of Otolaryngology 
and Head and Neck Surgery, the American Speech Language Hearing 
Association, the American Academy of Audiology, the Council on Education of 
the Deaf, and Directors of Speech and Hearing Programs in state health and 
Arizona Newborn Screening Program Guidelines – January, 2011 Page 80 
 
welfare agencies. The committee’s primary activity is publication of position 
statements on EHDI: 
http://www.jcih.org  
 
My Baby’s Hearing:  a website from the Boys Town National Research Hospital 
supported by the National Institute for Deafness and Communication Disorders 
(NIDCD): 
http://www.babyhearing.org  
 
National Institute on Deafness and Other Communication Disorders: is one of the 
Institutes that comprise the National Institutes of Health (NIH) and supports 
biomedical and behavioral research in the processes of hearing, balance, smell, 
taste, voice, speech and language: 
http://www.nidcd.nih.gov/index.asp  
 
American Society for Deaf Children
  
, a parent-helping-parent network that 
supports and educates families of deaf and hard of hearing children and 
advocates for high quality programs and services. 
http://www.deafchildren.org     
 
American Speech-Language-Hearing Association
  
 – the professional, scientific, 
and credentialing association for members and affiliates who are speech-
language pathologists, audiologists, and speech, language, and hearing 
scientists. 
http://www.asha.org 
 
National Center on Birth Defects and Developmental Disabilities, one of the 
Centers for Disease Control and Prevention
  
 (CDC) -  provides information about 
hearing loss in children. 
http://www.cdc.gov.ncbddd/hearingloss/index/html 
 
 
• Advocates for Newborn Screening 
 
Save Babies Through Screening Foundation, Inc. (SBTS): a national non-profit 
organization devoted exclusively to the advocacy of newborn screening: 
http://www.savebabies.org 
 
March of Dimes (MOD): a non-profit organization advocating pregnancy and 
baby health (preventing birth defects, premature birth and infant mortality) and 
universal newborn screening: 
http://www.marchofdimes.com  
 
American Academy of Pediatrics
  
 (AAP): the professional organization for 
pediatricians and pediatric medical subspecialists: 
http://www.aap.org  
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  AAP Newborn Screening Information and Fact Sheets: 
  http://www.aap.org/healthtopics/newbornscreening.cfm  
  Arizona Chapter: http://www.azaap.org/general/index.htm  
  AAP website for parents: http://www.HealthyChildren.org 
 
  
• Arizona Resources 
 
Arizona Health Care Cost Containment System (AHCCCS): Arizona’s Medicaid 
agency that provides health care to Arizonans that meet income and other 
eligibility requirements: 
http://www.azahcccs.gov  
 
Children’s Rehabilitative Services (CRS) is a program administered by AHCCCS 
through a contract with Arizona Physicians IPA.  CRS provides medical 
treatment, rehabilitation and related support services for children under age 21 
with qualifying chronic and disabling conditions. 
 
http://www.myapipa.com/en/members/refer_child.jsp?xlang=en&xrole=me
mbers&xstate=az&xplan=uhcaz&xproduct=CRS 
 
Arizona Early Intervention Program (AzEIP): a statewide system of support and 
services for families of children, birth to 3, with disabilities or developmental 
delays: 
https://egov.azdes.gov/CMSInternet/main.aspx?menu=98&id=3026  
  
Quest to Cure:  a parent support and advocacy group based in Phoenix, AZ for 
children with sickle cell disease: 
http://www.questtocure.org  
 
Cystic Fibrosis Foundation – Arizona Chapter
 
: 
http://www.cff.org/Chapters/arizona 
 
http://www.phoenixchildrens.com/emily-center/child-health-
topics/cysticfibrosis.html 
 
Phoenix Children’s Hospital, Pulmonology: an accredited CF care center: 
http://www.phoenixchildrens.com/medical-specialties/pulmonology.html 
 
Arizona Commission for the Deaf and Hard of Hearing:  a statewide information 
referral center for issues related to people with hearing loss: 
http://www.acdhh.org  
 
The EAR Foundation of Arizona: a non-profit association that provides 
information and resources to people who are hearing impaired: 
http://www.earfoundationaz.com  
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HEAR for Kids™: a program of the EAR Foundation of Arizona for children 0-18 
years of age that provides loaner hearing aids and permanent hearing aids if the 
family doesn’t have insurance and meets financial criteria: 
http://www.earfoundationaz.com/page_010_005.html  
 
Application for loaner hearing aids, vouchers and permanent hearing aids: 
http://aznewborn.com/pdf/hc_prov_loan_hear_aids.pdf  
 
Hands & Voices (Arizona): http://www.azhv.org   
 
Raising Special Kids (Arizona): a non-profit organization of families helping 
families of children with disabilities and special health needs (602-242-4366 or 
800-237-3007): 
http://www.raisingspecialkids.org  
 
Pilot Parents of Southern Arizona:  a parent training and information center for 
families of children with disabilities in Cochise, Gila, Graham, Greenlee, La Paz, 
Pima, Pinal, Santa Cruz and Yuma counties: 
http://www.pilotparents.org  
 
The Emily Center at Phoenix Children’s Hospital: the largest pediatric consumer 
health library in the Southwest located at Phoenix Children’s Hospital, 1919 E 
Thomas Rd, Phoenix, AZ  
(602) 546-1400  
http://www.phoenixchildrens.com/emily-center  
  
American Academy of Pediatrics, Arizona Chapter:
 http://www.azaap.org/general/index.htm 
 
 
 Note: 
These links to other websites are provided solely as a convenience to users and 
not as a guarantee, warranty, or recommendation by the Arizona Department of 
Health Services (ADHS) of the content on these websites or as an indication of 
any affiliation, sponsorship or endorsement of such third-party websites.  
 
ADHS is not responsible for the content of linked sites and does not make any 
representations regarding their privacy practices or the content or accuracy of 
materials on these websites.  
 
If you decide to access linked websites, you do so at your own risk. Your use of 
these websites is subject to the terms of use for each site.  
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6.4 Glossary 
 
# 
 
1-3-6 
EHDI guidelines: hearing screening before one month of age, evaluation 
before 3 months of age and intervention before 6 months of age 
 
 
A 
 
AABR  
  automated ABR hearing test 
 
AAC 
  Arizona Administrative Code  
 
abnormal 
a test value outside the reference range, a positive result 
 
ABR 
auditory brainstem response hearing test 
 
ACMG  
  American College of Medical Genetics  
 
ACT sheets 
Actions sheets developed by ACMG for use by physicians as a quick 
reference to NBS results and needed actions for possible disorders   
http://www.acmg.net/resources/policies/ACT/condition-analyte-links.htm  
 
acylcarnitine 
a fatty acyl ester of carnitine, the transport form for a fatty acid crossing 
the mitochondrial membrane. Acylcarnitines are named by the number of 
carbons in the acyl group (the side chain attached to carnitine): 
 C0:  no acyl group, free carnitine 
 C3:  3 carbon acyl group attached to carnitine - propionylcarnitine 
 C5OH: 5 carbon acyl group with hydroxyl on the 3rd
 
 carbon – 3-
hydroxyisovalerylcarnitine 
ADHS  
  Arizona Department of Health Services 
 
AHCCCS 
  Arizona Health Care Cost Containment System 
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American College of Medical Genetics (ACMG) 
the professional organization for biochemical, clinical, cytogenetic, medical 
and molecular geneticists, genetic counselors and other health care 
professionals committed to the practice of medical genetics.  ACMG 
provides education, resources and a voice for the medical genetics 
profession.  http://www.acmg.net  
 
ACMG 29 
29 original target disorders for newborn screening proposed by ACMG in 
the report entitled, Newborn Screening: Toward a Uniform Screening 
Panel and System (2006) and recommended by SACHDNC as the original 
core disorders of the Uniform Screening Panel 
http://www.acmg.net/AM/Template.cfm?Section=Practice_Guidelines&Te
mplate=/CM/HTMLDisplay.cfm&ContentID=3671  
 
analyte 
the chemical compound being tested for (e.g. the analyte for CAH testing 
is 17-OHP)  
  
Arizona Administrative Code (AAC) 
where the official rules of the state of Arizona that govern state agencies, 
boards and commissions are published.  See Rules.  
 
Arizona Department of Health Services (ADHS) 
the agency housing the State Laboratory and the Arizona Newborn 
Screening Program 
  http://www.azdhs.gov  
 
Arizona Health Care Cost Containment System (AHCCCS) 
Arizona’s Medicaid agency that provides health care to Arizonans that 
meet income and other eligibility requirements 
http://www.azahcccs.gov  
 
Arizona Revised Statutes (ARS) 
The statute establishing the Arizona Newborn Screening Program is found 
in ARS 36-694 (Report of blood tests; newborn screening program; 
committee; fees; definitions)   
http://www.azleg.gov/ars/36/00694.doc  
 
Arizona State Public Health Laboratory (State Lab) 
in the Bureau of State Laboratory Services, Division of Public Health 
Services, ADHS – the designated laboratory for newborn screening in 
Arizona 
  http://www.azdhs.gov/lab 
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ARS   
Arizona Revised Statutes 
 
ASA 
argininosuccinic acidemia/argininosuccinic aciduria, a core disorder of the 
Recommended Uniform Screening panel 
 
ASDB  
Arizona State Schools for the Deaf and the Blind 
 
ASL 
  American Sign Language 
 
assay  
  a test or analysis 
 
atresia  
congenital absence or closure of a normal body opening or tubular 
structure 
 
audiology 
the branch of science that studies hearing, balance, and related disorders.  
Audiologists test hearing and make recommendations about treatment 
options (hearing aids, cochlear implants, surgery) and appropriate medical 
referrals 
 
AutoDelfia® 
An automatic immunoassay system from PerkinElmer – the method used 
for TSH, 17-OHP and IRT testing by the State Lab 
 
auditory brain stem response (ABR) 
a method used for hearing screening which measures the brain’s 
response to sound.  A device near the ear makes clicking sounds while 
earpieces in the ear canals conduct the sound.  Electrode pads placed on 
the forehead and behind the ear track the sound moving through the ear 
to the brain.  Results are averaged and compared with normal hearing. 
This method may also be used in a more extensive, modified form as a 
diagnostic test. 
 
autosomal recessive inheritance 
inheritance pattern carried on a pair of the non-sex determining 
chromosomes (the 22 pairs of autosomes) where matching genes for a 
condition must be inherited from both parents 
All of the disorders on the newborn screening panel except congenital 
hypothyroidism and hearing loss are inherited in an autosomal recessive 
inheritance pattern. 
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AzEIP 
Arizona Early Intervention Program (acronym pronounced Ay-zip) 
 
 
B 
 
BAER  
brainstem auditory evoked response hearing test 
 
Barts 
an abnormal, usually transitory, type of hemoglobin that is not effective in 
oxygen transport.  It contains 4 gamma globin chains.  It is often present in 
small amounts in newborns but larger amounts indicate alpha thalassemia 
trait, Hemoglobin H disease or alpha thalassemia. 
 
BCAA  
 branched chain amino acids (leucine, isoleucine, valine) 
 
 
BIO 
biotinidase deficiency, a core disorder of the Recommended Uniform 
Screening panel 
 
Bio-Rad 
Bio-Rad Laboratories, supplier of the kit for the galactose-1-phosphate 
uridyl transferase assay to screen for galactosemia. 
http://www.bio-rad.com  
 
BKT 
beta-ketothiolase deficiency, a core disorder of the Recommended 
Uniform Screening panel 
 
borderline 
for some tests, an equivocal or borderline range is reported.  It is outside 
the reference range but is not frankly abnormal.  The program follows 
these results but not as immediately or aggressively (e.g. borderline TSH 
or 17-OHP results) 
 
branched chain amino acids 
leucine, isoleucine and valine 
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C 
 
CAH 
congenital adrenal hyperplasia, a core disorder of the Recommended 
Uniform Screening panel 
 
carrier 
a heterozygote for a recessively inherited disorder where two copies of the 
disease-causing gene must be present in order for the disease to be 
expressed.  Carriers or those with traits usually have no symptoms of 
disease or milder symptoms under stressful conditions. 
 
CBAVD 
congenital bilateral absence of the vas deferens, a common form of 
sterility in males with CF or CFTR mutations 
  
Cbl A, B 
methylmalonic acidemia (cobalamin defects), a core disorder of the 
Recommended Uniform Screening panel 
 
CDC  
Centers for Disease Control and Prevention – an agency of HHS 
 
Centers for Disease Control and Prevention (CDC)  
the agency of HHS providing community health protection through health 
promotion, prevention of disease, injury and disability and preparedness 
for new health threats.  
  http://www.cdc.gov  
  http://www.cdc.gov/newbornscreening  
 
CF 
cystic fibrosis, one of the 30 core disorders of the Recommended Uniform 
Screening panel 
  
CFR  
Code of Federal Regulations 
 
CFTR gene 
  cystic fibrosis transmembrane conductance regulator gene 
 
CH 
congenital hypothyroidism, a core disorder of the Recommended Uniform 
Screening panel  
 
 
 
 Arizona Newborn Screening Program Guidelines – January, 2011  Page 88 
 
 
CIT-1  
citrullinemia, type I, a core disorder of the Recommended Uniform 
Screening panel 
 
CLIA  
  Clinical Laboratory Improvement Act of 1965 (Amendments 1988) 
 
Clinical and Laboratory Standards Institute (CLSI) 
the developer and publisher of LA4-A5, Blood Collection on Filter Paper 
for Newborn Screening Programs; Approved Standard – Fifth Edition 
(July, 2007), I/LA27-A, Newborn Screening Follow-up; Approved Guideline 
(May, 2006) and I/LA31-A, Newborn Screening for Preterm, Low Birth 
Weight, and Sick Newborns: Approved Guideline (October, 2009) 
www.clsi.org  
 
clinical diagnosis 
diagnosis based on signs, symptoms and laboratory findings 
 
Clinical Laboratory Improvement Act of 1965 (CLIA) with amendments in 1988 
In order to ensure quality laboratory testing, the Centers for Medicare & 
Medicaid Services (CMS) in HHS regulates all laboratory testing (except 
research) performed on humans in the U.S. through the Clinical 
Laboratory Improvement Amendments (CLIA). In total, CLIA covers 
approximately 200,000 laboratory entities including the Arizona State 
Laboratory. http://www.cms.hhs.gov/CLIA/01_Overview.asp#TopOfPage  
 
CLSI  
  Clinical and Laboratory Standards Institute 
 
CMV  
  cytomegalovirus 
 
collection device 
another name for collection kit, filter paper kit, dried bloodspot card or 
newborn screening card (sometimes called the Guthrie card in honor of its 
developer) 
 
collection kit 
the numbered card with special filter paper attached for collection of drops 
of blood that are then dried before shipping and testing.  It has areas for 
demographic information, accession number, date stamp, bar code, etc.  
Each state designs their own card but all contain the same standardized 
filter paper  
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confirmatory/diagnostic test 
a test to show whether a condition suspected because of screening test 
results is present or not (for screening using dried blood spots, this testing 
is from a specimen other than the screening specimen). 
 
congenital 
present from birth, but not necessarily genetic  
  
congenital bilateral absence of the vas deferens (CBAVD) 
 a common form of sterility in males with CF or CFTR mutations 
 
Cooley’s anemia 
thalassemia major, ß° thalassemia 
 
CRS  
  Children’s Rehabilitative Services 
 
CUD  
carnitine uptake defect, a core disorder of the Recommended Uniform 
Screening panel 
 
cutoff 
the first value outside the reference range (the point where a result is 
reported as abnormal or positive for the disease tested for) 
 
Cystic fibrosis transmembrane conductance regulator gene (CFTR gene) 
Mutations to this gene can cause cystic fibrosis (over 1000 mutations to 
this gene have been identified).  The Arizona NBS program uses a DNA 
kit from Third Wave Technologies to detect 46 mutations to this gene. 
 
 
D 
 
DBS 
  dried blood spot 
 
DHHS 
  United States Department of Health and Human Services 
 
diagnosis 
identification of a disease by history, lab tests and symptoms 
 
dietary monitoring specimen 
To monitor phenylalanine levels so that diets can be adjusted for 
individuals with PKU, regardless of their ages, the State Lab receives 
specimens and reports phenylalanine levels only, at no charge 
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DOB 
  date of birth 
 
DOC 
  date of collection (of NBS sample) 
 
DOR 
  date of receipt of NBS sample by the State Lab 
 
DPOAE 
distortion product otoacoustic emissions 
 
dried blood spot 
blood collected usually from a heel stick and air dried on an approved filter 
paper card 
 
Duarte variant of galactosemia 
a usually benign form of galactosemia (D/G variant) where an individual 
inherits one gene for galactosemia (no enzyme activity) and one Duarte 
gene with reduced enzyme activity 
 
 
E 
 
ECMO  
extracorporeal membrane oxygenator – similar to a heart/lung bypass 
machine 
  
EHDI  
Early Hearing Detection and Intervention (acronym pronounced “eddy”).  
The Arizona EHDI program coordinates newborn hearing screening and 
intervention in the state. 
 
EI  
  early intervention 
 
ELBW  
  extremely low birth weight 
 
endocrine 
relating to or affecting those glands that secrete their products (hormones) 
directly into the bloodstream 
 
enteral 
within or by way of the intestine 
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enzyme 
a protein produced by living organisms that catalyzes (increases the rate 
of) a specific chemical reaction but is not consumed in the reaction or 
altered upon completion of the reaction  
 
Enzymes are inactivated by heat and/or humidity and both enzyme assays 
(for biotinidase and GALT activity) in the newborn screening panel can 
have false positive results particularly in the summer if samples have been 
exposed to heat, strong sunlight and/or humidity. 
 
extracorporeal membrane oxygenator (ECMO) 
similar to a heart/lung bypass machine, ECMO can be considered to be a 
continuous transfusion of red blood cells and other blood components and 
any NBS samples taken during ECMO are invalid.   
 
extremely low birth weight (ELBW) 
  birth weight less than 1000 g 
 
 
F 
 
false negative 
a negative (normal) result in an affected individual (one who has the 
disease) 
 
false positive 
a positive (abnormal) result in an individual without the disease 
 
fatty acid 
an organic saturated or unsaturated carboxylic acid containing a single 
carboxyl group and usually an even number of carbon atoms that can be 
combined with glycerol to form fats (glycerol plus 3 fatty acids make a 
triglyceride). 
 
fatty acid oxidation 
stepwise catabolism of fatty acids in which two-carbon fragments are 
successively removed from the carboxyl end of the chain 
 
fatty acid oxidation disorders (FODs) 
a group of genetic metabolic disorders in which the body is unable to 
oxidize (breakdown) fatty acids to make energy because an enzyme is 
either missing or not working correctly. When the supply of glucose, the 
main source of energy for the body, runs out, fat is broken down to supply 
energy but this can’t happen in individuals with one of these disorders.   
Support group:  FOD Family Support Group http://www.fodsupport.org   
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FFP 
fresh frozen plasma 
 
filter paper 
special standardized filter paper has been designed to collect blood spots 
for newborn screening in the circle so that punches from the circle will 
each contain the same amount of blood. 
 
filter paper kit 
another name for a specimen collection kit 
 
first screen 
the initial specimen collected from a newborn who is less than five days of 
age 
 
follow-up 
actions taken to ensure that a newborn whose screening test results are 
positive or unsatisfactory receives appropriate, prompt further testing and 
evaluation; and actions taken to ensure that the newborn screening 
system can evaluate the effectiveness of screening. 
 
fresh frozen plasma 
Transfusion of this blood product can produce false negative newborn 
screening results for biotinidase testing.  The effect is transitory and a 
valid repeat screen can be collected a few days to a week after 
transfusion. 
 
 
G 
 
GA-1 
glutaric acidemia type 1, a core disorder of the Recommended Uniform 
Screening panel 
 
galactose 
a simple sugar (an isomer of glucose) which in combination with glucose 
forms lactose 
http://www.galactosemia.org   
 
GALT  
galactosemia, a core disorder of the Recommended Uniform Screening 
panel 
 
Gal-1-PUT  
galactose-1-phosphate uridyltransferase: the enzyme whose absence or 
reduced activity causes galactosemia 
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GBYS 
Guide By Your Side Program, Hands and Voices 
 
genotype 
the genetic material of an individual, the pair of genes present for a 
particular characteristic or protein 
 
gestation 
the length of time from conception to birth. The average gestation in 
humans, calculated from the first day of the last normal menstrual period 
is 280 days (40 weeks), with a normal range of 259 days (37 weeks) to 
287 days (41 weeks).  Infants born prior to the 37th week are considered 
premature and those born after the 41st
 
 week, postmature. 
gestational age 
the length of the pregnancy at birth measured from the first day of the last 
menstrual period, in weeks.  
 
globin   
the protein portion of hemoglobin (consisting of 2 alpha chains and 2 beta 
chains in hemoglobin A) 
 
glucose 
a simple sugar; also called D-glucose or dextrose, released by digestion of 
starch and other sugars, absorbed by the small intestine and circulated to 
the liver where excess is converted to glycogen.  Within most cells, 
glucose is the primary energy source and is oxidized to carbon dioxide 
and water to produce energy.  
 
Guide-By-Your-Side Program 
a program of Hands and Voices to provide the support of experienced 
families of children who are deaf, to families at the time of their child’s 
identification of hearing loss and beyond. 
 
Guthrie, Robert 
  U.S. microbiologist (1916-1995), the “father of newborn screening” 
 
Guthrie test 
another name for a newborn screening test or a dried bloodspot test 
where blood is collected on filter paper.  This type of test was first 
developed for newborn screening by Dr. Robert Guthrie. 
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H 
 
Hb S/ß thal 
S, beta-thalassemia, a core disorder of the Recommended Uniform 
Screening panel 
 
Hb S/C 
S, C disease, a core disorder of the Recommended Uniform Screening 
panel 
 
Hb SS 
sickle cell disease or sickle cell anemia, a core disorder of the 
Recommended Uniform Screening panel 
 
HCY 
homocystinuria, a core disorder of the Recommended Uniform Screening 
panel 
 
health care provider 
a physician, physician assistant, registered nurse practitioner or midwife. 
 
Health Insurance Portability and Accountability Act of 1996 (HIPAA) 
a federal law creating national standards for recording and disclosing or 
keeping private protected health information (PHI).   
 
45 CFR 164.512 contains the exception where covered entities are not 
required to obtain written authorization for the disclosure of PHI for public 
health purposes: when the uses and disclosures are required by law or 
where they are disclosed to a public health authority “for the purpose of 
preventing or controlling disease...” 
 
HEAR  
hearing loss, a core disorder of the Recommended Uniform Screening 
panel 
 
heelstick 
a method for obtaining a blood sample from a newborn where the heel is 
punctured in the lateral or medial area of the plantar surface of the heel 
(avoiding the posterior curvature of the heel) to a depth of no more than 
2.4 mm. 
 
heme 
an iron compound that is the portion of hemoglobin that carries oxygen.  
There is one heme associated with each of the four globin chains of a 
hemoglobin molecule. 
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hemoglobin 
an iron-containing pigment of red blood cells that functions primarily in the 
transport of oxygen from the lungs to the tissues of the body, that consists 
of four polypeptide (globin) chains of which two are of the type designated 
alpha and two are of one of the types designated beta, gamma, or delta 
and each of which is linked to a heme molecule, that combines loosely 
and reversibly with oxygen in the lungs and with carbon dioxide in the 
tissues  
 
hemoglobin A (Hb A) 
the hemoglobin in the red blood cells of the normal human adult that 
contains two alpha and two beta globin chains, each with a heme attached 
 
hemoglobin A2 (Hb A2) 
a variant hemoglobin found in small quantities (1-2%) in normal human 
adults (two alpha and two delta globin chains)  
 
hemoglobin C (Hb C) 
an abnormal hemoglobin that differs from hemoglobin A in having a lysine 
residue substituted for the glutamic acid residue at position 6 of each of 
the two β globin chains in a hemoglobin molecule 
 
hemoglobin electrophoresis 
a test that measures the different types of hemoglobin in the blood by their 
movement as charged particles suspended in a liquid on gel under the 
influence of an applied electric field. 
 
hemoglobin F (Hb F) 
fetal hemoglobin (containing 2 alpha and 2 gamma globin chains) is the 
predominant hemoglobin found in the fetus and makes up more than half 
of a newborn’s total hemoglobin at birth. The amount of Hb F decreases 
after birth and a small amount of fetal hemoglobin (< 2%) can be present 
in adult hemoglobin. 
 
hemoglobin H (Hb H) 
an abnormal, fast migrating hemoglobin occurring in the red blood cells 
when alpha globin chains are present in reduced amounts and excess 
beta chains come together in tetramers (4 beta chains)   
 
hemoglobinopathy 
an inherited disorder of hemoglobin structure with characteristic clinical 
and laboratory abnormalities and often overt anemia. 
 
hemoglobin S (Hb S) 
an abnormal hemoglobin occurring in the red blood cells in sickle-cell 
anemia and sickle-cell trait and differing from hemoglobin A in having a 
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valine residue substituted for the glutamic acid residue in position 6 of the 
two ß globin chains in the hemoglobin molecule. 
 
hemolysis 
breakdown or destruction of red blood cells with liberation of hemoglobin 
 
HFK  
  Hear For Kids, a program of the EAR Foundation of Arizona 
 
HHS  
  U.S. Department of Health and Human Services 
 
high performance liquid chromatography (HPLC) 
the method by which hemoglobin results are confirmed at the State Lab 
a form of column chromatography used to separate, identify and quantify 
compounds based on their polarities and interactions with the column’s 
stationary phase (the particles packed in the column).  HPLC uses 
different types of stationary phase, a pump to move the mobile phase 
(sample dissolved in a liquid) through the column and a detector that 
records a retention time for the analyte. 
 
HIPAA  
  Health Insurance Portability and Accountability Act of 1996 
 
HI*TRACK 
the data management system from NCHAM used by hospitals, 
audiologists and the Newborn Screening Program to record and report 
hearing screening, diagnosis and early intervention information 
  http://www.hitrack.org   
 
HMG 
3-hydroxy-3-methylglutaric aciduria, a core disorder of the recommended 
Uniform Screening panel 
 
HOPS  
hearing outpatient screening - forms used for reporting outpatient hearing 
screening 
 
HPLC  
  high performance liquid chromatography 
 
hydrolysis 
any reaction in which water is one of the reactants; a chemical 
decomposition in which a substance is split into simpler compounds by the 
addition of or the taking up of the elements of water 
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17-α-hydroxyprogesterone 
an adrenal hormone that builds up in the absence of 21-hydroxylase and 
is used as the analyte for CAH testing 
 
hyperplasia 
abnormal increase in the number of normal cells in normal arrangement in 
an organ or tissue which increases its size or volume 
 
hypo-  (prefix) 
deficient, low in quantity 
 
hypochromic 
in red blood cells, a decrease in the quantity of hemoglobin present so that 
they are abnormally pale 
 
hypoplasia 
underdevelopment of a tissue, organ or body 
 
 
I 
 
idiopathic 
pertaining to conditions without clear pathogenesis, or disease without 
recognizable cause, as of spontaneous origin 
 
IEF 
  isoelectric focusing 
  
IEM  
  inborn errors of metabolism – another name for metabolic disorders 
 
incidence 
the rate at which an event occurs per unit time per person in the members 
of a defined population at risk; the rate of occurrence of new cases of a 
particular disease in a population being studied 
 
inconclusive 
a test result that cannot be determined to be either normal or abnormal 
because of some confounding factor.  A red blood cell transfusion prior to 
collecting a newborn screening sample would give an inconclusive result 
for hemoglobin since the sample contains cells that belong to the donor 
and not exclusively to the baby tested. 
 
Individuals with Disabilities Education Act (IDEA)  
a law enacted in 1975 ensuring services to children with disabilities. IDEA 
governs how states and public agencies provide early intervention, special 
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education and related services to more than 6.5 million eligible infants, 
toddlers, children and youth with disabilities.  Infants and toddlers with 
disabilities (birth-2) and their families receive early intervention services 
under IDEA Part C. Children and youth (ages 3-21) receive special 
education and related services under IDEA Part B. 
 
infant 
a baby from birth until a year of age (NBS rules identify an infant as one 
from 29 days of age until a year of age – for the first four weeks an infant 
is defined as a newborn). 
 
isoelectric focusing (IEF) 
the method used by the State Lab to identify variant hemoglobins.  Results 
are then confirmed by HPLC.  It is a technique for separating different 
proteins by their electrical charge differences (due to their relative content 
of acidic and basic side chains). 
 
Samples are distributed over a gel medium that has a pH gradient.  An 
electric current is passed through the medium, creating a positive and 
negative end.  Charged hemoglobin molecules migrate toward the 
oppositely charged end through the changing pH gradient until they reach 
a pH point that corresponds to their isoelectric points (pI) - the point where 
they no longer have a net charge.  No further migration takes place and 
the proteins become focused into bands at this point. 
 
IVA  
isovaleric acidemia, a core disorder of the recommended Uniform 
Screening panel 
 
 
J 
 
julian date 
consecutive numbering of the days of the year beginning with 001 for 
January 1st and ending with 365 for December 31st
 
 (in non-leap years) 
 
K 
 
ketone 
an organic compound with a carbonyl group (C=O) attached to two carbon 
atoms.  Acetone (C3H6
 
O) is a simple ketone.  Ketones are formed from 
incomplete metabolism of fatty acids, usually from carbohydrate 
deficiency. 
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kit number 
the unique number printed on the collection kits (under the bar code, in 
red on the upper right hand side of the demography entry sheets and 
above the circles on the filter paper).  This number follows the designation 
AZ and is sometimes known as the AZ number. 
 
 
L 
 
lab number 
unique identification number assigned by the State Lab to newborn 
screening bloodspot specimens (see accession number) 
 
lactose 
a disaccharide that on hydrolysis yields glucose and galactose 
  
lactose formula 
a milk-based formula with lactose as its carbohydrate source 
 
LBW  
  low birth weight  
 
LCHAD 
long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency, a core 
disorder of the recommended Uniform Screening panel 
 
linked kits 
double collection kits that can be taken apart at the middle perforation.  
The top kit is marked 1 and the bottom kit is marked 2.  These kits are 
intended to be used by hospitals to collect a first specimen with the 
number 1 kit.  The number 2 kit is to be placed in a bright pink envelope 
and sent home with the baby with instructions to take it to the first visit to 
the doctor (to be used to collect the second specimen).  The kit numbers 
allow the two parts to be matched in the system. 
 
lost to follow-up (LTF) 
a follow-up case closed when a baby whose family cannot be located for 
follow-up activities (further testing, referral to specialist, etc.) despite 
completion of follow-up activities per protocol. 
 
low birth weight (LBW) 
birth weight of 2500 g (5.5 pounds) or less  
 
LTF  
lost to follow-up 
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M 
 
mailer 
the lab report for each newborn screening test.  A copy is mailed to the 
submitter of the specimen and to the doctor listed who ordered the test. 
 
Maternal and Child Health Bureau (MCHB) 
a bureau of HRSA, HHS that provides the Maternal and Child Health 
Block Grant to state maternal and child health programs under Title V of 
the Social Security Act of 1935 
http://mchb.hrsa.gov  
 
MCAD 
medium chain acyl-CoA dehydrogenase deficiency, a core disorder of the 
recommended Uniform Screening panel 
 
3-MCC 
3-methylcrotonyl-CoA carboxylase deficiency, a core disorder of the 
recommended Uniform Screening panel 
 
MCD 
multiple carboxylase deficiency, a core disorder of the recommended 
Uniform Screening panel 
 
MCH  
  maternal and child health 
 
MCHB 
  Maternal and Child Health Bureau of HRSA, HHS 
  
MCH Block Grant 
funding provided by MCHB to states under Title V of the Social Security 
Act of 1935 and its amendments 
http://mchb.hrsa.gov/programs/blockgrant/overview.htm  
 
MCT oil 
  medium chain triglyceride oil 
  
meconium 
first feces of a newborn infant (greenish black and tarry) 
 
meconium ileus 
a blockage of the intestines with impacted meconium in a newborn – 
usually in infants with cystic fibrosis 
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metabolic disorders 
disorders affecting metabolism – usually inherited defects of enzyme 
production where specific enzymes are inactive and a metabolic pathway 
is blocked and certain substances build up to toxic levels. 
 
metabolic formula 
a formula food designed to meet the needs of individuals with metabolic 
disorders (e.g. for PKU, a formula with most or all of the phenylalanine 
removed) 
 
metabolic pathway 
a sequence of connected, enzyme-catalyzed reactions in cells that either 
builds a complex molecule (anabolic pathway) or breaks down a complex 
molecule into simpler compounds (catabolic pathway). 
 
metabolism 
the sum of the processes in the buildup and destruction of living tissue, 
the chemical changes in living cells by which energy is provided for vital 
processes and activities and new material is assimilated (see anabolism 
and catabolism). 
 
metabolite 
a compound that is a starting material for a metabolic process, an 
intermediate product of metabolism (a product of one metabolic process 
that is essential to another process in the same organism) or a metabolic 
end product that is usually excreted  
 
microcytic 
(related to red blood cells) abnormally small red blood cells present in 
some anemias  
 
microtia 
  unusually small and underdeveloped external ear 
 
MOD  
  March of Dimes 
 
MS/MS 
  tandem mass spectrometry 
 
MSUD 
maple syrup urine disease, a core disorder of the Recommended Uniform 
Screening panel 
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MUT 
methylmalonic acidemia – mutase deficiency, a core disorder of the 
Recommended Uniform Screening panel 
 
mutation 
a permanent transmissible change in the genetic material (DNA) 
 
 
N 
 
National Newborn Screening and Genetics Resource Center (NNSGRC) 
a cooperative agreement between the Maternal and Child Health Bureau 
(MCHB), Genetics Services Branch and the University of Texas Health 
Science Center at San Antonio, Department of Pediatrics that provides 
information and resources in the area of newborn screening and genetics 
  http://genes-r-us.uthscsa.edu  
 
National Newborn Screening Information System (NNSIS) 
housed at NNSGRC where states report their NBS statistics and national 
reports are published 
 
NBHS  
  newborn hearing screening 
 
NBS 
  newborn screening 
 
negative result 
a test value within the reference range, a normal result 
 
neonatal 
of, relating to, or affecting the newborn and especially the human infant 
during the first month after birth 
 
neonatologist 
a medical specialist (pediatrician) trained in the care of neonates that 
require intensive care. 
 
neurotology 
a clinical subspecialty within otolaryngology (ENT) that focuses on the 
neurology and neurosurgery of the ear related to sensorineural hearing 
and balance disorders 
 
newborn 
  a neonate: a term applied to human infants less than a month of age   
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newborn screening (NBS) 
testing done within days of birth to identify infants at increased risk for 
specific disorders so that treatment can begin as soon as possible; when a 
newborn screening result is positive, further diagnostic testing is usually 
required to confirm the results. 
 
Arizona Newborn Screening Program: http://www.aznewborn.com   
State NBS contacts:  http://genes-r-us.uthscsa.edu/state_contacts.pdf    
   
Newborn Screening Advisory Committee 
A committee appointed by the Director of ADHS to provide 
recommendations and advice to the department regarding tests that the 
committee believes should be included in the Newborn Screening 
Program.  It meets annually and includes the following members:  seven 
physicians who represent the medical specialties of endocrinology, 
pediatrics, neonatology, family practice, otology and obstetrics; a neonatal 
nurse practitioner; an audiologist, a representative of an agency that 
provides services under Part C of the individuals with disabilities education 
act; at least one parent of a child with a hearing loss or a congenital 
disorder; a representative from the insurance industry; the director of 
AHCCCS or designee; and a representative of the hospital or health care 
industry. See Rules. 
 
NICU 
  neonatal intensive care unit 
 
NIH 
  National Institutes of Health – the medical research agency of HHS 
 
NNSGRC 
  National Newborn Screening and Genetics Resource Center  
 
NNSIS 
  National Newborn Screening Information System 
 
 
O 
 
OAE 
  otoacoustic emissions 
 
OCSHCN 
Office for Children with Special Health Care Needs (acronym pronounced 
“ocean”) 
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Office for Children with Special Health Care Needs (OCSHCN)  
in the Arizona Department of Health Services 
http://www.azdhs.gov/phs/ocshcn/index.htm  
 
17-OHP 
17-α-hydroxyprogesterone, an adrenal hormone that builds up in the 
absence of 21-hydroxylase and is used as the analyte for CAH testing 
 
organic acid disorders (organic acidemias) 
rare inherited metabolic disorders (OAs) that occur when enzymes 
necessary in the breakdown of certain protein components and other 
substances are missing or not working properly.  This results in the 
excretion of non-amino organic acids in urine. 
Support group:  Organic Acidemia Association  http://www.oaanews.org  
 
otoacoustic emissions testing (OAE) 
a method used for hearing screening which measures a response from the 
cochlea that is generated in response to a sound.  An earpiece with a 
microphone measures the cochlea’s response to sound, listening for 
otoacoustic emissions.  If no otoacoustic emissions are recorded, it could 
mean possible hearing loss.  The OAE does not require the baby to 
respond to sound.  A pass result suggests that the cochlea is working 
normally.  A baby who doesn’t pass may have a temporary hearing loss 
because of fluid or it may indicate a permanent hearing loss. 
 
 
P 
 
packed red blood cells (PRBC) 
Transfusion of red blood cells can cause false negative newborn 
screening results for hemoglobinopathies and galactosemia.  A valid 
repeat screen can be collected 3 – 4 months after the last transfusion. 
 
parent refusal 
Parents are allowed to refuse a newborn screening test for their infant.  
For documentation, the physician obligated to order the test will have the 
parents sign a form acknowledging that they understand the possible 
consequences of not screening their infant.  The collection kit has a box to 
check for parent refusal.  The demographics should be filled out 
completely, the box checked and the kit sent without blood to the State 
Lab. 
 
patient number 
the lab number of the screen (usually a first screen) that a subsequent 
screen is linked to.  When a screen is unlinked its patient number is its lab 
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number. When a screen is linked to another screen, its patient number is 
the lab number of the screen it is linked to.  If the patient number is 
different from the lab number it signifies that this screen is linked to 
another.  If the patient number is the same as its lab number it shows that 
it is not linked to any other screen but other screens may be linked to it. 
 
Perkin Elmer 
Perkin Elmer, Inc. – supplier of the AutoDelphia automatic immunoassay 
systems, Waters Quattro Micro tandem mass spectrometers and assay 
kits for TSH, 17-OHP, hemoglobin, IRT and analytes for MS/MS. 
http://www.perkinelmer.com  
 
PHI 
  protected health information (kept confidential under HIPAA privacy rules) 
 
PKU  
phenylketonuria, a core disorder of the Recommended Uniform Screening 
panel  
 
positive predictive value 
the percentage of true cases of disease identified in a screening test (true 
positives) out of the total number of positive screens- the higher the 
percentage, the better the test results identify those with disease.  For 
example, a test where there were 10 abnormals reported and one true 
positive would have a PPV of 10% (a good test) and a test where there 
were 100 abnormals and one true positive would have a PPV of 1% (not 
as good a test). 
 
positive result 
a test value outside the reference range, an abnormal result 
 
practitioner 
one who has met the professional and legal requirements necessary to 
provide a health care service, such as a physician, nurse, dentist or 
physical therapist. 
 
premature 
born at any time prior to completion of the 37th week of gestation 
 
prevalence 
the frequency of a trait in a population, the percentage of a population that 
is affected with a particular disease at a given time 
 
PROP 
propionic acidemia, a core disorder of the Recommended Uniform 
Screening panel 
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prophylactic, prophylaxis 
measures designed to preserve health and prevent the spread of disease; 
protective or preventive treatment 
 
Propylthiouracil (PTU) 
a medication that suppresses thyroid hormone production and is used in 
the treatment of hyperthyroidism.  It crosses the placenta and if a pregnant 
woman is treated, her baby can have transient hypothyroidism. 
 
PTU  
  propylthiouracil, a medication that suppresses thyroid hormone  
 
 
Q 
 
QNS  
  quantity not sufficient 
 
 
R 
 
RBC  
  red blood cell 
 
recall screen 
a sample submitted after an abnormal repeat screen.  Only 3 circles of 
blood are needed since only the test for the previously abnormal 
analyte(s) is performed (at no charge by the State Lab) 
 
Recommended Uniform Screening Panel 
the list of 30 core disorders and 26 secondary disorders recommended by 
the Secretary’s Advisory Committee on Heritable Disorders in Newborns 
and Children (SACHDNC) for inclusion in every state newborn screening 
program.  In May, 2010, SCID and related T-cell lymphocyte deficiencies 
were added to the core disorders and secondary disorders respectively.  
Arizona screens for the original 29 core disorders and occasionally detects 
a secondary disorder, but does not yet screen for SCID. 
http://www.hrsa.gov/heritabledisorderscommittee/uniformscreeningpanel.h
tm  
 
reference range 
  the range of normal values for a particular analyte or test 
Rules 
Arizona Newborn Screening Rules in the Arizona Administrative Code 
(AAC), Title 9. Health Services, Chapter 13 Dept. of Health Services, 
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Article 1. Hearing Screening, Sections R9-13-101 through R9-13-110 
(effective 2/18/86) and Article 2. Newborn and Infant Screening, Sections 
R9-13-2-1 through R9-13-205 (effective 8/31/05).  
http://www.azsos.gov/PUBLIC_SERVICES/Title_09/9-13.htm  
 
 
S 
 
SACHDNC 
HHS Secretary’s Advisory Committee on Heritable Disorders in Newborns 
and Children (in the Maternal and Child Health Bureau of HRSA, HHS).      
 
salt-wasting, salt-losing CAH 
see congenital adrenal hyperplasia 
 
sample 
another name for specimen 
 
 SCID 
severe combined immunodeficiency disorder, a core disorder of the 
Recommended Uniform Screening panel (added to the panel in May, 
2010).  Arizona does not yet screen for SCID. 
 
screening test 
testing designed to identify individuals in a given population who are at 
higher risk of having or developing a particular disorder, or carrying a gene 
for a particular disorder 
 
second screen 
a specimen collected from a newborn after a first specimen has been 
collected or from an infant at least five days old and not older than one 
year of age, regardless of whether a first specimen was collected. 
 
Secretary’s Advisory Committee on Heritable Disorders in Newborns and 
Children (SACHDNC) 
in the Maternal and Child Health Bureau of HRSA, HHS.   
Source of the Recommended Uniform Screening Panel whose core 
disorders should be included in every newborn screening program.  The 
secondary target disorders are defined as disorders that can be detected 
in the differential diagnosis of a core disorder.  The SACHDNC maintains 
and periodically updates the panel.   In May, 2010, a 30th disorder (SCID) 
was added to the panel along with a related secondary disorder (related T-
cell lymphocyte deficiencies)  
http://www.hrsa.gov/heritabledisorderscommittee/uniformscreeningpanel.h
tm   
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sensorineural hearing loss 
occurs when there is damage to the inner ear (cochlea) or to the nerves 
from the inner ear to the brain and is considered to be a permanent loss.  
This can be caused by diseases, birth injury, drugs and genetic 
syndromes or as a result of noise exposure, head trauma, aging and 
tumors. 
 
 severe combined immunodeficiency disorder (SCID) 
the first disorder to be added to the Uniform Screening Panel since the 
original panel of 29 disorders was recommended by SACHDNC.  Arizona 
does not yet screen for SCID. 
an inherited immune system defect characterized by the absence of 
functional T cells and B cells. 
 
S-HPFH 
sickle/hereditary persistence of fetal hemoglobin – a much milder form of 
sickle cell disease  
 
SNHL 
sensorineural hearing loss 
 
soy formula 
infant formula with soy protein isolate as its protein source and usually 
sucrose as its carbohydrate source - used when babies cannot tolerate 
lactose in milk-based formulas 
 
specificity 
in a screening test – the proportion of people who are truly free of a 
specific disease and are so indentified by the test.  A test with high 
specificity would have a minimum of false positives.  
 
specimen 
a part of a thing intended to show kind and quality of the whole; for 
Newborn Screening, the filter paper containing dried blood spots and the 
identifying demographic information  
 
specimen kit 
the strip of filter paper for collecting a blood sample attached to a form for 
obtaining identifying information about the infant - another name for 
collection kit 
 
specimen number 
unique identification number assigned by the State Lab to each newborn 
screening bloodspot specimen (see accession number) 
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submitter    
any entity that submits newborn screening specimens to the State Lab for 
testing.  Each submitter is assigned an identifying code by the 
Demographic section of the Newborn Screening program.  Results are 
mailed to submitters and physicians ordering the tests.   
 
supplemental kits 
single NBS collection kits, usually used for repeat tests but containing 
check boxes to identify what type of specimen is being submitted 
 
 
T 
 
tandem mass spectrometry (MS/MS) 
an analytical method that can determine the substances present in a 
sample by separating them by their weights (masses) and then measuring 
the amounts of the substances present.  This is done by ionizing chemical 
compounds to generate charged molecules or molecule fragments and 
measuring their mass-to-charge ratios. 
As a newborn screening method, MS/MS can test for amino acids and 
acylcarnitines and detect amino acid, fatty acid oxidation and organic acid 
disorders. 
 
target cell 
a red blood cell with a darker round central area surrounded by a paler 
ring, which in turn is surrounded by a darker ring making it look like a bulls 
eye target. 
 
TEOAE 
transient evoked otoacoustic emissions 
 
testing fees 
Arizona NBS specimens are billed to submitters at $30.00 for a first 
screen and to insurance companies or responsible parties at $40.00 for a 
second screen.  These fees are set in Rules (R9-13-208) 
http://www.azsos.gov/PUBLIC_SERVICES/Title_09/9-13.htm  
 
TFP 
trifunctional protein deficiency, a core disorder of the Recommended 
Uniform Screening panel  
 
thalassemias 
a group of hereditary hemolytic anemias marked by a decreased rate of 
synthesis of one or more hemoglobin polypeptide (globin) chains classified 
according to the chain involved (α-thalassemia – absence or reduced 
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number of alpha chains available for combination into the globin portion of 
hemoglobin; ß-thalassemia – absence or reduced number of beta chains)  
 
Third Wave 
Third Wave Technologies, Inc. now Hologic, Inc., provider of the CFTR 
InPlex™ reagent kits used by the Arizona Newborn Screening Program to 
detect 46 mutations to the CFTR gene 
  http://www.twt.com  
 
Title V 
the section of the Social Security Act which funds State programs which 
improve health and welfare services for mothers and children.  These 
funds are provided in the Maternal and Child Health Services Title V Block 
Grant. 
 
 TRECs 
  T-cell receptor excision circles, a marker for SCID (absent or low amounts  
  indicate SCID) 
 
true positive 
a positive (abnormal) result in an individual with the disease 
 
TYR-1 
tyrosinemia type 1, a core disorder of the Recommended Uniform 
Screening panel 
 
 
U 
 
Uniform Screening Panel 
see Recommended Uniform Screening Panel, SACHDNC  
 
unilateral hearing loss 
  normal hearing in one ear and hearing loss in the other ear 
 
Universal Precautions 
an OSHA standard that protects employees who may be occupationally 
exposed to blood and other potential infectious materials like other body 
fluids. 
 
unsat 
an unsatifactory specimen which will be accessioned as specimen type 5 
(if it is a first screen or specimen type 6 if it is a second screen – if it is 
made unsat after accessioning, it will have unsat results listed for all tests 
on the panel but its specimen type will remain whatever it was originally) 
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unsatisfactory specimen 
a specimen which cannot be tested – no results other than the reason the 
specimen could not be tested will be reported 
 
urea cycle disorder 
an inherited disorder caused by a deficiency of one of the enzymes in the 
urea cycle which allows ammonia to build up in the blood where it can 
cause irreversible brain damage, coma and death. 
(of the screened disorders, citrullinemia and argininosuccinic acidemia are 
urea cycle disorders) 
 
U.S. Department of Health and Human Services (HHS) 
the federal government’s principal agency for protecting the health of all 
Americans and providing essential human services, 
  http://www.hhs.gov  
 
 
V 
 
very low birth weight (VLBW) 
  birth weight less than 1500 g 
  
VLCAD 
very long-chain acyl-CoA dehydrogenase deficiency, a core disorder of 
the Recommended Uniform Screening panel 
 
 
W 
 
WAL  
  within acceptable limits 
 
WNL  
  within normal limits 
 
Arizona Revised Statutes – Newborn Screening 
 
36-694. 
A. When a birth or stillbirth is reported, the attending physician or other person required to make 
a report of the birth shall state on the certificate whether a blood test for syphilis was made on a 
specimen of blood taken from the woman who bore the child or from the umbilical cord at 
delivery, as required by section 36-693, and the approximate date when the specimen was taken. 
Report of blood tests; newborn screening program; committee; fee; definitions 
B. When a birth is reported the attending physician or person who is required to make a report on 
the birth shall order or cause to be ordered tests for certain congenital disorders. The results of 
tests for these disorders must be reported to the department of health services. The department of 
health services shall specify in rule the disorders, the process for collecting and submitting 
specimens and the reporting requirements for test results. 
C. When a hearing test is performed on a newborn, the initial hearing test results and any 
subsequent hearing test results must be reported to the department of health services as 
prescribed by department rules. 
D. The director of the department of health services shall establish a newborn screening program 
within the department to ensure that the testing for congenital disorders and the reporting of 
hearing test results required by this section are conducted in an effective and efficient manner. 
The newborn screening program shall include an education program for the general public, the 
medical community, parents and professional groups. The director shall designate the state 
laboratory as the only testing facility for the program. 
E. The newborn screening program shall establish and maintain a central database of newborns 
and infants who are tested for hearing loss and congenital disorders that includes information 
required in rule. Test results are confidential subject to the disclosure provisions of sections 12-
2801 and 12-2802. 
F. If tests conducted pursuant to this section indicate that a newborn or infant may have a hearing 
loss or a congenital disorder, the screening program shall provide follow-up services to 
encourage the child's family to access evaluation services, specialty care and early intervention 
services. 
G. The director shall establish a committee to provide recommendations and advice to the 
department on at least an annual basis regarding tests that the committee believes should be 
included in the newborn screening program. Any recommendation by the committee that a test 
be added to the newborn screening program shall be accompanied by a cost-benefit analysis. 
H. The committee shall include the following members who are appointed by the director and 
who serve without compensation or reimbursement of expenses at the pleasure of the director: 
1. Seven physicians who are licensed pursuant to title 32, chapter 13 or 17 and who represent the 
medical specialties of endocrinology, pediatrics, neonatology, family practice, otology and 
obstetrics. 
2. A neonatal nurse practitioner who is licensed and certified pursuant to title 32, chapter 15. 
3. An audiologist who is licensed pursuant to chapter 17, article 4 of this title. 
4. A representative of an agency that provides services under part C of the individuals with 
disabilities education act. 
5. At least one parent of a child with a hearing loss or a congenital disorder. 
6. A representative from the insurance industry familiar with health care reimbursement issues.  
7. The director of the Arizona health care cost containment system or the director's designee. 
8. A representative of the hospital or health care industry. 
I. The director may establish by rule a fee that the department may collect for operation of the 
newborn screening program, including contracting for the testing pursuant to this section. The 
fee for the first specimen and hearing test shall not exceed thirty dollars. The fee for the second 
specimen and hearing test shall not exceed forty dollars. 
J. For the purposes of this section: 
1. "Infant" means a child who is twenty-nine days of age to two years of age. 
2. "Newborn" means a child who is not more than twenty-eight days of age.  
 
 
36-694.01. 
A. The newborn screening program fund is established. The department of health services shall 
administer the fund. The fund consists of fees collected pursuant to section 36-694 and gifts and 
donations received by the department. 
Newborn screening program fund; use; nonlapsing 
B. Subject to legislative appropriation, the department shall use fund monies to support the 
operation of the newborn screening program prescribed under section 36-694 and rules adopted 
under that section. 
C. Monies in the fund are exempt from the provisions of section 35-190 relating to lapsing of 
appropriations. 
 
TITLE 9. HEALTH SERVICES 
CHAPTER 13. DEPARTMENT OF HEALTH SERVICES 
HEALTH PROGRAMS SERVICES  
 
Supp. 06-2 
ARTICLE 1. HEARING SCREENING 
Article 1 consisting of Sections R9-13-101 through R9-13-110 adopted effective February 18, 1986. 
Former Article 1 consisting of Sections R9-13-111 through R9-13-117 repealed effective February 18, 1986 (Supp. 86-1). 
Section 
R9-13-101. Definitions 
R9-13-102. Hearing Screening Population 
R9-13-103. Hearing Screening Requirements  
R9-13-104. Criteria for Passing a Hearing Screening; Requirements for Performing a Second Hearing Screening 
R9-13-105. Referral; Notification; Follow-up 
R9-13-106. Repealed 
R9-13-107. Screener Qualifications 
R9-13-108. Equipment Standards 
R9-13-109. Recordkeeping, Reporting Requirements 
R9-13-110. Repealed 
R9-13-111. Repealed 
R9-13-112. Renumbered 
R9-13-113. Renumbered 
R9-13-114. Repealed 
R9-13-115. Repealed 
R9-13-116. Renumbered 
R9-13-117. Renumbered 
ARTICLE 2. NEWBORN AND INFANT SCREENING 
Article 2, consisting of R9-13-201 through R9-13-205, recodified from R9-14-501 through R9-14-505 at 11 A.A.R. 3577, effective 
August 31, 2005 (Supp. 05-3). 
Section 
R9-13-201. Definitions 
R9-13-202. Tests for Congenital Disorders 
R9-13-203. General Requirements for Newborn and Infant Bloodspot Tests 
R9-13-204. First Specimen Collection 
R9-13-205. Second Specimen Collection 
R9-13-206. Reporting Requirements for Specimens 
R9-13-207. Reporting Requirements for Hearing Test Results 
R9-13-208. Fees 
ARTICLE 3. REPEALED 
Article 3 consisting of Sections R9-13-301 through R9-13-304 adopted effective July 16, 1981. 
Article 3 consisting of Sections R9-13-301 through R9-13-306 repealed effective July 16, 1981. 
ARTICLE 4. REPEALED 
Article 4 consisting of Sections R9-13-401 through R9-13-406 repealed effective December 16, 1996 (Supp. 96-4). 
Article 4 consisting of Sections R9-13-401 through R9-13-406 adopted effective July 16, 1981. 
Article 4 consisting of Sections R9-13-401 through R9-13-407 repealed effective July 16, 1981. 
ARTICLE 5. REPEALED 
Article 5 consisting of Sections R9-13-501 through R9-13-504 adopted effective July 16, 1981. 
Article 5 consisting of Sections R9-13-501 through R9-13-511 repealed effective July 16, 1981. 
ARTICLE 6. REPEALED 
Article 6 consisting of Sections R9-13-601 through R9-13-606 repealed effective December 16, 1996 (Supp. 96-4).  
Article 6 consisting of Sections R9-13-601 through R9-13-606 adopted effective July 16, 1981. 
Article 6 consisting of Sections R9-13-601 through R9-13-605 repealed effective July 16, 1981. 
ARTICLE 7. REPEALED 
Article 7 consisting of Sections R9-13-701 through R9-13-704 adopted effective July 16, 1981. 
ARTICLE 8. REPEALED 
The rules in Article 8 (R9-13-801, R9-13-802, and R9-13-806) were automatically repealed June 1, 2000. The heading for Article 
8 was repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). 
Article 8 consisting of Sections R9-13-801 through R9-13-806 adopted effective July 16, 1981. 
Section 
R9-13-801. Repealed 
R9-13-802. Repealed 
R9-13-803. Repealed 
R9-13-804. Repealed 
R9-13-805. Repealed 
R9-13-806. Repealed 
ARTICLE 9. REPEALED 
Article 9, consisting of Section R9-13-901, repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-
1). 
Article 9 consisting of Section R9-13-901 adopted effective October 13, 1982. 
Section 
R9-13-901. Repealed 
R9-13-902. Emergency expired 
ARTICLE 10. REPEALED 
Section 
R9-13-1001. Repealed 
R9-13-1002. Repealed 
R9-13-1003. Repealed 
R9-13-1004. Repealed 
ARTICLE 11. REPEALED 
Section 
R9-13-1101. Repealed 
R9-13-1102. Repealed 
R9-13-1103. Repealed 
R9-13-1104. Repealed 
R9-13-1105. Repealed 
ARTICLE 12. REPEALED 
Section 
R9-13-1201. Repealed 
R9-13-1202. Emergency expired 
ARTICLE 13. REPEALED 
Article 13, consisting of Sections R9-13-1301 through R9-13-1303, repealed by final rulemaking at 7 A.A.R. 1082, effective 
February 13, 2001 (Supp. 01-1). 
Article 13 consisting of Sections R9-13-1301 through R9-13-1303 adopted effective November 23, 1983. 
Section 
R9-13-1301. Repealed 
R9-13-1302. Repealed 
R9-13-1303. Repealed 
ARTICLE 14. REPEALED 
Article 14, consisting of Sections R9-13-1401 through R9-13-1415, repealed by final rulemaking at 7 A.A.R. 1082, effective 
February 13, 2001 (Supp. 01-1). 
Article 14 consisting of Sections R9-13-1401 through R9-13-1415 adopted effective March 19, 1984. 
Article 14 consisting of Sections R9-13-1401 through R9-13-1417 adopted as an emergency effective November 29, 1983, 
pursuant to A.R.S. § 41-1003, valid for only 90 days. 
Section 
R9-13-1401. Repealed 
R9-13-1402. Repealed 
R9-13-1403. Repealed 
R9-13-1404. Repealed 
R9-13-1405. Repealed 
R9-13-1406. Repealed 
R9-13-1407. Repealed 
R9-13-1408. Repealed 
R9-13-1409. Repealed 
R9-13-1410. Repealed 
R9-13-1411. Repealed 
R9-13-1412. Repealed 
R9-13-1413. Repealed 
R9-13-1414. Repealed 
R9-13-1415. Repealed 
R9-13-1416. Emergency expired 
R9-13-1417. Emergency expired 
ARTICLE 15. RECODIFIED 
Editor's Note: Article 15, consisting of R9-13-1501 through R9-3-1503 and Exhibits, was recodified to 9 A.A.C. 25. 
Editor's Note: Former Article 15 was originally adopted, and subsequently amended by the addition of a new Section, under an 
exemption from the provisions of the Administrative Procedure Act which means that the rules were not reviewed by the 
Governor's Regulatory Review Council; the agency did not submit notice of proposed rulemaking to the Secretary of State for 
publication in the Arizona Administrative Register; the agency was not required to hold public hearings on the rules; and the 
Attorney General did not certify the rules.  
Article 15, consisting of Sections R9-13-1501 through R9-13-1503, recodified to 9 A.A.C. 25, R9-25-801 through R9-25-803 
(Supp. 98-1). 
ARTICLE 1. HEARING SCREENING 
R9-13-101. Definitions 
In this Article, unless the context otherwise requires: 
1. "Assistive listening device" has the meaning in A.R.S. § 36-1901. 
2. "Audiologist" means an individual licensed under A.R.S. Title 36, Chapter 17. 
3. "Audiometer" means an electronic device that generates signals used to measure hearing.  
4. "Calibration" means a determination of the accuracy of an instrument by measurement of a variation from a standard. 
5. "Cochlear implant" means a surgically inserted device that electrically stimulates the hearing nerve in the inner ear. 
6. "dB" means decibel. 
7. "dB HL" means decibel hearing level. 
8. "Deaf" has the meaning in A.R.S. § 36-1941. 
9. "Department" means the Arizona Department of Health Services. 
10. "Documentation" means signed and dated information in written, photographic, electronic, or other permanent form. 
11. "Effusion" means the escape of fluid from a blood or lymphatic vessel into tissue or a cavity. 
12. "Frequency" means the number of cycles per second of a sound wave.  
13. "Hard of hearing" has the meaning in A.R.S. § 36-1941. 
14. "Hearing aid" has the meaning in A.R.S. § 36-1901. 
15. "Hearing screening" means a test of a student's ability to hear certain frequencies at a consistent loudness performed in a 
school by an individual who meets the requirements in R9-13-107. 
16. "Hz" means Hertz, a unit of frequency equal to one cycle per second.  
17. "Immittance" means the ease of transmission of sound through the middle ear. 
18. "Inner ear" means the semicircular canals, auditory nerve, and cochlea. 
19. "Intensity" means the strength of a sound wave striking the eardrum resulting in the perception of loudness as expressed 
in decibels or decibels hearing level. 
20. "Kindergarten" means the grade level immediately preceding first grade. 
21. "Middle ear" means the eardrum, malleus, incus, stapes, and eustachian tube. 
22. "mm H2O" means millimeters of water. 
23. "Noise floor" means sounds present in the auditory canal from either the environment or bodily functions such as 
breathing and blood flow. 
24. "Otitis media" means inflammation of the middle ear. 
25. "Otoacoustic emissions" means the sounds generated from the inner ear. 
26. "Outer ear" means the pinna, lobe, and auditory canal. 
27. "Parent" has the meaning in A.R.S. § 15-101. 
28. "Physician" means an individual licensed under A.R.S. Title 32, Chapter 13 or 17. 
29. "Preschool" means the instruction preceding kindergarten provided to individuals three to five years old through a: 
a. School as defined in A.R.S. § 15-101, 
b. Accommodation school as defined in A.R.S. § 15-101, 
c. Charter school as defined in A.R.S. § 15-101, or 
d. Private school as defined in A.R.S. § 15-101. 
30. "Primary care practitioner" means an individual licensed as a registered nurse practitioner under A.R.S. Title 32, Chapter 
15 or a physician assistant under A.R.S. 32, Chapter 25. 
31. "Pure tone" means a single frequency sound. 
32. "Reproducibility" means the correlation of two responses measured simultaneously and reported by percentage. 
33. "School" means: 
a. School as defined in A.R.S. § 15-101; 
b. Preschool, 
c. Kindergarten, 
d. Accommodation school as defined in A.R.S. § 15-101, 
e. Charter school as defined in A.R.S. § 15-101, or 
f. Private school as defined in A.R.S. § 15-101 
34. "School administrator" means an individual or the individual's designee assigned to act on behalf of a school by the body 
organized for the government and the management of the school. 
35. "School year" means the period between July 1 and the following June 30. 
36. "Screener" means an individual qualified to perform a hearing screening in a school according to R9-13-107. 
37. "Special education" has the meaning in A.R.S. § 15-761. 
38. "Speech-language pathologist" means an individual licensed under A.R.S. Title 36, Chapter 17.  
39. "Student" means an individual enrolled in a school. 
40. "Supervision" has the meaning in A.R.S. § 36-401. 
41. "Tympanogram" means a chart of the indirect measurements of the ease of movement of the parts of the middle ear as 
air pressure in the auditory canal changes. 
42. "Tympanometer" means a device that indirectly measures the ease of movement of the parts of the middle ear as air 
pressure in the auditory canal changes. 
43. "Tympanometry" means the indirect measurement of the ease of movement of the parts of the middle ear as air pressure 
in the auditory canal changes.  
Historical Note 
Adopted effective February 18, 1986 (Supp. 86-1). Amended effective October 15, 1993 (Supp. 93-4). Amended by final 
rulemaking at 8 A.A.R. 3307, effective July 16, 2002 (Supp. 02-3). 
R9-13-102. Hearing Screening Population 
A. A school administrator shall ensure that the following students have a hearing screening each school year: 
1. A student enrolled in preschool, kindergarten, or grade 1, 2, 6, or 9; 
2. A student enrolled in grade 3, 4, or 5, unless there is written documentation that the student had a hearing screening in or 
after grade 2;  
3. A student enrolled in grade 7 or 8, unless there is written documentation that the student had a hearing screening in or 
after grade 6;  
4. A student enrolled in grade 10, 11, or 12 unless there is written documentation that the student had a hearing screening in 
or after grade 9; 
5. A student receiving special education; and 
6. A student who failed a second hearing screening in the prior school year. 
B. A school administrator shall ensure that a student has a hearing screening at the request of the student, the student's parent, a 
schoolteacher, a school nurse, a school psychologist, an audiologist, a physician, a primary care practitioner, a speech 
language pathologist, or Department staff. 
C. A hearing screening is not required if a: 
1. Student is age 16 years or over; 
2. Student's parent objects in writing to the screening as allowed under A.R.S. § 36-899.04;  
3. Written diagnosis or evaluation from an audiologist states that a student is deaf or hard of hearing; or 
4. Student has a hearing aid, an assistive listening device, or a cochlear implant. 
D. In addition to meeting the requirements in subsections (A) and (B), a school administrator shall ensure that a student who 
meets the criteria specified in State Board of Education rule R7-2-401 has a hearing screening required under R7-2-401. 
Historical Note 
Former Section R9-13-112 renumbered and amended as Section R9-13-102 effective February 18, 1986 (Supp. 86-1). 
Amended effective October 15, 1993 (Supp. 93-4). Amended by final rulemaking at 8 A.A.R. 3307, effective July 16, 
2002 (Supp. 02-3). 
R9-13-103. Hearing Screening Requirements 
A. Before performing a hearing screening, a screener shall visually inspect a student's outer ears for: 
1. Fluid or drainage, 
2. Blood, 
3. An open sore, or 
4. A foreign object. 
B. If a screener inspects a student's outer ears and finds any of the conditions in subsection (A), the screener shall not perform a 
hearing screening. 
C. A screener shall perform a hearing screening in each ear using one of the following hearing screening methods: 
1. Four-frequency, pure tone hearing screening that screens at each of the following frequencies and intensities: 
a. 500 Hz at 25 dB HL, 
b. 1000 Hz at 20 dB HL, 
c. 2000 Hz at 20 dB HL, and 
d. 4000 Hz at 20 dB HL;  
2. Three-frequency, pure tone hearing screening with tympanometry that: 
a. Includes a tympanogram that is generated automatically or is plotted at a minimum of the following three points: 
i. +100 mm H2O, 
ii. Point of maximum immittance, and 
iii. -200 mm H2O; and 
b. Screens at each of the following frequencies at 20 dB HL: 
i. 1000 Hz, 
ii. 2000 Hz, and 
iii. 4000 Hz; or 
3. Otoacoustic emissions hearing screening using otoacoustic emissions equipment that generates a pass or no pass result: 
a. Using a minimum of three frequencies, 
b. At no less than 3 dB above the noise floor, and 
c. With reproducibility greater than 50%. 
Historical Note 
Adopted effective February 18, 1986 (Supp. 86-1). Amended effective October 15, 1993 (Supp. 93-4). Amended by final 
rulemaking at 8 A.A.R. 3307, effective July 16, 2002 (Supp. 02-3). 
R9-13-104. Criteria for Passing a Hearing Screening; Requirements for Performing a Second Hearing Screening  
A. A student passes a hearing screening if: 
1. During a four-frequency, pure tone hearing screening, the student responds in each ear to each frequency at each intensity 
listed in R9-13-103(C)(1)(a) through (C)(1)(d); 
2. During a three-frequency, pure tone hearing screening with tympanometry, the student: 
a. Responds in each ear to each frequency as described in R9-13-103(C)(2)(b); and 
b. Reaches a point of maximum immittance in each ear within the range of +100mm H2O to -200mm H2O; or 
3. During an otoacoustic emissions hearing screening, the student receives a pass result in each ear according to R9-13-
103(C)(3). 
B. If a student does not pass a hearing screening according to subsection (A), a screener shall perform a second hearing screening 
on the student no earlier than 30 days and no later than 45 days from the date of the first hearing screening. The screener 
shall perform the second hearing screening using the same method as the first hearing screening. 
Historical Note 
Adopted effective February 18, 1986 (Supp. 86-1). Amended effective October 15, 1993 (Supp. 93-4). Amended by final 
rulemaking at 8 A.A.R. 3307, effective July 16, 2002 (Supp. 02-3). 
R9-13-105. Referral; Notification; Follow-up 
A. If a school administrator finds that a student does not require a hearing screening under R9-13-102(C)(3) or (C)(4), the school 
administrator shall provide to the student's parent, within 10 days from the date the finding is made, a referral to have the 
student's current hearing status evaluated by an audiologist, including an electroacoustic analysis of any hearing aid or 
assistive listening device, unless there is documentation from an audiologist specifying a different evaluation schedule. 
B. If a screener finds any of the conditions listed in R9-13-103(A) and a student does not have a hearing screening: 
1. A school administrator shall provide to the student's parent, within 10 days from the date the condition is found, a referral 
to have the student's outer ears evaluated by a physician or primary care practitioner; and 
2. A screener shall perform the hearing screening on the student no earlier than 30 days and no later than 45 days from the 
date the screener finds the condition. 
C. If a student does not pass a second hearing screening or does not complete a second hearing screening within the time period 
required under R9-13-104(B), a school administrator shall provide to the student's parent, within 10 days from the date of 
the second hearing screening or from the date the period for completing a second hearing screening ends, a referral to have 
the student's current hearing status evaluated by one of the following: 
1. An audiologist, a physician, or a primary care practitioner if the screener used only the four-frequency, pure tone hearing 
screening method; 
2. A physician or primary care practitioner if the student did not pass the tympanometry portion, but passed the three-
frequency, pure tone portion of the hearing screening; 
3. An audiologist if the student did not pass the three-frequency, pure tone portion, but passed the tympanometry portion of 
the hearing screening; or 
4. An audiologist, a physician, or a primary care practitioner if the screener used the otoacoustic emissions hearing screening 
method. 
D. A referral identified in subsection (C) is not required if a school-provided audiologist: 
1. Assesses a student's hearing status and the condition of the middle ear at the conclusion of a hearing screening; and 
2. Within 10 days from date of the assessment, provides the student's parent with a written diagnosis and recommendation 
for treatment, if applicable. 
E. A referral required under subsections (A), (B), or (C), shall include a form requesting the following: 
1. The name, address, and telephone number of the student evaluated;  
2. The date of evaluation; 
3. An assessment of the condition of the outer ear, if applicable;  
4. An assessment of hearing status and the condition of the middle ear, if applicable; 
5. A diagnosis and recommendation for treatment, if applicable;  
6. The signature and title of the individual evaluating the student and completing the form; and 
7. A request that the individual completing the form or the student's parent return the completed form to the school. 
F. Under State Board of Education rule R7-2-401, a school administrator shall ensure that a student referred under subsections 
(A) or (C) is evaluated.  
G. If a school receives notice of a diagnosis that a student is deaf or hard of hearing from an audiologist, the school administrator 
shall notify, within 10 days from the date the notice of diagnosis is received, each of the student's teachers and the person 
responsible for the school's special education services of the diagnosis. 
Historical Note 
Adopted effective February 18, 1986 (Supp. 86-1). Amended effective October 15, 1993 (Supp. 93-4). Amended by final 
rulemaking at 8 A.A.R. 3307, effective July 16, 2002 (Supp. 02-3). 
R9-13-106. Repealed 
Historical Note 
Adopted effective February 18, 1986 (Supp. 86-1). Amended effective October 15, 1993 (Supp. 93-4). Section repealed by 
final rulemaking at 8 A.A.R. 3307, effective July 16, 2002 (Supp. 02-3). 
R9-13-107. Screener Qualifications 
A. An audiologist may perform a hearing screening. 
B. An individual who is not an audiologist may perform a hearing screening only if the individual passes a hearing screener 
course that: 
1. Includes 90 minutes of classroom instruction in the introduction to hearing covering: 
a. Development of speech and language; 
b. Anatomy and physiology of the ear; 
c. Signs and prevention of hearing loss in children; and 
d. A.R.S. Title 36, Chapter 7.2 and 9 A.A.C. 13, Article 1; 
2. Includes 120 minutes of classroom instruction in hearing screening covering: 
a. Auditory development, 
b. Early identification of hearing loss, 
c. Principles of hearing screening, 
d. Selection of hearing screening methods, and  
e. Components of setting-up a hearing screening program;  
3. Includes 75 minutes of classroom instruction in referral and reporting covering: 
a. Results of a hearing screening, 
b. Responses to a hearing screening outcome, 
c. Procedures for recording and tracking, 
d. Communication with parents, 
e. Role of community resources, and 
f. Reporting hearing screening results; 
4. For an individual who will perform a hearing screening using three-frequency or four-frequency, pure tone hearing 
screening, includes 120 minutes of classroom instruction covering: 
a. Selecting and setting-up a hearing screening site, 
b. Performing a pure tone hearing screening, and 
c. Identifying children who need referral and evaluation; 
5. For an individual who will perform a hearing screening using tympanometry with three-frequency, pure tone hearing 
screening, includes 60 minutes of classroom instruction covering: 
a. The anatomy and functions of the middle ear,  
b. What tympanometry measures and identifies, 
c. Using a tympanometer, 
d. Performing a tympanometry hearing screening, and 
e. Identifying children who need referral and evaluation; 
6. For an individual who will perform a hearing screening using otoacoustic emissions hearing screening, includes 60 
minutes of classroom instruction covering: 
a. What otoacoustic emissions identify and measure, 
b. Using otoacoustic emissions equipment, 
c. Performing an otoacoustic emissions hearing screening, and 
d. Identifying children who need referral and evaluation;  
7. Requires an individual to pass the course by scoring 80% or more on an examination that tests what the individual has 
learned;  
8. Is taught by an individual who: 
a. Is an audiologist, or 
b. Meets the screener qualifications in subsection (B) or (C) and has performed at least 50 hearing screenings within 24 
months before teaching a hearing screener course; and 
9. Provides an individual who passes the course with a certificate of completion that includes: 
a. The individual's name; 
b. Whether the following were completed: 
i. Introduction to hearing, 
ii. Hearing screening, 
iii. Referral and reporting, 
iv. Pure tone hearing screening,  
v. Tympanometry hearing screening, and 
vi. Otoacoustic emissions hearing screening; 
c. An attestation that the course meets the requirements in subsection (B) or (C); and 
d. The name and signature of the individual who taught the course. 
C. Every five years after completing a hearing screener course described in subsection (B), a screener who is not an audiologist 
shall pass a hearing screener course that: 
1. Includes 195 minutes of classroom instruction covering the material required under subsections (B)(1), (B)(2), and (B)(3); 
2. For an individual who will perform a hearing screening using three-frequency or four-frequency, pure tone hearing 
screening, includes 60 minutes of classroom instruction covering the material required under subsection (B)(4); 
3. For an individual who will perform a hearing screening using tympanometry with three-frequency, pure tone hearing 
screening, includes 30 minutes of classroom instruction covering the material required under subsection (B)(5); 
4. For an individual who will perform a hearing screening using otoacoustic emissions hearing screening, includes 30 
minutes of classroom instruction covering the material required under subsection (B)(6); and 
5. Meets the requirements in subsections (B)(7), (B)(8), and (B)(9). 
D. Before performing a hearing screening, an individual who passes a hearing screener course described in subsection (B) or (C) 
shall give a copy of the certificate of completion described in subsection (B)(9) to the school. 
E. An individual who does not meet the screener qualifications in subsection (A), (B), or (C) may perform a four-frequency, pure 
tone hearing screening, other than a second hearing screening required under R9-25-104(B), only under the supervision of 
an individual who meets the screener qualifications in subsection (A), (B), or (C). 
Historical Note 
Former Section R9-13-113 renumbered and amended as Section R9-13-107 effective February 18, 1986 (Supp. 86-1). 
Amended effective October 15, 1993 (Supp. 93-4). Amended by final rulemaking at 8 A.A.R. 3307, effective July 16, 
2002 (Supp. 02-3). 
R9-13-108. Equipment Standards 
A. A school administrator shall ensure that a pure tone audiometer used to perform a three-frequency or four-frequency, pure 
tone hearing screening is: 
1. Calibrated every 12 months according to the American National Standard Specification for Audiometers, S3.6-1996, 
Standards Secretariat, c/o Acoustical Society of America, 120 Wall Street, 32nd Floor, New York, New York 10005-
3993, January 12, 1996, incorporated by reference in R9-16-209(B)(1); and 
2. Inspected within 24 hours before use to ensure that: 
a. The calibration complies with subsection (A)(1), 
b. The power source and power indicator are working, 
c. The earphone cords are securely connected and have no breaks, 
d. Each frequency and intensity required under R9-13-103(C)(1) is present, 
e. A signal does not cross from one earphone to the other, and 
f. Each earphone is free of noise or distortion that could interfere with a hearing screening. 
B. A school administrator shall ensure that a tympanometer used to perform the tympanometry portion of a hearing screening: 
1. Is calibrated every 12 months according to the American National Standard Specifications for Instruments to Measure 
Aural Acoustic Impedance and Admittance, S3.39-1987, Standards Secretariat, Acoustical Society of America, 335 
East 45th Street, New York, New York 10017-3483, October 5, 1987, not including any later amendments or editions, 
incorporated by reference and on file with the Department and the Office of the Secretary of State; and 
2. Is inspected within 24 hours before use to ensure that the calibration complies with subsection (B)(1). 
C. A school administrator shall ensure that otoacoustic emissions equipment used to perform an otoacoustic emissions hearing 
screening is: 
1. Calibrated every 12 months according to manufacturer's specifications; and 
2. Inspected within 24 hours before use to ensure that: 
a. The calibration complies with manufacturer's specifications, 
b. No obstruction is in the probe microphone, and 
c. The test signal is present. 
Historical Note 
Adopted effective February 18, 1986 (Supp. 86-1). Amended effective October 15, 1993 (Supp. 93-4). Amended by final 
rulemaking at 8 A.A.R. 3307, effective July 16, 2002 (Supp. 02-3). 
R9-13-109. Recordkeeping, Reporting Requirements 
A. A school administrator shall retain, for Department review and inspection, a written record of: 
1. The date and results of a student's hearing screening for no less than three complete school years beginning on the first 
July 1 after the student's last date of attendance at the school, and 
2. All calibration dates for a piece of hearing screening equipment currently used in the school. 
B. By June 30th of each year, a school administrator shall submit to the Department the following information for the school year 
ending that June 30th: 
1. On a form available from the Department, the number of students by grade in each of the following categories: 
a. Were enrolled at the time of a first hearing screening, 
b. Did not have a first hearing screening under R9-13-102(C), 
c. Had a first hearing screening, 
d. Did not pass a first hearing screening, 
e. Had a second hearing screening, 
f. Did not pass a second hearing screening, 
g. Were evaluated by an audiologist, 
h. Were evaluated by a physician or a primary care practitioner, 
i. Were first diagnosed as deaf or hard of hearing during the current school year, and 
j. Were diagnosed as deaf or hard of hearing during a prior school year; and 
2. The name of each individual who performed a hearing screening in the school and: 
a. The individual's license number to practice audiology, or 
b. Evidence that the individual successfully completed a hearing screening course described in R9-13-107(B) or (C). 
Historical Note 
Former Section R9-13-116 renumbered and amended as Section R9-13-109 effective February 18, 1986 (Supp. 86-1). 
Amended effective October 15, 1993 (Supp. 93-4). Amended by final rulemaking at 8 A.A.R. 3307, effective July 16, 
2002 (Supp. 02-3). 
R9-13-110. Repealed 
Historical Note 
Former Section R9-13-117 renumbered and amended as Section R9-13-110 effective February 18, 1986 (Supp. 86-1). 
Repealed effective October 15, 1993 (Supp. 93-4). 
R9-13-111. Repealed 
Historical Note 
Effective 4-72. Amended effective November 18, 1976 (Supp. 76-5). Repealed effective February 18, 1986 (Supp. 86-1). 
R9-13-112. Renumbered 
Historical Note 
Effective 4-72. Amended effective November 18, 1976 (Supp. 76-5). Section R9-13-112 renumbered and amended as 
Section R9-13-102 effective February 18, 1986 (Supp. 86-1). 
R9-13-113. Renumbered 
Historical Note 
Effective 4-72. Amended effective November 18, 1976 (Supp. 76-5). Section R9-13-113 renumbered and amended as 
Section R9-13-107 effective February 18, 1986 (Supp. 86-1). 
R9-13-114. Repealed 
Historical Note 
Effective 4-72. Amended effective November 18, 1976 (Supp. 76-5). Repealed effective February 18, 1986 (Supp. 86-1). 
R9-13-115. Repealed 
Historical Note 
Effective 4-72. Amended effective November 18, 1976 (Supp. 76-5). Repealed effective February 18, 1986 (Supp. 86-1). 
R9-13-116. Renumbered 
Historical Note 
Effective 4-72. Correction, Section R9-13-116 omitted in Supp. 76-5 (Supp. 77-5). Section R9-13-116 renumbered and 
amended as Section R9-13-109 effective February 18, 1986 (Supp. 86-1). 
R9-13-117. Renumbered 
Historical Note 
Effective 4-72. Correction, Section R9-13-117 omitted in Supp. 76-5 (Supp. 77-5). Section R9-13-117 renumbered and 
amended as Section R9-13-110 effective February 18, 1986 (Supp. 86-1). 
ARTICLE 2. NEWBORN AND INFANT SCREENING 
R9-13-201. Definitions 
In this Article, unless otherwise specified: 
1. "Abnormal result" means an outcome that deviates from the range of values established by the Department for an analysis 
performed as part of a bloodspot test, or for a hearing test. 
2. "Admitted" means the same as in A.A.C. R9-10-201. 
3. "AHCCCS" means the Arizona Health Care Cost Containment System. 
4. "Argininosuccinic acidemia" means a congenital disorder characterized by an inability to metabolize the amino acid 
argininosuccinic acid due to defective argininosuccinate lyase activity. 
5. "Audiological equipment" means instruments used to measure a physiological response to determine the presence, type, 
or degree of hearing loss. 
6. "Audiologist" means an individual licensed under A.R.S. Title 36, Chapter 17. 
7. "Beta-ketothiolase deficiency" means a congenital disorder characterized by an inability to metabolize 2-methyl-
acetoacetyl-CoA due to defective mitochondrial acetoacetyl-CoA thiolase activity. 
8. "Biotinidase deficiency" means a congenital disorder characterized by defective biotinidase activity that causes abnormal 
biotin metabolism. 
9. "Birth center" means a health care facility that is not a hospital and is organized for the sole purpose of delivering 
newborns. 
10. "Blood sample" means capillary or venous blood, but not cord blood, applied to the filter paper of a specimen collection 
kit. 
11. "Bloodspot test" means multiple laboratory analyses performed on a blood sample to detect the presence of congenital 
disorders listed in R9-13-202. 
12. "Carnitine uptake defect" means a congenital disorder characterized by a decrease in the amount of free carnitine due to 
defective sodium ion-dependent carnitine transporter OCTN2 activity. 
13. "Citrullinemia" means a congenital disorder characterized by an inability to convert the amino acid citrulline and 
aspartic acid into argininosuccinic acid due to defective argininosuccinate synthetase activity. 
14. "Classic galactosemia" means a congenital disorder characterized by abnormal galactose metabolism due to defective 
galactose-1-phosphate uridyltranferase activity. 
15. "Congenital adrenal hyperplasia" means a congenital disorder characterized by decreased cortisol production and 
increased androgen production due to defective 21-hydroxylase activity. 
16. "Congenital disorder" means an abnormal condition present at birth, as a result of heredity or environmental factors, that 
impairs normal physiological functioning of a human body. 
17. "Congenital hypothyroidism" means a congenital disorder characterized by deficient thyroid hormone production. 
18. "Cystic fibrosis" means a congenital disorder caused by defective functioning of a transmembrane regulator protein and 
characterized by damage to and dysfunction of various organs, such as the lungs, pancreas, and reproductive organs. 
19. "Department" means the Arizona Department of Health Services. 
20. "Discharge" means the termination of inpatient services to a newborn or infant. 
21. "Disorder" means a disease or medical condition that may be identified by a laboratory analysis. 
22. "Document" means to establish and maintain information in written, photographic, electronic, or other permanent form. 
23. "Educational materials" means printed or electronic information provided by the Department, explaining newborn and 
infant screening, any of the congenital disorders listed in R9-13-202, or hearing loss. 
24. "Electronic" means the same as in A.R.S. § 44-7002. 
25. "First specimen" means the initial specimen that is collected from a newborn who is less than five days of age and sent 
to the screening laboratory for testing and recording of demographic information. 
26. "Glutaric acidemia type I" means a congenital disorder characterized by an accumulation of glutaric acid due to 
defective glutaryl-CoA dehydrogenase activity. 
27. "Guardian" means an individual appointed by a court under A.R.S. Title 14, Chapter 5, Article 2. 
28. "Health care facility" means a health care institution defined in A.R.S. § 36-401 where obstetrical care or newborn care 
is provided. 
29. "Health care provider" means a physician, physician assistant, registered nurse practitioner, or midwife. 
30. "Health-related services" means the same as in A.R.S. § 36-401. 
31. "Hearing test" means an evaluation of both ears of a newborn or infant, using audiological equipment, for the presence, 
type, or degree of hearing loss. 
32. "Hemoglobin S/Beta-thalassemia" means a sickle cell disease in which an individual has one sickle cell gene and one 
gene for beta thalassemia, another inherited hemoglobinopathy. 
33. "Hemoglobin S/C disease" means a sickle cell disease in which an individual has one sickle cell gene and one gene for 
another inherited hemoglobinopathy called hemoglobin C. 
34. "Hemoglobinopathy" means a congenital disorder characterized by abnormal production, structure, or functioning of 
hemoglobin. 
35. "Home birth" means delivery of a newborn, outside a health care facility, when the newborn is not hospitalized within 72 
hours of delivery. 
36. "Homocystinuria" means a congenital disorder characterized by abnormal methionine and homocysteine metabolism due 
to defective cystathione-ß-synthase activity. 
37. "Hospital" means the same as in A.A.C. R9-10-201. 
38. "Hospital services" means the same as in A.A.C. R9-10-201. 
39. "3-Hydroxy-3-methylglutaric aciduria" means a congenital disorder characterized by the accumulation of 3-hydroxy-3-
methylglutaric acid due to a defective 3-hydroxy-3-methylglutaryl-CoA lyase activity. 
40. "Identification code" means a unique set of numbers or letters, or a unique set of both numbers and letters, assigned by 
the Department to a health care facility, a health care provider, an audiologist, or another person submitting specimen 
collection kits to the screening laboratory or hearing test results to the Department. 
41. "Infant" means the same as in A.R.S. § 36-694. 
42. "Inpatient" means an individual who: 
a. Is admitted to a hospital, 
b. Receives hospital services for 24 consecutive hours, or 
c. Is admitted to a birth center. 
43. "Inpatient services" means medical services, nursing services, or other health-related services provided to an inpatient in 
a health care facility. 
44. "Isovaleric acidemia" means a congenital disorder characterized by an accumulation of isovaleric acid due to defective 
isovaleryl-CoA dehydrogenase activity. 
45. "Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency" means a congenital disorder characterized by an inability 
to metabolize fatty acids that are 12 to 16 carbon atoms in length due to defective long-chain 3-hydroxy acyl-CoA 
dehydrogenase activity. 
46. "Maple syrup urine disease" means a congenital disorder of branched chain amino acid metabolism due to defective 
branched chain-keto acid dehydrogenase activity. 
47. "Medical services" means the same as in A.R.S. § 36-401. 
48. "Medium chain acyl-CoA dehydrogenase deficiency" means a congenital disorder characterized by an inability to 
metabolize fatty acids that are 6 to 10 carbon atoms in length due to defective medium-chain acyl-CoA dehydrogenase 
activity. 
49. "3-Methylcrotonyl-CoA carboxylase deficiency" means a congenital disorder characterized by an accumulation of 3-
methylcrotonyl-glycine due to defective 3-methylcrotonyl-CoA carboxylase activity. 
50. "Methylmalonic acidemia (Cbl A,B)" means a congenital disorder characterized by an accumulation of methylmal- 
onic acid due to defective activity of methylmalonyl-CoA racemase or adenosylcobalamin synthetase. 
51. "Methylmalonic acidemia (mutase deficiency)" means a congenital disorder characterized by an accumulation of 
methylmalonic acid due to defective methylmalonyl-CoA mutase activity. 
52. "Midwife" means an individual licensed under A.R.S. Title 36, Chapter 6, Article 7, or certified under A.R.S. Title 32, 
Chapter 15. 
53. "Multiple carboxylase deficiency" means a congenital disorder characterized by an inability to transport or metabolize 
biotin that leads to defective activity of propionyl-CoA carboxylase, beta-methylcrotonyl-CoA carboxylase, and 
pyruvate carboxylase. 
54. "Newborn" means the same as in A.R.S. § 36-694. 
55. "Newborn care" means medical services, nursing services, and health-related services provided to a newborn. 
56. "Nursing services" means the same as in A.R.S. § 36-401. 
57. "Obstetrical care" means medical services, nursing services, and health-related services provided to a woman throughout 
her pregnancy, labor, delivery, and postpartum. 
58. "Organ" means a somewhat independent part of a human body, such as a salivary gland, kidney, or pancreas, which 
performs a specific function. 
59. "Parent" means a natural, adoptive, or custodial mother or father of a newborn or infant. 
60. "Person" means the state, a municipality, district, or other political subdivision, a cooperative, institution, corporation, 
company, firm, partnership, individual, or other legal entity. 
61. "Phenylketonuria" means a congenital disorder characterized by abnormal phenylalanine metabolism due to defective 
phenylalanine hydroxylase activity. 
62. "Physician" means an individual licensed under A.R.S. Title 32, Chapters 13, 14, 17, or 29. 
63. "Physician assistant" means an individual licensed under A.R.S. Title 32, Chapter 25. 
64. "Propionic acidemia" means a congenital disorder characterized by an accumulation of glycine and 3-hydroxypropionic 
acid due to defective propionyl-CoA carboxylase activity. 
65. "Registered nurse practitioner" means the same as in A.R.S. § 32-1601. 
66. "Screening laboratory" means an entity contracted with the Department under A.R.S. § 36-694(I) to perform the 
bloodspot test. 
67. "Second specimen" means a specimen that is sent to the screening laboratory for testing and recording of demographic 
information, after being collected: 
a. From a newborn after a first specimen; or 
b. From an individual at least five days and not older than one year of age, regardless of whether a first specimen was 
collected. 
68. "Sickle cell anemia" means a sickle cell disease in which an individual has two sickle cell genes. 
69. "Sickle cell disease" means a hemoglobinopathy characterized by an abnormally shaped red blood cell resulting from the 
abnormal structure of the protein hemoglobin. 
70. "Sickle cell gene" means a unit of inheritance that is involved in producing an abnormal type of the protein hemoglobin, 
in which the amino acid valine is substituted for the amino acid glutamic acid at a specific location in the hemoglobin. 
71. "Specimen" means a blood sample obtained from and demographic information about a newborn or infant. 
72. "Specimen collection kit" means a strip of filter paper for collecting a blood sample attached to a form for obtaining the 
information specified in R9-13-203(A)(3) about a newborn or infant. 
73. "Test" means a laboratory analysis performed on body fluid, tissue, or excretion to determine the presence or absence of 
a disorder. 
74. "Transfer" means a health care facility discharging a newborn and sending the newborn to a hospital for inpatient 
medical services without the intent that the patient will be returned to the sending health care facility. 
75. "Transfusion" means the infusion of blood or blood products into the body of an individual. 
76. "Trifunctional protein deficiency" means a congenital disorder characterized by an inability to metabolize fatty acids that 
are 12 to 18 carbon atoms in length due to defective mitochondrial trifunctional protein activity. 
77. "Tyrosinemia type I" means a congenital disorder characterized by an accumulation of the amino acid tyrosine due to 
defective fumarylacetoacetate hydrolase activity. 
78. "Verify" means to confirm by obtaining information through a source such as the newborn screening program, a health 
care provider, a health care facility, or a documented record. 
79. "Very long-chain acyl-CoA dehydrogenase deficiency" means a congenital disorder characterized by an inability to 
metabolize fatty acids that are 14 to 18 carbon atoms in length due to defective very long-chain acyl-CoA 
dehydrogenase activity. 
80. "Working day" means 8:00 a.m. through 5:00 p.m. Monday through Friday, excluding state holidays. 
Historical Note 
Amended effective October 26, 1977 (Supp. 77-5). Former Section R9-13-201 repealed, new Section R9-13-201 adopted 
effective July 16, 1981 (Supp. 81-4). Amended as an emergency effective September 21, 1982, pursuant to A.R.S. § 
41-1003, valid for only 90 days (Supp. 82-5). Emergency expired. Permanent rule adopted effective March 22, 1983 
(Supp. 83-2). Amended by adding paragraphs (3), (5) and (7) and renumbering remaining paragraphs effective 
November 23, 1983. Amended as an emergency, by adding paragraphs (32) and (42) and renumbering remaining 
paragraphs, effective November 23, 1983, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency amendment expired. Permanent amendment, adding paragraphs (32) and (42) and renumbering remaining 
paragraphs adopted effective March 19, 1984 (Supp. 84-2). Amended as an emergency effective November 6, 1989, 
pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 89-4). Emergency expired. Readopted as an emergency 
effective February 7, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-1). Re-adopted as an 
emergency with changes effective May 7, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-2). 
Readopted as an emergency with changes effective August 6, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 
days (Supp. 90-3). Readopted as an emergency without change effective October 31, 1990, pursuant to A.R.S. § 41-
1026, valid for only 90 days (Supp. 90-4). Readopted as an emergency with changes effective January 16, 1991, 
pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-1). Readopted as an emergency without change 
effective April 11, 1991, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-2). Emergency amendments 
permanently adopted with changes effective July 3, 1991 (Supp. 91-3). Amended effective December 16, 1996 (Supp. 
96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 146, effective September 24, 1998 (Supp. 99-1). 
New Section recodified from R9-14-501 at 11 A.A.R. 3577, effective August 31, 2005 (Supp. 05-3). Amended by final 
rulemaking at 12 A.A.R. 1166, effective April 4, 2006 (Supp. 06-2). 
R9-13-202. Tests for Congenital Disorders 
A bloodspot test shall include laboratory analyses for the following congenital disorders: 
1. Argininosuccinic acidemia, 
2. Biotinidase deficiency, 
3. Citrullinemia, 
4. Classic galactosemia, 
5. Congenital adrenal hyperplasia, 
6. Congenital hypothyroidism, 
7. Hemoglobin S/Beta-thalassemia, 
8. Hemoglobin S/C disease, 
9. Homocystinuria, 
10. Maple syrup urine disease, 
11. Phenylketonuria, 
12. Sickle cell anemia, 
13. Tyrosinemia type I, 
14. 3-Methylcrotonyl-CoA carboxylase deficiency, 
15. 3-Hydroxy-3-methylglutaric aciduria, 
16. Beta-ketothiolase deficiency, 
17. Carnitine uptake defect, 
18. Glutaric acidemia type I, 
19. Isovaleric acidemia, 
20. Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency, 
21. Medium chain acyl-CoA dehydrogenase deficiency, 
22. Methylmalonic acidemia (Cbl A,B), 
23. Methylmalonic acidemia (mutase deficiency), 
24. Multiple carboxylase deficiency, 
25. Propionic acidemia, 
26. Trifunctional protein deficiency, 
27. Very long-chain acyl-CoA dehydrogenase deficiency, and 
28. Cystic fibrosis. 
Historical Note 
Amended effective October 26, 1977 (Supp. 77-5). Former Section R9-13-202 repealed, new Section R9-13-202 adopted 
effective July 16, 1981 (Supp. 81-4). Repealed by emergency effective November 6, 1989, pursuant to A.R.S. § 41-
1026, valid for only 90 days (Supp. 89-4). Emergency expired. Emergency repeal readopted effective February 7, 1990, 
pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-1). Emergency repeal readopted effective May 7, 1990, 
pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-2). Emergency repeal readopted effective August 6, 
1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-3). Emergency repeal readopted effective October 
31, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-4). Emergency repeal readopted effective 
January 16, 1991, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-1). Emergency repeal readopted 
effective April 11, 1991, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-2). Repealed permanently 
effective July 3, 1991 (Supp. 91-3). New Section recodified from R9-14-502 at 11 A.A.R. 3577, effective August 31, 
2005 
(Supp. 05-3). Section repealed; new Section made by final rulemaking at 12 A.A.R. 1166, effective April 4, 2006 
(Supp. 06-2). 
R9-13-203. General Requirements for Newborn and Infant Bloodspot Tests 
A. When a bloodspot test is ordered for a newborn or an infant, a health care facility's designee, a health care provider, or the 
health care provider's designee shall: 
1. Only use a specimen collection kit supplied by the Department; 
2. Collect a blood sample from the newborn or infant on a specimen collection kit; 
3. Complete the following information on the specimen collection kit: 
a. The newborn's or infant's name, gender, race, ethnicity, medical record number, and if applicable, AHCCCS 
identification number; 
b. The newborn's or infant's type of food or food source; 
c. Whether the newborn or infant is from a single or multiple birth; 
d. If the newborn or infant is from a multiple birth, the birth order of the newborn or infant; 
e. Whether the newborn or infant has a medical condition that may affect the bloodspot test results; 
f. Whether the newborn or infant received antibiotics or a blood transfusion and, if applicable, the date of the last blood 
transfusion; 
g. The method of blood sample collection; 
h. The date and time of birth, and the newborn's or infant's weight at birth; 
i. The date and time of blood sample collection, and the newborn's or infant's weight when the blood sample is 
collected; 
j. The name and identification code of the health care facility or health care provider submitting the specimen collection 
kit; 
k. The name, identification code, and address of the health care provider responsible for the management of medical 
services provided to the newborn or infant; 
l. Except as provided in subsection (A)(3)(m), the mother's first and last names, date of birth, name before first 
marriage, mailing address, phone number, and if applicable, AHCCCS identification number; and 
m. If the newborn's or infant's mother does not have physical custody of the newborn or infant, the first and last names, 
mailing address, and phone number of the person who has physical custody of the newborn or infant; and 
4. Submit the specimen collection kit to the screening laboratory no later than 24 hours or the next working day after the 
blood sample is collected. 
B. A health care facility or a health care provider submitting a first specimen to the screening laboratory shall pay the Department 
the fee in R9-13-208(A). 
C. A person who submits a second specimen to the screening laboratory shall: 
1. Pay the fee in R9-13-208(B) to the Department, or 
2. Provide the following information to the screening laboratory for billing purposes: 
a. The name, mailing address, and phone number of the newborn's or infant's parent or the individual responsible for 
paying, if not the parent; and 
b. If the individual responsible for paying has health care insurance for the newborn or infant, information about the 
health care insurance, including: 
i. The policyholder's name; 
ii. The name and billing address of the health care insurance company; 
iii. The member identification number; 
iv. The group number, if applicable; and 
v. The effective date of the health care insurance; or 
c. That the individual responsible for paying has no health care insurance for the newborn or infant. 
D. When a health care insurance company or an individual responsible for paying is identified as specified in subsection (C)(2), 
the health care insurance company or the individual responsible for paying shall pay the Department the fee in R9-13-
208(B). 
E. The screening laboratory shall perform a bloodspot test on a blood sample from a specimen collection kit if: 
1. The blood sample on the specimen collection kit: 
a. Contains a sufficient quantity of blood to complete the bloodspot test, 
b. Is not clotted or layered, 
c. Does not have serum rings, 
d. Is not diluted or discolored, 
e. Will elute from the filter paper, 
f. Has not been applied to both sides of the filter paper, and 
g. Is not contaminated; 
2. The filter paper on the specimen collection kit is not contaminated, scratched, or abraded; 
3. The information on the specimen collection kit is sufficient to identify: 
a. The newborn or infant, and 
b. The person who ordered the bloodspot test or caused the bloodspot test to be ordered; and 
4. The screening laboratory receives the specimen collection kit within 14 days after the blood sample is collected. 
F. When a home birth not attended by a health care provider is reported to a local registrar, a deputy local registrar, or the state 
registrar under A.R.S. § 36-333: 
1. The local registrar, deputy local registrar, or state registrar shall notify the local health department of the county where the 
birth occurred; and 
2. The local health department's designee shall collect a specimen from the newborn or infant according to the requirements 
in R9-13-204(A)(2) or R9-13-205(C). 
G. A health care facility's designee, a health care provider, or the health care provider's designee shall ensure that: 
1. Educational materials are provided to the parent or guardian of a newborn or infant for whom a bloodspot test is ordered, 
and 
2. The newborn's or infant's parent or guardian is informed of the requirement for a second specimen if the second specimen 
has not been collected. 
H. For a home birth, a health care provider or the health care provider's designee shall provide educational materials to the parent 
or guardian of a newborn or infant for whom a bloodspot test is ordered. 
Historical Note 
Effective 11-74; Former Section R9-13-203 repealed, new Section R9-13-203 adopted effective July 16, 1981 (Supp. 81-4). 
Amended effective December 16, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 
146, effective September 24, 1998 (Supp. 99-1). New Section recodified from R9-14-503 at 11 A.A.R. 3577, effective 
August 31, 2005 
(Supp. 05-3). Section repealed; new Section made by final rulemaking at 12 A.A.R. 1166, effective April 4, 2006 
(Supp. 06-2). 
R9-13-204. First Specimen Collection 
A. When a newborn is born in a hospital, the hospital's designee shall collect a first specimen from the newborn according to 
whichever of the following occurs first: 
1. Before a transfusion, unless specified otherwise by a physician, physician assistant, or registered nurse practitioner; 
2. When the newborn is at least 24 but not more than 72 hours old; or 
3. Before the newborn is discharged, unless the newborn: 
a. Is transferred to another hospital before the newborn is 48 hours old; or 
b. Dies before the newborn is 72 hours old. 
B. If a newborn is admitted or transferred to a hospital before the newborn is 48 hours old, the receiving hospital's designee shall: 
1. Verify that the first specimen was collected before admission or transfer, or 
2. Collect a first specimen from the newborn according to the requirements in subsection (A). 
C. When a newborn is born in a birth center, the birth center's designee shall collect a first specimen from the newborn according 
to subsections (A)(1) or (A)(2). 
D. For a home birth attended by a health care provider, the health care provider or the health care provider's designee shall collect 
a first specimen from the newborn according the requirements in subsection (A)(2). 
Historical Note 
Effective 11-74; Former Section R9-13-204 repealed, new Section R9-13-204 adopted effective July 16, 1981 (Supp. 81-4). 
Amended effective December 6, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 
146, effective September 24, 1998 (Supp. 99-1). New Section recodified from R9-14-504 at 11 A.A.R. 3577, effective 
August 31, 2005 
(Supp. 05-3). Section repealed; new Section made by final rulemaking at 12 A.A.R. 1166, effective April 4, 2006 
(Supp. 06-2). 
R9-13-205. Second Specimen Collection 
A. After discharge from a health care facility or after a home birth, a health care provider or the health care provider's designee 
shall: 
1. Collect a second specimen from a newborn or infant: 
a. When the newborn is at least 5 but not more than 10 days old; or 
b. At the time of a newborn's or infant's first visit to the health care provider; or 
2. Verify that a different health care provider has collected the second specimen from the newborn or infant. 
B. If a newborn is an inpatient of a health care facility at 5 days of age, the health care facility's designee shall collect a second 
specimen from the newborn: 
1. When the newborn is at least 5 but not more than 10 days old; or 
2. If the newborn is discharged from the facility when the newborn is at least 5 but not more than 10 days old, before 
discharge. 
C. For a home birth not attended by a health care provider, a local health department's designee shall collect a specimen from a 
newborn or infant if a second specimen has not already been collected from the newborn or infant. 
D. A health care provider or the health care provider's designee shall ensure that a subsequent specimen is ordered for a newborn 
or child one year of age or less, according to the requirements in R9-13-203, when the health care provider or the health care 
provider's designee: 
1. Begins providing health care to the newborn or child, and 
2. Cannot verify the results of a bloodspot test that was conducted on a second specimen from the newborn or child. 
Historical Note 
Effective 11-74; Former Section R9-13-205 repealed, new Section R9-13-205 adopted effective July 16, 1981 (Supp. 81-4). 
Amended effective December 6, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 
146, effective September 24, 1998 (Supp. 99-1). New Section recodified from R9-14-505 at 11 A.A.R. 3577, effective 
August 31, 2005 
(Supp. 05-3). Section repealed; new Section made by final rulemaking at 12 A.A.R. 1166, effective April 4, 2006 
(Supp. 06-2). 
R9-13-206. Reporting Requirements for Specimens 
A. The screening laboratory shall: 
1. Report in written or electronic format: 
a. The results of a bloodspot test on a specimen; and 
b. For a specimen that does not meet the requirements for testing specified in R9-13-203(E): 
i. That the bloodspot test was not performed on the specimen; and 
ii. The reason the bloodspot test was not performed; and 
2. Send the report to: 
a. The health care provider identified on the specimen collection kit; 
b. If applicable, the health care facility identified on the specimen collection kit; and 
c. The Department. 
B. The screening laboratory shall begin reporting bloodspot test results for the congenital disorders specified in: 
1. R9-13-202 (1) through (13), on the effective date of these rules; 
2. R9-13-202(14) through (27), no later than August 31, 2006; and 
3. R9-13-202(28), no later than June 30, 2007. 
C. A health care facility's designee, a health care provider, or the health care provider's designee, who orders a subsequent test on 
a newborn or infant in response to an abnormal result on a bloodspot test, shall send the results of the subsequent test in 
writing to the Department, if the subsequent test is not performed by the screening laboratory. 
D. Bloodspot test results are confidential subject to the disclosure provisions of 9 A.A.C. 1, Article 3, and A.R.S. §§ 12-2801 and 
12-2802. 
Historical Note 
Effective 11-74; Repealed effective July 16, 1981 (Supp. 81-4). Adopted as an emergency effective November 6, 1989, 
pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 89-4). Emergency expired. Readopted as an emergency 
effective February 7, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-1). Emergency expired. 
Readopted as an emergency with changes effective May 7, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 days 
(Supp. 90-2). Readopted as an emergency with changes effective August 6, 1990, pursuant to A.R.S. § 41-1026, valid 
for only 90 days (Supp. 90-3). Readopted as an emergency without change effective October 31, 1990, pursuant to 
A.R.S. § 41-1026, valid for only 90 days (Supp. 90-4). Readopted as an emergency without change effective January 
16, 1991, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-1). Readopted as an emergency without 
change effective April 11, 1991, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-2). Emergency rule 
permanently adopted with changes effective July 3, 1991 (Supp. 91-3). Amended effective December 16, 1996 (Supp. 
96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 146, effective September 24, 1998 (Supp. 99-1). 
New Section made by final rulemaking at 12 A.A.R. 1166, effective April 4, 2006 (Supp. 06-2). 
R9-13-207. Reporting Requirements for Hearing Test Results 
A. When an initial hearing test is performed on a newborn, a health care facility's designee, a health care provider, or the health 
care provider's designee shall provide to the Department, as specified in subsection (E), the following information: 
1. The newborn's name, date of birth, gender, and medical record number; 
2. Whether the newborn is from a single or multiple birth; 
3. If the newborn is from a multiple birth, the birth order of the newborn; 
4. The newborn's mother's first and last names; 
5. The name and identification code of the health care facility or health care provider submitting the hearing test results; 
6. The name and identification code of the health care facility of birth; 
7. The name of the health care provider responsible for the coordination of medical services for the newborn; 
8. The date of the hearing test; 
9. Whether or not the hearing test was performed when the newborn was an inpatient; 
10. The audiological equipment used for the hearing test and the type of hearing test performed; 
11. The hearing test result for each of the newborn's ears; and 
12. The name, address, and phone number of the contact person for the health care facility or health care provider. 
B. In addition to the information in subsection (A), if the reported results of an initial hearing test on a newborn include an 
abnormal result, a health care facility's designee, a health care provider, or the health care provider's designee shall provide 
to the Department, as specified in subsection (E), the following information: 
1. The newborn's race, ethnicity, and if applicable, AHCCCS identification number; 
2. Except as provided in subsection (B)(3), the mother's date of birth, name before first marriage, mailing address, and phone 
number; 
3. If the newborn's mother does not have physical custody of the newborn, the first and last names, mailing address, and 
phone number of the person who has physical custody of the newborn; 
4. The name of the health care provider who will be responsible for the coordination of medical services for the newborn 
after the newborn is discharged from the health care facility; and 
5. The name and phone number of the person to whom the newborn's mother or other person who has physical custody of 
the newborn was referred for a subsequent hearing test. 
C. When a hearing test is performed on a newborn or an infant after an initial hearing test, the designee of the health care facility, 
health care provider, or other person that performs the subsequent hearing test shall provide to the Department, as specified 
in subsection (E), the following information: 
1. The newborn's or infant's name, date of birth, and gender; 
2. Whether the newborn or infant is from a single or multiple birth; 
3. If the newborn or infant is from a multiple birth, the birth order of the newborn or infant; 
4. The newborn's or infant's mother's first and last names and date of birth; 
5. The name of the health care facility where the initial hearing test was performed, or the name and address of the health 
care provider who performed the initial hearing test;  
6. The name of the health care facility of birth; 
7. The name and identification code of the person submitting the subsequent hearing test results; 
8. The date of the subsequent hearing test; 
9. The audiological equipment used for the subsequent hearing test and the type of hearing test performed; 
10. The result for each of the newborn's or infant's ears on the subsequent hearing test; and 
11. The name, address, and phone number of the contact person for the health care facility, health care provider, or other 
person that performed the subsequent hearing test. 
D. In addition to the information in subsection (C), if the reported results of a subsequent hearing test on a newborn or infant 
include an abnormal result, the person submitting the report on the subsequent hearing test shall provide to the Department, 
as specified in subsection (E), the following information: 
1. Except as provided in subsection (D)(2), the newborn's or infant's mother's mailing address and phone number; 
2. If the newborn's or infant's mother does not have physical custody of the newborn or infant, the first and last names, 
mailing address, and phone number of the person who has physical custody of the newborn or infant; 
3. The name of the health care provider who is responsible for the coordination of medical services for the newborn or 
infant; and 
4. If applicable, the name and phone number of the person to whom the newborn's or infant's parent was referred for further 
hearing tests, evaluation services, specialty care, or early intervention. 
E. A health care facility's designee, health care provider, health care provider's designee, or other person required to report under 
subsections (A), (B), (C), or (D) shall submit, in an electronic format specified by the Department, the information specified 
in subsections (A), (B), (C), or (D) for hearing tests performed each week by the sixth day of the subsequent week. 
Historical Note 
Effective 11-74; Repealed effective July 16, 1981 (Supp. 81-4). New Section made by final rulemaking at 12 A.A.R. 1166, 
effective April 4, 2006 (Supp. 06-2). 
R9-13-208. Fees 
A. The fee for a first specimen is $30.00. 
B. The fee for a second specimen is $40.00. 
Historical Note 
New Section made by final rulemaking at 12 A.A.R. 1166, effective April 4, 2006 (Supp. 06-2). 
ARTICLE 3. REPEALED 
R9-13-301. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-301 repealed, new Section R9-13-301 adopted effective July 16, 1981 (Supp. 81-4). 
Amended effective December 16, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 
146, effective September 10, 1997 (Supp. 99-1). 
R9-13-302. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-302 repealed, new Section R9-13-302 adopted effective July 16, 1981 (Supp. 81-4). 
Amended effective December 16, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 
146, effective September 10, 1997 (Supp. 99-1). 
R9-13-303. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-303 repealed, new Section R9-13-303 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-304. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-304 repealed, new Section R9-13-304 adopted effective July 16, 1981 (Supp. 81-4). 
Amended effective December 16, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 
146, effective September 10, 1997 (Supp. 99-1). 
R9-13-305. Repealed 
Historical Note 
Effective 11-74; Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-306. Repealed 
Historical Note 
Effective 11-74; Repealed effective July 16, 1981 (Supp. 81-4). 
ARTICLE 4. REPEALED 
R9-13-401. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-401 repealed, new Section R9-13-401 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-402. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-402 repealed, new Section R9-13-402 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-403. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-403 repealed, new Section R9-13-403 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-404. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-404 repealed, new Section R9-13-404 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-405. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-405 repealed, new Section R9-13-405 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-406. Repealed 
Historical Note 
Effective 11-74; Former Section R9-13-406 repealed, new Section R9-13-406 adopted effective July 16, 1981 (Supp. 81-4). 
Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-407. Repealed 
Historical Note 
Effective 11-74; Repealed effective July 16, 1981 (Supp. 81-4). 
ARTICLE 5. REPEALED 
R9-13-501. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-501 repealed, new Section R9-13-501 adopted 
effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed by final rulemaking at 3 A.A.R. 146, effective March 23, 1997 (Supp. 99-1). 
R9-13-502. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-502 repealed, new Section R9-13-502 adopted 
effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed by final rulemaking at 3 A.A.R. 146, effective March 23, 1997 (Supp. 99-1). 
R9-13-503. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-503 repealed, new Section R9-13-503 adopted 
effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-504. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-504 repealed, new Section R9-13-504 adopted 
effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed by final rulemaking at 3 A.A.R. 146, effective March 23, 1997 (Supp. 99-1). 
R9-13-505. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-506. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-507. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-508. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-509. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-510. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
R9-13-511. Repealed 
Historical Note 
Adopted effective 1977 (Supp. 77-5). Repealed effective July 16, 1981 (Supp. 81-4). 
ARTICLE 6. REPEALED 
R9-13-601. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-601 repealed, new Section R9-13-601 adopted 
effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-602. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-602 repealed, new Section R9-13-602 adopted 
effective July 16, 1981 (Supp. 81-4). Amended effective July 3, 1991 (Supp. 91-3). Repealed effective December 16, 
1996 (Supp. 96-4). 
R9-13-603. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-603 repealed, new Section R9-13-603 adopted 
effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-604. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-604 repealed, new Section R9-13-604 adopted 
effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-605. Repealed 
Historical Note 
Adopted effective October 26, 1977 (Supp. 77-5). Former Section R9-13-605 repealed, new Section R9-13-605 adopted 
effective July 16, 1981 (Supp. 81-4). Amended effective July 3, 1991 (Supp. 91-3). Repealed effective December 16, 
1996 (Supp. 96-4). 
R9-13-606. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
ARTICLE 7. REPEALED 
R9-13-701. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed by final rulemaking at 3 A.A.R. 146, effective June 1, 1997 (Supp. 99-1). 
R9-13-702. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed by final rulemaking at 3 A.A.R. 146, effective June 1, 1997 (Supp. 99-1). 
R9-13-703. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-704. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed by final rulemaking at 3 A.A.R. 146, effective June 1, 1997 (Supp. 99-1). 
ARTICLE 8. REPEALED 
R9-13-801. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed June 1, 2000 (Supp. 01-1). 
R9-13-802. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended by emergency effective November 6, 1989, pursuant to A.R.S. § 
41-1026, valid for only 90 days (Supp. 89-4). Emergency expired, Readopted as an emergency effective February 7, 
1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-1). Emergency expired. Readopted as an 
emergency with changes effective May 7, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 90-2). 
Readopted as an emergency with changes effective August 6, 1990, pursuant to A.R.S. § 41-1026, valid for only 90 
days (Supp. 90-3). Readopted as an emergency without change effective October 31, 1990, pursuant to A.R.S. § 41-
1026, valid for only 90 days (Supp. 90-4). Readopted as an emergency without change effective January 16, 1991, 
pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-1). Readopted as an emergency without change 
effective April 11, 1991, pursuant to A.R.S. § 41-1026, valid for only 90 days (Supp. 91-2). Emergency rule 
permanently adopted effective July 3, 1991 (Supp. 91-3). Amended effective December 16, 1996 (Supp. 96-4). Section 
automatically repealed June 1, 2000 (Supp. 01-1). 
R9-13-803. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-804. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Repealed effective December 16, 1996 (Supp. 96-4). 
R9-13-805. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended effective July 3, 1991 (Supp. 91-3). Amended effective December 
16, 1996 (Supp. 96-4). Section automatically repealed by final rulemaking at 3 A.A.R. 146, effective June 30, 1998 
(Supp. 99-1). 
R9-13-806. Repealed 
Historical Note 
Adopted effective July 16, 1981 (Supp. 81-4). Amended effective December 16, 1996 (Supp. 96-4). Section automatically 
repealed June 1, 2000 (Supp. 01-1). 
ARTICLE 9. REPEALED 
R9-13-901. Repealed 
Historical Note 
Adopted as an emergency effective April 6, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-2). Former 
Section R9-13-901 expired, new Section R9-13-901 adopted as a permanent rule effective October 13, 1982 (Supp. 82-
5). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). 
R9-13-902. Emergency expired 
Historical Note 
Adopted as an emergency effective April 6, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-2). Former 
Section R9-13-902 expired (Supp. 82-5). 
ARTICLE 10. REPEALED 
R9-13-1001. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1002. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1003. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1004. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). 
ARTICLE 11. REPEALED 
R9-13-1101. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1102. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1103. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). 
R9-13-1104. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1105. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). New Section made by final rulemaking at 8 
A.A.R. 2323, effective May 9, 2002 (Supp. 02-2). Section repealed by final rulemaking at 12 A.A.R. 649, effective 
April 8, 2006 (Supp. 06-1). 
ARTICLE 12. REPEALED 
R9-13-1201. Repealed 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired. Permanent rule adopted effective March 22, 1983 (Supp. 83-2). Section repealed by final 
rulemaking at 12 A.A.R. 649, effective April 8, 2006 (Supp. 06-1). 
R9-13-1202. Emergency expired 
Historical Note 
Adopted as an emergency effective September 21, 1982, pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 82-5). 
Emergency expired (Supp. 83-2). 
ARTICLE 13. REPEALED 
R9-13-1301. Repealed 
Historical Note 
Adopted effective November 23, 1983 (Supp. 83-6). Section repealed by final rulemaking at 7 A.A.R. 1082, effective 
February 13, 2001 (Supp. 01-1). 
R9-13-1302. Repealed 
Historical Note 
Adopted effective November 23, 1983 (Supp. 83-6). Section repealed by final rulemaking at 7 A.A.R. 1082, effective 
February 13, 2001 (Supp. 01-1). 
R9-13-1303. Repealed 
Historical Note 
Adopted effective November 23, 1983 (Supp. 83-6). Section repealed by final rulemaking at 7 A.A.R. 1082, effective 
February 13, 2001 (Supp. 01-1). 
ARTICLE 14. REPEALED 
R9-13-1401. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1403 renumbered and amended as permanent rule R9-13-1401 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1402. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1404 renumbered and amended as permanent rule R9-13-1402 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1403. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1405 renumbered as permanent rule R9-13-1403 effective March 19, 1984 
(Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). 
R9-13-1404. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1406 renumbered and amended as permanent rule R9-13-1404 without 
change effective March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective 
February 13, 2001 (Supp. 01-1). 
R9-13-1405. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1407 renumbered and amended as permanent rule R90-13-1405 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1406. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1408 renumbered and amended as permanent rule R9-13-1406 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1407. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1409 renumbered and amended as permanent rule R9-13-1407 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1408. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1410 renumbered and amended as permanent rule R9-13-1408 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1409. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1411 renumber and amended as permanent rule R9-13-1409 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1410. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1412 renumbered and amended as permanent rule R9-13-1410 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1411. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1413 renumbered and amended as permanent rule R9-13-1411 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1412. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1414 renumbered and amended as permanent rule R9-13-1412 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1413. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1415 renumbered and amended as permanent rule R9-13-1413 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1414. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1416 renumbered and amended as permanent rule R9-13-1414 effective 
March 19, 1984 (Supp. 84-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 
(Supp. 01-1). 
R9-13-1415. Repealed 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1417 renumbered and amended as permanent rule R9-13-1415 effective 
March 19, 1984 (Supp. 84-2). Correction in subsection (C)(2) to insert the word `not' which was inadvertently omitted 
(Supp. 94-2). Section repealed by final rulemaking at 7 A.A.R. 1082, effective February 13, 2001 (Supp. 01-1). 
R9-13-1416. Emergency expired 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1416 renumbered and amended as permanent rule R9-13-1414 effective 
March 19, 1984 (Supp. 84-2). 
R9-13-1417. Emergency expired 
Historical Note 
Adopted as an emergency effective November 29, 1983 pursuant to A.R.S. § 41-1003, valid for only 90 days (Supp. 83-6). 
Emergency expired. Former Section R9-13-1417 renumbered and amended as permanent rule R9-13-1414 effective 
March 19, 1984 (Supp. 84-2). 
Editor's Note: Article 15 was recodified to 9 A.A.C. 25, Article 8 (Supp. 98-1). 
Editor's Note: Former Article 15 contained Sections and Exhibits which were adopted under an exemption from the 
provisions of the Administrative Procedure Act (A.R.S. Title 41, Chapter 6) pursuant to A.R.S. § 36-2205(C). Exemption from 
A.R.S. Title 41, Chapter 6 means that the Department of Health Services did not submit these rules to the Governor's 
Regulatory Review Council for review; the Department did not submit notice of proposed rulemaking to the Secretary of State 
for publication in the Arizona Administrative Register; the Department was not required to hold public hearings on these 
rules; and the Attorney General did not certify these rules. 
ARTICLE 15. RECODIFIED 
R9-13-1501. Recodified 
Historical Note 
Adopted effective July 11, 1994; received by the Office of the Secretary of State August 4, 1994, under an exemption from 
the provisions of the Administrative Procedure Act pursuant to A.R.S. § 36-2005(C) (Supp. 94-3). Former Section R9-
13-1501 recodified to A.A.C. R9-25-801 (Supp. 98-1). 
R9-13-1502. Recodified 
Historical Note 
Adopted effective October 12, 1994; received by the Office of the Secretary of State October 24, 1994, under an exemption 
from the provisions of the Administrative Procedure Act pursuant to A.R.S. § 36-2205(C) (Supp. 94-4). Former Section 
R9-13-1502 recodified to A.A.C. R9-25-802 (Supp. 98-1). 
Exhibit 1. Recodified 
Historical Note 
Adopted effective July 11, 1994; received by the Office of the Secretary of State August 4, 1994, under an exemption from 
the provisions of the Administrative Procedure Act pursuant to A.R.S. § 36-2005(C) (Supp. 94-3). Former R9-13-1502, 
Exhibit 1 recodified to A.A.C. R9-25-802, Exhibit 1 (Supp. 98-1). 
Exhibit 2. Recodified 
Historical Note 
Adopted effective July 11, 1994; received by the Office of the Secretary of State August 4, 1994, under an exemption from 
the provisions of the Administrative Procedure Act pursuant to A.R.S. § 36-2005(C) (Supp. 94-3). Former R9-13-1502, 
Exhibit 2 recodified to A.A.C. R9-25-802, Exhibit 2 (Supp. 98-1). 
Exhibit 3. Recodified 
Historical Note 
Adopted effective July 11, 1994; received by the Office of the Secretary of State August 4, 1994, under an exemption from 
the provisions of the Administrative Procedure Act pursuant to A.R.S. § 36-2005(C) (Supp. 94-3). Former R9-13-1502, 
Exhibit 3 recodified to A.A.C. R9-25-802, Exhibit 3 (Supp. 98-1). 
Exhibit 4. Recodified 
Historical Note 
Adopted effective July 11, 1994; received by the Office of the Secretary of State August 4, 1994, under an exemption from 
the provisions of the Administrative Procedure Act pursuant to A.R.S. § 36-2005(C) (Supp. 94-3). Former R9-13-1502, 
Exhibit 4 recodified to A.A.C. R9-25-802, Exhibit 4 (Supp. 98-1). 
R9-13-1503. Recodified 
Historical Note 
Adopted effective November 27, 1995, under an exemption from the provisions of the Administrative Procedure Act 
pursuant to A.R.S. § 36-2205(C) (Supp. 95-4). Former Section R9-13-1503 recodified to A.A.C. R9-25-803 (Supp. 98-
1). 
Exhibit 1. Recodified 
Historical Note 
Adopted effective November 27, 1995, under an exemption from the provisions of the Administrative Procedure Act 
pursuant to A.R.S. § 36-2205(C) (Supp. 95-4). Former R9-13-1503, Exhibit 1 recodified to A.A.C. R9-25-803, Exhibit 
1 (Supp. 98-1). 
 
 
 NEWBORN SCREENING - PARENT REFUSAL FORM  
  
  
_______________________________________ 
Name of Infant           Hospital of Birth  
_______________________________________ 
  
_______________________________________ _______________________________________  
Date of Birth           Hospital Street Address  
  
_______________________________________ _______________________________________  
Medical Record Number         City/State/Zip  
 
  
I, _______________________________, have received current information about the Arizona Department   
  Parent’s Name   
of Health Services’ Newborn Screening Program. I understand there are many rare, inherited disorders for which 
Arizona newborns are screened.   
  
I have been informed and understand that these tests are offered by State Law for all infants born in Arizona.  
  
I have been informed and understand that, if untreated, these conditions may cause permanent damage to my 
child, including serious mental retardation, growth failure and, in some cases, death.  
  
I have discussed the testing requirements with ______________________________
             Healthcare Provider  
.  I have had the   
testing requirements explained to me, and I understand all the risks involved if the screening tests are not given to 
my child.  
  
I have been informed and understand the nature of the screening tests and how these tests are given.  
  
I object to these tests, and I do not want ______________________________ tested for the conditions at  
            Child’s Name 
this time.  I understand that I may request the Newborn Screening from my physician at a future date, but no later 
than my child is one year of age.  
  
My decision was freely made without undue influence or encouragement by any person.  
  
  
_______________________________________ 
Printed Name           Relationship to Child  
_______________________________________ 
  
  
_______________________________________ 
Signature            Date  
_______________________________________ 
  
  
_______________________________________ 
Printed Name of Witness       Witness Title/Address  
_______________________________________ 
  
  
_______________________________________ 
Witness Signature         Date  
_______________________________________ 
  
Original: Infant’s Medical Record  
Copies: Newborn Screening Follow-up Program  
 Parent, Healthcare Provider  

 
 

Item Number Unit Units Ordered
Units 
Shipped
NBS-PB
Pkg.
NBS-EHDI01
Pkg.
NBS-NHS
Roll
Pkg.
Pkg.
Ea.
G:\GROUPS\NBRN_SCR\ADMIN\BROCHURE DISTRIBUTION\NBS brochure order form 022208_Current.xls
250 N. 17th Ave., 1st Floor
      Max:  2
Your Baby's Hearing (Spanish) for Doctors/Clinics
Arizona Pediatric Audiology Guidelines
100/Pkg                        
Max: 10 Pkgs.
(602) 364-1495
Phoenix, AZ  85007-3231
If You Have Any Questions, Please Call (602) 364-1409 or 1-800-548-8381 (outside Phoenix area) 
Please Allow Two (2) Weeks for Your Order to be Processed and Shipped
Attn:  Newborn Screening Program
Newborn Screening Program Order Form
Date of Request Requestor's Area Code & Telephone Number
Newborn Screening:  A Guide for Parents
(English/Spanish)
100/Pkg                                         
Max: 10 Pkgs.
StateCity
Ship to the Attention of (Name)
Please Print and Fill Out the Following Information Completely.
Please See the Unit Quantities and Maximums and Enter Your Requirements Accordingly.
Incomplete Information Will Cause a Delay in Processing Your Order.
Number & Street Address
Your Baby's Hearing (English) for Doctors/Clinics
100/Pkg                                   
Max: 10 Pkgs.
Date Order Received @ NBS Date Order Sent
Requestor's Area Code and Fax Number
Organization or Agency
Room No./Floor
Zip Code
Department
By
MAIL YOUR ORDER TO:
Arizona Department of Health Services
You May Fax or Mail Your Order to the Newborn Screening Program:
Arizona Hospitals' Universal Newborn Hearing Screening 
Guidelines
Ea.
FAX YOUR ORDER TO:
         Max:  2
These Items will be shipped directly from Standard Register.
These Items will be Shipped from Newborn Screening.
No per Unit 
MaximumsBrochure or Item Name
Universal Newborn Hearing Screening
(English/Spanish) for Hospitals
25/Pkgs.                              
Max:  10 Pkgs.
Newborn Hearing Screening Labels                                               
(for back of Lifetime Immunization Record)
250/Roll              
Max:  10 Rolls
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HEMOGLOBIN RESULTS 
 Hemoglobin results are reported in order of predominance with the highest percentage listed first: 
 F = fetal hemoglobin (2 alpha globin chains, 2 gamma globin chains) 
A = adult hemoglobin (2 alpha globin chains, 2 beta globin chains) 
S, C, D, G, E, O = hemoglobin, each with a different mutation in the beta globin chains 
U = unidentified hemoglobin variant 
Barts = non-oxygen carrying, transient hemoglobin variant (4 gamma globin chains) 
Mnemonic Description 
FA Normal newborn infant hemoglobin pattern with fetal hemoglobin (F) predominant 
plus measurable A hemoglobin 
AF Normal older infant result where fetal hemoglobin is declining and A hemoglobin 
is greater than 50%. It could also indicate a possible transfusion in a newborn. 
PAH Predominantly adult hemoglobin (would be reported as AA in older individuals) in 
an infant less than 60 days old.  This indicates a probable prior transfusion. 
AA Normal child or adult hemoglobin with A hemoglobin present and no other variant 
hemoglobin in measurable amounts 
FS, SS Probable sickle cell anemia - could also be S/ß° thalassemia or S/hereditary 
persistence of fetal hemoglobin (Hb S/HPFH)  
FSU Possible sickle cell anemia or sickle ß thalassemia 
FSA, SA Possible S/ß+ thalassemia or Sickle cell trait 
FSA1 Sickle cell trait or possible S/ß+ thalassemia 
FAS, AFS, 
ASF, AS 
Probable sickle cell trait 
FSC, SC Probable Sickle C disease 
FC Probable Hemoglobin C disease (homozygous) or Hemoglobin C with 
thalassemia 
FAC, AFC, 
ACF 
Probable Hemoglobin C trait 
 
F only Possible ß thalassemia in full term infant or a premature infant (not yet producing 
measurable A hemoglobin) 
FE, EE Possible Hemoglobin E disease (homozygous) or Hemoglobin E with thalassemia 
FSE Possible Sickle E disease 
FAE, AFE, 
AEF, AE 
Probable Hemoglobin E trait 
FD Possible Hemoglobin D disease (homozygous) or Hemoglobin D with 
thalassemia 
FAD, AFD, 
AD 
Probable Hemoglobin D trait 
 
FAD/G Possible Hemoglobin D or G trait 
FAG Probable Hemoglobin G trait 
FAO Probable Hemoglobin O trait 
FU Possible unidentified hemoglobin disease 
FUA Possible ß+ thalassemia trait or Thalassemia Intermedia 
FAU, AFU Possible unknown (slow migrating) hemoglobin variant 
FA fast , 
AFFAST 
Possible unknown (fast migrating) hemoglobin variant 
Bart 10 At least 10% Barts along with F and A hemoglobin - Possible alpha thalassemia 
trait.  Barts may be present in normal newborns and is even more likely to appear 
in premature infants 
Bart 15 15% or more Barts along with F and A hemoglobin - Possible alpha thalassemia 
trait or Hemoglobin H disease 
Office of Newborn Screening - 07/2010  
Healthcare professional 
orders screen and provides 
information about newborn 
screening to parents
Specimen collected at 24-36 
hours of age
State Lab tests specimen
Normal 
Results
Mailers to submitter 
(hospital) and 
healthcare 
professional ordering 
screen
Results documented 
in baby's medical 
record
Highly 
Abnormal 
Results
Phone call and fax to 
medical home/hospital, and 
notification to specialist
Immediate further testing 
(including second screen) 
and consultation with 
specialist
2nd NBS Normal:
Mailers to hospital 
and doctor, close 
case
Diagnosis, treatment begun 
(test results from other labs 
sent to NBS Follow-up
Abnormal or 
Borderline 
Results
Notification to doctors 
(mailer and letter) and 
parents (letter)
Further testing 
(including 2nd NBS)
2nd NBS Normal:
Mailers to 
hospital and 
doctor, close case
Diagnosis, 
treatment, (all 
test results from 
other labs sent to 
NBS Follow-up
Hemoglobin 
Trait Result
Notification to doctor 
of record (mailer and 
letter) and parents 
(letter)
No further follow-up
Unsatisfactory 
Specimen
Notification to submitter 
(hospital, lab) and request 
to collect another specimen
If no repeat screen, 
reminder letters to doctor 
of record and parents
No further follow-up
Prompt transport to State Lab 
(within 24 hours of collection) 
First Bloodspot Screen Flow Chart 
Office of Newborn Screening - 07/2010 
 
Hearing screening in 
hospital prior to 
discharge
PASS
Results recorded in medical 
record, on immunization card 
and in Hi*Track
*High risk
Diagnostic test by 
audiologist at 6-9 
months
Well 
babies
No further follow-
up
REFER
Results recorded in medical 
record, on immunization 
card and in Hi*Track
Well 
babies
Return for out-
patient screening
PASS REFER
Did not return for 
out-patient 
rescreen by 1 
month of age
Newborn Hearing 
Screening Follow-
up
Notification of 
parents and 
medical home
Diagnostic test
PASS DIAGNOSIS OF HEARING LOSS
Enrollment in early 
intervention 
program
*High risk
No rescreen in 
hospital
Discharged from 
hospital
Hearing Screen Flow Chart 
Newborn Screening ID BiologicalS Y S T E M S
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ID Biological
S Y S T E M S
 Sample Collection and Handling Procedure
* Text and images reprinted with the permission of The New York State Department of Health
Before collecting the sample, the following  materials must be gathered:
• Sterile lancet with tip less than 2.4mm long
• Sterile 70% alcohol pads
• Sterile gauze pads
• Warm moist towel or compress
• Fully completed, in-date filter paper blood collection form
• Sterile gloves
All fields on the form must be completed. Take steps to 
ensure that the filter paper is not touched or contami-
nated in any way during this process. If a submitter’s 
copy is present, remove it and keep it for your records.
Areas on the side of the heel containing
hatch marks are acceptable puncture sites.
21 3
Warm puncture site for 3-5 minutes 
with a warm, moist towel no hotter 
than 42˚C. 
4
Cleanse the puncture site with a sterile 
alcohol pad and allow to air dry.
5 6
Puncture skin and wipe away the first drop of 
blood. Allow a second large drop to form
Lightly touch the filter paper to the second drop 
of blood. Allow the blood to soak through and fill 
the preprinted circle. DO NOT APPLY MORE THAN 
ONE DROP TO A CIRCLE. Fill all remaining circles 
in this manner.  If blood flow is diminished, 
repeat steps 3-6 with sterile equipment.
7
Allow the speciment to dry in a horizontal position for at least three  
hours, away from direct contact with surfaces, heat, and sunlight.
Send the specimen to the appropriate location no more 
than 24 hours after collection.
8
Blood Spot Check ID BiologicalS Y S T E M S
• Filter paper circle incompletely filled or not saturated
• Blood applied to filter paper with needle or capillary tube
• Contamination of surface of filter paper circle
Quantity of blood insufficient
• Blood applied improperly with capillary tube or by other means
Scratched or abraded blood spots
• Specimen not properly dried before mailing
Wet or discolored blood spots
• Excess blood applied to the filter paper, usually with capillary 
   tube or needle
• Blood applied to both sides of the filter paper
Supersaturated blood spots
• Puncture site squeezed or "milked" to expel blood
• Exposure of blood spots to direct heat
• Contamination of filter paper before or after blood collection by   
   gloved or ungloved hands or by substances such as alcohol, 
   feeding or antiseptic solutions, hand lotion or powder
Diluted blood spots
• Alcohol not allowed to dry completely before skin puncture is made
• Allowing filter paper to come in contact with alcohol, water, 
   hand lotion, etc.
• Squeezing the area around the puncture site excessively
• Drying the specimen improperly
• Applying blood to filter paper with a capillary tube
Serum rings evident in blood spots
• Touching the same filter paper circle to a blood drop 
   several times 
• Filling the circle from both sides of the filter paper
Clotted or layered blood spots
• Failure to obtain any blood
No blood
UNACCEPTABLE SPECIMENS POSSIBLE CAUSES
ACCEPTABLE SPECIMEN
• No foreign substances have contaminated the filter paper.
• The blood fills all printed circles and is applied evenly on one side  
   of the filter paper only, free of layering and clots.
• The specimen dried in a horizontal position for at least three hours,  
   away from direct contact with surfaces, heat, and sunlight.
• The speciemen is sent to the appropriate location no more than 24 
   hours after collection.
* Text and images reprinted with the permission of The New York State Department of Health
USA:  17 P & N Drive • Greenville, SC 29611 USA • Tel. (864) 299-8787 • Fax (864) 299-8797 • id-biological.com • bdavin@id-biological.com • ggaillard@id-bioloigcal.com
UK:    15 Tanners Hill • Abbots Langley • Hertfordshire WD5 0LT UK • Tel. + 44 (0) 7525 844431 • Fax + 44 (0) 1923 682120 • id-biological.com • jdinan@id-biological.com 
ID Biological
S Y S T E M S
  Arizona Newborn Screening Program 
  Specimen Rejection Quick Reference.doc  2/10 
REASONS FOR SPECIMEN REJECTION (UNSATS) -  (with codes for Arizona unsats) 
 
Code Reason Comments 
Problems with the family or baby 
UPR Parent refusal Document the refusal in the medical record and submit the card with no 
blood (check the “parent refused testing” box) 
UIO Infant too old  
(>1 year of age) 
Reference ranges apply only to newborn infants and cannot accurately 
indicate risk of disease when collected from older children 
Problems with the card 
UCE Expired collection 
card 
Valid results cannot be reported if the card has expired per CLIA.  
Check the date printed above the circles for blood. 
UNI No identifying 
information 
Results cannot be reported if the infant cannot be identified. 
UNO No blood on the 
card 
Tests cannot be performed without blood. 
Problems with collection of the blood  
UCC Clotted or caked 
blood 
Uniform amounts of blood cannot be taken from samples with extra 
clotted blood in some areas of the spot. 
UIS Insufficient 
specimen 
Not enough blood was submitted to complete the whole panel of tests 
UMA Multiple specimen 
applications 
Blood may have been applied to both sides of the filter paper or with 
overlapping drops of blood instead of one big drop in each circle.  
UNS Uneven saturation With some areas more saturated with blood than other areas of the 
spot instead of one big drop in each circle, uniform amounts of blood 
cannot be taken for testing. 
UTS Torn or scratched With areas where filter paper is missing or bunched up, uniform 
amounts of blood cannot be taken for testing.  This usually happens 
when capillary tubes are used to collect the blood.  The rough edges of 
the tubes can abrade the filter paper if they are dragged along the 
surface.   
UST Serum or tissue fluid 
separation 
This can happen if the first drop of blood is not wiped away, if a liquid 
contaminant is allowed to come in contact with the blood spots, if the 
area around the puncture site is squeezed excessively (“milking”), or if 
the specimen is dried vertically so that gravity can separate blood 
components before complete drying. 
Problems in handling and shipping  
UTO Specimen too old 
(>14 days from 
collection date) 
Blood components degrade with age and exposure to heat and light 
and cannot be accurately measured. 
USD Specimen detached 
from form 
Results cannot be reported if the infant may be incorrectly identified. 
USC Contaminated 
 
Filter paper has come in contact with gloved or ungloved hands or 
substances such as alcohol, formula, antiseptic solutions, water, hand 
lotion or powder, etc. before or after specimen collection.  
Contaminated specimens yield unreliable results. 
Problem in the lab 
URS Results inconsistent Repeat testing of the same sample gives results that are greatly 
different from one another.  This could indicate that the sample was 
unevenly saturated or damaged in some way. 
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Timing of NBS Specimen Collection and Factors that Influence Results  
 
Disorder Appearance of 
symptoms &/or 
need for treatment 
Risk 
of 
acute 
crisis? 
Best 
Screening 
Window 
Factors causing false positive 
result 
Factors causing false 
negative result 
Duration of Effect Comments 
CH first year of life, 
treatment by 2 
weeks of age 
prevents mental 
retardation, 
developmental 
delays 
no 12 - 72 hr and  
2 - 6 weeks 
TSH surge in first 12-24 hours 
of life 
 
 
until 12 - 24 hours of age  
topical iodine on baby or 
breastfeeding mother 
 2 - 6 weeks after topical 
iodine discontinued 
 
maternal hyperthyroidism 
treated with PTU 
 
 until drug clears – typically 
7 - 14 days 
transient 
hypothyroidism 
acute illness  until recovered  
iodine deficiency  until supplemented  
 delayed rise of TSH in affected 
infants, particularly if preterm 
(immature hypothalamic-
pituitary-thyroid axis)  
up to 6 weeks of age  
 dopamine therapy (suppresses 
TSH) 
until drug therapy is 
stopped 
 
 steroid treatment (suppresses 
TSH & T4) 
unknown – depends on 
class of steroid and dose; 
estimate of 1 - 2 weeks 
 
CAH first week of life  yes 12 - 48 hr and 
2 - 4 weeks 
preterm birth or LBW 
 
 until stable  
sick or stressed infant 
 
 until recovered  
mother with CAH and elevated 
17-OHP 
 unknown – estimate of  
3 - 7 days 
 
early collection (<24 hr of age)  until 24 hours of age  
 maternal steroid treatment 
 
unknown – depends on 
class of steroid and dose; 
estimate of 1 - 2 weeks 
suppresses 
fetal adrenal 
function 
 steroid (dexamethasone) 
treatment in infant 
unknown – depends on 
dose; estimate of 1 - 2 
weeks 
 
Hb 
diseases 
first months of life, 
prophylactic 
penicillin by 6 weeks 
of age prevents 
infection and early 
complications 
no birth - 72 hours variants found with uncertain 
clinical significance 
  not affected by 
maternal 
conditions or 
treatments 
 red blood cell transfusion, 
ECMO 
3 - 4 months after the last 
RBC transfusion 
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Disorder Appearance of 
symptoms &/or 
need for treatment 
Risk 
of 
acute 
crisis? 
Best 
Screening 
Window 
Factors causing false positive 
result 
Factors causing false 
negative result 
Duration of Effect Comments 
BIO 1 week – 10 years 
of age (most show 
symptoms between 
3 – 6 months of age)  
no birth - 72 hr heat with humidity damage to 
specimen 
 until another specimen 
(protected from heat and 
promptly delivered to the 
lab) is tested 
not affected by 
maternal 
conditions or 
treatments 
prematurity 
 
 until 40 weeks gestational 
age 
 
liver disease,  jaundice  until resolved  
 transfusion of plasma or other 
blood products 
transient effect: 1 – 3 days 
after transfusion  
 
GAL first week of life yes birth - 48 hours heat damage to specimen, age 
of specimen (received by lab 
more than 4 – 5 days after 
collection) 
 
 until another specimen 
(protected from heat and 
promptly delivered to the 
lab) is tested 
not affected by 
maternal 
conditions or 
treatments 
 red blood cell transfusion 3 - 4 months after the last 
RBC transfusion 
 
PKU 6 - 8 months of age 
(irreversible brain 
damage happens if 
treatment is not 
started in first weeks 
of life) 
no 24 - 48 hours PN  
 
 4 - 24 hours after 
discontinuing PN 
 
liver dysfunction or immaturity  a few weeks or until 
resolved 
 
maternal PKU or hyperphe 
uncontrolled by diet or 
medication 
 12 - 24 hours unless infant 
has PKU 
transient 
hyperphe 
 early collection (<24 hours of 
age) or collection only a few 
hours after transfusion or 
discontinuation of ECMO 
1 – 3 days after transfusion  
MSUD first two weeks of 
life 
yes 24 - 48 hours PN  
 
 4 - 24 hours after 
discontinuing PN 
 
liver dysfunction or immaturity  a few weeks or until 
resolved 
 
 early collection (<24 hours of 
age) or collection only a few 
hours after transfusion or 
discontinuation of ECMO 
1 – 3 days after transfusion  
HCY  no 3 - 7 days PN 
 
 4 - 24 hours after 
discontinuing PN 
 
liver dysfunction or immaturity  a few weeks or until 
resolved 
 
 early collection, pyridoxine 
responsive cases are not 
identified by NBS 
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Disorder Appearance of 
symptoms &/or 
need for treatment 
Risk 
of 
acute 
crisis? 
Best 
Screening 
Window 
Factors causing false positive 
result 
Factors causing false 
negative result 
Duration of Effect Comments 
CIT & 
ASA 
first two weeks of 
life 
yes 24 - 48 hours PN  4 - 24 hours after 
discontinuing PN 
 
liver dysfunction or immaturity  a few weeks or until 
resolved 
 
 early collection or collection only 
a few hours after transfusion or 
discontinuation of ECMO 
1 – 3 days after transfusion  
TYR 1 3 – 4 months of age 
(liver is damaged by 
that time) 
no more than 1 
week of age 
liver dysfunction or immaturity  a few weeks or until 
resolved 
 
FAO 
disorders 
first few days to 
months or years 
(more easily 
detected during 
acute illnesses or 
during times of 
increased energy 
need) 
yes birth - 48 hours carnitine supplementation, 
MCT oil 
 
 
for duration of 
supplementation and some 
weeks later 
 
 well-fed state 
(later collection) 
could be until fasting or ill  
 transfusion or ECMO 1 – 3 days after transfusion  
fatty liver of pregnancy or 
HELLP syndrome* can cause 
elevated even chain 
acylcarnitines 
 unknown  
CUD  yes birth - 48 hours maternal carnitine deficiency  unknown  
 carnitine supplementation for duration of 
supplementation and some 
weeks later 
 
MCD, 
MMAs, 
PA 
 yes 24 - 48 hours maternal Vitamin B12  deficiency  a number of days 
depending on nutrition 
provided 
 
Organic 
acid 
disorders 
first two weeks of 
life 
yes 24 - 48 hours PN  
 
 4 - 24 hours after 
discontinuing PN 
 
IVA first two weeks of 
life 
yes 24 - 48 hours pivalic acid antibiotic therapy  24 hours after discontinuing 
therapy 
 
3MCC  yes 24 - 48 hours asymptomatic mother with 
3MCC, unaffected infant 
 unknown  
Arizona Newborn Screening Program 
Timing of NBS Specimen Collection  01/10
 - 4 - 
 
Disorder Appearance of 
symptoms &/or 
need for treatment 
Risk 
of 
acute 
crisis? 
Best 
Screening 
Window 
Factors causing false positive 
result 
Factors causing false 
negative result 
Duration of Effect Comments 
CF first months of life – 
early treatment 
prevents early, 
progressive damage  
no 24 hr - 7 days hypoxic organ damage, 
neonatal stress (low Apgar), 
respiratory distress, 
hypoglycemia, acute illness, 
preterm birth, trisomies, early 
collection (<12 hours of age) 
 
 
until recovered, until 40 
weeks gestational age 
(will elevate IRT but won’t 
be reported unless a 
mutation is found) 
not affected by 
maternal 
conditions or 
treatments 
elevated IRT and a single 
mutation detected 
 a sweat test  is needed to 
rule out CF and confirm 
carrier status  
not always 
false positive - 
CF has been 
diagnosed with 
only one 
mutation 
detected by the 
screening panel 
 in-range IRT and no DNA 
testing done 
 
without elevated IRT, no 
mutation testing will be 
done 
 
 later collection (IRT declines 
with age, even in affected 
infants) 
without elevated IRT, no 
mutation testing will be 
done  
 
 the mutation panel used – 
mutations vary among ethnic 
groups 
only mutations on the 
screening panel will be 
detected 
 
 
ECMO: extra corporeal membrane oxygenation 
PTU:  propylthiouracil, an antithyroid medication 
PN:  parenteral nutrition 
HELLP: Hemolysis, Elevated Liver enzymes, Low Platelets.  Mothers carrying fetuses with FAO disorders have a 16% chance of developing HELLP syndrome compared with the general population risk of 
0.88%. 
Arizona Early Hearing Detection and Intervention 
Arizona Department of Health Services 
Hearing Out-Patient Screening Form 
 
Screener or Contact Name: ____________________________________________ 
Screener or Contact Phone:____________________________________________ 
Date Submitted:______________________ 
Facility Name: __________________________________________________ 
 
FAX TO 602-364-1495 within one week of screening 
 
• Submit for all infants screened up to two years of age.   
• Do not submit if previous testing shows normal hearing and child is being screened for otitis media.  
• Submit diagnostic report form if diagnostic testing was completed 
 
Patient Last Name:        Date of Birth:        Gender: 
 Male       Female 
Patient First Name:        Birth Order (if multiple births): 
 A      B         C          D 
Mother’s Full Name:        Birth Facility:        
Mother’s Date of Birth:        Date of Screen:       
Primary Care Physician:        Right:    Pass    Fail Left    Pass    Fail 
Comments:         OAE                 ABR                 Behavioral 
 
Patient Last Name:       Date of Birth:        Gender: 
 Male       Female 
Patient First Name:       Birth Order (if multiple births): 
 A       B          C         D 
Mother’s Full Name:        Birth Facility:        
Mother’s Date of Birth:        Date of Screen:        
Primary Care Physician:        Right:    Pass    Fail Left    Pass    Fail 
Comments:         OAE                 ABR                  Behavioral 
 
Patient Last Name:        Date of Birth:        Gender: 
 Male       Female 
Patient First Name:        Birth Order (if multiple births): 
 A       B         C         D 
Mother’s Full Name:        Birth Facility:        
Mother’s Date of Birth:        Date of Screen:        
Primary Care Physician:        Right:    Pass    Fail Left    Pass    Fail 
Comments:         OAE                 ABR                   Behavioral 
 
Fax to: 602-364-1495     Questions call 602-364-1409 
Always start a new log sheet after faxing to ADHS 
 Within one week of screening, submit results to the Arizona Department of Health Services.    
 Fax to 602-364-1495 or mail to:  Newborn Screening Program 
      150 North 18th Avenue Suite 320 
      Phoenix, Arizona  85007-3242       
If you have questions or need help finding resources for further testing call 800-548-8381            
First Name__________________Last Name_________________________Gender______ 
Birth Hospital____________________ Birth Order _______Date of Birth (DOB)_________ 
Mother’s First Name_______________Last Name (prior to first marriage) ______________  
Mother’s DOB_____________ Clinic Site_______________________________________   
                  
       
                              
 □   Periodic  Screen 
          Child’s       Days        ⁭  2 - 4      
     Age          Months    ⁭ 1      ⁭ 2      ⁭ 4      ⁭ 6      ⁭ 9       ⁭ 12      ⁭ 15      ⁭ 18     ⁭ 24     ⁭ 36 
  
 
 
 
 
 
 
 
 
 
     
 
    
  
 □   Pre-Referral Rescreen (Conduct rescreen; refer for Audiological Assessment unless OAE pass is obtained.)  
 □   Other     __________________________________________________________________________________ 
●   Is this the first time the OAE hearing screening has been performed on this child in your clinic/practice?   
     ⁭ No  ⁭ Yes--if Yes:  
                 Was child screened for hearing loss at birth? ⁭ Unknown   ⁭ Not Screened    ⁭ Passed     ⁭ Referred 
                    Any neonatal risk factors or complications?  ⁭ Unknown   ⁭ No ⁭Yes: ________________________________ 
                    Any family history of early hearing loss?          ⁭ No  ⁭Yes: ____________________________ 
 
●  Is the parent/caregiver concerned about the child’s:      Hearing?   ⁭ No ⁭Yes: ____________________________ 
           Speech?    ⁭ No ⁭Yes: ____________________________ 
 
●  Has the child experienced:                                        Head trauma?   ⁭ No    ⁭Yes: ____________________________     
                   Recurrent ear infections?   ⁭ No    ⁭Yes: ____________________________ 
    
●  Does the child have Pressure Equalization (PE) tubes? ⁭ No    ⁭Yes: ____________________________ 
  
  
RIGHT        
                               
    
      Pass  ⁭  Pass  ⁭     Pass ⁭                  
    
 
 
 
 
      
  
 
 
 
  ⁭ Schedule Pre-Referral Rescreen (w/in 2 weeks) or 
     ⁭ Refer for Audiological Assessment  
 
    
 
      
 *Can’t Can’t
  test ⁭  test ⁭ 
 Refer ⁭ Refer ⁭           Refer ⁭ 
  
⁭ If wax removal     
⁭ If OM or other 
Middle Ear Evaluation   
(Tympanometry/Pneumatic Otoscopy)
OAE 1 OAE 2 
⁭  Rescreen 4 weeks after medical clearance or 
  ⁭ Refer for Audiological Assessment as needed; 
       also if OM remains unresolved after 3 months   
    
Hearing 
Screening 
Record 
 □   Periodic  Screen 
          Child’s       Days        ⁭  2 - 4      
     Age          Months    ⁭ 1      ⁭ 2      ⁭ 4      ⁭ 6      ⁭ 9       ⁭ 12      ⁭ 15      ⁭ 18     ⁭ 24     ⁭ 36 
  
 
 
 
 
 
 
 
 
 
     
 
  
□   Pre-Referral Rescreen (Conduct rescreen; refer for Audiological Assessment unless OAE pass is obtained.)  
□   Other     __________________________________________________________________________________ 
   Is this the first time the OAE hearing screening has been performed on this child in your clinic/practice?  
     ⁭ No  ⁭ Yes--if Yes:  
                 Was child screened for hearing loss at birth? ⁭ Unknown   ⁭ Not Screened    ⁭ Passed     ⁭ Referred 
                    Any neonatal risk factors or complications?  ⁭ Unknown   ⁭ No ⁭Yes: ________________________________ 
                    Any family history of early hearing loss?          ⁭ No  ⁭Yes: ____________________________ 
 
●  Is the parent/caregiver concerned about the child’s:      Hearing?   ⁭ No ⁭Yes: ____________________________ 
           Speech?     o ⁭Yes: ____________________________ 
 
●  Has the child experienced:                                        Head trauma?   ⁭ No    ⁭Yes: ____________________________     
                   Recurrent ear infections?   ⁭ No    ⁭Yes: ____________________________ 
    
●  Does the child have Pressure Equalization (PE) tubes? ⁭ No    ⁭Yes: ____________________________ 
  
LEFT        
                               
    
      Pass  ⁭  Pass  ⁭     Pass ⁭                  
    
 
 
 
 
 Screener: __________________________    Date: ____/____/____   Recommendations :      
  Target Date  ___/___/___    
   Dx Code _______ 
   Referred to :___ ____ ____ ____  
  ⁭ Schedule Pre-Referral Rescreen (w/in 2 weeks) or 
     ⁭ Refer for Audiological Assessment  
 
    
 
      
 *Can’t Can’t
  test ⁭  test ⁭ 
 Refer ⁭ Refer ⁭           Refer ⁭ 
  
⁭ If wax removal     
⁭ If OM or other 
Middle Ear Evaluation   
(Tympanometry/Pneumatic Otoscopy)
OAE 1 OAE 2 
⁭  Rescreen 4 weeks after medical clearance or 
  ⁭ Refer for Audiological Assessment as needed; 
          also if OM remains unresolved after 3 months   
*If can’t test, indicate why:  ⁭child uncooperative ⁭internal noise ⁭ external noise ⁭ear wax  ⁭drainage ⁭equipment problem 
 
 
REFERRAL AND TRACKING FORM  
ARIZONA EARLY HEARING DETECTION AND INTERVENTION &  
ARIZONA STATE SCHOOLS FOR THE DEAF AND THE BLIND 
PHOENIX 
 
PLEASE FAX WITH ASSESSMENT RESULTS WITHIN 48 HOURS TO:   
ASDB fax: 602-544-1704     phone:  602-771-5200 
AzEHDI fax: 602-364-1495     phone:  602-364-1409 
 
 
NAME OF CHILD:         CHILD  BIRTH DATE: 
 
DATE REFERRED:   BIRTH HOSPITAL:                                                      MALE    FEMALE     
 
MOTHER’S FULL NAME:   
 
  MOTHER BIRTHDATE:   
 
ADDRESS WITH CITY & ZIP:   
 
PRIMARY PERSON TO CONTACT:       HOME PHONE:   
 
CELL PHONE:     WORK PHONE:      HOME LANGUAGE :   
 
TO WHAT AGENCY OR SPECIALIST HAVE YOU REFERRED THIS CHILD? 
 
DDD REFERRAL MADE: YES   NO   ALREADY ENROLLED    
CRS REFERRAL MADE: YES   NO   ALREADY ENROLLED   
ENT REFERRAL MADE: YES   NO   ENT PROVIDER NAME:  ________________________ 
 
OTHER AGENCY: ___________________________________________________________________________ 
 
OTHER SPECIALTY:  __     ___________________________________________________________________ 
 
 
AUDIOLOGIST NAME:           DATE OF EVALUATION:  ____________      
 
Revised 8/20/09 
 Fax to both if… 
o Under 3 years 
of age 
o Bilateral 
hearing loss  
o Sensorineural 
or Permanent 
Conductive  
o Auditory 
Neuropathy 
 
 Fax to AzEHDI 
only if... 
o Over 3 years of 
age or 
o Unilateral 
o Ruled out 
Hearing Loss in 
a Child under 3 
(normal 
hearing results) 
TESTING THAT DETERMINED HEARING LOSS (MARK ALL THAT APPLY) 
  
ABR:     BEHAVIORAL:   
  CLICKS    VRA 
  TONE BURSTS/PIPS   BOA 
  BONE CONDUCTION   PLAY 
  ASSR    CONVENTIONAL 
 
HEARING LOSS:     
             CONFIRMED        Preliminary  NEXT APPT: ___________ 
 
DEGREE:   RIGHT    LEFT                 TYPE:  RIGHT  LEFT 
    NORMAL     CONDUCTIVE 
    MILD     PERMANENT CONDUCTIVE 
    MODERATE     MIXED 
    SEVERE     SENSORINEURAL 
    PROFOUND    NEUROPATHY 
 
 AMPLIFICATION:   RIGHT   LEFT    ANTICIPATED FITTING DATE:  _____________  
 
OTHER DISABILITIES/CONCERNS:  _______________________________________ 
__________________________________________________________________
__________________________________________________________________
_________________________________________________________________
 
 
 
REFERRAL AND TRACKING FORM  
ARIZONA EARLY HEARING DETECTION AND INTERVENTION &  
ARIZONA STATE SCHOOLS FOR THE DEAF AND THE BLIND 
FLAGSTAFF 
 
PLEASE FAX WITH ASSESSMENT RESULTS WITHIN 48 HOURS TO:   
ASDB fax: 928-773-9229     phone:  928-774-0655 
AzEHDI fax: 602-364-1495     phone:  602-364-1409 
 
 
NAME OF CHILD:         CHILD  BIRTH DATE: 
 
DATE REFERRED:   BIRTH HOSPITAL:                                                      MALE    FEMALE     
 
MOTHER’S FULL NAME:   
 
  MOTHER BIRTHDATE:   
 
ADDRESS WITH CITY & ZIP:   
 
PRIMARY PERSON TO CONTACT:       HOME PHONE:   
 
CELL PHONE:     WORK PHONE:      HOME LANGUAGE :   
 
TO WHAT AGENCY OR SPECIALIST HAVE YOU REFERRED THIS CHILD? 
 
DDD REFERRAL MADE: YES   NO   ALREADY ENROLLED    
CRS REFERRAL MADE: YES   NO   ALREADY ENROLLED   
ENT REFERRAL MADE: YES   NO   ENT PROVIDER NAME:  ________________________ 
 
OTHER AGENCY: ___________________________________________________________________________ 
 
OTHER SPECIALTY:  __     ___________________________________________________________________ 
 
 
AUDIOLOGIST NAME:           DATE OF EVALUATION:  ____________      
 
Revised 8/20/09 
 Fax to both if… 
o Under 3 years 
of age 
o Bilateral 
hearing loss  
o Sensorineural 
or Permanent 
Conductive  
o Auditory 
Neuropathy 
 
 Fax to AzEHDI 
only if... 
o Over 3 years of 
age or 
o Unilateral 
o Ruled out 
Hearing Loss in 
a Child under 3 
(normal 
hearing results) 
TESTING THAT DETERMINED HEARING LOSS (MARK ALL THAT APPLY) 
  
ABR:     BEHAVIORAL:   
  CLICKS    VRA 
  TONE BURSTS/PIPS   BOA 
  BONE CONDUCTION   PLAY 
  ASSR    CONVENTIONAL 
 
HEARING LOSS:     
             CONFIRMED        Preliminary  NEXT APPT: ___________ 
 
DEGREE:   RIGHT    LEFT                 TYPE:  RIGHT  LEFT 
    NORMAL     CONDUCTIVE 
    MILD     PERMANENT CONDUCTIVE 
    MODERATE     MIXED 
    SEVERE     SENSORINEURAL 
    PROFOUND    NEUROPATHY 
 
 AMPLIFICATION:   RIGHT   LEFT    ANTICIPATED FITTING DATE:  _____________  
 
OTHER DISABILITIES/CONCERNS:  _______________________________________ 
__________________________________________________________________
__________________________________________________________________
_________________________________________________________________
 
 
 
REFERRAL AND TRACKING FORM  
ARIZONA EARLY HEARING DETECTION AND INTERVENTION &  
ARIZONA STATE SCHOOLS FOR THE DEAF AND THE BLIND 
TUCSON 
 
PLEASE FAX WITH ASSESSMENT RESULTS WITHIN 48 HOURS TO:   
ASDB fax: 520-770-3010      phone:  520-770-3703 
AzEHDI fax: 602-364-1495     phone:  602-364-1409 
 
 
NAME OF CHILD:         CHILD  BIRTH DATE: 
 
DATE REFERRED:   BIRTH HOSPITAL:                                                      MALE    FEMALE     
 
MOTHER’S FULL NAME:   
 
  MOTHER BIRTHDATE:   
 
ADDRESS WITH CITY & ZIP:   
 
PRIMARY PERSON TO CONTACT:       HOME PHONE:   
 
CELL PHONE:     WORK PHONE:      HOME LANGUAGE :   
 
TO WHAT AGENCY OR SPECIALIST HAVE YOU REFERRED THIS CHILD? 
 
DDD REFERRAL MADE: YES   NO   ALREADY ENROLLED    
CRS REFERRAL MADE: YES   NO   ALREADY ENROLLED   
ENT REFERRAL MADE: YES   NO   ENT PROVIDER NAME:  ________________________ 
 
OTHER AGENCY: ___________________________________________________________________________ 
 
OTHER SPECIALTY:  __     ___________________________________________________________________ 
 
 
AUDIOLOGIST NAME:           DATE OF EVALUATION:  ____________      
 
Revised 8/20/09 
 Fax to both if… 
o Under 3 years 
of age 
o Bilateral 
hearing loss  
o Sensorineural 
or Permanent 
Conductive  
o Auditory 
Neuropathy 
 
 Fax to AzEHDI 
only if... 
o Over 3 years of 
age or 
o Unilateral 
o Ruled out 
Hearing Loss in 
a Child under 3 
(normal 
hearing results) 
TESTING THAT DETERMINED HEARING LOSS (MARK ALL THAT APPLY) 
  
ABR:     BEHAVIORAL:   
  CLICKS    VRA 
  TONE BURSTS/PIPS   BOA 
  BONE CONDUCTION   PLAY 
  ASSR    CONVENTIONAL 
 
HEARING LOSS:     
             CONFIRMED        Preliminary  NEXT APPT: ___________ 
 
DEGREE:   RIGHT    LEFT                 TYPE:  RIGHT  LEFT 
    NORMAL     CONDUCTIVE 
    MILD     PERMANENT CONDUCTIVE 
    MODERATE     MIXED 
    SEVERE     SENSORINEURAL 
    PROFOUND    NEUROPATHY 
 
 AMPLIFICATION:   RIGHT   LEFT    ANTICIPATED FITTING DATE:  _____________  
 
OTHER DISABILITIES/CONCERNS:  _______________________________________ 
__________________________________________________________________
__________________________________________________________________
_________________________________________________________________
 
 
 
REFERRAL AND TRACKING FORM  
ARIZONA EARLY HEARING DETECTION AND INTERVENTION &  
ARIZONA STATE SCHOOLS FOR THE DEAF AND THE BLIND 
YUMA 
 
PLEASE FAX WITH ASSESSMENT RESULTS WITHIN 48 HOURS TO:   
ASDB fax: 928-783-4941     phone:  928-783-4003 
AzEHDI fax: 602-364-1495     phone:  602-364-1409 
 
 
NAME OF CHILD:         CHILD  BIRTH DATE: 
 
DATE REFERRED:   BIRTH HOSPITAL:                                                      MALE    FEMALE     
 
MOTHER’S FULL NAME:   
 
  MOTHER BIRTHDATE:   
 
ADDRESS WITH CITY & ZIP:   
 
PRIMARY PERSON TO CONTACT:       HOME PHONE:   
 
CELL PHONE:     WORK PHONE:      HOME LANGUAGE :   
 
TO WHAT AGENCY OR SPECIALIST HAVE YOU REFERRED THIS CHILD? 
 
DDD REFERRAL MADE: YES   NO   ALREADY ENROLLED    
CRS REFERRAL MADE: YES   NO   ALREADY ENROLLED   
ENT REFERRAL MADE: YES   NO   ENT PROVIDER NAME:  ________________________ 
 
OTHER AGENCY: ___________________________________________________________________________ 
 
OTHER SPECIALTY:  __     ___________________________________________________________________ 
 
 
AUDIOLOGIST NAME:           DATE OF EVALUATION:  ____________      
 
Revised 8/20/09 
 Fax to both if… 
o Under 3 years 
of age 
o Bilateral 
hearing loss  
o Sensorineural 
or Permanent 
Conductive  
o Auditory 
Neuropathy 
 
 Fax to AzEHDI 
only if... 
o Over 3 years of 
age or 
o Unilateral 
o Ruled out 
Hearing Loss in 
a Child under 3 
(normal 
hearing results) 
TESTING THAT DETERMINED HEARING LOSS (MARK ALL THAT APPLY) 
  
ABR:     BEHAVIORAL:   
  CLICKS    VRA 
  TONE BURSTS/PIPS   BOA 
  BONE CONDUCTION   PLAY 
  ASSR    CONVENTIONAL 
 
HEARING LOSS:     
             CONFIRMED        Preliminary  NEXT APPT: ___________ 
 
DEGREE:   RIGHT    LEFT                 TYPE:  RIGHT  LEFT 
    NORMAL     CONDUCTIVE 
    MILD     PERMANENT CONDUCTIVE 
    MODERATE     MIXED 
    SEVERE     SENSORINEURAL 
    PROFOUND    NEUROPATHY 
 
 AMPLIFICATION:   RIGHT   LEFT    ANTICIPATED FITTING DATE:  _____________  
 
OTHER DISABILITIES/CONCERNS:  _______________________________________ 
__________________________________________________________________
__________________________________________________________________
_________________________________________________________________
 
 AABR – Automated Auditory Brainstem Response 
OAE – Otoacoustic Emissions          Doctor Resource Revised 9/2010 
1 
Month 
 Health Care Providers - Screen All Babies by One Month 
Resources for Outpatient Hearing Screening 
 
If a baby did not pass the newborn hearing screening at birth, it is important that the baby is screened again as soon as possible, no later than 1 month of 
age.  If the baby was in the NICU for more than 5 days or has a risk indicator for hearing loss, the baby should not
NOTE: Not all hospitals can screen infants over 1 month of age. 
 receive an outpatient screen but should 
go directly to a pediatric audiologist for testing.  The family may need a referral from the primary care provider in order to schedule an appointment. 
Phoenix (Metro Area) - Central, North and Scottsdale 
OAE/A-ABR   HOSPITALS OAE/AABR OTHER PROVIDERS 
              √ Banner Good Samaritan 602-839-2178    √                 Affiliated Audiology 602-254-6041 
   √        √      Maricopa Medical Audiology Clinic 602-344-5185    √          √      Arizona Balance & Hearing 602-265-9000 
             √ John C. Lincoln North Mountain 
             √     Paradise Valley Hospital 
             √      Phoenix Baptist Hospital 
             √ St. Joseph’s Hospital 
602-277-4161 x44 * 
               √ Neonatology Associates (NAL) 602-277-4161 x44 * 
   √                 Mountain Park Clinic – Baseline 602-243-7277 
   √                 North Valley ENT 602-688-6500 
   √        √       Phoenix Children’s Audiology 602-546-0905    √          √      Premiere ENT Surgeons 602-678-5001 
             √      Scottsdale Healthcare (North) 480-323-3638   √              Valley ENT 480-614-0499 
             √       Scottsdale Healthcare Osborn 480-882-4171  
Phoenix Area – West Valley 
OAE/AABR   HOSPITALS OAE/AABR   OTHER PROVIDERS 
              √      Arrowhead Hospital 
              √      Banner Thunderbird Medical 
              √      Maryvale Hospital 
              √     West Valley Hospital 
602-277-4161 x44 * 
   √               Adelante Healthcare 623-544-5108 
   √               Valley ENT 623-566-4718 
   √                 Mayo Clinic – Arrowhead 623-561-5282 
   √          √      West Valley ENT 602-843-4844 
              √ Banner Estrella Medical Ctr. 623-327-5873    √          √      Metro Hearing Services 623-866-0147 
              √ Banner Del E. Webb 602-344-1015                 √      Neonatology Associates (NAL) 602-277-4161 x44 * 
Phoenix Area – East Valley 
OAE/AABR   HOSPITALS OAE/AABR  OTHER PROVIDERS 
              √      Banner Baywood Medical Ctr. 
              √ Banner Gateway Medical Ctr. 
              √ Chandler Regional Hospital 
              √      Mercy Gilbert Medical Ctr 
              √      Mountain Vista Medical 
602-277-4161 x44 * 
  √                Advance Hearing Group 480-218-1328 
  √          √       ASU Speech and Hearing 480-965-2373 
  √          √       Arizona Ear and Hearing 480-292-7100 
  √                Arizona Hearing and Balance 480-558-5306 
  √                Cigna Healthcare Hearing Ctr. 480-464-6870 
 √          √      Cardon Children’s/Banner Desert 480-412-4099   √          √       Desert Sounds 480-497-3285 
 √          √      Phoenix Children’s Audiology 602-546-0905   √                 ENT Specialists of Arizona 480-894-5550 X502 
 √          √       Tempe St. Luke’s 480-784-5557   √          √       Good Sound Audiology 480-497-0780 
    √                Harper Hearing Solutions 480-838-1212 
    √                Hearing Solutions of Arizona 480-833-4330 
    √          √       Premier ENT Surgeons 602-678-5001 
Tucson Area & Southern Arizona 
OAE/AABR  HOSPITALS OAE/AABR  OTHER PROVIDERS 
  √          √     Carondelet St. Joseph’s 520-873-3761 √          Adobe Hearing Center 520-322-8211 
  √          √      Carondelet St. Mary’s 520-872-4846 √          Carlson Ear, Nose & Throat 520-795-8777 
              √      Northwest Medical Center 520-877-4021 √          Grunewald Blitz (U of A) 520-621-7070 
  √          √      Tucson Medical Center 520-324-2075 √            √      Marana Health Center 520-682-4560 
  √                The Children’s Clinic  520-324-3600 √   Oro Valley & Tanque Verde Aud 520-751-3901 
              √      Casa Grande Regional 520-381-6475 √   Tucson ENT 520-777-0495 
  √          √      Carondelet Holy Cross (Nogales) 520-287-8048 √   Birth and Women’s Health Center 520-795-9912 
              √      Cobre Valley Community (Safford) 928-402-1260 √   Chricahua Health (Douglas) 520-364-3285 
              √      Mt. Graham (Safford) 928-348-4185 √            √      Audiology Inc. (Safford) 928-428-1613 
  √          √      Sierra Vista Hospital 520-417-3184 √   Southern AZ Hearing & Balance 520-459-0688 
  √          √      Yuma Regional Medical Ctr 928-336-3893 √            √      Cochise ENT Assoc (Sierra Vista) 520-458-4919 
  √                     Sells Special Services Program 520-383-8665 
Flagstaff Area & Northern Arizona 
OAE/AABR   HOSPITALS OAE/AABR  OTHER PROVIDERS 
  √           √     Flagstaff Medical Ctr. Audiology 928-214-3728 √                  North Country CHC (Flagstaff) 928-213-6154 
  √           √     Verde Valley (Cottonwood) 928-639-6521 √                 Northern Arizona University 928-523-8110 
               √     Little Colorado (Winslow) 928-289-4691 √            √      Audiology Inc (Show Low) 928-537-3456 
  √           √     Tuba City IHS 928-283-2629 √               ASDB Eastern Highland Reg. Coop 928-524-6770 
               √     Payson Regional 928-472-1226 √                Fort Defiance 928-729-8915 
  √           √     Banner Page Hospital  928-645-0777 √            √      Chinle IHS Audiology 928-674-7223 
               √     Summit Healthcare 928-537-6362                √      White River IHS (Whiteriver) 928-338-4911 x3728 
               √     Havasu Regional 928-453-0660 √            √      White Mtn Hearing Svc (Lakeside) 928-537-7373 
               √     Kingman Regional  928-757-0690 √            √      AZ Coast ENT (Lake Havasu) 928-854-5368 
               √     WARMC (Bullhead City) 928-763-0676 √            Valley View (Fort Mohave) 928-788-7095 
  √           √     Yavapai Regional 928-771-5200 √                 Tri State Audiology (Bullhead City) 928-758-3337 
  √            Prescott ENT 928-778-9190 
 Doctor Resource Revised 9/2010 
3 
Months 
 Health Care Providers – Diagnostic Evaluation by Three Months 
Resources for Infant Diagnostic Hearing Testing 
 
If a baby has failed the outpatient screen, or has been in the NICU for more than five days, the baby should be referred by their 
primary care provider to a pediatric audiologist for a diagnostic evaluation. Under three to six months of age the testing is 
usually completed without sedation/anesthesia.  After an infant is older than six months of age, sedation/anesthesia may be 
required to complete the test.   
 
SITES MARKED WITH * ARE ABLE TO PERFORM TESTING WITH SEDATION/ANESTHESIA IF NEEDED 
 
Phoenix Area (Metro Area, Central, North & Scottsdale) 
*Phoenix Children’s Hospital (Phoenix & East Valley locations) 602-546-0905 
*St. Joseph’s Hospital Children’s Rehabilitative Services 602-406-6420 
Arizona Balance & Hearing Associates 602-265-9000 
Maricopa Medical Audiology Clinic 602-344-5185 
Phoenix Indian Medical Center 602-263-1514 
Premier ENT Surgeons 602-678-5001 
Phoenix Area – West Valley 
Valley ENT (Glendale) 623-566-4718 
Phoenix Area – East Valley 
*Arizona Hearing and Balance Center (Chandler) 480-558-5306 
*Cardon’s Children’s/Banner Desert Audiology (Mesa) 480-412-4099 
Arizona State University Speech and Hearing Clinic (Tempe) 480-965-2373 
Arizona Ear & Hearing (Queen Creek) 480-292-7100 
Desert Sounds Audiology (Mesa) 480-497-3285 
Good Sound Audiology (Mesa) 480-497-0780 
Tucson Area & Southern Arizona 
*Carondelet St. Joseph’s Hospital Hearing Services 520-873-3761 
*Tucson Medical Center Audiology Department 520-324-2075 
Carondelet St. Mary’s Audiology Department 520-872-4846 
Tucson ENT (East & Northwest Tucson) 520-777-0495 
University of Arizona Grunewald-Blitz Center 520-621-7070 
Audiology Inc. (Safford) 928-428-1613 
Flagstaff Area & Northern Arizona 
*Chinle Indian Health Services Audiology Department 928-674-7223 
*Flagstaff Medical Center Audiology Department 928-214-3728 
White Mountain Hearing Services (Lakeside) 928-537-7373 
Audiology Inc. (Show Low) 928-537-3456 
 
NOTE: Sites have self identified as providing services and are not endorsed or recommended. 
 
If you have questions or concerns about the hearing screening or would like more information, you can call the Arizona Department of Health 
Services Newborn Screening Program at 602-364-1409 or visit online at www.aznewborn.com
 
. 
Si usted tiene algunas preguntas o preocupaciones sobre la prueba auditiva o si quisiera más información, puede llamar al Departamento de 
Servicios de Salud de Arizona al Programa de Análisis para el Niño Recién Nacido al número 602-364-1409.  También puede visitarnos en el 
Internet a www.aznewborn.com. 
*previsión del español disponible en 602-277-4161x 43      Parent Resource Revised 9/2010 
1 
Month 
Screen All Babies by One Month 
Resources for Parents for Outpatient Hearing Screening 
Your baby did not pass the newborn hearing screening.  It is important that your baby is screened again as soon as possible (before 1 month of age).  
Contact one of the places listed below to schedule an appointment.  If you need a referral for insurance, talk to your baby’s doctor as soon as possible. 
 
Su bebé no pasó la prueba de audición del recién nacido.  Es importante que haga otra prueba auditiva para su bebé lo más pronto posible.  Debe hacer esta prueba antes 
que su bebé cumpla 1 mes de edad.  Llame a uno de los lugares en la lista abajo para hacer una cita.  Si usted necesita una referencia de su seguro médico, hable con el 
doctor de su bebé lo más pronto posible. 
NOTE: Not all hospitals can screen infants over 1 month of age. 
Phoenix (Metro Area) - Central, North and Scottsdale 
HOSPITALS OTHER PROVIDERS 
Banner Good Samaritan 602-839-2178 Affiliated Audiology 602-254-6041 
Maricopa Medical Audiology Clinic 602-344-5185 Arizona Balance & Hearing 602-265-9000 
John C. Lincoln North Mountain 
Paradise Valley Hospital 
Phoenix Baptist Hospital 
St. Joseph’s Hospital 
602-277-4161 x44 * 
Mayo Clinic – Scottsdale 480-301-8484 
Neonatology Associates (NAL) 602-277-4161 x44 * 
Mountain Park Clinic – Baseline 602-243-7277 
Phoenix Children’s Audiology 602-546-0905 North Valley ENT 602-688-6500 
Scottsdale Healthcare (North) 480-323-3638 Premiere ENT Surgeons 602-678-5001 
Scottsdale Healthcare Osborn 480-882-4171 Valley ENT 480-614-0499 
Phoenix Area – West Valley 
HOSPITALS OTHER PROVIDERS 
Arrowhead Hospital 
Banner Thunderbird Medical 
Maryvale Hospital 
West Valley Hospital 
602-277-4161 x44 * 
Adelante Healthcare 623-544-5108 
Valley ENT 623-566-4718 
Mayo Clinic – Arrowhead 623-561-5282 
West Valley ENT 602-843-4844 
Banner Estrella Medical Ctr. 623-327-5873 Metro Hearing Services 623-866-0147 
Banner Del E. Webb 602-344-1015 Neonatology Associates (NAL) 602-277-4161 x44 * 
Phoenix Area – East Valley 
HOSPITALS OTHER PROVIDERS 
Banner Baywood Medical Ctr. 
Banner Gateway Medical Ctr. 
Chandler Regional Hospital 
Mercy Gilbert Medical Ctr 
Mountain Vista Medical 
602-277-4161 x44 * 
Advance Hearing Group 480-218-1328 
ASU Speech and Hearing 480-965-2373 
Arizona Ear and Hearing 480-292-7100 
Arizona Hearing and Balance 480-558-5306 
Cigna Healthcare Hearing Ctr. 480-464-6870 
Cardon’s Children’s/Banner Desert 480-412-4099 Desert Sounds 480-497-3285 
Phoenix Children’s Audiology 602-546-0905 ENT Specialists of Arizona 480-894-5550 X502 
Tempe St. Luke’s 480-784-5557 Good Sound Audiology 480-497-0780 
  Harper Hearing Solutions 480-838-1212 
  Hearing Solutions of Arizona 480-833-4330 
  Premier ENT Surgeons 602-678-5001 
Tucson Area & Southern Arizona 
HOSPITALS OTHER PROVIDERS 
Carondelet St. Joseph’s 520-873-3761 Adobe Hearing Center 520-322-8211 
Carondelet St. Mary’s 520-872-4846 Carlson Ear, Nose & Throat 520-795-8777 
Northwest Medical Center 520-877-4021 Grunewald Blitz (U of A) 520-621-7070 
Tucson Medical Center 520-324-2075 Marana Health Center 520-682-4560 
The Children’s Clinic  520-324-3600 Oro Valley & Tanque Verde Aud 520-751-3901 
Casa Grande Regional 520-381-6475 Tucson ENT 520-777-0495 
Carondelet Holy Cross (Nogales) 520-287-8048 Birth and Women’s Health Center 520-795-9912 
Cobre Valley Community (Safford) 928-402-1260 Chricahua Health (Douglas) 520-364-3285 
Mt. Graham (Safford) 928-348-4185 Audiology Inc. (Safford) 928-428-1613 
Sierra Vista Hospital 520-417-3184 Southern AZ Hearing & Balance 520-459-0688 
Yuma Regional Medical Ctr. 928-336-3893 Cochise ENT Assoc. (Sierra Vista) 520-458-4919 
 Sells Special Services Program 520-383-8665 
Flagstaff Area & Northern Arizona 
HOSPITALS OTHER PROVIDERS 
Flagstaff Medical Ctr. Audiology 928-214-3728 North Country CHC (Flagstaff) 928-213-6154 
Verde Valley (Cottonwood) 928-639-6521 Northern Arizona University 928-523-8110 
Little Colorado (Winslow) 928-289-4691 Audiology Inc (Show Low) 928-537-3456 
Tuba City IHS 928-283-2629 ASDB Eastern Highland Regional Coop 928-524-6770 
Payson Regional 928-472-1226 Fort Defiance 928-729-8915 
Page Hospital  928-645-0777 Chinle Indian Health Services Audiology 928-674-7223 
Summit Healthcare 928-537-6362 White River IHS (Whiteriver) 928-338-4911 x3728 
Havasu Regional 928-453-0660 White Mtn Hearing Svc (Lakeside) 928-537-7373 
Kingman Regional  928-757-0690 AZ Coast ENT (Lake Havasu) 928-854-5368 
WARMC (Bullhead City) 928-763-0676 Valley View (Fort Mohave) 928-788-7095 
Yavapai Regional 928-771-5200 Tri State Audiology (Bullhead City) 928-758-3337 
  Prescott ENT 928-778-9190 
      Parent Resource Revised 9/2010 
3 
Months 
Diagnostic Evaluation by Three Months 
Resources Parents for Infant Diagnostic Hearing Testing 
 
If your baby does not pass a second screen, further testing will be needed to see if your baby  
has a hearing loss. 
 
Si su bebé no pasa la segunda prueba auditiva, será necesario hacer pruebas adicionales para determinar si 
su bebé tiene una pérdida auditiva.   
SITES MARKED WITH * ARE ABLE TO PERFORM TESTING WITH SEDATION IF NEEDED 
 
Phoenix Area (Metro Area, Central, North & Scottsdale) 
*Phoenix Children’s Hospital (Phoenix & East Valley locations) 602-546-0905 
*St. Joseph’s Hospital Children’s Rehabilitative Services 602-406-6420 
Arizona Balance & Hearing Associates 602-265-9000 
Maricopa Medical Audiology Clinic 602-344-5185 
Phoenix Indian Medical Center 602-263-1514 
Premiere ENT Surgeons 602-678-5001 
Phoenix Area – West Valley 
Valley ENT (Glendale) 623-566-4718 
Phoenix Area – East Valley 
*Arizona Hearing and Balance Center (Chandler) 480-558-5306 
*Cardon’s Children’s/Banner Desert Audiology (Mesa) 480-412-4099 
Arizona State University Speech and Hearing Clinic (Tempe) 480-965-2373 
Arizona Ear & Hearing (Queen Creek) 480-292-7100 
Desert Sounds Audiology (Mesa) 480-497-3285 
Good Sound Audiology (Mesa) 480-497-0780 
Tucson Area & Southern Arizona 
*Carondelet St. Joseph’s Hospital Hearing Services 520-873-3761 
*Tucson Medical Center Audiology Department 520-324-2075 
Carondelet St. Mary’s Audiology Department 520-872-4846 
Tucson ENT (East & Northwest Tucson) 520-777-0495 
University of Arizona Grunewald-Blitz Center 520-621-7070 
Audiology Inc. (Safford) 928-428-1613 
Flagstaff Area & Northern Arizona 
*Chinle Indian Health Services Audiology Department 928-674-7223 
*Flagstaff Medical Center Audiology Department 928-214-3728 
White Mountain Hearing Services (Lakeside) 928-537-7373 
Audiology Inc. (Show Low) 928-537-3456 
 
NOTE: Sites have self identified as providing services and are not endorsed or recommended. 
 
If you have questions or concerns about the hearing screening or would like more information, you can call the Arizona Department of Health 
Services Newborn Screening Program at 602-364-1409 or visit online at www.aznewborn.com
 
. 
Si usted tiene algunas preguntas o preocupaciones sobre la prueba auditiva o si quisiera más información, puede llamar al Departamento de 
Servicios de Salud de Arizona al Programa de Análisis para el Niño Recién Nacido al número 602-364-1409.  También puede visitarnos en el 
Internet a www.aznewborn.com. 
Birth Before 1 Month Before 3 Months Before 6 Months
Newborn Screening Screening Completed Diagnostic Evaluation Intervention Services
Early Hearing Detection and Intervention (EHDI)
Guidelines for Pediatric Medical Home Providers
Identify a Medical Home 
for every infant
Hospital-based 
Inpatient Screening 
OAE/AABR* (only AABR or 
ABR if NICU* 5+ days)
All results sent to
Medical Home
Pediatric Audiologic
Evaluationb with 
Capacity to Perform:
Home
Birthsa
Pass
Pass
Failc
Failed 
Screen, or 
Missed, or 
Incompleteac
Normal
Hearing
Hearing
Loss
Unilateral/Bilateral;
Sensorineural/
Conductive/Mixed;
Mild/Moderate/
Severe/
Profound
OAE*
ABR* 
Frequency-specific
tone bursts
Air & bone conduction
Sedation capability 
(only needed for some infants)
Audiologist Reports to State 
EHDI* Program 
Every child with a permanent 
hearing loss, as well as all normal 
follow-up results  
Refer to IDEA* Part C
Coordinating agency for early 
intervention
 
Team Advises Family About:
All communication options; 
different communication modes; 
assistive listening devices 
(hearing aids, cochlear implants, 
etc); parent support programs
 
Medical & Otologic Evaluations
To recommend treatment and 
provide clearance for hearing 
aid fitting
 
Pediatric Audiology
Hearing aid fitting and monitoring
Continued enrollment 
in IDEA* Part C 
(transition to Part B at 
3 years of age) 
 
Referrals by Medical 
Home for specialty 
evaluations, to 
determine etiology 
and identify related 
conditions:
Otolaryngologist 
(required)
Ophthalmologist 
(recommended)
Geneticist (recommended) 
Developmental 
pediatrics, neurology, 
cardiology, nephrology 
(as needed)
 
Pediatric audiology
Behavioral response 
audiometry
Ongoing monitoring
Outpatient
Re-Screeninga
(OAE/AABR*)
All results sent to
Medical Home 
and State EHDI* 
Program
No more 
than 2 
screening
attempts
recommended
prior to
discharge
Notes: 
(a) In screening programs that do not 
provide Outpatient Screening, infants 
will be referred directly from Inpatient 
Screening to Pediatric Audiologic 
Evaluation. Likewise, infants at 
higher risk for hearing loss (or loss 
to follow-up) also may be referred 
directly to Pediatric Audiology.
(b) Part C of IDEA* may provide 
diagnostic audiologic evaluation 
services as part of Child Find activities. 
(c) Even infants who fail screening in 
only one ear should be referred for 
further testing of both ears
(d) Includes infants whose parents 
refused initial or follow-up hearing 
screening.
*OAE = Otoacoustic Emissions, AABR 
= Automated Auditory Brainstem 
Response, ABR = Auditory Brainstem 
Response, EHDI = Early Hearing 
Detection and Intervention, IDEA = 
Individuals with Disabilities Education 
Act, NICU = Newborn Intensive Care 
Unit, AAP = American Academy of 
Pediatrics 
February 2010 - American Academy of Pediatrics Task Force for Improving Newborn Hearing Screening, Diagnosis and Intervention (www.medicalhomeinfo.org)
Ongoing Care of All Infantsd; Coordinated by the Medical Home Provider
 
• Provide parents with information about hearing, speech, and language milestones
• Identify and aggressively treat middle ear disease
• Provide vision screening (and referral when indicated) as recommended in the AAP “Bright Futures Guidelines, 3rd Ed.”
• Provide ongoing developmental screening (and referral when indicated) per the AAP “Bright Futures Guidelines, 3rd Ed.”
• Refer promptly for audiology evaluation when there is any parental concern‡ regarding hearing, speech, or language development
• Refer for audiology evaluation (at least once before age 30 months) infants who have any risk indicators for later-onset hearing loss:
 - Family history of permanent childhood hearing loss‡
 - Neonatal intensive care unit stay of more than 5 days duration, or any of the following (regardless of length of stay):
        ECMO‡, mechanically-assisted ventilation, ototoxic medications or loop diuretics, exchange transfusion for hyperbiliruinemia 
 - In utero infections such as cytomegalovirus‡, herpes, rubella, syphilis, and toxoplasmosis
 - Postnatal infections associated with hearing loss‡, including bacterial and viral meningitis
 - Craniofacial anomalies, particularly those that involve the pinna, ear canal, ear tags, ear pits, and temporal bone anomalies
 - Findings suggestive of a syndrome associated with hearing loss (Waardenburg, Alport, Jervell and Lange-Nielsen, Pendred)
 - Syndromes associated with progressive or delayed-onset hearing loss‡ (neurofibromatosis, osteopetrosis, Usher Syndrome)
 - Neurodegenerative disorders‡ (such as Hunter Syndrome) or sensory motor neuropathies (such as Friedreich’s ataxia and 
  Charcot Marie Tooth disease)
 - Head trauma, especially basal skull/temporal bone fracture that requires hospitalization
 - Chemotherapy‡
                                                                                ‡Denotes risk indicators of greater concern. Earlier and/or more frequent referral should be considered.
The recommendations in this document do not indicate an exclusive course 
of treatment or serve as a standard of medical care. Variations, taking into 
account individual circumstances, may be appropriate.
Copyright © 2002 American Academy of Pediatrics, revised 2010. No part 
of this document may be reproduced in any form or by any means without 
prior written permission from the American Academy of Pediatrics except 
for 1 copy for personal use.
This project is funded by an educational grant from the Maternal and 
Child Health Bureau, Health Resources and Services Administration, 
US Department of Health and Human Services.
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
1. Audiologist knowledgeable in pediatric 
 screening and amplification
5. Speech/language therapist and/or aural rehabilitation 
 therapist knowledgeable in pediatric hearing loss 9. Equipment vendor(s)
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
2. Otolaryngologist knowledgeable in
 pediatric hearing loss
6. Sign language classes if parents 
 choose manual approach
10. State EHDI Coordinator
   http://www.infanthearing.org/status/cnhs.html
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
3. Local early intervention service coordinator
7. Ophthalmologist knowledgeable in co-morbid 
 conditions in children with hearing loss
11. AAP Chapter Champion
   www.medicalhomeinfo.org/screening/hearing.html
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
Name:
Telephone number:
Fax:
Date of referral:
4. Family support resources, financial resources
8. Clinical geneticist knowledgeable 
 in hearing loss 12. Family physician(s)
Alexander Graham Bell 
Association for the Deaf and 
Hard of Hearing (AG Bell)
202/337-5220
www.agbell.org
American Academy of Audiology (AAA)
800/AAA-2336
www.audiology.org
American Academy of Pediatrics
847/434-4000
www.aap.org
American Society for Deaf Children
717/703-0073
www.deafchildren.org
American Speech-Language- Hearing 
Association (ASHA)
800/498-2071
www.asha.org
Boys Town Center for
Childhood Deafness
www.babyhearing.org
Centers for Disease Control
and Prevention
www.cdc.gov/ncbddd/ehdi
Families for Hands and Voices
217/357-3647
www.handsandvoices.org
Laurent Clerc National Deaf 
Education Center and Clearing- 
house at Gallaudet University
clerccenter.gallaudet.
edu/InfoToGo
National Association of
the Deaf (NAD)
301/587-1788
www.nad.org
National Center on Hearing 
Assessment and Management 
(NCHAM)
435/797-3584
www.infanthearing.org
National Institute on 
Deafness and Other 
Communication 
Disorders (NIDCD)
800/241-1044
www.nidcd.nih.gov
Oberkotter Foundation
www.oraldeafed.org
National Resources
A
p
p
ro
p
ri
a
te
 R
e
fe
rr
a
ls
DOI: 10.1542/peds.2007-2333 
 2007;120;898-921 Pediatrics
Joint Committee on Infant Hearing 
 Detection and Intervention Programs
Year 2007 Position Statement: Principles and Guidelines for Early Hearing
 http://www.pediatrics.org/cgi/content/full/120/4/898
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275. 
Grove Village, Illinois, 60007. Copyright © 2007 by the American Academy of Pediatrics. All 
and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk
publication, it has been published continuously since 1948. PEDIATRICS is owned, published, 
PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly
 by on November 15, 2008 www.pediatrics.orgDownloaded from 
POLICY STATEMENT
Year 2007 Position Statement:
Principles and Guidelines for Early
Hearing Detection and Intervention
Programs
Joint Committee on Infant Hearing
THE POSITION STATEMENT
The Joint Committee on Infant Hearing (JCIH) endorses early detection of and
intervention for infants with hearing loss. The goal of early hearing detection and
intervention (EHDI) is to maximize linguistic competence and literacy develop-
ment for children who are deaf or hard of hearing. Without appropriate oppor-
tunities to learn language, these children will fall behind their hearing peers in
communication, cognition, reading, and social-emotional development. Such de-
lays may result in lower educational and employment levels in adulthood.1 To
maximize the outcome for infants who are deaf or hard of hearing, the hearing of
all infants should be screened at no later than 1 month of age. Those who do not
pass screening should have a comprehensive audiological evaluation at no later
than 3 months of age. Infants with confirmed hearing loss should receive appro-
priate intervention at no later than 6 months of age from health care and educa-
tion professionals with expertise in hearing loss and deafness in infants and young
children. Regardless of previous hearing-screening outcomes, all infants with or
without risk factors should receive ongoing surveillance of communicative devel-
opment beginning at 2 months of age during well-child visits in the medical
home.2 EHDI systems should guarantee seamless transitions for infants and their
families through this process.
2007 JCIH POSITION STATEMENT UPDATES
The following are highlights of updates made since the 2000 JCIH statement3:
1. Definition of targeted hearing loss
● The definition has been expanded from congenital permanent bilateral, uni-
lateral sensory, or permanent conductive hearing loss to include neural
hearing loss (eg, “auditory neuropathy/dyssynchrony”) in infants admitted to
the NICU.
2. Hearing-screening and -rescreening protocols
● Separate protocols are recommended for NICU and well-infant nurseries.
NICU infants admitted for more than 5 days are to have auditory brainstem
response (ABR) included as part of their screening so that neural hearing loss
will not be missed.
● For infants who do not pass automated ABR testing in the NICU, referral
should be made directly to an audiologist for rescreening and, when indi-
cated, comprehensive evaluation including ABR.
● For rescreening, a complete screening on both ears is recommended, even if
only 1 ear failed the initial screening.
● For readmissions in the first month of life for all infants (NICU or well infant),
when there are conditions associated with potential hearing loss (eg, hyper-
www.pediatrics.org/cgi/doi/10.1542/
peds.2007-2333
doi:10.1542/peds.2007-2333
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bilirubinemia that requires exchange transfusion or
culture-positive sepsis), a repeat hearing screening
is recommended before discharge.
3. Diagnostic audiology evaluation
● Audiologists with skills and expertise in evaluating
newborn and young infants with hearing loss
should provide audiology diagnostic and auditory
habilitation services (selection and fitting of ampli-
fication device).
● At least 1 ABR test is recommended as part of a
complete audiology diagnostic evaluation for chil-
dren younger than 3 years for confirmation of per-
manent hearing loss.
● The timing and number of hearing reevaluations
for children with risk factors should be customized
and individualized depending on the relative like-
lihood of a subsequent delayed-onset hearing loss.
Infants who pass the neonatal screening but have a
risk factor should have at least 1 diagnostic audiol-
ogy assessment by 24 to 30 months of age. Early
and more frequent assessment may be indicated for
children with cytomegalovirus (CMV) infection,
syndromes associated with progressive hearing loss,
neurodegenerative disorders, trauma, or culture-
positive postnatal infections associated with senso-
rineural hearing loss; for children who have re-
ceived extracorporeal membrane oxygenation
(ECMO) or chemotherapy; and when there is care-
giver concern or a family history of hearing loss.
● For families who elect amplification, infants in
whom permanent hearing loss is diagnosed should
be fitted with an amplification device within 1
month of diagnosis.
4. Medical evaluation
● For infants with confirmed hearing loss, a genetics
consultation should be offered to their families.
● Every infant with confirmed hearing loss should be
evaluated by an otolaryngologist who has knowl-
edge of pediatric hearing loss and have at least 1
examination to assess visual acuity by an ophthal-
mologist who is experienced in evaluating infants.
● The risk factors for congenital and acquired hearing
loss have been combined in a single list rather than
grouped by time of onset.
5. Early intervention
● All families of infants with any degree of bilateral or
unilateral permanent hearing loss should be con-
sidered eligible for early intervention services.
● There should be recognized central referral points
of entry that ensure specialty services for infants
with confirmed hearing loss.
● Early intervention services for infants with con-
firmed hearing loss should be provided by profes-
sionals who have expertise in hearing loss, includ-
ing educators of the deaf, speech-language
pathologists, and audiologists.
● In response to a previous emphasis on “natural
environments,” the JCIH recommends that both
home-based and center-based intervention options
be offered.
6. Surveillance and screening in the medical home
● For all infants, regular surveillance of developmen-
tal milestones, auditory skills, parental concerns,
and middle-ear status should be performed in the
medical home, consistent with the American Acad-
emy of Pediatrics (AAP) pediatric periodicity sched-
ule. All infants should have an objective standard-
ized screening of global development with a
validated assessment tool at 9, 18, and 24 to 30
months of age or at any time if the health care
professional or family has concern.
● Infants who do not pass the speech-language por-
tion of a medical home global screening or for
whom there is a concern regarding hearing or lan-
guage should be referred for speech-language eval-
uation and audiology assessment.
7. Communication
● The birth hospital, in collaboration with the state
EHDI coordinator, should ensure that the hearing-
screening results are conveyed to the parents and
the medical home.
● Parents should be provided with appropriate fol-
low-up and resource information, and hospitals
should ensure that each infant is linked to a med-
ical home.
● Information at all stages of the EHDI process is to be
communicated to the family in a culturally sensi-
tive and understandable format.
● Individual hearing-screening information and au-
diology diagnostic and habilitation information
should be promptly transmitted to the medical
home and the state EHDI coordinator.
● Families should be made aware of all communica-
tion options and available hearing technologies
(presented in an unbiased manner). Informed fam-
ily choice and desired outcome guide the decision-
making process.
8. Information infrastructure
● States should implement data-management and
-tracking systems as part of an integrated child
health information system to monitor the quality of
EHDI services and provide recommendations for
improving systems of care.
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● An effective link between health and education
professionals is needed to ensure successful transi-
tion and to determine outcomes of children with
hearing loss for planning and establishing public
health policy.
BACKGROUND
It has long been recognized that unidentified hearing
loss at birth can adversely affect speech and language
development as well as academic achievement and so-
cial-emotional development. Historically, moderate-to-
severe hearing loss in young children was not detected
until well beyond the newborn period, and it was not
unusual for diagnosis of milder hearing loss and unilat-
eral hearing loss to be delayed until children reached
school age.
In the late 1980s, Dr C. Everett Koop, then US Sur-
geon General, on learning of new technology, encour-
aged detection of hearing loss to be included in the
Healthy People 20004 goals for the nation. In 1988, the
Maternal and Child Health Bureau (MCHB), a division
of the US Health Resources and Services Administration
(HRSA), funded pilot projects in Rhode Island, Utah, and
Hawaii to test the feasibility of a universal statewide
screening program to screen newborn infants for hear-
ing loss before hospital discharge. The National Institutes
of Health, through the National Institute on Deafness
and Other Communication Disorders (NIDCD), issued in
1993 a consensus statement on early identification of
hearing impairment in infants and young children.5 In
the statement the authors concluded that all infants
admitted to the NICU should be screened for hearing loss
before hospital discharge and that universal screening
should be implemented for all infants within the first 3
months of life.4 In its 1994 position statement, the JCIH
endorsed the goal of universal detection of infants with
hearing loss and encouraged continuing research and
development to improve methods for identification of
and intervention for hearing loss.6,7 The AAP released a
statement that recommended newborn hearing screen-
ing and intervention in 1999.8 In 2000, citing advances
in screening technology, the JCIH endorsed the univer-
sal screening of all infants through an integrated, inter-
disciplinary system of EHDI.3 The Healthy People 2010
goals included an objective to “increase the proportion of
newborns who are screened for hearing loss by one
month, have audiological evaluation by 3 months, and
are enrolled in appropriate intervention services by 6
months.”9
The ensuing years have seen remarkable expansion in
newborn hearing screening. At the time of the National
Institutes of Health consensus statement, only 11 hospi-
tals in the United States were screening more than 90%
of their newborn infants. In 2000, through the support
of Representative Jim Walsh (R-NY), Congress autho-
rized the HRSA to develop newborn hearing screening
and follow-up services, the Centers for Disease Control
and Prevention (CDC) to develop data and tracking sys-
tems, and the NIDCD to support research in EHDI. By
2005, every state had implemented a newborn hearing-
screening program, and approximately 95% of newborn
infants in the United States were screened for hearing
loss before hospital discharge. Congress recommended
cooperation and collaboration among several federal
agencies and advocacy organizations to facilitate and
support the development of state EHDI systems.
EHDI programs throughout the United States have
demonstrated not only the feasibility of universal new-
born hearing screening (UNHS) but also the benefits of
early identification and intervention. There is a growing
body of literature indicating that when identification
and intervention occur at no later than 6 months of age
for newborn infants who are deaf or hard of hearing, the
infants perform as much as 20 to 40 percentile points
higher on school-related measures (vocabulary, articu-
lation, intelligibility, social adjustment, and behav-
ior).10–13 Still, many important challenges remain. De-
spite the fact that approximately 95% of newborn
infants have their hearing screened in the United States,
almost half of newborn infants who do not pass the
initial screening do not have appropriate follow-up to
either confirm the presence of a hearing loss and/or
initiate appropriate early intervention services (see
www.infanthearing.org, www.cdc.gov/ncbddd/ehdi, and
www.nidcd.nih.gov/health).
State EHDI coordinators report system-wide problems
including failure to communicate information to families
in a culturally sensitive and understandable format at all
stages of the EHDI process, lack of integrated state data-
management and -tracking systems, and a shortage of
facilities and personnel with the experience and exper-
tise needed to provide follow-up for infants who are
referred from newborn screening programs.14 Available
data indicate that a significant number of children who
need further assessment do not receive appropriate fol-
low-up evaluations. However, the outlook is improving
as EHDI programs focus on the importance of strength-
ening follow-up and intervention.
PRINCIPLES
All children with hearing loss should have access to
resources necessary to reach their maximum potential.
The following principles provide the foundation for ef-
fective EHDI systems and have been updated and ex-
panded since the 2000 JCIH position statement.
1. All infants should have access to hearing screening
using a physiologic measure at no later than 1 month
of age.
2. All infants who do not pass the initial hearing screen-
ing and the subsequent rescreening should have ap-
propriate audiological and medical evaluations to
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confirm the presence of hearing loss at no later than
3 months of age.
3. All infants with confirmed permanent hearing loss
should receive early intervention services as soon as
possible after diagnosis but at no later than 6 months
of age. A simplified, single point of entry into an
intervention system that is appropriate for children
with hearing loss is optimal.
4. The EHDI system should be family centered with
infant and family rights and privacy guaranteed
through informed choice, shared decision-making,
and parental consent in accordance with state and
federal guidelines. Families should have access to in-
formation about all intervention and treatment op-
tions and counseling regarding hearing loss.
5. The child and family should have immediate access to
high-quality technology including hearing aids, co-
chlear implants, and other assistive devices when ap-
propriate.
6. All infants and children should be monitored for
hearing loss in the medical home.15 Continued assess-
ment of communication development should be pro-
vided by appropriate professionals to all children with
or without risk indicators for hearing loss.
7. Appropriate interdisciplinary intervention programs
for infants with hearing loss and their families should
be provided by professionals who are knowledgeable
about childhood hearing loss. Intervention programs
should recognize and build on strengths, informed
choices, traditions, and cultural beliefs of the families.
8. Information systems should be designed and imple-
mented to interface with electronic health charts and
should be used to measure outcomes and report the
effectiveness of EHDI services at the patient, practice,
community, state, and federal levels.
GUIDELINES FOR EHDI PROGRAMS
The 2007 guidelines were developed to update the 2000
JCIH position statement principles and to support the
goals of universal access to hearing screening, evalua-
tion, and intervention for newborn and young infants
embodied in Healthy People 2010.9 The guidelines provide
current information on the development and implemen-
tation of successful EHDI systems.
Hearing screening should identify infants with specif-
ically defined hearing loss on the basis of investigations
of long-term, developmental consequences of hearing
loss in infants, currently available physiologic screening
techniques, and availability of effective intervention in
concert with established principles of health screen-
ing.15–18 Studies have demonstrated that current screen-
ing technologies are effective in identifying hearing loss
of moderate and greater degree.19 In addition, studies of
children with permanent hearing loss indicate that mod-
erate or greater degrees of hearing loss can have signif-
icant effects on language, speech, academic, and social-
emotional development.20 High-risk target populations
also include infants in the NICU, because research data
have indicated that this population is at highest risk of
having neural hearing loss.21–23
The JCIH, however, is committed to the goal of iden-
tifying all degrees and types of hearing loss in childhood
and recognizes the developmental consequences of even
mild degrees of permanent hearing loss. Recent evi-
dence, however, has suggested that current hearing-
screening technologies fail to identify some infants with
mild forms of hearing loss.24,25 In addition, depending on
the screening technology selected, infants with hearing
loss related to neural conduction disorders or “auditory
neuropathy/auditory dyssynchrony” may not be de-
tected through a UNHS program. Although the JCIH
recognizes that these disorders may result in delayed
communication,26–28 currently recommended screening
algorithms (ie, use of otoacoustic emission [OAE] testing
alone) preclude universal screening for these disorders.
Because these disorders typically occur in children who
require NICU care,21 the JCIH recommends screening
this group with the technology capable of detecting au-
ditory neuropathy/dyssynchrony: automated ABR mea-
surement.
All infants, regardless of newborn hearing-screening
outcome, should receive ongoing monitoring for devel-
opment of age-appropriate auditory behaviors and com-
munication skills. Any infant who demonstrates delayed
auditory and/or communication skills development,
even if he or she passed newborn hearing screening,
should receive an audiological evaluation to rule out
hearing loss.
Roles and Responsibilities
The success of EHDI programs depends on families
working in partnership with professionals as a well-
coordinated team. The roles and responsibilities of each
team member should be well defined and clearly under-
stood. Essential team members are the birth hospital,
families, pediatricians or primary health care profession-
als (ie, the medical home), audiologists, otolaryngolo-
gists, speech-language pathologists, educators of chil-
dren who are deaf or hard of hearing, and other early
intervention professionals involved in delivering EHDI
services.29,30 Additional services including genetics, oph-
thalmology, developmental pediatrics, service coordina-
tion, supportive family education, and counseling
should be available.31
The birth hospital is a key member of the team. The
birth hospital, in collaboration with the state EHDI co-
ordinator, should ensure that parents and primary
health care professionals receive and understand the
hearing-screening results, that parents are provided with
appropriate follow-up and resource information, and
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that each infant is linked to a medical home.2 The hos-
pital ensures that hearing-screening information is
transmitted promptly to the medical home and appro-
priate data are submitted to the state EHDI coordinator.
The most important role for the family of an infant
who is deaf or hard of hearing is to love, nurture, and
communicate with the infant. From this foundation,
families usually develop an urgent desire to understand
and meet the special needs of their infant. Families gain
knowledge, insight, and experience by accessing re-
sources and through participation in scheduled early
intervention appointments including audiological, med-
ical, habilitative, and educational sessions. This experi-
ence can be enhanced when families choose to become
involved with parental support groups, people who are
deaf or hard of hearing, and/or their children’s deaf or
hard-of-hearing peers. Informed family choices and de-
sired outcomes guide all decisions for these children. A
vital function of the family’s role is ensuring direct access
to communication in the home and the daily provision
of language-learning opportunities. Over time, the child
benefits from the family’s modeling of partnerships with
professionals and advocating for their rights in all set-
tings. The transfer of responsibilities from families to the
child develops gradually and increases as the child ma-
tures, growing in independence and self-advocacy.
Pediatricians, family physicians, and other allied
health care professionals, working in partnership with
parents and other professionals such as audiologists,
therapists, and educators, constitute the infant’s medical
home.2 A medical home is defined as an approach to
providing health care services with which care is acces-
sible, family centered, continuous, comprehensive, co-
ordinated, compassionate, and culturally competent.
The primary health care professional acts in partnership
with parents in a medical home to identify and access
appropriate audiology, intervention, and consultative
services that are needed to develop a global plan of
appropriate and necessary health and habilitative care
for infants identified with hearing loss and infants with
risk factors for hearing loss. All children undergo sur-
veillance for auditory skills and language milestones.
The infant’s pediatrician, family physician, or other pri-
mary health care professional is in a position to advocate
for the child and family.2,16
An audiologist is a person who, by virtue of academic
degree, clinical training, and license to practice, is qual-
ified to provide services related to the prevention of
hearing loss and the audiological diagnosis, identifica-
tion, assessment, and nonmedical and nonsurgical treat-
ment of persons with impairment of auditory and ves-
tibular function, and to the prevention of impairments
associated with them. Audiologists serve in a number of
roles. They provide newborn hearing-screening program
development, management, quality assessment, service
coordination and referral for audiological diagnosis, and
audiological treatment and management. For the fol-
low-up component, audiologists provide comprehensive
audiological diagnostic assessment to confirm the exis-
tence of the hearing loss, ensure that parents understand
the significance of the hearing loss, evaluate the infant
for candidacy for amplification and other sensory devices
and assistive technology, and ensure prompt referral to
early intervention programs. For the treatment and
management component, audiologists provide timely
fitting and monitoring of amplification devices.32 Other
audiologists may provide diagnostic and auditory treat-
ment and management services in the educational set-
ting and provide a bridge between the child/family and
the audiologist in the clinic setting as well as other
service providers. Audiologists also provide services as
teachers, consultants, researchers, and administrators.
Otolaryngologists are physicians whose specialty in-
cludes determining the etiology of hearing loss; identi-
fying related risk indicators for hearing loss, including
syndromes that involve the head and neck; and evalu-
ating and treating ear diseases. An otolaryngologist with
knowledge of childhood hearing loss can determine if
medical and/or surgical intervention may be appropri-
ate. When medical and/or surgical intervention is pro-
vided, the otolaryngologist is involved in the long-term
monitoring and follow-up with the infant’s medical
home. The otolaryngologist provides information and
participates in the assessment of candidacy for amplifi-
cation, assistive devices, and surgical intervention, in-
cluding reconstruction, bone-anchored hearing aids, and
cochlear implantation.
Early intervention professionals are trained in a vari-
ety of academic disciplines such as speech-language pa-
thology, audiology, education of children who are deaf
or hard of hearing, service coordination, or early child-
hood special education. All individuals who provide ser-
vices to infants with hearing loss should have specialized
training and expertise in the development of audition,
speech, and language. Speech-language pathologists
provide both evaluation and intervention services for
language, speech, and cognitive-communication devel-
opment. Educators of children who are deaf or hard of
hearing integrate the development of communicative
competence within a variety of social, linguistic, and
cognitive/academic contexts. Audiologists may provide
diagnostic and habilitative services within the individu-
alized family service plan (IFSP) or school-based individ-
ualized education plan. To provide the highest quality of
intervention, more than 1 provider may be required.
The care coordinator is an integral member of the
EHDI team and facilitates the family’s transition from
screening to evaluation to early intervention.33 This per-
son must be a professional (eg, social worker, teacher,
nurse) who is knowledgeable about hearing loss. The
care coordinator incorporates the family’s preferences
for outcomes into an IFSP as required by federal legisla-
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tion. The care coordinator supports the family members
in their choice of the infant’s communicative develop-
ment. Through the IFSP review, the infant’s progress in
language, motor, cognitive, and social-emotional devel-
opment is monitored. The care coordinator assists the
family in advocating for the infant’s unique develop-
mental needs.
The deaf and hard-of-hearing community includes
members with direct experience with signed language,
spoken language, hearing-aid and cochlear implant use,
and other communication strategies and technologies.
Optimally, adults who are deaf or hard-of-hearing
should play an integral part in the EHDI program. Both
adults and children in the deaf and hard-of-hearing
community can enrich the family’s experience by serv-
ing as mentors and role models. Such mentors have
experience in negotiating their way in a hearing world,
raising infants or children who are deaf or hard of hear-
ing, and providing families with a full range of informa-
tion about communication options, assistive technology,
and resources that are available in the community.
A successful EHDI program requires collaboration be-
tween a variety of public and private institutions and
agencies that assume responsibility for specific compo-
nents (eg, screening, evaluation, intervention). Roles
and responsibilities may differ from state to state. Each
state has defined a lead coordinating agency with over-
sight responsibility. The lead coordinating agency in
each state should be responsible for identifying the pub-
lic and private funding sources available to develop,
implement, and coordinate EHDI systems.
Hearing Screening
Multidisciplinary teams of professionals, including audi-
ologists, physicians, and nursing personnel, are needed
to establish the UNHS component of EHDI programs. All
team members work together to ensure that screening
programs are of high quality and are successful. An
audiologist should be involved in each component of the
hearing-screening program, particularly at the level of
statewide implementation and, whenever possible, at
the individual hospital level. Hospitals and agencies
should also designate a physician to oversee the medical
aspects of the EHDI program.
Each team of professionals responsible for the hospi-
tal-based UNHS program should review the hospital in-
frastructure in relationship to the screening program.
Hospital-based programs should consider screening
technology (ie, OAE or automated ABR testing); validity
of the specific screening device; screening protocols, in-
cluding the timing of screening relative to nursery dis-
charge; availability of qualified screening personnel;
suitability of the acoustical and electrical environments;
follow-up referral criteria; referral pathways for follow-
up; information management; and quality control and
improvement. Reporting and communication protocols
must be well defined and include the content of reports
to physicians and parents, documentation of results in
medical charts, and methods for reporting to state reg-
istries and national data sets.
Physiologic measures must be used to screen new-
borns and infants for hearing loss. Such measures in-
clude OAE and automated ABR testing. Both OAE and
automated ABR technologies provide noninvasive re-
cordings of physiologic activity underlying normal audi-
tory function, both are easily performed in neonates and
infants, and both have been successfully used for
UNHS.19,34–37 However, there are important differences
between the 2 measures. OAE measurements are ob-
tained from the ear canal by using a sensitive micro-
phone within a probe assembly that records cochlear
responses to acoustic stimuli. Thus, OAEs reflect the
status of the peripheral auditory system extending to the
cochlear outer hair cells. In contrast, ABRmeasurements
are obtained from surface electrodes that record neural
activity generated in the cochlea, auditory nerve, and
brainstem in response to acoustic stimuli delivered via
an earphone. Automated ABR measurements reflect the
status of the peripheral auditory system, the eighth
nerve, and the brainstem auditory pathway.
Both OAE and ABR screening technologies can be
used to detect sensory (cochlear) hearing loss19; how-
ever, both technologies may be affected by outer or
middle-ear dysfunction. Consequently, transient condi-
tions of the outer and middle ear may result in a “failed”
screening-test result in the presence of normal cochlear
and/or neural function.38 Moreover, because OAEs are
generated within the cochlea, OAE technology cannot
be used to detect neural (eighth nerve or auditory brain-
stem pathway) dysfunction. Thus, neural conduction
disorders or auditory neuropathy/dyssynchrony without
concomitant sensory dysfunction will not be detected by
OAE testing.
Some infants who pass newborn hearing screening
will later demonstrate permanent hearing loss.25 Al-
though this loss may reflect delayed-onset hearing loss,
both ABR and OAE screening technologies will miss
some hearing loss (eg, mild or isolated frequency region
losses).
Interpretive criteria for pass/fail outcomes should re-
flect clear scientific rationale and should be evidence
based.39,40 Screening technologies that incorporate auto-
mated-response detection are necessary to eliminate the
need for individual test interpretation, to reduce the
effects of screener bias or operator error on test outcome,
and to ensure test consistency across infants, test condi-
tions, and screening personnel.41–45 When statistical
probability is used to make pass/fail decisions, as is the
case for OAE and automated ABR screening devices, the
likelihood of obtaining a pass outcome by chance alone
is increased when screening is performed repeatedly.46–48
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This principle must be incorporated into the policies of
rescreening.
There are no national standards for the calibration of
OAE or ABR instrumentation. Compounding this prob-
lem, there is a lack of uniform performance standards.
Manufacturers of hearing-screening devices do not al-
ways provide sufficient supporting evidence to validate
the specific pass/fail criteria and/or automated algo-
rithms used in their instruments.49 In the absence of
national standards, audiologists must obtain normative
data for the instruments and protocols they use.
The JCIH recognizes that there are important issues
differentiating screening performed in the well-infant
nursery from that performed in the NICU. Although the
goals in each nursery are the same, numerous method-
ologic and technological issues must be considered in
program design and pass/fail criteria.
Screening Protocols in the Well-Infant Nursery
Many inpatient well-infant screening protocols provide
1 hearing screening and, when necessary, a repeat
screening no later than at the time of discharge from the
hospital, using the same technology both times. Use of
either technology in the well-infant nursery will detect
peripheral (conductive and sensory) hearing loss of 40
dB or greater.19 When automated ABR is used as the
single screening technology, neural auditory disorders
can also be detected.50 Some programs use a combina-
tion of screening technologies (OAE testing for the initial
screening followed by automated ABR for rescreening
[ie, 2-step protocol5]) to decrease the fail rate at dis-
charge and the subsequent need for outpatient follow-
up.34,35,37,51–53 With this approach, infants who do not pass
an OAE screening but subsequently pass an automated
ABR test are considered a screening “pass.” Infants in the
well-infant nursery who fail automated ABR testing
should not be rescreened by OAE testing and “passed,”
because such infants are presumed to be at risk of having
a subsequent diagnosis of auditory neuropathy/dyssyn-
chrony.
Screening Protocols in the NICU
An NICU is defined as a facility in which a neonatologist
provides primary care for the infant. Newborn units are
divided into 3 categories:
● Level I: basic care, well-infant nurseries
● Level II: specialty care by a neonatologist for infants at
moderate risk of serious complications
● Level III: a unit that provides both specialty and sub-
specialty care including the provision of life support
(mechanical ventilation)
A total of 120 level-II NICUs and 760 level-III NICUs
have been identified in the United States by survey, and
infants who have spent time in the NICU represent 10%
to 15% of the newborn population.54
The 2007 JCIH position statement includes neonates
at risk of having neural hearing loss (auditory neuropa-
thy/auditory dyssynchrony) in the target population to
be identified in the NICU,55–57 because there is evidence
that neural hearing loss results in adverse communica-
tion outcomes.22,50 Consequently, the JCIH recommends
ABR technology as the only appropriate screening tech-
nique for use in the NICU. For infants who do not pass
automated ABR testing in the NICU, referral should be
made directly to an audiologist for rescreening and,
when indicated, comprehensive evaluation, including
diagnostic ABR testing, rather than for general outpa-
tient rescreening.
Conveying Test Results
Screening results should be conveyed immediately to
families so that they understand the outcome and the
importance of follow-up when indicated. To facilitate
this process for families, primary health care profession-
als should work with EHDI team members to ensure
that:
● communications with parents are confidential and
presented in a caring and sensitive manner, preferably
face-to-face;
● educational materials are developed and disseminated
to families that provide accurate information at an
appropriate reading level and in a language they are
able to comprehend; and
● parents are informed in a culturally sensitive and un-
derstandable manner that their infant did not pass
screening and informed about the importance of
prompt follow-up; before discharge, an appointment
should be made for follow-up testing.
To facilitate this process for primary care physicians,
EHDI systems should ensure that medical professionals
receive:
● the results of the screening test (pass, did not pass, or
missed) as documented in the hospital medical chart;
and
● communication directly from a representative of the
hospital screening program regarding each infant in its
care who did not pass or was missed and recommen-
dations for follow-up.
Outpatient Rescreening for Infants Who Do Not Pass the
Birth Admission Screening
Many well-infant screening protocols will incorporate
an outpatient rescreening within 1 month of hospital
discharge to minimize the number of infants referred for
follow-up audiological and medical evaluation. The out-
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patient rescreening should include the testing of both
ears, even if only 1 ear failed the inpatient screening.
Outpatient screening at no later than 1 month of age
should also be available to infants who were discharged
before receiving the birth admission screening or who
were born outside a hospital or birthing center. State
EHDI coordinators should be aware of some of the fol-
lowing situations under which infants may be lost to the
UNHS system:
● Home births and other out-of-hospital births: states
should develop a mechanism to systematically offer
newborn hearing screening for all out-of-hospital
births.
● Across-state-border births: states should develop writ-
ten collaborative agreements among neighboring
states for sharing hearing-screening results and fol-
low-up information.
● Hospital-missed screenings: when infants are dis-
charged before the hearing screening is performed, a
mechanism should be in place for the hospital to con-
tact the family and arrange for an outpatient hearing
screening.
● Transfers to in-state or out-of-state hospitals: dis-
charge and transfer forms should contain the informa-
tion of whether a hearing screening was performed
and the results of any screening. The recipient hospital
should complete a hearing screening if one was not
previously performed or if there is a change in medical
status or a prolonged hospitalization.
● Readmissions: for readmissions in the first month of
life when there are conditions associated with poten-
tial hearing loss (eg, hyperbilirubinemia that requires
exchange transfusion or culture-positive sepsis), an
ABR screening should be performed before discharge.
Additional mechanisms for states to share hearing-
screening results and other medical information include
(l) incorporating the hearing-screening results in a state-
wide child health information system and (2) providing
combined metabolic screening and hearing-screening re-
sults to the primary care physician.
Confirmation of Hearing Loss in Infants Referred From UNHS
Infants who meet the defined criteria for referral should
receive follow-up audiological and medical evaluations
with fitting of amplification devices, as appropriate, at no
later than 3 months of age. Once hearing loss is con-
firmed, coordination of services should be expedited by
the infant’s medical home and Part C coordinating agen-
cies for early intervention services, as authorized by the
Individuals With Disabilities Education Act, following
the EHDI algorithm developed by the AAP (Appendix 1).
Audiological Evaluation
Comprehensive audiological evaluation of newborn and
young infants who fail newborn hearing screening
should be performed by audiologists experienced in pe-
diatric hearing assessment. The initial audiological test
battery to confirm a hearing loss in infants must include
physiologic measures and, when developmentally ap-
propriate, behavioral methods. Confirmation of an in-
fant’s hearing status requires a test battery of audiologi-
cal test procedures to assess the integrity of the auditory
system in each ear, to estimate hearing sensitivity across
the speech frequency range, to determine the type of
hearing loss, to establish a baseline for further monitor-
ing, and to provide information needed to initiate am-
plification-device fitting. A comprehensive assessment
should be performed on both ears even if only 1 ear
failed the screening test.
Evaluation: Birth to 6 Months of Age
For infants from birth to a developmental age of approx-
imately 6 months, the test battery should include a child
and family history, an evaluation of risk factors for con-
genital hearing loss, and a parental report of the infant’s
responses to sound. The audiological assessment should
include:
● Child and family history.
● A frequency-specific assessment of the ABR using air-
conducted tone bursts and bone-conducted tone
bursts when indicated. When permanent hearing loss
is detected, frequency-specific ABR testing is needed
to determine the degree and configuration of hear-
ing loss in each ear for fitting of amplification de-
vices.
● Click-evoked ABR testing using both condensation
and rarefaction single-polarity stimulus, if there are
risk indicators for neural hearing loss (auditory neu-
ropathy/auditory dyssynchrony) such as hyperbiliru-
binemia or anoxia, to determine if a cochlear micro-
phonic is present.28 Furthermore, because some
infants with neural hearing loss have no risk indica-
tors, any infant who demonstrates “no response” on
ABR elicited by tone-burst stimuli must be evaluated
by a click-evoked ABR.55
● Distortion product or transient evoked OAEs.
● Tympanometry using a 1000-Hz probe tone.
● Clinician observation of the infant’s auditory behavior
as a cross-check in conjunction with electrophysi-
ologic measures. Behavioral observation alone is not
adequate for determining whether hearing loss is
present in this age group, and it is not adequate for the
fitting of amplification devices.
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Evaluation: 6 to 36 Months of Age
For subsequent testing of infants and toddlers at devel-
opmental ages of 6 to 36 months, the confirmatory
audiological test battery includes:
● Child and family history.
● Parental report of auditory and visual behaviors and
communication milestones.
● Behavioral audiometry (either visual reinforcement or
conditioned-play audiometry, depending on the
child’s developmental level), including pure-tone au-
diometry across the frequency range for each ear and
speech-detection and -recognition measures.
● OAE testing.
● Acoustic immittance measures (tympanometry and
acoustic reflex thresholds).
● ABR testing if responses to behavioral audiometry are
not reliable or if ABR testing has not been performed
in the past.
Other Audiological Test Procedures
At this time, there is insufficient evidence for use of the
auditory steady-state response as the sole measure of
auditory status in newborn and infant populations.58
Auditory steady-state response is a new evoked-poten-
tial test that can accurately measure auditory sensitivity
beyond the limits of other test methods. It can determine
frequency-specific thresholds from 250 Hz to 8 kHz.
Clinical research is being performed to investigate its
potential use in the standard pediatric diagnostic test
battery. Similarly, there are insufficient data for routine
use of acoustic middle-ear muscle reflexes in the initial
diagnostic assessment of infants younger than 4
months.59 Both tests could be used to supplement the
battery or could be included at older ages. Emerging
technologies, such as broad-band reflectance, may be
used to supplement conventional measures of middle-
ear status (tympanometry and acoustic reflexes) as the
technology becomes more widely available.59
Medical Evaluation
Every infant with confirmed hearing loss and/or middle-
ear dysfunction should be referred for otologic and other
medical evaluation. The purpose of these evaluations is
to determine the etiology of hearing loss, to identify
related physical conditions, and to provide recommen-
dations for medical/surgical treatment as well as referral
for other services. Essential components of the medical
evaluation include clinical history, family history of
childhood-onset permanent hearing loss, identification
of syndromes associated with early- or late-onset per-
manent hearing loss, a physical examination, and indi-
cated radiologic and laboratory studies (including ge-
netic testing). Portions of the medical evaluation, such as
urine culture for CMV, a leading cause of hearing loss,
might even begin in the birth hospital, particularly for
infants who spend time in the NICU.60–62
Pediatrician/Primary Care Physician
The infant’s pediatrician or other primary health care
professional is responsible for monitoring the general
health, development, and well-being of the infant. In
addition, the primary care physician must assume re-
sponsibility to ensure that the audiological assessment is
conducted on infants who do not pass screening and
must initiate referrals for medical specialty evaluations
necessary to determine the etiology of the hearing loss.
Middle-ear status should be monitored, because the
presence of middle-ear effusion can further compromise
hearing. The primary care physician must partner with
other specialists, including the otolaryngologist, to facil-
itate coordinated care for the infant and family. Because
30% to 40% of children with confirmed hearing loss will
demonstrate developmental delays or other disabilities,
the primary care physician should closely monitor de-
velopmental milestones and initiate referrals related to
suspected disabilities.63 The medical home algorithm for
management of infants with either suspected or proven
permanent hearing loss is provided in Appendix 1.15
The pediatrician or primary care physician should
review every infant’s medical and family history for the
presence of risk indicators that require monitoring for
delayed-onset or progressive hearing loss and should
ensure that an audiological evaluation is completed for
children at risk of hearing loss at least once by 24 to 30
months of age, regardless of their newborn screening
results.25 Infants with specific risk factors, such as those
who received ECMO therapy and those with CMV in-
fection, are at increased risk of delayed-onset or progres-
sive hearing loss64–67 and should be monitored closely. In
addition, the primary care physician is responsible for
ongoing surveillance of parent concerns about language
and hearing, auditory skills, and developmental mile-
stones of all infants and children regardless of risk status,
as outlined in the pediatric periodicity schedule pub-
lished by the AAP.16
Children with cochlear implants may be at increased
risk of acquiring bacterial meningitis compared with
children in the general US population.68 The CDC
recommends that all children with, and all potential
recipients of, cochlear implants follow specific recom-
mendations for pneumococcal immunization that ap-
ply to cochlear implant users and that they receive
age-appropriate Haemophilus influenzae type b vac-
cines. Recommendations for the timing and type of
pneumococcal vaccine vary with age and immuniza-
tion history and should be discussed with a health care
professional.69
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Otolaryngologist
Otolaryngologists are physicians and surgeons who di-
agnose, treat, and manage a wide range of diseases of the
head and neck and specialize in treating hearing and
vestibular disorders. They perform a full medical diag-
nostic evaluation of the head and neck, ears, and related
structures, including a comprehensive history and phys-
ical examination, leading to a medical diagnosis and
appropriate medical and surgical management. Often, a
hearing or balance disorder is an indicator of, or related
to, a medically treatable condition or an underlying sys-
temic disease. Otolaryngologists work closely with other
dedicated professionals, including physicians, audiolo-
gists, speech-language pathologists, educators, and oth-
ers, in caring for patients with hearing, balance, voice,
speech, developmental, and related disorders.
The otolaryngologist’s evaluation includes a compre-
hensive history to identify the presence of risk factors for
early-onset childhood permanent hearing loss, such as
family history of hearing loss, having been admitted to
the NICU for more than 5 days, and having received
ECMO (see Appendix 2).70,71
A complete head and neck examination for craniofa-
cial anomalies should document defects of the auricles,
patency of the external ear canals, and status of the
eardrum and middle-ear structures. Atypical findings on
eye examination, including irises of 2 different colors or
abnormal positioning of the eyes, may signal a syndrome
that includes hearing loss. Congenital permanent con-
ductive hearing loss may be associated with craniofacial
anomalies that are seen in disorders such as Crouzon
disease, Klippel-Feil syndrome, and Goldenhar syn-
drome.72 The assessment of infants with these congenital
anomalies should be coordinated with a clinical geneti-
cist.
In large population studies, at least 50% of congenital
hearing loss has been designated as hereditary, and
nearly 600 syndromes and 125 genes associated with
hearing loss have already been identified.72,73 The eval-
uation, therefore, should include a review of family
history of specific genetic disorders or syndromes, in-
cluding genetic testing for gene mutations such as GJB2
(connexin-26), and syndromes commonly associated
with early-onset childhood sensorineural hearing
loss72,74–76 (Appendix 2). As the widespread use of newly
developed conjugate vaccines decreases the prevalence
of infectious etiologies such as measles, mumps, rubella,
H influenzae type b, and childhood meningitis, the per-
centage of each successive cohort of early-onset hearing
loss attributable to genetic etiologies can be expected to
increase, prompting recommendations for early genetic
evaluations. Approximately 30% to 40% of children
with hearing loss have associated disabilities, which can
be of importance in patient management. The decision
to obtain genetic testing depends on informed family
choice in conjunction with standard confidentiality
guidelines.77
In the absence of a genetic or established medical
cause, a computed tomography scan of the temporal
bones may be performed to identify cochlear abnormal-
ities, such as Mondini deformity with an enlarged ves-
tibular aqueduct, which have been associated with pro-
gressive hearing loss. Temporal bone imaging studies
may also be used to assess potential candidacy for sur-
gical intervention, including reconstruction, bone-an-
chored hearing aid, and cochlear implantation. Recent
data have shown that some children with electrophysi-
ologic evidence suggesting auditory neuropathy/dyssyn-
chrony may have an absent or abnormal cochlear nerve
that may be detected with MRI.78
Historically, an extensive battery of laboratory and
radiographic studies was routinely recommended for
newborn infants and children with newly diagnosed
sensorineural hearing loss. However, emerging technol-
ogies for the diagnosis of genetic and infectious disorders
have simplified the search for a definitive diagnosis,
which obviates the need for costly diagnostic evaluations
in some instances.70,71,79
If, after an initial evaluation, the etiology remains
uncertain, an expanded multidisciplinary evaluation
protocol including electrocardiography, urinalysis, test-
ing for CMV, and further radiographic studies is indi-
cated. The etiology of neonatal hearing loss, however,
may remain uncertain in as many as 30% to 40% of
children. Once hearing loss is confirmed, medical clear-
ance for hearing aids and initiation of early intervention
should not be delayed while this diagnostic evaluation is
in process. Careful longitudinal monitoring to detect and
promptly treat coexisting middle-ear effusions is an es-
sential component of ongoing otologic management of
these children.
Other Medical Specialists
The medical geneticist is responsible for the interpreta-
tion of family history data, the clinical evaluation and
diagnosis of inherited disorders, the performance and
assessment of genetic tests, and the provision of genetic
counseling. Geneticists or genetic counselors are quali-
fied to interpret the significance and limitations of new
tests and to convey the current status of knowledge
during genetic counseling. All families of children with
confirmed hearing loss should be offered, and may ben-
efit from, a genetics evaluation and counseling. This
evaluation can provide families with information on
etiology of hearing loss, prognosis for progression, asso-
ciated disorders (eg, renal, vision, cardiac), and likeli-
hood of recurrence in future offspring. This information
may influence parents’ decision-making regarding inter-
vention options for their child.
Every infant with a confirmed hearing loss should
have an evaluation by an ophthalmologist to document
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visual acuity and rule out concomitant or late-onset
vision disorders such as Usher syndrome.1,80 Indicated
referrals to other medical subspecialists, including devel-
opmental pediatricians, neurologists, cardiologists, and
nephrologists, should be facilitated and coordinated by
the primary health care professional.
Early Intervention
Before newborn hearing screening was instituted uni-
versally, children with severe-to-profound hearing loss,
on average, completed the 12th grade with a 3rd- to
4th-grade reading level and language levels of a 9- to
10-year-old hearing child.81 In contrast, infants and chil-
dren with mild-to-profound hearing loss who are iden-
tified in the first 6 months of life and provided with
immediate and appropriate intervention have signifi-
cantly better outcomes than later-identified infants and
children in vocabulary development,82,83 receptive and
expressive language,12,84 syntax,85 speech produc-
tion,13,86–88 and social-emotional development.89 Children
enrolled in early intervention within the first year of life
have also been shown to have language development
within the normal range of development at 5 years of
age.31,90
Therefore, according to federal guidelines, once any
degree of hearing loss is diagnosed in a child, a referral
should be initiated to an early intervention program
within 2 days of confirmation of hearing loss (CFR
303.321d). The initiation of early intervention services
should begin as soon as possible after diagnosis of hear-
ing loss but at no later than 6 months of age. Even when
the hearing status is not determined to be the primary
disability, the family and child should have access to
intervention with a provider who is knowledgeable
about hearing loss.91
UNHS programs have been instituted throughout the
United States for the purpose of preventing the signifi-
cant and negative effects of hearing loss on the cognitive,
language, speech, auditory, social-emotional, and aca-
demic development of infants and children. To achieve
this goal, hearing loss must be identified as quickly as
possible after birth, and appropriate early intervention
must be available to all families and infants with perma-
nent hearing loss. Some programs have demonstrated
that most children with hearing loss and no additional
disabilities can achieve and maintain language develop-
ment within the typical range of children who have
normal hearing.12,13,85,90 Because these studies were de-
scriptive and not causal studies, the efficacy of specific
components of intervention cannot be separated from
the total provision of comprehensive services. Thus, the
family-centered philosophy, the intensity of services, the
experience and training of the provider, the method of
communication, the curricula, the counseling proce-
dures, the parent support and advocacy, and the deaf
and hard-of-hearing support and advocacy are all vari-
ables with unknown effects on the overall outcomes of
any individual child. The key component of providing
quality services is the expertise of the provider specific to
hearing loss. These services may be provided in the
home, a center, or a combination of the 2 locations.
The term “intervention services” is used to describe
any type of habilitative, rehabilitative, or educational
program provided to children with hearing loss. In some
cases of mild hearing losses, amplification technology
may be the only service provided. Some parents choose
only developmental assessment or occasional consulta-
tion, such as parents with infants who have unilateral
hearing losses. Children with high-frequency losses and
normal hearing in the low frequencies may only be seen
by a speech-language pathologist, and those with signif-
icant bilateral sensorineural hearing losses might be seen
by an educator of the deaf and receive additional ser-
vices.
Principles of Early Intervention
To ensure informed decision-making, parents of infants
with newly diagnosed hearing loss should be offered
opportunities to interact with other families who have
infants or children with hearing loss as well as adults and
children who are deaf or hard of hearing. In addition,
parents should also be offered access to professional,
educational, and consumer organizations and provided
with general information on child development, lan-
guage development, and hearing loss. A number of prin-
ciples and guidelines have been developed that offer a
framework for quality early intervention service delivery
systems for children who are deaf or hard of hearing and
their families.92 Foundational characteristics of develop-
ing and implementing early intervention programs in-
clude a family-centered approach, culturally responsive
practices, collaborative professional-family relationships
and strong family involvement, developmentally appro-
priate practice, interdisciplinary assessment, and com-
munity-based provision of services.
Designated Point of Entry
States should develop a single point of entry into inter-
vention specific for hearing impairment to ensure that,
regardless of geographic location, all families who have
infants or children with hearing loss receive information
about a full range of options regarding amplification and
technology, communication and intervention, and ac-
cessing appropriate counseling services. This state sys-
tem, if separate from the state’s Part C system, should
integrate and partner with the state’s Part C program.
Parental consent must be obtained according to state and
federal requirements to share the IFSP information with
providers and transmit data to the state EHDI coordina-
tor.
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Regular Developmental Assessment
To ensure accountability, individual, community, and
state health and educational programs should assume
the responsibility for coordinated, ongoing measure-
ment and improvement of EHDI process outcomes. Early
intervention programs must assess the language, cogni-
tive skills, auditory skills, speech, vocabulary, and social-
emotional development of all children with hearing loss
at 6-month intervals during the first 3 years of life by
using assessment tools that have been standardized on
children with normal hearing and norm-referenced as-
sessment tools that are appropriate to measure progress
in verbal and visual language.
The primary purpose of regular developmental mon-
itoring is to provide valuable information to parents
about the rate of their child’s development as well as
programmatic feedback concerning curriculum deci-
sions. Families also become knowledgeable about expec-
tations and milestones of typical development of hearing
children. Studies have shown that valid and reliable
documentation of developmental progress is possible
through parent questionnaires, analysis of videotaped
conversational interactions, and clinically administered
assessments.* Documentation of developmental progress
should be provided on a regular basis to parents and,
with parental release of information, to the medical
home and audiologist. Although criterion-referenced
checklists may provide valuable information for estab-
lishing intervention strategies and goals, these assess-
ment tools alone are not sufficient for parents and in-
tervention professionals to determine if a child’s
developmental progress is comparable with his or her
hearing peers.
Opportunities for Interaction With Other Parents of Children
With Hearing Loss
Intervention professionals should seek to involve par-
ents at every level of the EHDI process and develop true
and meaningful partnerships with parents. To reflect the
value of the contributions that selected parents make to
development and program components, these parents
should be paid as contributing staff members. Parent
representatives should be included in all advisory board
activities. In many states, parents have been integral and
often have taken leadership roles in the development of
policy, resource material, communication mechanisms,
mentoring and advocacy opportunities, dissemination of
information, and interaction with the deaf community
and other individuals who are deaf or hard of hearing.
Parents, often in partnership with people who are deaf
and hard of hearing, have also participated in the train-
ing of professionals. They should be participants in the
regular assessment of program services to ensure ongo-
ing improvement and quality assurance.
Opportunities for Interaction With Individuals Who Are Deaf
or Hard of Hearing
Intervention programs should include opportunities for
involvement of individuals who are deaf or hard of
hearing in all aspects of EHDI programs. Because inter-
vention programs serve children with mild-to-profound,
unilateral or bilateral, permanent conductive, and sen-
sory or neural hearing disorders, role models who are
deaf or hard of hearing can be significant assets to an
intervention program. These individuals can serve on
state EHDI advisory boards and be trained as mentors for
families and children with hearing loss who choose to
seek their support. Almost all families choose at some
time during their early childhood programs to seek out
both adults and child peers with hearing loss. Programs
should ensure that these opportunities are available and
can be delivered to families through a variety of com-
munications means, such as Web sites, e-mail, newslet-
ters, videos, retreats, picnics and other social events, and
educational forums for parents.
Provision of Communication Options
Research studies thus far of early-identified infants with
hearing loss have not found significant differences in the
developmental outcomes by method of communication
when measured at 3 years of age.† Therefore, a range of
options should be offered to families in a nonbiased
manner. In addition, there have been reports of children
with successful outcomes for each of the different meth-
ods of communication. The choice is a dynamic process
on a continuum, differs according to the individual
needs of each family, and can be adjusted as necessary
on the basis of a child’s rate of progress in developing
communication skills. Programs need to provide families
with access to skilled and experienced early intervention
professionals to facilitate communication and language
development in the communication option chosen by
the family.
Skills of the Early Intervention Professional
All studies with successful outcomes reported for early-
identified children who are deaf or hard of hearing have
intervention provided by specialists who are trained in
parent-infant intervention services.12,90,97 Early interven-
tion programs should develop mechanisms to ensure
that early intervention professionals have special skills
necessary for providing families with the highest quality
of service specific to children with hearing loss. Profes-
sionals with a background in deaf education, audiology,
and speech-language pathology will typically have the
skills needed for providing intervention services. Profes-
sionals should be highly qualified in their respective
fields and should be skilled communicators who are
knowledgeable and sensitive to the importance of en-
*Refs 10–13, 51, 85, 87–90, and 93–96. †Refs 10–13, 85, 87, 88, 90, 93, and 96.
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hancing families’ strengths and supporting their priori-
ties. When early intervention professionals have knowl-
edge of the principles of adult learning, it increases their
success with parents and other professionals.
Quality of Intervention Services
Children with confirmed hearing loss and their families
have the right to prompt access to quality intervention
services. For newborn infants with confirmed hearing
loss, enrollment into intervention services should begin
as soon after hearing-loss confirmation as possible and
no later than 6 months of age. Successful early interven-
tion programs (1) are family centered, (2) provide fam-
ilies with unbiased information on all options regarding
approaches to communication, (3) monitor develop-
ment at 6-month intervals with norm-referenced instru-
ments, (4) include individuals who are deaf or hard of
hearing, (5) provide services in a natural environment in
the home or in the center, (6) offer high-quality service
regardless of where the family lives, (7) obtain informed
consent, (8) are sensitive to cultural and language dif-
ferences and provide accommodations as needed, and
(9) conduct annual surveys of parent satisfaction.
Intervention for Special Populations of Infants and Young
Children
Developmental monitoring should also occur at regular
6-month intervals for special populations of children
with hearing loss, including those with minimal and
mild bilateral hearing loss,98 unilateral hearing loss,99,100
and neural hearing loss,22 because these children are at
risk of having speech and language delay. Research find-
ings indicate that approximately one third of children
with permanent unilateral loss experience significant
language and academic delays.99–101
Audiological Habilitation
Most infants and children with bilateral hearing loss and
many with unilateral hearing loss benefit from some
form of personal amplification device.32 If the family
chooses personal amplification for its infant, hearing-aid
selection and fitting should occur within 1 month of
initial confirmation of hearing loss even when additional
audiological assessment is ongoing. Audiological habili-
tation services should be provided by an audiologist who
is experienced with these procedures. Delay between
confirmation of the hearing loss and fitting of an ampli-
fication device should be minimized.51,102
Hearing-aid fitting proceeds optimally when the re-
sults of physiologic audiological assessment including
diagnostic ABR, OAE, and tympanometry and medical
examination are in accord. For infants who are below a
developmental age of 6 months, hearing-aid selection
will be based on physiologic measures alone. Behavioral
threshold assessment with visual reinforcement audiom-
etry should be obtained as soon as possible to cross-
check and augment physiologic findings (see www.au-
diology.org).
The goal of amplification-device fitting is to provide
the infant with maximum access to all of the acoustic
features of speech within an intensity range that is safe
and comfortable. That is, amplified speech should be
comfortably above the infant’s sensory threshold but
below the level of discomfort across the speech fre-
quency range for both ears. To accomplish this in in-
fants, amplification-device selection, fitting, and verifi-
cation should be based on a prescriptive procedure that
incorporates individual real-ear measures that account
for each infant’s ear-canal acoustics and hearing loss.32
Validation of the benefits of amplification, particularly
for speech perception, should be examined in the clinical
setting as well as in the child’s typical listening environ-
ments. Complementary or alternative technology, such
as frequency modulation (FM) systems or cochlear im-
plants, may be recommended as the primary and/or
secondary listening device depending on the degree of
the infant’s hearing loss, the goals of auditory habilita-
tion, the infant’s acoustic environments, and the fami-
ly’s informed choices.3 Monitoring of amplification, as
well as the long-term validation of the appropriateness
of the individual habilitation program, requires ongoing
audiological assessment along with electroacoustic, real-
ear, and functional checks of the hearing instruments.
As the hearing loss becomes more specifically defined
through audiological assessments and as the child’s ear-
canal acoustics change with growth, refinement of the
individual prescriptive hearing-aid gain and output tar-
gets is necessary. Monitoring also includes periodic val-
idation of communication, social-emotional, and cogni-
tive development and, later, academic performance to
ensure that progress is commensurate with the child’s
abilities. It is possible that infants and young children
with measurable residual “hearing” (auditory responses)
and well-fit amplification devices may fail to develop
auditory skills necessary for successful spoken commu-
nication. Ongoing validation of the amplification device
is accomplished through interdisciplinary evaluation and
collaboration with the early intervention team and fam-
ily.
Cochlear implantation should be given careful con-
sideration for any child who seems to receive limited
benefit from a trial with appropriately fitted hearing
aids. According to US Food and Drug Administration
guidelines, infants with profound bilateral hearing loss
are candidates for cochlear implantation at 12 months of
age and children with bilateral severe hearing loss are
eligible at 24 months of age. The presence of develop-
mental conditions (eg, developmental delay, autism) in
addition to hearing loss should not, as a rule, preclude
the consideration of cochlear implantation for an infant
or child who is deaf. Benefits from hearing aids and
cochlear implants in children with neural hearing loss
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have also been documented. The benefit of acoustic
amplification for children with neural hearing loss is
variable.28,103 Thus, a trial fitting is indicated for infants
with neural hearing loss until the usefulness of the fit-
ting can be determined. Neural hearing loss is a hetero-
geneous condition; the decision to continue or discon-
tinue use of hearing aids should be made on the basis
of the benefit derived from amplification. Use of co-
chlear implants in neural hearing loss is growing, and
positive outcomes have been reported for many chil-
dren.28
Infants and young children with unilateral hearing
loss should also be assessed for appropriateness of hear-
ing-aid fitting. Depending on the degree of residual
hearing in unilateral loss, a hearing aid may or may not
be indicated. Use of “contralateral routing of signals”
amplification for unilateral hearing loss in children is not
recommended.104 Research is currently underway to de-
termine how to best manage unilateral hearing loss in
infants and young children.
The effect of otitis media with effusion (OME) is
greater for infants with sensorineural hearing loss than
for those with normal cochlear function.73 Sensory or
permanent conductive hearing loss is compounded by
additional transient conductive hearing loss associated
with OME. OME further reduces access to auditory cues
necessary for the development of spoken English. OME
also negatively affects the prescriptive targets of the
hearing-aid fitting, decreasing auditory awareness and
requiring adjustment of the amplification characteristics.
Prompt referral to either the primary care physician or
an otolaryngologist for treatment of persistent OME is
indicated in infants with sensorineural hearing loss.105
Definitive resolution of OME should never delay the
fitting of an amplification device.73,106
Medical and Surgical Intervention
Medical intervention is the process by which a physician
provides medical diagnosis and direction for medical
and/or surgical treatment options for hearing loss and/or
related medical disorder(s) associated with hearing loss.
Treatment varies from the removal of cerumen and the
treatment of OME to long-term plans for reconstructive
surgery and assessment of candidacy for cochlear im-
plants. If necessary, surgical treatment of malformation
of the outer and middle ears, including bone-anchored
hearing aids, should be considered in the intervention
plan for infants with permanent conductive or mixed
hearing loss when they reach an appropriate age.
Communication Assessment and Intervention
Language is acquired with greater ease during certain sen-
sitive periods of infant and toddler development.107–109
The process of language acquisition includes learning the
precursors of language, such as the rules that pertain to
selective attention and turn taking.20,110,111 Cognitive, so-
cial, and emotional development are influenced by the
acquisition of language. Development in these areas is
synergistic. A complete language evaluation should be
performed at regular intervals for infants and toddlers
with hearing loss. The evaluation should include an
assessment of oral, manual, and/or visual mechanisms as
well as cognitive abilities.
A primary focus of language intervention is to support
families in fostering the communication abilities of their
infants and toddlers who are deaf or hard of hearing.20
Spoken- and/or sign-language development should be
commensurate with the child’s age and cognitive abili-
ties and should include acquisition of phonologic (for
spoken language), visual/spatial/motor (for signed lan-
guage), morphologic, semantic, syntactic, and pragmatic
skills, depending on the family’s preferred mode of com-
munication.
Early intervention professionals should follow family-
centered principles to assist in developing communica-
tive competence of infants and toddlers who are deaf or
hard of hearing.112–114 Families should be provided with
information specific to language development and access
to peer and language models as well as family-involved
activities that facilitate language development of chil-
dren with normal hearing and children who are hard of
hearing or deaf.115,116 Depending on family choices, fam-
ilies should be offered access to children and adults with
hearing loss who are appropriate and competent lan-
guage models. Information on spoken language and
signed language, such as American Sign Language117 and
cued speech, should be provided.
Continued Surveillance, Screening, and Referral of Infants and
Toddlers
Appendix 2 presents 11 risk indicators that are associ-
ated with either congenital or delayed-onset hearing
loss. A single list of risk indicators is presented in the
current JCIH statement, because there is significant
overlap among those indicators associated with congen-
ital/neonatal hearing loss and those associated with de-
layed-onset/acquired or progressive hearing loss.
Heightened surveillance of all infants with risk indica-
tors, therefore, is recommended. There is a significant
change in the definition of risk-indicator 3, which has
been modified from NICU stay more than 48 hours to
NICU stay more than 5 days. Consistent with 2000 JCIH
position statement,3 the 2007 position statement recom-
mends use of risk indicators for hearing loss for 3 pur-
poses. Historically, the first use of risk indicators is for
the identification of infants who should receive audio-
logical evaluation but who live in geographic locations
(eg, developing nations, remote areas) where universal
hearing screening is not yet available.‡ This use has
become less common as a result of the expansion of
‡Refs 3, 19, 21, 24, 25, 64, and 118–124.
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UNHS. The second purpose of risk-indicator identifica-
tion is to help identify infants who pass the neonatal
screening but are at risk of developing delayed-onset
hearing loss and, therefore, should receive ongoing med-
ical, speech and language, and audiological surveillance.
Third, the risk indicators are used to identify infants who
may have passed neonatal screening but have mild
forms of permanent hearing loss.25
Because some important indicators, such as family
history of hearing loss, may not be determined during
the course of UNHS,14,72 the presence of all risk indicators
for acquired hearing loss should be determined in the
medical home during early well-infant visits. Risk indi-
cators that are marked with a section symbol in Appen-
dix 2 are of greater concern for delayed-onset hearing
loss. Early and more frequent assessment may be indi-
cated for children with CMV infection,118,125,126 syn-
dromes associated with progressive hearing loss,72
neurodegenerative disorders,72 trauma,127–129 or culture-
positive postnatal infections associated with sensorineu-
ral hearing loss130,131; for children who have received
ECMO64 or chemotherapy132; and when there is care-
giver concern or a family history of hearing loss.16
For all infants with and without risk indicators for
hearing loss, developmental milestones, hearing skills,
and parent concerns about hearing, speech, and lan-
guage skills should be monitored during routine medical
care consistent with the AAP periodicity schedule.
The JCIH has determined that the previously recom-
mended approach to follow-up of infants with risk indi-
cators for hearing loss only addressed children with
identifiable risk indicators and failed to consider the
possibility of delayed-onset hearing loss in children
without identifiable risk indicators. In addition, concerns
were raised about feasibility and cost associated with the
2000 JCIH recommendation for audiological monitoring
of all infants with risk indicators at 6-month intervals.
Because approximately 400 000 infants are cared for
annually in NICUs in the United States, and the 2000
JCIH recommendation included audiology assessments
at 6-month intervals from 6 months to 36 months of age
for all infants admitted to an NICU for more than 48
hours, an unreasonable burden was placed on both pro-
viders of audiology services and families. In addition,
there was no provision for identification of delayed-
onset hearing loss in infants without an identifiable risk
indicator. Data from 2005 for 12 388 infants discharged
from NICUs in the National Perinatal Information Net-
work indicated that 52% of infants were discharged
within the first 5 days of life, and these infants were
significantly less likely to have an identified risk indica-
tor for hearing loss other than NICU stay. Therefore, the
2007 JCIH recommends an alternative, more inclusive
strategy of surveillance of all children within the medical
home based on the pediatric periodicity schedule. This
protocol will permit the detection of children with either
missed neonatal or delayed-onset hearing loss irrespec-
tive of the presence or absence of a high-risk indicator.
The JCIH recognizes that an optimal surveillance and
screening program within the medical home would in-
clude the following:
● At each visit, consistent with the AAP periodicity
schedule, infants should be monitored for auditory
skills, middle-ear status, and developmental mile-
stones (surveillance). Concerns elicited during surveil-
lance should be followed by administration of a vali-
dated global screening tool.133 A validated global
screening tool is administered to all infants at 9, 18,
and 24 to 30 months or, if there is physician or pa-
rental concern about hearing or language, sooner.133
● If an infant does not pass the speech-language portion
of the global screening in the medical home or if there
is physician or caregiver concern about hearing or
spoken-language development, the child should be
referred immediately for further evaluation by an au-
diologist and a speech-language pathologist for a
speech and language evaluation with validated
tools.133
● Once hearing loss is diagnosed in an infant, siblings
who are at increased risk of having hearing loss should
be referred for audiological evaluation.14,75,134,135
● All infants with a risk indicator for hearing loss (Ap-
pendix 2), regardless of surveillance findings, should
be referred for an audiological assessment at least once
by 24 to 30 months of age. Children with risk indica-
tors that are highly associated with delayed-onset
hearing loss, such as having received ECMO or having
CMV infection, should have more frequent audiologi-
cal assessments.
● All infants for whom the family has significant con-
cerns regarding hearing or communication should be
promptly referred for an audiological and speech-lan-
guage assessment.
● A careful assessment of middle-ear status (using pneu-
matic otoscopy and/or tympanometry) should be
completed at all well-child visits, and children with
persistent middle-ear effusion that last for 3 months or
longer should be referred for otologic evaluation.136
Protecting the Rights of Infants and Families
Each agency or institution involved in the EHDI process
shares responsibility for protecting infant and family
rights in all aspects of UNHS, including access to infor-
mation including potential benefits and risks in the fam-
ily’s native language, input into decision-making, and
confidentiality.77 Families should receive information
about childhood hearing loss in easily understood lan-
guage. Families have the right to accept or decline hear-
ing screening or any follow-up care for their newborn
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infant within the statutory regulations, just as they have
for any other screening or evaluation procedures or
intervention.
EHDI data merit the same level of confidentiality and
security afforded all other health care and education
information in practice and law. The infant’s family has
the right to confidentiality of the screening and fol-
low-up assessments and the acceptance or rejection of
suggested intervention(s). In compliance with federal
and state laws, mechanisms should be established that
ensure parental release and approval of all communica-
tions regarding the infant’s test results, including those
to the infant’s medical home and early intervention–
coordinating agency and programs. The Health Insur-
ance Portability and Accountability Act (Pub L No. 104-
191 [1996]) regulations permit the sharing of health
information among health care professionals.
Information Infrastructure
In its 2000 position statement,3 the JCIH recommended
development of uniform state registries and national
information databases that incorporate standardized
methodology, reporting, and system evaluation. EHDI
information systems are to provide for the ongoing and
systematic collection, analysis, and interpretation of data
in the process of measuring and reporting associated
program services (eg, screening, evaluation, diagnosis,
and/or intervention). These systems are used to guide
activities, planning, implementation, and evaluation of
programs and to formulate research hypotheses.
EHDI information systems are generally authorized
by legislators and implemented by public health officials.
These systems vary from a simple system that collects
data from a single source to electronic systems that re-
ceive data from many sources in multiple formats. The
number and variety of systems will likely increase with
advances in electronic data interchange and integration
of data, which will also heighten the importance of
patient privacy, data confidentiality, and system secu-
rity. The appropriate agencies and/or officials should be
consulted for any projects regarding public health sur-
veillance.69
Federal and state agencies are collaborating in the
standardization of data definitions to ensure the value of
data sets and to prevent misleading or unreliable infor-
mation. Information management is used to improve
services to infants and their families; to assess the quan-
tity and timeliness of screening, evaluation, and enroll-
ment into intervention; and to facilitate collection of
demographic data on neonatal and infant hearing loss.
The JCIH endorses the concept of a limited national
database to permit documentation of the demographics
of neonatal hearing loss, including prevalence and etiol-
ogy across the United States. The information obtained
from the information-management system should assist
both the primary health care professional and the state
health agency in measuring quality indicators associated
with program services (eg, screening, diagnosis, and in-
tervention). The information system should provide
measurement tools to determine the degree to which
each process is stable and sustainable and conforms to
program benchmarks. Timely and accurate monitoring
of relevant quality measures is essential.
Since 1999, the CDC and the Directors of Speech and
Hearing Programs in State Health and Welfare Agencies
(DSHPSHWA) have collected annual aggregate EHDI
program data needed to address the national EHDI goals.
In 1999, a total of 22 states provided data for the DSHP-
SHWA survey. Participation had increased to 48 states, 1
territory, and the District of Columbia in 2003. However,
many programs have been unable to respond to all the
questions on the survey because of lack of a statewide
comprehensive data-management and reporting system.
The Government Performance and Results Act
(GPRA) of 1993 (Pub L No. 103-62) requires that federal
programs establish measurable goals approved by the US
Office of Management and Budget (OMB) that can be
reported as part of the budgetary process, thus linking
future funding decisions with performance. The HRSA
has modified its reporting requirements for all grant
programs. The GPRA measures that must be reported to
the OMB by the MCHB annually for the EHDI program
are:
● the number of infants screened for hearing loss before
discharge from the hospital;
● the number of infants with confirmed hearing loss at
no later than 3 months of age;
● the number of infants enrolled in a program of early
intervention at no later than 6 months of age;
● the number of infants with confirmed or suspected
hearing loss referred to an ongoing source of compre-
hensive health care (ie, medical home); and
● the number of children with nonsyndromic hearing
loss who have developmentally appropriate language
and communication skills at school entry.
One GPRA measure that must be reported to the
OMB by the CDC annually for the EHDI program is the
percentage of newborn infants with a positive screening
result for hearing loss who are subsequently lost to
follow-up.
EHDI programs have made tremendous gains in their
ability to collect, analyze, and interpret data in the pro-
cess of measuring and reporting associated program ser-
vices. However, only a limited number of EHDI pro-
grams are currently able to accurately report the number
of infants screened, evaluated, and enrolled in interven-
tion, the age of time-related objectives (eg, screening by
1 month of age), and the severity or laterality of hearing
loss. This is complicated by the lack of data standards and
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by privacy issues within the regulations of the Family
Educational Rights and Privacy Act of 1974 (Pub L No.
93-380).
Given the current lack of standardized and readily
accessible sources of data, the CDC EHDI program, in
collaboration with the DSHPSHWA, developed a revised
survey to obtain annual EHDI data from states and ter-
ritories in a consistent manner to assess progress toward
meeting the national EHDI goals and the Healthy People
2010 objectives. In October 2006, the OMB, which is
responsible for reviewing all government surveys, ap-
proved the new EHDI hearing screening and follow-up
survey. To facilitate this effort, the CDC EHDI Data Com-
mittee is establishing the minimum data elements and
definitions needed for information systems to be used to
assess progress toward the national EHDI goals.
The JCIH encourages the CDC and HRSA to continue
their efforts to identify barriers and explore possible
solutions with EHDI programs to ensure that children in
each state who seek hearing-related services in states
other than where they reside receive all recommended
screening and follow-up services. EHDI systems should
also be designed to promote the sharing of data regard-
ing early hearing loss through integration and/or linkage
with other child health information systems. The CDC
currently provides funds to integrate the EHDI system
with other state/territorial screening, tracking, and sur-
veillance programs that identify children with special
health care needs. Grantees of the MCHB are encour-
aged to link hearing-screening data with such child
health data sets as electronic birth certificates, vital sta-
tistics, birth defects registries, metabolic or newborn
dried “blood-spot” screenings, immunization registries,
and others.
To promote the best use of public health resources,
EHDI information systems should be evaluated periodi-
cally, and such evaluations should include recommen-
dations for improving quality, efficiency, and usefulness.
The appropriate evaluation of public health surveillance
systems becomes paramount as these systems adapt to
revise case definitions, address new health-related
events, adopt new information technology, ensure data
confidentiality, and assess system security.69
Currently, federal sources of systems support include
Title V block grants to states for maternal and child
health care services, Title XIX (Medicaid) federal and
state funds for eligible children, and competitive US
Department of Education personnel preparation and re-
search grants. The NIDCD provides grants for research
related to early identification and intervention for chil-
dren who are deaf or hard of hearing.137
Universities should assume responsibility for special-
track, interdisciplinary, professional education programs
for early intervention for infants and children with hear-
ing loss. Universities should also provide training in fam-
ily systems, the grieving process, cultural diversity, au-
ditory skill development, and deaf culture. There is a
critical need for in-service and preservice training of
professionals related to EHDI programs, which is partic-
ularly acute for audiologists and early interventionists
with expertise in hearing loss. This training will require
increased and sustained funding for personnel prepara-
tion.
Benchmarks and Quality Indicators
The JCIH supports the concept of regular measurements
of performance and recommends routine monitoring of
these measures for interprogram comparison and con-
tinuous quality improvement. Performance benchmarks
represent a consensus of expert opinion in the field of
newborn hearing screening and intervention. The
benchmarks are the minimal requirements that should
be attained by high-quality EHDI programs. Frequent
measures of quality permit prompt recognition and cor-
rection of any unstable component of the EHDI pro-
cess.138
Quality Indicators for Screening
● Percentage of all newborn infants who complete
screening by 1 month of age; the recommended
benchmark is more than 95% (age correction for pre-
term infants is acceptable).
● Percentage of all newborn infants who fail initial
screening and fail any subsequent rescreening before
comprehensive audiological evaluation; the recom-
mended benchmark is less than 4%.
Quality Indicators for Confirmation of Hearing Loss
● Of infants who fail initial screening and any subse-
quent rescreening, the percentage who complete a
comprehensive audiological evaluation by 3 months
of age; the recommended benchmark is 90%.
● For families who elect amplification, the percentage of
infants with confirmed bilateral hearing loss who re-
ceive amplification devices within 1 month of confir-
mation of hearing loss; the recommended benchmark
is 95%.
Quality Indicators for Early Intervention
● For infants with confirmed hearing loss who qualify
for Part C services, the percentage for whom parents
have signed an IFSP by no later than 6 months of age;
the recommended benchmark is 90%.
● For children with acquired or late-identified hearing
loss, the percentage for whom parents have signed an
IFSP within 45 days of the diagnosis; the recom-
mended benchmark is 95%.
● The percentage of infants with confirmed hearing loss
who receive the first developmental assessment with
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standardized assessment protocols (not criterion refer-
ence checklists) for language, speech, and nonverbal
cognitive development by no later than 12 months of
age; the recommended benchmark is 90%.
CURRENT CHALLENGES, OPPORTUNITIES, AND FUTURE
DIRECTIONS
Despite the tremendous progress made since 2000, there
are challenges to the success of the EHDI system.
Challenges
All of the following listed challenges are considered im-
portant for the future development of successful EHDI
systems:
● Too many children are lost between the failed screen-
ing and the rescreening and between the failed re-
screening and the diagnostic evaluation.
● There is a shortage of professionals with skills and
expertise in both pediatrics and hearing loss, including
audiologists, deaf educators, speech-language pathol-
ogists, early intervention professionals, and physi-
cians.
● There is often a lack of timely referral for diagnosis of,
and intervention for, suspected hearing loss in chil-
dren.
● Consistent and stable state and federal funding is
needed for program sustainability.
● When compared with services provided for adults,
pediatric services in all specialties are poorly reim-
bursed.
● Access to uniform Part C services is inadequate among
states and within states.
● There is a lack of integrated state data-management
and -tracking systems.
● Demographics and cultural diversity are changing rap-
idly.
● Funding for hearing aids, loaner programs, cochlear
implants, and FM systems is needed.
● There is a lack of specialized services for children with
multiple disabilities and hearing loss.
● Children may not qualify for services (state Part C
guidelines) before demonstrating language delays
(prevention model versus deficit model).
● Children may not qualify for assistive technology (pre-
vention model versus deficit model).
● There is a lack of in-service education for key profes-
sionals.
● There are regulatory barriers to sharing information
among providers and among states.
● No national standards exist for the calibration of OAE
or ABR instrumentation, and there is a lack of uniform
performance standards.
Opportunities for System Development and Research
● Establish programs to ensure the development of com-
munication for infants and children with all degrees
and types of hearing loss, allowing them access to all
educational, social, and vocational opportunities
throughout their life span.
● Develop improved, rapid, reliable screening technol-
ogy designed to differentiate specific types of hearing
loss.
● Develop and validate screening technologies for iden-
tifying minimal hearing loss.
● Develop state data-management systems with the ca-
pacity for the accurate determination of the preva-
lence for delayed-onset or progressive hearing loss.
● Develop state data-tracking systems to follow infants
with suspected and confirmed hearing loss through
individual state EHDI programs.
● Track the certification credentials of the service pro-
viders for children with confirmed hearing loss who
are receiving Part C early intervention services and
early childhood special education.
● Track genetic, environmental, and pharmacologic fac-
tors that contribute to hearing loss, thus allowing for
tailored prevention and intervention strategies.
● Continue to refine electrophysiologic diagnostic tech-
niques, algorithms, and equipment to enable frequen-
cy-specific threshold assessment for use with very
young infants.
● Continue to refine techniques to improve the selec-
tion and fitting of appropriate amplification devices in
infants and young children.
● Conduct translational research pertaining to young
children with hearing loss, in particular, genetic, diag-
nostic, and outcomes studies.
● Initiate prospective population-based studies to deter-
mine the prevalence and natural history of auditory
neural conduction disorders.
● Conduct efficacy studies to determine appropriate
early intervention strategies for infants and children
with all degrees and types of hearing loss.
● Conduct additional studies on the efficacy of interven-
tion for infants and children who receive cochlear
implants at younger than 2 years.
● Conduct additional studies on the efficacy of hearing-
aid use in infants and children younger than 2 years.
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● Conduct additional studies of the auditory develop-
ment of children who have appropriate amplification
devices in early life.
● Expand programs within health, social service, and
education agencies associated with early intervention
and Head Start programs to accommodate the needs of
the increasing numbers of early-identified children.
● Adapt education systems to capitalize on the abilities
of children with hearing loss who have benefited from
early identification and intervention.
● Develop genetic and medical procedures that will de-
termine more rapidly the etiology of hearing loss.
● Ensure transition from Part C (early intervention) to
Part B (education) services in ways that encourage
family participation and ensure minimal disruption of
child and family services.
● Study the effects of parents’ participation in all aspects
of early intervention.
● Test the utility of a limited national data set and de-
velop nationally accepted indicators of EHDI system
performance.
● Encourage the identification and development of cen-
ters of expertise in which specialized care is provided
in collaboration with local service providers.
● Obtain the perspectives of individuals who are deaf or
hard of hearing in developing policies regarding med-
ical and genetic testing and counseling for families
who carry genes associated with hearing loss.139
CONCLUSIONS
Since the 2000 JCIH statement, tremendous and rapid
progress has been made in the development of EHDI
systems as a major public health initiative. The percent-
age of infants screened annually in the United States has
increased from 38% to 95%. The collaboration at all
levels of professional organizations, federal and state
government, hospitals, medical homes, and families has
contributed to this remarkable success. New research
initiatives to develop more sophisticated screening and
diagnostic technology, improved digital hearing-aid and
FM technologies, speech-processing strategies in co-
chlear implants, and early intervention strategies con-
tinue. Major technological breakthroughs have been
made in facilitating the definitive diagnosis of both ge-
netic and nongenetic etiologies of hearing loss. In addi-
tion, outcomes studies to assess the long-term outcomes
of special populations, including infants and children
with mild and unilateral hearing loss, neural hearing
loss, and severe or profound hearing loss managed with
cochlear implants, have been providing information on
the individual and societal impact and the factors that
contribute to an optimized outcome. It is apparent, how-
ever, that there are still serious challenges to be over-
come and system barriers to be conquered to achieve
optimal EHDI systems in all states in the next 5 years.
Follow-up rates remain poor in many states, and fund-
ing for amplification in children is inadequate. Funding
to support outcome studies is necessary to guide inter-
vention and to determine factors other than hearing loss
that affect child development. The ultimate goal, to op-
timize communication, social, academic, and vocational
outcomes for each child with permanent hearing loss,
must remain paramount.
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APPENDIX 2: RISK INDICATORS ASSOCIATEDWITH
PERMANENT CONGENITAL, DELAYED-ONSET, OR
PROGRESSIVE HEARING LOSS IN CHILDHOOD
Risk indicators that are marked with a “§” are of greater
concern for delayed-onset hearing loss.
1. Caregiver concern§ regarding hearing, speech, lan-
guage, or developmental delay.62
2. Family history§ of permanent childhood hearing
loss.24,140
3. Neonatal intensive care of more than 5 days or any of
the following regardless of length of stay: ECMO,§
assisted ventilation, exposure to ototoxic medications
(gentimycin and tobramycin) or loop diuretics (furo-
semide/Lasix), and hyperbilirubinemia that requires
exchange transfusion.64,131
4. In utero infections, such as CMV,§ herpes, rubella,
syphilis, and toxoplasmosis.64–67,125,126
5. Craniofacial anomalies, including those that involve
the pinna, ear canal, ear tags, ear pits, and temporal
bone anomalies.24
6. Physical findings, such as white forelock, that are as-
sociated with a syndrome known to include a senso-
rineural or permanent conductive hearing loss.24
7. Syndromes associated with hearing loss or progres-
sive or late-onset hearing loss,§ such as neurofibro-
matosis, osteopetrosis, and Usher syndrome131; other
frequently identified syndromes include Waarden-
burg, Alport, Pendred, and Jervell and Lange-
Nielson.72
8. Neurodegenerative disorders,§ such as Hunter syn-
drome, or sensory motor neuropathies, such as Fried-
reich ataxia and Charcot-Marie-Tooth syndrome.131
9. Culture-positive postnatal infections associated with
sensorineural hearing loss,§ including confirmed
bacterial and viral (especially herpes viruses and
varicella) meningitis.130,131,141
10. Head trauma, especially basal skull/temporal bone
fracture§ that requires hospitalization.127–129
11. Chemotherapy.§132
APPENDIX 1 Algorithm for Hearing Screening. Available at: http://www.medicalhomeinfo.org/screening/Screen%20Materials/Algorithm.pdf
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Child’s Name: ______________________________ 
 
Child’s Date of Birth: _______/_________/_______ A Family’s Checklist – Infant Hearing 
 
 
 
 
 
 
 
s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Many babies meet normal 
milestones even if they have 
a hearing loss in one or both 
ears.  You should only use 
these milestones to monitor 
your baby’s hearing and 
development if your baby 
has PASSED the hearing 
screening or been evaluated 
by a Pediatric Audiologist… 
 
Months 
of Age 
2     Quiets when hearing a 
 familiar voice. Makes 
 vowel sounds like ahh, 
 ohh 
 
4    Looks for sounds with 
 his eyes. Uses sounds 
 such as squeals, 
 whimpers, chuckles 
 
6     Turns head toward 
 sound. Babbles ba-ba, 
 ma-ma, da-da 
 
9     Imitates speech sounds 
 of others. Understands 
 no-no or bye-bye. 
 Turns head toward 
 soft sounds. 
 
12    Correctly uses ma-ma or 
 da-da.  
 
         
         
Hospital Inpatient Screen 
 
Place: _____________________ 
Screen Date: ____/_____/_____ 
 
Results:   
Left Ear        Right Ear             
Pass 
 
 
 
 
Refer 
 
 
 
         Repeat Screen     
 
Place: ______________________ 
Screen Date: _____/_____/_____ 
 
Results:         
Left Ear                    Right Ear 
Pass 
 
 
 
Refer 
 
 
 
 
 
 
 
 
If your baby passes, testing is done. 
Watch for normal milestones. 
 
Be sure your doctor gets the results. 
www.AZNewborn.com 
If your baby does not pass the 
screening in one or both ears, talk to 
your doctor about seeing a Pediatric 
Audiologist as soon as possible.
 
         Evaluation by Pediatric 
         Audiologist. Be sure your 
 doctor gets the results.          
Place: ______________________ 
Date: _____/______/______ 
 
Results: 
Right Ear   Left Ear 
              
 
Normal 
 
 
 
Hearing Loss          
   
  
  
 
 Evaluation by an ENT 
 (Ear, Nose, and Throat) 
 doctor 
 
Place: ______________________ 
Date: _____/______/______ 
 
Hearing aid fitting (if   
appropriate) of loaner or 
permanent hearing aids by a 
Pediatric Audiologist. 
 
          Contact Hands & Voices 
 for family support: by phone 
 at 866-685-1050 or 
 www.AZHV.org  
                     
Normal Milestones Before 1 Month Before 3 Months 
You may need a referral from your 
doctor to see these specialists. 
If your baby has a HEARING 
LOSS, the next steps are: 
 
         Enroll in Early Intervention 
 program, if hearing loss in  
 both ears 
 
Program: __________________ 
Date: ____/_____/_____ 
 
         Learn about communication   
         Options 
 
Learn about cochlear 
implants, if applicable 
          
         Regular visits to a  
         Pediatric Audiologist 
  
Evaluations: 
 
        Ophthalmologist (eye doctor) 
 
 
Place: _____________________ 
Date: ___/____/____ 
 
         
        Genetic Specialist 
 
 
Place: _____________________ 
Date: ___/____/____ 
 
Before 6 Months 
Take this to your baby’s doctor  
Lista de Comprobación Familiar – Audición Infantil Nombre del Niño: ___________________________ 
Fecha de Nacimiento: ______/_______/_________ 
 
 
 
 
 
 
s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Muchos bebés alcanzan las 
etapas normales aunque 
sean sordos de uno o ambos 
oídos. Sólo debe usar estas 
etapas para vigilar el 
desarrollo de la audición de 
su niño si este ha PASADO 
la prueba de audición o ha 
sido revisado por un 
Audiólogo Pediátrico… 
 
Meses de Edad 
 
2     Se calla cuando oye una 
voz conocida. Hace 
sonidos de vocales como 
a-a-ah, o-o-o 
 
4    Busca los sonidos con 
 sus ojos. Usa sonidos
 como chillidos, 
 quejidos, risitas 
 
6     Voltea hacia el sonido. 
Balbuce ba-ba,  ma-ma, 
da-da 
 
9     Imita a los demás. 
Entiende no-no o bye-
bye. Voltea la cabeza 
hacia los sonidos suaves. 
 
12    Usa correctamente ma- 
ma o da-da 
 
         
         
Prueba en el Hospital  
 
Lugar: _____________________ 
Fecha de la Prueba: ___/____/____ 
 
Resultados:                   
Oído Izq.        Oído Derecho      
 
 Pasó 
 
 
 
 
              Recomendación 
 
 
         Repetición de la Prueba     
 
Lugar: ______________________ 
Fecha de la Prueba: ____/___/___ 
 
Resultados:         
Oído Izq.        Oído Derecho        
 Pasó 
 
 
             Recomendación 
 
  
 
 
 
 
 
 
Si su bebé pasa, se hace la prueba y 
usted debe esperar etapas normales. 
 
Asegúrese que su doctor reciba los 
resultados. 
 
www.AZNewborn.com 
 
Evaluación del Audiólogo 
Pediátrico. Asegúrese que su 
doctor reciba el resultado. 
Lugar: ___________________ 
Fecha: _____/______/______ 
 
Resultados: 
Oído Derecho   Oído Izq. 
              
 
Normal 
 
 
 
   Sordera          
   
  
  
 
Prueba de un 
Otorrinolaringólogo (Oído, 
Nariz y Garganta) 
Lugar: ___________________ 
Fecha: _____/______/______ 
 
Medida del audífono (si es 
apropiado) prestado o 
audífonos permanentes por 
un Audiólogo Pediátrico. 
 
Contacte a Hands & Voices 
para apoyo familiar; por 
teléfono al 866-685-1050 o  
en www.AZHV.org  
 
Etapas Normales Antes de 1 Mes Antes de 3 Meses 
Quizá necesite recomendación de su 
doctor para ver a estos especialistas 
 
Regístrelo en el programa 
de Intervención Temprana, 
si es sordo de los dos oídos 
 
Programa: __________________ 
Fecha: ____/_____/_____ 
 
Aprenda sobre opciones           
de comunicación 
 
Aprenda sobre implantes   
cocleares, si es aplicable 
        
         Visitas regulares a un  
         Audiólogo Pediátrico 
  
Evaluaciones: 
 
        Oftalmólogo (oculista) 
 
 
Lugar: __________________ 
Fecha: ___/____/____ 
 
         
        Especialista en Genética 
 
 
Lugar: __________________ 
Fecha: ___/____/____ 
 
Si su bebé no pasa la evaluación en 
uno o en ambos oídos, hable con su 
doctor para que lo mande con un 
Audiólogo Pediátrico lo más 
pronto posible. 
Si su bebé tiene SORDERA, los 
pasos a seguir son: 
Antes de 6 Meses 
Lleve esto al doctor de su bebé  


 
 
Newborn Hearing Screening Training Curriculum Scripts  
 
 
Informing Parents of the Screen: 
Hi! Congratulations on the birth of your baby. You have received information that we 
provide hearing screening to all babies born. We are going to screen your baby now.  
Informing Parents of the Screen (Spanish): 
¡Hola! Felicitaciones por el nacimiento de su bebé. Usted recibió información sobre el 
tamizaje auditivo que le hacemos a todos los recién nacidos.  Ahora vamos a hacerle el 
tamizaje a su bebé.  
 
 
Passing:  
Congratulations on the birth of your baby.  We just completed the hearing screen; the 
results are a pass.  Here is a brochure that talks about development of speech and 
language.  It is always important to monitor the progress of your baby’s development, 
especially their speech and language because your baby’s hearing can change any 
time. If you are ever worried that your baby can’t hear, talk to your baby’s doctor right 
away and ask for a referral to an audiologist that is skilled at testing infants and young 
children. 
Passing (Spanish): Pasó:  
Felicitaciones por el nacimiento de su bebé.  Acabamos de finalizar el tamizaje auditiva 
de su bebé y él/ella la pasó.  Este es un folleto que trata sobre el desarrollo del habla y 
del lenguaje.  Es importante observar el desarrollo de su bebé especialmente de su 
habla y lenguaje ya que la audición de su bebé puede cambiar en cualquier momento.  
Si usted está preocupado de que su bebé no pueda oír, hable con el médico pediatra 
inmediatamente y pídale que lo envíe a donde un audiólogo especializado en hacer 
pruebas a bebés y niños pequeños.  
 
 
Not Passing:  
Congratulations on the birth of your baby.  We just finished screening your baby’s 
hearing. Your baby did not pass the screen today.  This does not necessarily mean that 
your baby has a permanent hearing loss, but without additional testing we can’t be sure.  
The screening results will be provided to your baby’s doctor. Please be sure you make 
or keep (depending on your hospital’s protocol) the appointment for further hearing 
testing. 
Not Passing (Spanish): No Pasó:  
Felicitaciones por el nacimiento de su bebé.  Los resultados del tamizaje auditivo que le 
hicimos hoy a su bebé indican que él/ella no lo pasó.  Esto no necesariamente significa 
que su bebé tenga una pérdida auditiva permanente, pero sin hacer pruebas adicionales 
no podemos estar seguros.  Los resultados del tamizaje le serán enviados al médico de 
su bebé.  Asegúrese de hacer una cita para hacer más exámenes auditivos o acudir a 
esta (dependiendo del protocolo de su hospital).   
 
 
 
 
 
 
Inconclusive: 
Although we attempt to provide newborn hearing screening to all babies born at our 
hospital, we were unable to complete the screening on your baby.  It is important that 
your baby be screened as soon as possible.  Let’s schedule a time for the screening to 
be completed within the next 2 weeks.   
Inconclusive (Spanish): No Concluyente: 
Aunque tratamos de hacerle un tamizaje auditivo a todos los recién nacidos en nuestro 
hospital,  no pudimos completar el tamizaje de su bebé.  Es importante hacerlo lo más 
pronto posible.  Hagamos una cita para terminar de hacerle la prueba durante las dos 
semanas entrantes.  
 
 
Not Passing Outpatient Rescreen: 
Your baby did not pass the second screen.  The screening does not tell us whether your 
baby has a hearing loss; it just tells us that further testing should be done as soon as 
possible.  The next step is to get a diagnostic ABR as soon as possible.  This should be 
discussed immediately with your baby’s doctor who may need to help you with obtaining 
a referral to a pediatric audiologist. 
Not Passing Outpatient (Spanish): No Pasó El Segundo Tamizaje 
Auditivo: 
Su bebé no pasó el segundo tamizaje auditivo.  Esto no significa que su bebé tiene una 
pérdida auditiva; solamente nos indica que se deben hacer más pruebas lo más pronto 
posible.  El siguiente paso es realizar una prueba de potenciales evocados auditivos del 
tronco cerebral (conocida por sus siglas en inglés ABR).  Hable de manera inmediata 
con el médico de su bebé quien puede ayudarle a conseguir una cita con un audiólogo 
pediatra. 
 
 
High Risk: Passing: 
Congratulations on the birth of your baby. We screened your baby’s hearing and the 
results are a pass. However, because your baby has had some medical problems at 
birth, there is a chance that your baby can develop a hearing loss after you leave the 
hospital. Your baby’s hearing is critical for normal speech and language development, so 
it is important that you speak to your baby’s doctor who can help you in knowing when 
your baby should have further tests with a pediatric audiologist and can also help you to 
monitor for normal speech and language development.   
High Risk: Passing (Spanish)   
Felicitaciones por el nacimiento de su bebé.  Su bebé pasó el tamizaje auditivo que le 
realizamos.  Sin embargo y  debido a que tuvo algunas complicaciones médicas durante 
su nacimiento , existe la posibilidad de que desarrolle una pérdida auditiva  después de 
que sea dado de alta del hospital.  La audición es importante para el desarrollo normal 
del habla y lenguaje de su bebé.  Es importante que hable con el médico de su bebé 
quien le puede indicar cuando debe ser visto por un audiólogo  pediatra y también le 
puede ayudar a hacer el seguimiento del desarrollo del habla y lenguaje de su bebé. 
 
 
 
 
 
High Risk: Not Passing    
Congratulations on the birth of your baby. Your baby received a hearing screen and the 
results show that your baby did not pass. There can be simple reasons for this, but 
without further testing with a pediatric audiologist, I cannot tell you what your baby hears.  
Because your baby has had some medical problems at birth, your baby is at a greater 
risk for a hearing loss.  Please discuss these results with your baby’s doctor and ask 
them to help you schedule diagnostic tests with a pediatric audiologist as soon as 
possible.  Finding out about hearing issues as early as possible will help to ensure that 
your baby has the best chance to develop normal speech and language. 
High Risk: Not Passing (Spanish) 
Felicitaciones por el nacimiento de su bebé.  Su bebé no pasó el tamizaje auditivo que 
le realizamos.  Las razones no son necesariamente complicadas pero sin tener 
resultados de exámenes realizados por un audiólogo pediatra no puedo informarle cual 
es la capacidad auditiva de su bebé.  Debido a que su bebé tuvo algunas 
complicaciones médicas durante su nacimiento tiene una mayor posibilidad de 
desarrollar una pérdida auditiva.  Es importante que discuta estos resultados con el 
médico de su bebé, él le puede ayudar a hacer una cita con un audiólogo pediatra lo 
más pronto posible.  El diagnóstico de problemas auditivos lo más temprano posible 
ayudará a que su bebé tenga una mejor oportunidad para desarrollar un habla y 
lenguaje normal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequently Asked Questions Parent’s May Ask 
(English and Spanish) 
 
Why screen my baby’s hearing? 
Hearing loss is one of the most common conditions present at birth. It is easy 
to miss hearing loss because you usually can’t see anything different.  
Without screening, hearing loss is often not detected until the baby is 2 years 
old and not talking.  Early identification and intervention means that your baby 
won’t fall behind other children in speech and language development. 
¿Por qué  hacerle una prueba auditiva a mi hijo? 
La pérdida auditiva es una de las condiciones más comunes que se 
presentan en los recién nacidos.  Es fácil no percatarse de su existencia 
porque uno no puede ver nada diferente en el bebé.  Sin la prueba auditiva, 
es frecuente que la pérdida auditiva no se detecte hasta que el niño tiene 2 
años y no habla.  La identificación e intervención temprana hacen que su 
bebé no tenga un retrazo en su habla y desarrollo del lenguaje. 
 
How do you check my baby’s hearing? 
OAE: Soft sounds are made into the baby’s ear.  If the ear is working 
normally, it will send back sounds that the computer can pick up and analyze. 
Your baby doesn’t have to do anything other than be quiet. 
ABR: Soft sounds are made into the baby’s ear and electrodes or little 
sensors pick up the brain’s response to the sounds.  
¿Cómo le hace la prueba auditiva a mi hijo? 
OAE: Por medio de una sonda se introducen sonidos suaves en el oído del 
bebé.  Si el oído funciona normalmente, éste producirá sonidos que son 
detectados y analizados por la computadora.  Su bebé no tiene que hacer 
nada solamente permanecer callado. 
ABR: Por medio de una sonda se introducen sonidos suaves en el oído de su 
bebé.  Electrodos localizados en la frente y  en los lóbulos de las orejas 
detectan la respuesta del cerebro a estos sonidos. 
 
What does Pass or Refer mean? 
Pass means that your baby’s ears are working normally today.  However, 
some babies develop hearing loss later so if you are concerned, you should 
always talk to your baby’s medical provider about getting a hearing test. 
Refer means that your baby did not pass the hearing screening and needs 
additional testing. 
 
 
 
 
¿Qué significa cuando mi bebé pasa/no pasa la prueba? 
Si su bebé pasa la prueba, esto significa que los oídos de su bebé funcionan 
bien. Sin embargo, algunos bebés pueden desarrollar una pérdida auditiva 
después de la primera prueba. Si usted está preocupado debe hablar con la 
persona que provee los servicios de salud a su hijo sobre la posibilidad de 
hacerle otra prueba auditiva.  Si su bebé no pasa la prueba esto significa que 
necesita exámenes adicionales. 
 
What happens if my baby Refers? 
If your baby refers a second time, it is very important that you make an 
appointment with a pediatric audiologist as soon as possible to have a 
complete hearing test called an Auditory Brainstem Response test or an ABR.  
¿Qué pasa si mi bebé no pasa la prueba auditiva por segunda vez? 
Si su bebé no pasa la prueba por segunda vez, es importante que haga una 
cita con un audiólogo pediatra lo más pronto posible para que realicen un 
examen que se llama ABR (por sus siglas en ingles). 
 
How long does the hearing screen take? 
Usually it takes 10 to 15 minutes depending on how quiet your baby is during 
the screening. 
¿Cuánto tiempo toma hacer el examen? 
Usualmente de 10 a 15 minutos dependiendo de que tan callado esté el niño 
durante la prueba. 
 
Will hearing screening hurt my baby? 
No.  Most babies sleep through the screen. 
¿Le dolerá a mi bebé? 
No.  La mayoría de los bebés duermen durante la prueba. 
 
Where is the hearing screening done? 
Your baby’s hearing can be screened at this hospital, as part of the newborn 
hearing screening program. 
¿Dónde se realiza la prueba? 
La prueba auditiva se puede realizar en este hospital, como parte del 
programa de pruebas auditivas de recién nacidos. 
 
 
 
 
 
 
What can be done if hearing loss is detected? 
Hearing loss cannot be determined by screening.  Screening tells us if further 
testing by a pediatric audiologist is needed.  If an audiologist finds that your 
baby has a hearing loss he or she will talk with you about what happens next.  
¿Cuál es el siguiente paso si se sospecha la existencia de una pérdida 
auditiva? 
Una pérdida auditiva no puede ser confirmada por la prueba auditiva, esta 
indica que un audiólogo pediatra necesita realizar más pruebas.  Si un 
audiólogo diagnostica una pérdida auditiva, él o ella le dirán cual es el 
siguiente paso a seguir. 
 
What if I choose not to allow the hearing screen? 
You will be asked to sign a refusal form and your baby’s doctor will be 
advised of your decision.  We recommend that you think about the screening. 
Please ask questions about your concerns.  Finding a hearing loss as early 
as possible is critical in order for children to develop normal speech and 
language. 
¿Qué pasa si tomo la decisión de no permitir que se le haga a mi bebé la 
prueba auditiva? 
Se le pedirá que firme un documento y se le comunicará al doctor de su bebé 
su decisión.  Le recomendamos que piense su decisión.  Por favor haga 
preguntas sobre sus preocupaciones.  El diagnóstico de una pérdida auditiva 
los más temprano posibles es importante para que los niños desarrollen un 
habla y lenguaje normal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How Does Your Child Hear and Talk?  
Here is a checklist that you can follow to check your child's hearing and understanding 
development.  You should talk to your child's doctor about anything on the list that your 
child is not doing and you have checked "No”. 
Birth to 3 Months Yes No
Reacts to loud sounds ___  ___ 
Quiets or smiles when spoken to ___  ___ 
Seems to recognize your voice and quiets if crying ___  ___ 
Increases or decreases sucking behavior in response to sound ___  ___ 
Makes noise when talked to ___  ___ 
   
4 – 6  Months Yes No
Moves eyes in direction of sounds ___ ___
Responds to changes in tone of your voice ___ ___
Notices toys that make sounds ___ ___
Pays attention to music ___ ___
   
7 Months to 1 Year Yes No
Enjoys games like peek-a-boo and pat-a-cake  ___ ___
Turns and looks in direction of sounds  ___ ___
Listens when spoken to ___ ___
Recognizes words for common items like “cup”, “shoe”, or “juice” ___ ___
Begins to respond to requests (e.g. “come here” or “want more”?) ___ ___
 
 
 
Parents: This is simply a guide to help you check your baby’s development at different ages 
and stages. It should not be used to replace a hearing test. If you ever have concerns about 
your child’s hearing, contact your baby’s doctor immediately. 
f you or your child/student 
talk or sign... if you talk and
sign, or cue, or care, we 
need you.  If you are directly, 
indirectly, or potentially involved 
with children who are deaf or 
hard of hearing and their fami-
lies, we need you.  We need 
to be united by our hands and 
our voices.  We are parents, professionals, adult men-
tors, consumers, and others who are in so many ways 
connected to a cause and to each other through the 
community of the Deaf and Hard of Hearing.  We are 
Hands & Voices. 
Our philosophy of unbiased support makes Hands & 
Voices unique among Deaf/HH organizations. There are 
many wonderful organizations that provide support and 
information about methods and modes of communica-
tion, but at Hands & Voices, we rally around the need 
to improve educational outcomes for our kids, and to 
enhance their quality of life.
Our organization is parent-driven, but highly collaborative 
with professionals who are represented on our advisory 
board, and make up approximately one third of our 
membership.  We work at both the local and national 
levels.  Our state chapters provide local and regional 
support consistent with the Hands & Voices non-biased 
philosophy and mission.  In addition to family support, 
we strive to be meaningfully involved at the systems 
development level.
Whether we’re at work locally or nationally, Hands & 
Voices continues to be driven by the need to improve 
the educational outcomes and quality of life for children 
who are deaf or hard of hearing. 
Be a part of this dynamic movement….become a Hands 
& Voices member today!
Hands & Voices 
P0 Box 371926
Denver, CO 80237
Phone (303) 300-9763 
Toll free (866) 422-0422
Email: parentadvocate@handsandvoices.org
Website:  www.handsandvoices.org
Hands & Voices is a
non profi t 501(c)(3) organization
Non-biased support for families of 
children who are deaf 
and hard of hearing
www.handsandvoices.org
A Rallying Cry:  
We Need All Your
HANDS &  VOICES 
National Information:
Arizona Hands & VoicesI
What Works
for your Child
is What Makes
the Choice Right
PO Box 50423
Phoenix AZ,  85076
ph #: 1-866-685-1050
Phoenix Area and Northern AZ please contact: 
Helen Cartwright
hcartwright@azhv.org
Tucson and Southern AZ please contact:
Carmen Haber
chaber@azhv.org
www.azhv.org
register@azhv.org
• Deaf Ed Reform - Educational Excellence
• “Medical Home” Initiative
• Communication Access for Children who are 
Deaf and Hard of Hearing
• Hearing Aid Coverage by Insurance Companies
• Universal Newborn Hearing Systems
• Parent/Professional Collaboration
• Deaf/HH Adult Mentoring
• Parent Education and Support
• Deaf Child’s Bill of Rights
• Natural Environments and Children who are 
Deaf/HH
• Parent’s right to make informed communication 
choices
• Meaningful Parent Involvement
• Educational Advocacy and Training
We invite you to become a member of Hands 
& Voices.  Your membership benefi ts include: 
the quarterly Hands & Voices Newspaper, THE 
COMMUNICATOR; reduced fees to attend 
workshops; advocacy assistance priority.
Hands & Voices
Areas of Focus Include:
Tell us Who You Are
Hands & Voices 
Resources 
Available to 
Parents and 
Professional  May 
Include:
• Website
• The Resource Guide for Parents
• Quarterly publication,  “The Communicator”
• Lending Library
• IEP Facilitation/Advocacy
• Public Speakers Bureau
• State Chapters Affi liate Support
• “We are Hands & Voices” video
• Statewide workshops
• Legislative advocacy
• Parent perspective representation on statewide/na-
tional issues
• Regional Parent Coordinators
• Spanish Speaking parent coordinator
• Unilateral Hearing Loss parent Coordinator
• Teacher/professional pre-service and in-service 
training
• Deaf /HH Adult Role Models
Our Mission:
amilies for Hands and 
Voices is dedicated 
to supporting families 
with children who are Deaf 
or Hard of Hearing without a 
bias around communication 
modes or methodology.  We’re 
a parent-driven, non-profit 
organization providing families 
with the resources, networks, 
and information they need to 
improve communication access 
and educational outcomes for 
their children. Our outreach activities, parent/profes-
sional collaboration, and advocacy efforts are focused 
on enabling Deaf and Hard-of-Hearing children to reach 
their highest potential.
What People say about Hands & Voices:
“Hands & Voices supported my personal decision about my 
son and how he would learn to communicate with the world as 
a deaf Person.  Hands & Voices did not judge, but supported 
my choice.” 
Shirley Swope,
parent and advocate, Colorado
“Hands & Voices is what our state has been waiting for. I 
had several requests for specifi c information which sent me 
scrambling for some appropriate resources and information. 
Hands & Voices was where I found it.”
Lorna Irwin,
parent and consultant, Idaho
“For too long we have debated what communication mode is 
best, rather than work to provide the variety of options neces-
sary to meet the diverse needs of deaf/hh children.  The broad 
vision of Hands & Voices comes at exactly the right time.”  
Lawrence Siegel,
Natl. Deaf Education Project
Parent Support and Advocacy for 
Children who are Deaf and
Hard of Hearing
Annual
Membership Dues
Sign up for: Price
Parent of deaf/ hh child*
Deaf or hard of hearing adult
Student
Professional
Organization / agency
Additional Donation
$25.00
$25.00
$25.00
$40.00
$50.00
Subtotal: 
*Scholarships available for parents check here
Total: 
Name
Address
Children’s Ages
Phone
Check
Cash
Scholarship - Parent
Method of Payment
F
Please include payment with registration
Guide By Your Side 
provides. . .
!
!
!
!
CALL Guide by Your Side TODAY
toll free: 866‐685‐1050
or
520‐331‐3125
EMAIL Guide By Your Side
gbys@azhv.org
WRITE TO Guide By Your Side
P.O. Box 64091
Tucson, AZ 85705
!
!
Arizona Hands & Voices
Guide By Your Side
P.O. Box 64091
Tucson, AZ 85728
Toll free: 1-866-685-1050
Fax: 1-520 843-2070
Email: gbys@azhv.org
!
!
Providing unbiased, emotional 
support and resources by 
trained Parent Guides to 
families families with children 
who are deaf, hard of hearing 
and hearing impaired.       
For Families
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LLAME Guide by Your Side
sin pager: 866-685-1050
o
520-331-3125
EMAIL Guide By Your Side
gbys@azhv.org
ESCRIBA A Guide By Your Side
P.O. Box 64091
Tucson, AZ 85705
Arizona Hands & Voices
Guide By Your Side
P.O. Box 64091
Tucson, AZ 85728
Toll free: 1-866-685-1050
Fax: 1-520 843-2070
Email: gbys@azhv.org
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Cuanto cuesta? 
• El programa Guide By Your 
Side es gratis para las familias 


  
Hearing Aids – Resources for Parents 
 
 
Hearing aids as well as other audiological services 
can be quite expensive and unaffordable for many 
families. Fortunately there are programs in Arizona 
that can help families and children that are in need 
of assistance.  
 
 
Loaners: 
Your first option would be to check with your 
audiologist about loaner hearing aids. Loaner 
hearing aids are also available to any Arizona 
family, through the HEAR for Kids Program with the 
EAR Foundation of Arizona. Loaners are usually 
available for up to six months. Longer loan periods 
are possible for special circumstances such as 
assessment for cochlear implantation.  The program 
is funded by grants and donations.  
 
 
Purchasing Equipment: 
Research on how to purchase and pay for 
permanent hearing aids should begin as soon as 
possible. It may take several months to determine 
eligibility for some programs. The answers to some 
of the questions listed below may help you find the 
assistance that is right for your family.  
 
Q.  Is your child enrolled in an AHCCCS or 
KidsCare health plan?  
 
NO     You may be eligible for other programs as  
           described below.  
 
YES    Your child may be eligible for hearing 
            services through Children’s Rehabilitative 
            Services (CRS).  Information about CRS 
            services and how to apply are on the next  
            page.  
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Q.  Does your health plan cover hearing 
aids?  
 
 NO     There may be an appeals process to 
            challenge limits or restrictions on  
             coverage.  You may be eligible for  
             other programs described below.        
 
 YES     Call your health plan Member 
             Services and ask for information  
              about your hearing service benefits. 
                
 
Q.  Are your financial resources limited? 
 
 NO       Ask your audiologist if the office 
              or facility where you receive  
              audiological services can arrange a 
              payment plan. 
 
 YES      There are several programs   
               available to those with financial  
               needs.  
  
Your audiologist may participate in some of the 
following programs, which are described in 
more detail on the next few pages.  Your 
audiologist may be helpful in deciding which 
program/s best suit your needs.  Please note 
that some programs may require you to 
change providers.  
 
 HEAR for Kids  
 
 UnitedHealthCare Foundation for 
Children  (higher income levels)  
 
 Starkey Foundation’s HEAR Now 
Program  
 
 Lions Affordable Hearing Aid Program  
 
 Sertoma Clubs 
 
Children’s Rehabilitative Services (CRS) 
 
CRS provides medical care and support services to 
children and youth who have certain chronic or 
disabling conditions.  CRS recipients can get 
hearing related services in one of four 
MultiSpecialty Interdisciplinary Clinics (MSICs) 
located in Flagstaff, Tucson, Yuma and Phoenix.   
 
The Arizona Health Care Cost Containment System 
has contracted with Arizona Physicians IPA (APIPA) 
to administer the CRS program, as APIPA-CRS. 
 
To be eligible for APIPA-CRS services you must: 
Eligibility: 
• Have an eligible medical condition 
(Most hearing impairments are eligible 
conditions) 
• Live in Arizona 
• Be under age 21 
• Be a U.S. citizen or qualified alien. 
 
APIPA-CRS recipients must also be enrolled in an 
AHCCCS acute health plan or ALTCS (Arizona 
Long Term Care System) plan.  You may call 
Member Services toll-free at 1-866-275-5776 for 
more information.  
 
APIPA-CRS covered services are provided at no 
cost to recipients.  Hearing services, including 
hearing aids, earmolds and fitting are covered for 
qualified APIPA-CRS recipients.  Hearing aids may 
be replaced every three years or more often if there 
is a significant change in hearing.  Hearing aids are 
covered for loss or damage by a two year 
replacement warranty.  If the original hearing aid(s) 
are lost or damaged, families are encouraged to 
purchase insurance for the replacement aid(s).   
Hearing Aids and Cost to the Family  
 
For some types of hearing aids, prior authorization 
may be needed before APIPA-CRS can provide 
them.   Your APIPA-CRS hearing services provider 
will take care of this for you.    
 
 
 
 
For families who have ALTCS, APIPA-CRS 
and private insurance 
APIPA-CRS will coordinate benefits with your 
private insurance and you will not be billed for 
any remaining cost, when you get hearing 
services at an MSIC or APIPA-CRS provider. 
 
APIPA-CRS recipients who receive hearing 
services may also be eligible for additional 
medical specialty services like ENT, Genetics, 
Ophthalmology, among others at their MSIC.                         
Additional Services  
 
To get an application or information: 
Apply by Filling Out an Application: 
• Call Member Services toll-free at:        
1-866-275-5776. 
• Visit the APIPA-CRS web site at 
www.myapipacrs.com,  
• Call the Office for Children with Special 
Health Care Needs (OCSHCN) at 602-
542-1860,  
• Call 1-800-232-1676 and ask for the 
CRS Program, or 
• Download an application from the 
OCSHCN web site at 
www.azdhs.gov/phs/ocshcn/crs/crs_az.
htm.    
 
 
 
 
 
  
 
HEAR for Kids 
                                                                       
HEAR for Kids is a program of the EAR Foundation 
of Arizona.  Most of the funding is provided by St. 
Luke’s Health Initiatives and private donations as 
well as grants from Arizona Community Foundation, 
Nina Mason Pulliam Charitable Trust and others.  
Authorization is generally available within 48 hours 
of the application. 
 
Eligibility is based on family income, household 
size/dependent care, and expenses.  If the child is 
covered by AHCCCS or KidsCare or other 
insurance that covers hearing aids, they are not 
eligible for HEAR for Kids.  Children must be 
currently living in Arizona to be eligible. 
Eligibility: 
 Income:  Total Household income for the 
past 12 months:  Wages/Salary, Pension, 
Social Security, Child Support and any other 
income. 
 Expenses:  Total Allowed Deductions for the 
past 12 months include medical/dental not 
paid for by health insurance or third party, 
annual rent or mortgage payments, annual 
payments for primary vehicle. 
 Dependent Care:   Use the following 
calculations: 
• Number of children in childcare_____ x 
$200 x number of months_____= $_____  
• Number of incapacitated adults receiving 
care____x$100x number of 
months_____=$____  
 
Using the amounts you calculated above, find 
Annual Income. Take Income minus Expenses 
minus Dependent Care = Annual Income.  Using 
the chart below, find the number of people in your 
family and the corresponding maximum Annual 
Income to be eligible.  (current as of 3/2010).  
 
      Number in Family             Annual Income 
1 $16,245 
2 21,855 
3 27,465 
4 33,075 
5 38,685 
6 44,295 
For each additional person, add $5,610 
 
Cost to the Family: 
As long as the family qualifies under the 
financial criteria above, there are no costs.  
Earmolds are covered for the first year as 
many times as needed.  Earmolds maybe 
covered after the first year if the family 
continues to meet the financial criteria.  
Repairs or new aids are covered as needed if 
the family qualifies. 
 
 
Hearing Aids:  
Any aid selected by the audiologist will have a 
1 or 2 year warranty.  There is no restriction on 
type of hearing aid although the least 
expensive aid available with the features 
needed is generally purchased to ensure that 
the funding is available for all in need.  Some 
repairs and replacement of cochlear implant 
parts may also be available. 
 
Applications can be downloaded on the EAR 
Foundation website at 
www.earfoundationaz.com but must be 
submitted by the audiologist who will be 
helping select and fit the hearing aid(s). 
 
The Ear Foundation can be contacted directly 
by calling 602-690-3975, or e-mail to: 
lylisolsen@msn.com 
 
                                       
 
 
                                                     
UnitedHealthCare Children’s Foundation  
 
The UnitedHealthCare Children’s Foundation is a 
 
An application must be submitted to the 
501(c)(3)non-profit charity dedicated to facilitating 
access to medical-related services that are not fully 
covered by the available commercial health benefit 
plan.  This “support” is in the form of a medical grant 
to be used for medical services not covered or not 
completely covered by commercial health benefit 
plans. 
 
The applicant must be covered by a commercial 
health benefit plan and limits for the requested 
service are either exceeded, or no coverage is 
available and/or the copayments are a serious 
financial burden on the family. The 
UnitedHealthCare Children's Foundation requires a 
commercial health benefit plan.  If your health plan 
is an AHCCCS, ALTCS or KidsCare plan, you will 
not be eligible for this grant, but you may be eligible 
for CRS. Read more about CRS on page 2. 
 
The applicant must be 16 years old or younger and 
live in the United States and receive and pay for 
care/items in the United States. 
Eligibility: 
Financial need of the child's family will be evaluated 
and documented through information provided on 
the application and by submission of a photocopy of 
the most recently filed Federal tax return (Internal 
Revenue Service 1040, 1040-A, or 1040-EZ). The 
following scale will be used to determine financial 
eligibility:  
Your Family Size 
As reported on your IRS 
1040 
Adjusted Gross Income 
As reported on your IRS 
1040 
2 $40,000 or less  
3 $60,000 or less  
4 $80,000 or less  
5 or more  $100,000 or less  
NOTE:
Foundation prior to the receipt of services. The 
Foundation does not pay for past medical 
expenses 
  Awards will NOT be granted to individuals 
in families whose Adjusted Gross Income (AGI) 
exceeds the scale. 
 
The UnitedHealthcare Children’s Foundation 
has a specific set of items that are excluded 
from grant consideration. For a complete list of 
exclusions see 
Exclusions: 
www.uhccf.org.  
 
There does not appear to be any restriction on 
types of hearing aids other than a limit of 
$5,000 or 85% of the fund balance, whichever 
amount is less per year. Awards to any one 
individual are limited to a lifetime maximum of 
$7,500. 
Hearing Aids: 
                                                
If a grant is approved by the Regional Board of 
Directors for your child, the grant will help pay 
for approved medical services/items after your 
commercial health benefit plan submits 
payment, if any. The grant funds are not paid 
to you or the child outright - you work with the 
Foundation on submitting invoices/bills for 
approved medical services/items after your 
commercial health benefit plan submits initial 
payment (if any) to the  health care provider  
 
 
 
Applications and further information on criteria 
and services can be found at the link below or 
by calling (952) 992-4459. 
Applications: 
www.uhccf.org  
 
Starkey Foundation’s 
HEAR Now Program 
  
HEAR Now is a national non-profit program 
committed to assisting those permanently residing 
the in the U.S. who are deaf or hard of hearing,  
who qualify under the National Poverty Guidelines 
for assistance and have no other resources to 
acquire hearing aids. 
 
All applicants are asked to call HEAR Now to 
discuss eligibility for the program.  Please call 800-
648-4327. 
Eligibility: 
 
Income Guidelines:  All income figures are based on 
take-home wages (net income) from all members of 
the household 
 
Size of 
Family 
Unit 
HEAR 
NOW 
Income 
Guideline
s 
Size of 
Family 
Unit 
HEAR 
NOW 
Income 
Guideline
s 
1 $17,867 4 $36,137 
2 $23,957 5 $42,227 
3 $30,047 6 $48,317 
 
NOTE: For family units with more than 6 members, 
add $6,090 for each additional member. 
 
HEAR Now also considers family assets such as 
savings, retirement funds, life insurance and 
annuities. 
 
The family is responsible for finding a hearing health 
care professional willing to work with them and the 
HEAR Now Program.  HEAR Now does not provide 
a list of hearing health care professionals or make 
referrals to practitioners.  Check the listings in your 
local phone book under “Audiologists” and/or 
“Hearing Aids” and call to ask if they are a HEAR 
Now provider.  If they are a provider, ask if they can 
Cost to the Family 
take you on as a new client.  Most Pediatric  
Audiologists in Arizona are not participating 
providers and you may be responsible for the cost 
of the fitting and programming of the hearing aids. 
 
The family is responsible for the cost of the 
evaluation/assessment and the non-refundable 
processing fee to HEAR Now.  Once the aids 
are provided, the family is responsible for the 
purchase of batteries and extended warranty 
coverage for the aids. 
 
The Hearing Aids are selected by the 
Foundation and will be Starkey products.  
Starkey makes behind-the-ear, in-the-ear and 
bone conduction hearing aids.  A one year 
warranty is provided.  Check with the 
audiologist to make sure that these hearing 
aids will meet your child’s needs before 
pursuing this option. 
 
This information is current as of March 2010. 
You can access the website link below for 
more current information and to access the 
application process or call 1(800) 328-9602. 
Additional Information and Application: 
 
www.sotheworldmayhear.org 
 
 
 
 
 
 
 
 
 
Lions Affordable Hearing Aid 
Program (AHAP) 
 
Sertoma Clubs 
 
The  Lions AHAP is rooted in a continuum of care 
 
Sertoma stands for SERvice TO MAnkind.  
 Community Hearing Aid 
Program, Inc. (CHAP) 
 
CHAP is an independent charity funded by St. 
Luke’s Health Initiatives, BHHS Legacy Foundation, 
 
This list was compiled to 
assist families in obtaining 
funding to cover the costs of 
model involving hearing care professionals and  
focuses on low-income beneficiaries. The hearing 
aid is one part of the solution to hearing impairment.                
     
Also needed are the services of hearing care 
professionals to conduct tests, order ear molds, 
program the hearing aids and do follow-up care. 
 
Currently Lions AHAP is distributing two hearing 
aids through a partnership with Rexton, Inc. in 
cooperation with participating Lions foundations, 
districts and clubs, and hearing care professionals. 
Lions clubs, districts and hearing programs are able 
to order one or both aids from Lions AHAP. 
 
A Lions club decides the eligibility of a person, and 
the person is tested by a hearing care professional. 
The Lions club sends the order to Lions AHAP, who 
notifies the manufacturer. The hearing aid is 
shipped to the hearing care professional listed on 
the order form. The hearing care professional fits 
the hearing aid for the person. Individuals cannot 
apply directly to Lions Club International 
Foundation; he/she must work through his/her local 
Lions club. 
How does the Lions AHAP program work? 
 
 
 
The criteria for eligibility are income-based. This 
includes using the federal government's poverty 
guidelines and adjusting it to the local economy. 
The hearing aids are for the segment of the 
population who would never be able to purchase 
hearing aids.  
Eligibility 
 
Each club has their own criteria and application 
process.  For further information on the program, 
contact the Lions AHAP office at (630) 468-6771 or 
e-mail LionsAHAP@lionsclubs.org 
You can also contact a club near you by going to 
the Lions International website:  www.lionsclubs.org 
Sertoma’s primary focus is on assisting the 
more than 50 million people with hearing 
health issues and educating the public on the 
issues surrounding hearing health. In order to 
achieve these goals Sertoma has undertaken 
a multi-faceted approach by launching 
programs that address both the treatment and 
prevention aspects of hearing health. 
 
 
 
Communicative Disorders Scholarships 
There is a $1,000 Scholarship  for hard of 
hearing or deaf students that have clinically 
significant bilateral hearing loss. Graduating 
high school seniors or undergraduate students 
must be pursuing a four year degree.  
 
There is also a $1,000 Scholarship  for 
graduate students who have been accepted 
into a graduate level program in audiology or 
speech-language pathology at institutions in 
the United States. Sertoma provides more 
funds nationally for graduate level study in 
communicative disorders than any other single 
organization.  
 
 
Other Services: 
Sertoma Affiliates are non-profit hearing and 
speech facilities that have established a 
relationship with a Sertoma Club or have an 
independent relationship with Sertoma. This 
relationship results in greater service to people 
with communicative disorders by supporting 
the professional staff and programs of the 
affiliate.  
 
There are 7 Sertoma clubs in Arizona.  
Locations and contact information can be 
found on their website or by calling 1 (816) 
333-8300.  
www.sertoma.org 
 
Board of Visitors, Virginia G. Piper Charitable 
Health Trust, Sertoma Clubs and private donations.  
 
The criteria for eligibility are based on 
income,hearing loss, and residency status. Total 
household income for the past 12 months is taken 
into consideration.  Income received from 
wages/salary, pension, Social Security, child 
support and any other income by any wage earner 
in the family is taken into consideration.  Total 
Household income must be at or below 200% of the 
Federal Poverty Level (FPL). 
Eligibility 
 
There is an application fee of $75 per hearing aid 
requested that is due along with the application and 
supporting documentation.  There are no additional 
costs.   
Additional Cost to the Family 
 
The CHAP Preferred Audiologist who provides the 
fitting will select the most appropriate hearing aid for 
the patient’s loss and listening demands.  Hearing 
aids are both behind the ear and in the ear models.  
The majority of aids fit are new; however, there are 
a few very high end digital aids that have been 
certified to manufacturer specification that can be 
requested.  All repairs to CHAP hearing aids are 
paid for by CHAP.  If the hearing aid is old and/or 
deemed no longer repairable, an application for a 
new hearing aid would be required for a 
replacement aid.  
HEARING AIDS 
 
Applications can be downloaded from the CHAP 
website 
Applications 
www.communityhearingaidprogram.org 
 
If you have questions you can call Kimberly Langer-
Roedel @ 623-748-8814 or email 
theearlady@cox.net 
hearing aids.  The 
information should be 
verified before decisions are 
made as programs, funding 
and eligibility may change 
over time.  Talk with your 
audiologist about other 
options.   
 
If you have questions or 
would like to update the 
information you can contact: 
Arizona Early Hearing 
Detection and Intervention 
State Coordinator: 
Lylis E Olsen, MS, MPH 
602-690-3975 
lylisolsen@msn.com 
 
 
  
Aparatos auditivos – Recursos para Padres 
 
 
Los aparatos auditivos y otros servicios 
audiológicos pudieran ser demasiado caros e 
imposibles de pagar para muchas familias. Por 
suerte, hay programas en Arizona que pueden 
ayudar a las familias y a los niños que necesitan 
ayuda.  
 
 
Prestados 
Primero debería preguntarle a su audiólogo/a si 
tiene aparatos auditivos que le puedan prestar. 
También hay aparatos auditivos disponibles para 
cualquier familia de Arizona mediante el programa 
HEAR for Kids de la Fundación EAR de Arizona. 
Por lo común, puede usar los prestados por hasta 
seis meses. Pudiera usarlos por más tiempo en 
circunstancias especiales, tales como evaluaciones 
para implantes de cócleas. El programa se sufraga 
con subvenciones y donativos.  
 
 
Compra de equipo 
Debe comenzar a investigar lo más pronto posible 
cómo comprar y pagar los aparatos auditivos 
permanentes. Pudieran tardarse varios meses para 
determinar si reúne los requisitos de algún 
programa. A continuación se responde a algunas 
preguntas que pudieran ayudarles a conseguir la 
ayuda correcta para su familia  
 
P.  ¿Está inscrito/a su niño/a en el plan médico 
de AHCCCS o KidsCare?  
 
NO     Pudiera reunir los requisitos para participar 
en otros programas que se describen a 
renglón seguido.  
 
SÍ       Su niño o niña pudiera reunir los requisitos 
para recibir servicios de la audición mediante 
los Servicios de Rehabilitación de Niños/ 
Children’s Rehabilitative Services (CRS).  En 
las páginas siguientes se le informarán los 
servicios de CRS y cómo solicitarlos.  
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P.  ¿Cubre su plan médico los aparatos 
auditivos?  
 
 NO     Existe un recurso de apelación para 
oponerse a límites o restricciones de 
cobertura. Pudiera reunir los requisitos 
para otros programas que se describen 
a continuación. 
 
 SÍ      Llame a los Servicios de Miembros de 
su plan médico y pida información 
acerca de sus prestaciones para 
servicios de audición. 
              
P.  ¿Tiene recursos económicos limitados? 
 
 NO    Pregúntele a su audiólogo/a si el 
consultorio o la instalación en la que se 
le prestan servicios audiológicos puede 
ofrecerle un plan de pagos. 
 
 SÍ      Hay varios programas disponibles para 
los que tienen necesidades 
económicas.  
  
Su audiólogo/a pudiera participar en algunos 
de los programas que se describen con más 
detalles en las páginas siguientes. Le podrá 
ayudar a decidir qué programa(s) le 
convendrían más a sus necesidades. Por 
favor, tenga en cuenta que algunos programas 
pudieran conllevar que tuviera que cambiar de 
proveedores.  
 
 HEAR for Kids  
 
 Fundación para Niños de UnitedHealthCare  
(para ingresos más altos)  
 
 Programa HEAR Now  
de la Fundación Starkey 
 
 Programa de Aparatos Auditivos 
Asequibles de los Leones  
 
 Clubes Sertoma 
 
Children’s Rehabilitative Services (CRS) 
Servicios de Rehabilitación de Niños 
 
El programa CRS proporciona atenciones médicas y 
servicios de apoyo para niños y jóvenes que tengan 
ciertas condiciones críticas o incapacitantes. Las 
personas que reciban servicios de CRS podrán 
conseguir servicios de la audición en una de las cuatro 
Clínicas Interdisciplinarias de Especialidades Múltiples 
(MSIC, por sus siglas en inglés) que se encuentran en 
Flagstaff, Tucsón, Yuma y Phoenix.   
 
El plan médico público Arizona Health Care Cost 
Containment System (AHCCCS) contrató a la asociación 
de consultorios individuales Arizona Physicians IPA 
(APIPA, por sus siglas en inglés) para que administre el 
programa CRS con el nombre de APIPA-CRS. 
 
Pare reunir los requisitos de los servicios de APIPA-
CRS, debe: 
Requisitos 
• Tener una afección o condición médica que 
califique (la mayoría de los defectos de la 
audición son afecciones que califican) 
• Vivir en Arizona 
• Tener menos de 21 años de edad 
• Ser ciudadano/a de los EE. UU. o extranjero/a 
calificado/a. 
 
Los que reciban servicios de APIPA-CRS deberán 
inscribirse también en un plan médico de afecciones 
agudas de AHCCCS o en el plan del Sistema de 
Atenciones a Largo Plazo de Arizona (Arizona Long 
Term Care System; ALTCS, por sus siglas en inglés). 
Puede llamar gratis a Servicios de Miembros para mayor 
información al 1-866-275-5776.  
 
Los servicios que cubre APIPA-CRS se proporcionan 
gratis a los que los reciben. A los que reúnan los 
requisitos del programa se les cubrirán los servicios de 
la audición (entre ellos los aparatos auditivos, los 
aparatos conchas y los ajustes). Los aparatos pueden 
reemplazarse cada tres años o antes si hay cambio 
notable en la audición. Una garantía de reemplazo de 
dos años asegura las pérdidas o daños a los aparatos 
auditivos. Si se perdiera(n) o dañara(n) el o los 
aparato(s) auditivo(s) original(es), se anima a los 
familiares a que compren un seguro para los aparatos 
auditivos de reemplazo.   
Aparatos auditivos y costos para la familia  
 
 
 
Pudiera hacer falta autorización de antemano para 
que APIPA-CRS proporcionara ciertos tipos de 
aparatos auditivos. Su proveedor(a) de servicios 
audiológicos de APIPA-CRS se encargará de esto 
por parte suya.   
 
Para las familias que tengan ALTCS, APIPA-
CRS y seguro privado 
Cuando reciba servicios de la audición mediante 
un(a) proveedor(a) de una clínica MSIC o de 
APIPA-CRS, el programa coordinará las 
prestaciones con su seguro particular y no se le 
cobrará a usted por los costos restantes. 
 
Los que reciban servicios de audición de APIPA-
CRS también pudieran reunir los requisitos para 
otros servicios médicos especializados en su 
clínica MSIC, tales como otorrinolaringología, 
genética, oftalmología y demás.                         
Otros servicios 
 
Obtenga así la solicitud o la información: 
Rellene una solicitud para pedirlos 
• Llame gratis a Servicios de Miembros al:        
1-866-275-5776. 
• Visite la página de Internet de APIPA-CRS 
al www.myapipacrs.com,  
• Llame a la Oficina para Niños con 
Necesidades Especiales de Cuidado de 
Salud (OCSHCN) al 602-542-1860,  
• Llame al 1-800-232-1676 y procure el 
programa CRS, o 
• Descargue una solicitud de la página de 
Internet de OCSHCN al 
www.azdhs.gov/phs/ocshcn/crs/crs_az.htm.    
 
HEAR for Kids 
HEAR para Niños 
 
HEAR for Kids es un programa de la Fundación EAR de 
Arizona.  Las Iniciativas de Salud del Hospital San Lucas 
(St. Luke’s Health Initiatives, en inglés) y los donativos 
particulares, junto con las subvenciones de la Fundación 
Comunitaria de Arizona (Arizona Community Foundation), 
el Fideicomiso Caritativo de Nina Mason Pulliam y otras 
organizaciones, sufragan la mayoría de los costos del 
programa. Por lo común, las solicitudes se aprueban a las 
48 horas. 
 
Se califica basándose en el ingreso familiar, así como en la 
cantidad de personas al igual que las atenciones de 
dependientes y los gastos del hogar. Si el o la niño/a 
cuenta con seguro de AHCCCS, KidsCare u otro seguro 
que cubra los aparatos auditivos, no reunirán los requisitos 
para HEAR for Kids. Para calificar, los niños deben vivir en 
la actualidad en Arizona. 
Requisitos 
 Ingreso: El ingreso del hogar por los 12 meses 
pasados: sueldos y salarios, pensiones, Seguro 
Social, pensión alimentaria de menores y todo otro 
ingreso. 
 Gastos: Suma de deducciones que se permiten 
por los 12 meses pasados, incluso gastos médicos 
y dentales en dicho plazo que no pague un plan 
médico o terceros, alquiler o pago de hipoteca 
anual, pagos anuales para el vehículo principal. 
 Atenciones de dependientes:   Calcule lo 
siguiente: 
• Cantidad de niños en guarderías _____ x $200 
x cantidad de meses _____= $_____  
• Cantidad de adultos incapacitados que reciban 
atenciones ____x $100 x cantidad de meses 
_____=$____  
 
Use las cantidades que calculó para determinar el ingreso 
anual. Ingreso menos Gastos menos Atenciones de 
dependientes = Ingreso Anual. Use la tabla siguiente 
para determinar la cantidad de personas que componen a 
su familia y el ingreso anual máximo correspondiente para 
reunir los requisitos. (Actualizado para marzo de 2010)  
 
      Personas de Familia             Ingreso Anual 
1   $16,245 
2   21,855 
3   27,465 
4   33,075 
5   38,685 
6   44,295 
 
Sume $5,610 por cada persona de familia que añada 
 
 
 
Costo a la familia 
Siempre que la familia reúna los requisitos 
económicos anteriores, no tendrán que pagar 
costos. Los aparatos conchas se cubren el primer 
año las veces que hagan falta. Pudieran seguirse 
cubriendo los aparatos conchas después del 
primer año si los familiares siguieran cumpliendo 
con los requisitos económicos. Se cubrirán los 
arreglos o los aparatos nuevos que hagan falta si 
la familia califica. 
 
 
Aparatos auditivos 
Todo aparato que escoja su audiólogo/a contará 
con una garantía de 1 ó 2 años. No hay 
limitaciones en cuanto al tipo de aparato auditivo, 
aunque por lo común se compra el aparato menos 
caro que cuente con las funciones necesarias a fin 
de asegurarse de que haya dinero para todos los 
que lo necesiten. También habrá disponibles 
algunos arreglos y reemplazos de piezas de 
implantes de cóclea. 
 
Puede descargar las formas de solicitud mediante 
la página de Internet de la Fundación EAR al 
www.earfoundationaz.com, pero deberá 
presentarla su audiólogo/a que le ayudará a 
escoger y a ajustar su(s) aparato(s) auditivo(s). 
 
Se puede comunicar directamente con la 
Fundación Ear por teléfono al 602-690-3975, o 
envíele un mensaje electrónico a: 
lylisolsen@msn.com                 
 
 
                                                     
UnitedHealthCare Children’s Foundation  
Fundación para Niños de UnitedHealthCare 
 
La Fundación para Niños de UnitedHealthCare es una 
sociedad caritativa constituida de conformidad con el 
apartado fiscal federal 501(c)(3) que se dedica a facilitar 
el acceso a los servicios médicos y afines que no cubran 
los planes médicos particulares disponibles. Este 
“suplemento” funciona como subvención médica para 
los servicios médicos que los planes particulares no 
cubran por completo o en absoluto. 
 
La persona a cuyo nombre se solicite deberá tener un 
plan médico particular y o bien excederá o bien no 
contará con la cobertura, o bien los copagos resultarán 
una carga económica de gravedad para la familia. La 
Fundación para Niños de  UnitedHealthCare exige que 
ya tenga un plan médico particular. Si su plan médico es 
de AHCCCS, ALTCS o KidsCare, no reunirá los 
requisitos para esta subvención, pero pudiera calificar 
para el programa CRS. Entérese mejor acerca del CRS 
en la página 2. 
 
La persona a cuyo nombre se solicite deberá tener 16 
años de edad o menos, vivir en los Estados Unidos, y 
recibir al igual que pagar por las atenciones y los 
artículos en los Estados Unidos. 
Requisitos 
Las necesidades económicas de la familia del o de la 
menor se evaluarán y se harán constar mediante la 
información que se incluya en la solicitud y con fotocopia 
de la declaración de impuestos federales más reciente 
que se haya radicado (formas de Servicio de Rentas 
Internas/Internal Revenue Service 1040, 1040-A, o 
1040-EZ). Se usará la escala siguiente para determinar 
si reúne los requisitos económicos:  
Personas en la familia 
que reportó en la 
declaración de impuestos 
federales IRS 1040 
Ingreso Bruto Ajustado  
que reportó en la 
declaración de impuestos 
federales IRS 1040 
2 $40,000 o menos 
3 $60,000 o menos 
4 $80,000 o menos  
5 ó más  $100,000 o menos 
NOTA
 
 NO se otorgarán subvenciones a las familias 
cuyos ingresos brutos ajustados (AGI, por sus siglas en 
inglés) excedan lo indicado. 
 
Se remitirá una solicitud a la Fundación antes de 
que se reciban los servicios. La Fundación no 
pagará gastos médicos anteriores 
 
La Fundación para Niños de UnitedHealthcare 
enumera ciertos artículos en concreto que no se 
pueden tomar en cuenta para las subvenciones. 
La enumeración completa aparece en 
Exclusiones 
www.uhccf.org.  
 
Parece que no hay restricciones en cuanto a qué 
clase de aparatos auditivos, aparte de un límite de 
$5,000 o del 85% del saldo del fondo, lo que 
resulte menos cada año. No se le otorgará más de 
$7,500 en la vida a persona alguna. 
Aparatos auditivos 
                                                
Si la Mesa Regional de Directores aprobara la 
subvención, la misma ayudará a pagar los 
servicios o artículos médicos aprobados después 
de que su plan médico particular presente sus 
pagos, de haberlos. El dinero de la subvención no 
se le pagará directamente a usted ni a su niño/a: 
usted colaborará con la Fundación para presentar 
las facturas por los servicios y artículos médicos 
aprobados después de que su plan médico 
particular efectúe los pagos iniciales (de haberlos) 
a su proveedor(a) de atenciones médicas. 
 
 
 
Consiga las solicitudes y mayor información en 
cuanto a requisitos o servicios si visita el enlace de 
Internet siguiente o si llama al (952) 992-4459. 
Solicitudes 
www.uhccf.org  
 
 
Starkey Foundation’s HEAR Now Program 
Programa HEAR Now de la Fundación Starkey 
 
HEAR Now es un programa nacional sin fines de lucro 
que se dedica a ayudar a los que viven 
permanentemente en los EE. UU. y que son sordos o 
medio sordos, que reúnen los requisitos de las Pautas 
Nacionales de Pobreza para que les ayuden y que no 
tienen otros recursos para adquirir aparatos auditivos. 
 
Se le pide a todos los que soliciten que llamen a HEAR 
Now para platicar acerca de cómo calificar para el 
programa. Llame por favor al 800-648-4327. 
Requisitos 
 
Pautas de ingreso: Todas las cifras de ingreso se basan 
en los sueldos netos (lo que le sobra para llevarse a 
casa) de todos los que vivan en el hogar. 
 
Personas 
en el hogar 
Pautas de 
ingreso de 
HEAR NOW 
 
Personas 
en el hogar 
Pautas de 
ingreso de 
HEAR NOW 
 
1 $17,867 4 $36,137 
2 $23,957 5 $42,227 
3 $30,047 6 $48,317 
 
NOTA: Si hubiera más de 6 personas en la familia, 
sume $6,090 por cada persona que añada. 
 
HEAR Now también toma en cuenta bienes familiares, 
tales como ahorros, fondos de jubilación, seguros de 
vida y anualidades. 
 
La familia se encargará de conseguir a un(a) 
profesionista médico/a de la audición que esté 
dispuesto/a a actuar con ellos y con el programa HEAR 
Now.  El programa no proporcionará una lista de 
profesionistas médicos ni les referirá a los mismos. 
Revise las listas de su guía telefónica del área en la 
sección de “Audiólogos (Audiologists)” y hasta de 
“Aparatos Auditivos (Hearing Aids)” y llámelos para 
enterarse de si proporcionan servicios mediante HEAR 
Now.  Si los proporcionan, pregúnteles si le podrían 
aceptar de cliente nuevo/a. La mayoría de los 
audiólogos pediátricos de Arizona no participan en el 
programa, y pudiera tener que encargarse del costo de 
ajustar y programar los aparatos auditivos. 
Costos a la familia 
 
 
 
 
 
La familia se encargará de la evaluación y de 
la tarifa de trámite no reembolsable para 
HEAR Now.  En cuanto se le proporcionen los 
aparatos, la familia se encargará de comprar 
pilas y garantía de cobertura extensa para los 
aparatos. 
 
La Fundación escogerá los aparatos, que 
serán productos Starkey. Starkey fabrica 
aparatos auditivos curvetas, conchas y 
vibradores de conducción ósea. Se 
proporciona una garantía por un año. Antes de 
acogerse a esta opción, asesórese con su 
audiólogo/a para asegurarse de que estos 
aparatos cumplirán con las necesidades de su 
niño o niña. 
 
Esta información se había actualizado en 
marzo de 2010. Para conseguir información 
más actual y para lograr acceso al proceso de 
solicitud, puede ir al enlace de Internet 
siguiente o llamar al 1(800) 328-9602. 
Solicitud y más información 
 
www.sotheworldmayhear.org 
 
 
 
 
 
 
 
 
 
 Programa de Aparatos Auditivos 
Asequibles (AHAP) de los Leones  
Lions Affordable Hearing Aid 
Program (AHAP) 
 
Sertoma Clubs 
Clubes Sertoma  
 
El programa AHAP de los Leones se desprende de una 
gama continua de modelos de atenciones en los que 
participan los profesionistas audiológicos y se enfoca en 
personas de ingresos bajos. El aparato auditivo es una 
parte de la solución a los defectos auditivos.                
     
También hacen falta los servicios de los profesionistas 
audiológicos para llevar a cabo estudios, pedir conchas 
auditivas, programar los aparatos y proporcionar 
atenciones de seguimiento. 
 
El programa AHAP de los Leones distribuye en la 
actualidad dos aparatos auditivos en alianza con la 
Rexton, Inc. y cooperando con las fundaciones, distritos 
y clubes de Leones, aparte de los profesionistas 
audiológicos. Los clubes y distritos de Leones, así como 
los programas de audición, pueden pedir uno o ambos 
aparatos al programa AHAP. 
 
¿Cómo funciona el programa AHAP de los Leones? 
 
Cierto Club de Leones decidirá si la persona reúne los 
requisitos, y un(a) profesionista audiológico le practicará 
un estudio de la audición. El Club de Leones le envía el 
pedido al programa AHAP, quien a su vez le avisa al 
fabricante. Se envía el aparato auditivo al o a la 
profesionista audiológico/a que se mencione en el 
pedido. Tal profesionista ajusta el aparato a la persona. 
Los individuos no pueden solicitarle directamente a la 
Fundación Internacional de Clubes de Leones; debe 
actuar mediante su Club de Leones más cercano. 
Los requisitos a reunir se basan en los ingresos. Entre 
otras, se aplican las pautas de pobreza federales y se 
ajustan a la economía local. Los aparatos auditivos son 
para el segmento de la población que jamás podría 
comprarlos.  
Requisitos 
 
Cada club tiene sus propios requisitos y trámite de 
solicitud. Comuníquese con la oficina del programa 
AHAP de Leones al (630) 468-6771 o envíe un mensaje 
electrónico a  LionsAHAP@lionsclubs.org para mayor 
información. También puede comunicarse con un club 
cercano si visita la página de Internet de los Leones 
Internacionales:  www.lionsclubs.org 
 
La palabra Sertoma se compone de las siglas en 
inglés “SERvice TO MAnkind” (Servicio a la 
humanidad).  Sertoma se concentra principalmente 
en ayudar a más de 50 millones de personas que 
padecen de males médicos de la audición y a 
enseñarle al público los asuntos que afectan la 
salud auditiva. A fin de lograr tales metas, Sertoma 
acometió una estrategia multifacética al inaugurar 
programas que atiendan tanto el aspecto del 
tratamiento como el de la prevención en cuanto a 
la salud auditiva. 
 
 
Becas para trastornos de la comunicación 
Existe una beca de $1,000 para los estudiantes 
semisordos o sordos que tengan pérdida auditiva 
bilateral de importancia. Los que estén por 
recibirse de preparatoria (High School) o los 
estudiantes de licenciatura deberán avocarse a 
estudiar una carrera de licenciatura. 
  
También existe una beca de $1,000 para 
estudiantes de postgrado que se les admita a un 
programa de posgrado en audiología o patología 
del habla y de la lengua en instituciones 
estadounidenses.  Sertoma proporciona más 
fondos por toda la nación para estudios de 
postgrado en trastornos de la comunicación que 
cualquier otra organización aparte.  
 
 
Otros servicios 
Las afiliadas de Sertoma son instalaciones sin 
fines de lucro para la audición y el habla que 
entablaron alianza con un Club Sertoma o que 
mantienen una relación independiente con 
Sertoma. La relación resulta en más servicios para 
las personas que tengan trastornos de la 
comunicación porque apoyan a los empleados 
profesionistas y a los programas de la afiliada.  
 
Hay 7 Clubes Sertoma en Arizona. Consiga sus 
direcciones e información para comunicarse en la 
página de Internet (www.sertoma.org) o por 
teléfono al 1 (816) 333-8300.  
 
Community Hearing Aid 
Program,  Inc.  (CHAP) 
 
CHAP es una entidad caritativa independiente que se 
sufraga con las Iniciativas de Salud del Hospital San 
Lucas (St. Luke’s Health Initiatives), La Fundación del 
Patrimonio BHHS (BHHS Legacy Foundation), Board of 
Visitors, el Fideicomiso Médico Caritativo Virginia G. 
Piper, los Clubes Sertoma y los donativos particulares.  
 
Los requisitos a reunir se basan en los ingresos, la 
pérdida de la audición y la condición de residencia. Se 
tomará en cuenta el ingreso del hogar por los 12 meses 
anteriores. Se captarán los ingresos que se reciban de 
sueldos y salarios, pensiones, el Seguro Social, la 
pensión alimentaria de niños y otras entradas de todos 
los que devenguen sueldos en la familia. El ingreso total 
del hogar no deberá exceder el 200% del Nivel Federal 
de Pobreza (FPL, por sus siglas en inglés). 
Requisitos 
 
Se pide una tarifa de solicitud de $75 por aparato 
auditivo junto con la solicitud y los comprobantes. No 
hay más costos.   
Costos para la familia 
 
El o la Audiólogo/a Preferida por CHAP que le 
proporcione los ajustes escogerá el aparato auditivo 
más apropiado para las necesidades y pérdidas 
auditivas del o de la paciente. Se dispone de aparatos 
auditivos en modelos de curvetas y conchas. La mayoría 
de los aparatos que se ajusten serán nuevos; sin 
embargo, se pueden solicitar ciertos dispositivos 
digitales de precios elevadísimos que se certifique que 
cumplan con las precisiones de fábrica. El programa 
CHAP pagará por todos los arreglos que se le hagan a 
los aparatos de su programa. Si el aparato fuera viejo o 
hasta se estimara que ya no pudiera componerse, habrá 
que presentar una solicitud de aparato nuevo para que 
se reemplace.  
Aparatos auditivos 
 
Puede descargar las solicitudes de la página de Internet 
de CHAP 
Solicitudes 
 
www.communityhearingaidprogram.org 
Si tuviera dudas, pudiera comunicarse con Kimberly 
Langer-Roedel al 623-748-8814 o enviarle un mensaje 
electrónico a theearlady@cox.net 
 
 
Se compuso esta lista para 
ayudar a las familias a 
obtener recursos para pagar 
los costos de aparatos 
auditivos. Deberá verificarse 
la información antes de tomar 
decisiones, puesto que los 
programas, fondos y 
requisitos pudieran cambiar 
con el tiempo. Hable con su 
audiólogo/a acerca de otras 
opciones. 
 
Si tuviera dudas o quisiera 
actualizar la información, 
podría comunicarse con la 
Coordinadora Estatal de 
Detección e Intervención 
Temprana de Arizona:   
Lylis E. Olsen, MS, MPH 
602-690-3975 
lylisolsen@msn.com 
 
 
 HEAR for Kids      
 
Loaner aids  
• No income eligibility requirements 
• Standard loan is up to 6 months 
• Longer loans for exceptional circumstances (such as cochlear implant trial) 
• Loan requests are made online at earfoundationaz.com by the audiologist 
• Youngest children first if there is a shortage 
• Hearing aids are almost all digital and include BAHA, Bone conduction, AVR and others 
• Participating audiologists donate their services 
Vouchers 
• See financial eligibility table below 
• Legal residency status is not an issue 
• Families who are enrolled in AHCCCS, KidsCare do not qualify 
• Families eligible but still working on enrollment in AHCCCS or KidsCare may qualify 
• Insured families may qualify if their insurance does not cover hearing 
• Exceptions can be made for unusual circumstances especially if a child is “stuck” 
• Vouchers cover behavioral, sedated or unsedated ABR, medical clearance for hearing aid 
• Not for monitoring ongoing otitis media 
Permanent Hearing Aids 
• Same financial eligibility as the vouchers 
• The managing audiologist chooses the most appropriate hearing aid for the child 
• Colors and swirls are routinely approved 
• Youngest children first if there is a shortage of money 
Income  
Total Household income for the past 12 months:  $_________________________ 
Include: Wages/salary, Pension, Social Security, Child Support and any other income. 
Expenses 
Number of family members living in the household:______________ 
Total Allowed Deductions for the past 12 months:  $________________________  
Include: Total medical/dental not paid for by health insurance or third party, Annual rent or mortgage payment, 
Annual payments for primary vehicle, Dependent Care.  For dependant care, use the following calculations: 
 Number of children in childcare  ____ x $200 x number of months ____=____ 
 Number of incapacitated adults receiving care ____x$100 x number of months ____=____ 
Determine eligibility by subtracting the amount in the Expenses section from the amount in the Income 
section and reviewing the following chart (based on 150% of federal poverty, current as of 5/05) 
Number in 
Family 
Annual 
Income 
Number in 
Family 
Annual 
Income 
Number in 
Family 
Annual 
Income 
1 $14,355 3 $24,135 5 $33,915 
2 $19,245 4 $29,025 6 $38,805 
For each additional person, add $4,890 
 
Contact Lylis Olsen at lylisolsen@msn.com   602-690-3975 (phone)    602-296-0425 (fax) 
 
Applications can be found at http://earfoundationaz.com/page_010_005.html 
For People Who Have Sickle Cell Trait (AS)
BE INFORMED: Here are 5 things to know
 You have one Sickle gene (S).
• Genes are what cause parents to pass traits 
 (like eye color) or health conditi ons (like   
 Diabetes) along to their children. The Sickle 
 gene (S) aff ects the red blood cells.
• Sickle Cell Trait (AS) occurs when a person
inherits a Normal gene (A) from one parent, and 
a Sickle gene (S) from the other.
 Sickle Cell Trait is usually a very mild conditi on.
• Sickle Cell Disease is a serious blood disease that
can be very painful.
• Sickle Cell Trait is NOT Sickle Cell Disease. It does 
not make people sick the way Sickle Cell Disease 
does.
 Problems with Sickle Cell Trait are RARE.
• Most people with Sickle Cell Trait (AS) cannot tell
that they have it.  Millions of people have Sickle 
Cell Trait (AS).  They are fi ne, and they lead 
acti ve lives.
• A few people with the Trait (AS) may have:
• Blood in the urine, from ti me to ti me
• Some pain and discomfort at high alti tudes
(like in the mountains or in certain citi es that 
are high above sea level)
• Problems with extreme exercise in hot, humid
weather, when not drinking enough water.
Each parent has two genes,
and each parent passes one gene along to the baby.
 The Sickle gene (S) runs in many families.
The Sickle gene (S) is found in people from many 
diff erent countries. It is found in:
• Africans, African-Americans, West Indians
• Lati nos, Brazilians and in other people from
Central and South America
• Italians, Greeks and other people from other
Mediterranean countries
• East Indians, Asians and people from countries in
the Middle East
 MOST IMPORTANT: You CAN have a baby with 
Sickle Cell Disease, in the future.
• You can pass your Sickle gene (S) along to any of
your children in the future.
• So, fi nd out if your partner also has a gene that
can cause Sickle Cell Disease.  It could be an (S) 
gene or another gene. If so, any of your children 
can be born with the disease.  Ask, him or her to 
be tested to fi nd out.
• Most important both parents should be tested.
Individuals with Sickle Cell Trait should inform their 
doctor about their conditi on.  If you have further 
questi ons please contact:
Your local Sickle Cell Disease Organizati on 
Quest to Cure at:
www.questt ocure.org
Offi  ce for Children with Special Healthcare Needs
602-542-1860  or  1-800-232-1676
Contact Nati onal Coordinati ng and Evaluati on 
Center:
410-528-1555 (Phone)
410-528-1495 (Fax)
1-800-421-8453 (Toll Free)
www.sicklecelldisease.net
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Para Personas Que Tienen El Rasgo De Glóbulos 
Falciformes. ENTÉRESE: 5 hechos a saber
 Usted porta un gen Falciforme (S).
•  Los genes transmiten los rasgos (tales como el color 
de los ojos) o las condiciones de la salud (tales como 
la diabetes) de los padres a los hijos. El gen Falciforme 
(S) afecta a los glóbulos rojos de la sangre.
•  El Rasgo de Glóbulos Falciformes (AS) sucede cuando 
la persona hereda un gen normal (A) de uno de los 
padres y un gen Falciforme (S) del otro.
Cada padre ti ene dos genes,
y cada padre le transmite uno de los genes a su bebé.
  El Rasgo de Glóbulos Falciformes suele ser una 
condición muy leve.
•  La Anemia de Glóbulos Falciformes es un mal grave de 
la sangre que puede ser muy doloroso.
•  Ser portador del Rasgo de Glóbulos Falciformes NO es 
padecer la Anemia de Glóbulos Falciformes.  El rasgo 
no hace padecer a la gente de la forma que la Anemia 
de Glóbulos Falciformes enferma.
  Es RARO que el Rasgo de Glóbulos Falciformes 
cause problemas.
•  La mayoría de los portadores del Rasgo de Glóbulos 
Falciformes (AS) no se dan cuenta del rasgo. Millones 
de personas son portadoras del Rasgo de Glóbulos 
Falciformes (AS). Están bien, y llevan vidas acti vas.
•  Unos pocos portadores del Rasgo (AS) pudieran 
presentar:
• Sangre en la orina de vez en cuando
•  Ciertos dolores y molesti as en elevaciones altas (tales como 
las montañas o ciertas ciudades muy sobre el nivel del mar)
•  Complicaciones al ejercitarse extremadamente en climas 
cálidos y húmedos si no se tomara sufi ciente agua.
CONSEJO
DE UN VISTAZO
 El Falciforme (S) se presenta en muchas familias. 
El gen Falciforme (S) se encuentra entre familias de 
muchos países. Se encuentra entre:
• Africanos, Afro-estadounidenses, Anti llanos
•  Hispanoamericanos, Brasileños y otras personas de la 
América Central y del Sur
•  Italianos, Griegos y otras personas de otros países 
Mediterráneos
•  procedentes de la India, de otros países Asiáti cos y 
hasta del Mediano Oriente
  LO MÁS IMPORTANTE: En el futuro PUDIERE 
tener un bebe con la Anemia de Glóbulos 
Falciformes.
•  Pudiere transmiti rle su gen Falciforme (S) a cualquiera 
de sus niños futuros.
•  Por lo tanto, entérese de si su pareja también porta 
un gen que pudiera causar la Anemia de Glóbulos 
Falciformes.  Pudiera ser el gen Falciforme (S) o algún 
otro gen.  De ser así, cualquiera de sus niños pudiere 
nacer con el mal. Pídale a su pareja que se haga un 
estudio para enterarse.
•  Lo más importante es que ambos padres se hagan la 
prueba.
Comuníquese con la organización de Anemia de 
Glóbulos Falciformes o clínica más cercana:
www.questt ocure.org
La Ofi cina de Niños con
Necesidades Especiales de Cuidado de Salud
(602) 542.1860   o   1 (800) 232.1676
Comuníquese con nuestra ofi cina nacional:
Sickle Cell Disease and Newborn Screening Program
Contact Nati onal Coordinati ng and Evaluati on Center
at SCDAA Nati onal Headquarters
231 E. Balti more Street Suite 800
Balti more, MD 21202
410.528.1555 (Phone) 
410.528.1495 (Fax) 
1.800.421.8453 (Toll Free) 
www.sicklecelldisease.net
NBS-004 (REV. 6/10)
 
 Cystic Fibrosis Newborn Screening (CF NBS)  
Frequently Asked Questions (FAQ)  
  
1. What is a “positive CF NBS” and what does it mean?  
  
It means that the immunoreactive trypsinogen assay (IRT) tested above the 97.8%ile or the 
day of the test.  This triggered DNA analysis for 46 common CF genes in our population.  
That test was positive for at least 1 CF gene mutation. This test is only done on the first 
sample.  
  
2. Does that mean my patient has CF?  
  
That means that child possesses at least 1 common gene for CF gene mutation.  It also means 
one of their parents also must carry the gene.  Your patient is at least a carrier of one CF gene 
mutation.  
  
3. I thought you needed 2 gene mutations to have CF?  
  
This is true.  CF is an autosomal recessive disease.  A child could have one common CF 
gene mutation and one uncommon CF gene mutation.  Only the common CF gene 
mutation would be detected in the newborn screen.  This panel of 46 common CF gene 
mutations accounts for about 92% of CF disease.  At this time there are over 1400 known CF 
gene mutations.  That’s why the positive NBS needs further evaluation.  
  
4. Why don’t we just send a genetic test for DNA?  
  
Unless you test for all the genes with expanded testing (which takes weeks and is very 
expensive) you will not have a definitive answer.  Sometimes after the genetics are obtained 
the answers still remain unclear.  The patient may have a new novel gene mutation and may 
even involve testing other family members as well.  It is an expensive process that can delay 
an accurate diagnosis.    
  
5. So the patient has a +NBS; what should I do now?  
  
At a minimum the child needs to obtain a sweat chloride test at a qualified testing center 
facility.  Currently, those centers are at Phoenix Children’s Hospital and Saint Joseph’s 
Hospital in Phoenix and University Medical Center in Tucson.   
  
6. What will happen at the NBS clinic visit?  
  
After you receive a call from the CF center regarding the +NBS, a test can be arranged, 
including follow up management of the patient and testing.  The child may be seen at the 
time of the sweat chloride exam.  During this visit the child is assessed for early subtle signs 
of CF.  The family is also given accurate information about CF and given genetic counseling 
for family regarding the CF gene mutation.  This service includes information back to your 
office about the testing and any further implications for your patient and their family. 
Providing accurate and rapid testing for your patient and information to you and your patient’s 
family will follow.   
Please have your referral coordinator obtain an authorization for both a 
visit/consultation and testing. The ICD-9 code is 796.6.   
  
7. If a child had a positive CF NBS what should we do about a sibling?  
  
The CF NBS in Arizona started in 10/07.  If a child has a + NBS for CF, any siblings that 
have not been previously screened (because they were born before Arizona began screening or 
were born in a state that didn’t screen for CF) should have a sweat chloride.    
  
8. Does the NBS detect all CF patients?  
  
CF NBS detection rate is about 92%.  Meaning 8 % of children could be lost to care through 
a variety of reasons.  The program detailed above is an attempt to limit some of the 
extraneous factors causing a delay to diagnosis or misinformation about CF.  
  
9. Now that there is a CF NBS can I take CF out of a patient differential diagnosis?  
  
Absolutely not, as mentioned above CF NBS could miss 8 % of diagnoses.  This means that 
any child with, for example, failure to thrive, recurrent pneumonia, chronic diarrhea or 
malabsorption it should be left high in the differential.   CF is a common illness present in 
1/3,100 in the Caucasian population.  Please obtain a sweat chloride for that child; it is an 
easy, inexpensive test that can aid your diagnostic process.  
  
10. If I have further questions who can I call?  
  
• Pediatric CF and NBS director at Phoenix Children’s Hospital, Department of 
Pediatric Pulmonology (602) 546-0985. 
   
• Dr. Wayne Morgan, Tucson Cystic Fibrosis Center at (520) 626-7780.  
 
• A pediatric pulmonologist of your choice   
  
 
Another source of accurate information regarding CF is the Cystic Fibrosis Foundation 
at www.CFF.org.  
  
  
  
Thanks to Dana Valletta from PCH CF Center for creating this valuable resource. She can be 
reached at 602-546-0985  
Arizona Hemoglobin Bart’s  
Fact Sheet for Health Care Providers 
 
Hemoglobin Barts
Alpha thalassemia is caused by deletions of the alpha globin genes on 
chromosome 16. Normal individuals have 4 copies of the gene with 2 
on each chromosome. It is possible to lose 1 to 4 of these genes. The 
presence of hemoglobin Bart’s on newborn screen usually suggests 
that the infant is missing at least 1 alpha gene. 
 
 
Your patient has been found on the Arizona Newborn Genetic Screen 
to have a hemoglobin electrophoresis pattern consistent with          
"FA Bart’s". The acronym stands for the hemoglobin species present in 
the baby's blood in descending order of prevalence. The F designates 
fetal hemoglobin (a2 y2), A denotes hemoglobin A (a2ß2) and Bart’s 
represents hemoglobin Bart's, a tetramer of y-globin molecules (y4). 
Hemoglobin Barts (y4) appears in the newborn when one or more of 
the 4 human a-globin genes are missing. The relative over abundance 
of y-globin molecules leads to y4 production and the diagnosis of 
Hemoglobin Barts. 
 
 
 
The silent carrier: One deleted Alpha Gene
 
 
 
Neonates and children with three functional alpha genes have a 
complete or nearly completely silent phenotype. The red cell indices 
are normal and remain so for life. When only one a gene is non-
functional, the hemoglobin Barts percentage is usually 1-2% in the 
newborn, and is not detectable when the fetal hemoglobin synthesis 
stops at 6 months of age. As the newborn matures, the red cells can 
rarely exhibit a reduced MCV, MCH, but will show normal HBA2 and F 
levels if the hemoglobin electrophoresis is repeated. This condition is 
clinically benign, and these patients require no other evaluation or 
special health care. 
Alpha thalassemia trait: Two Deleted Alpha Genes 
 
Neonates and children with only 2 functional alpha genes will show 
alpha thalassemia trait. In the newborn period, Hemoglobin Barts is 
detected in the range of 5-6%. Most alpha thalassemia carriers will be 
mildly anemic, won't respond to iron therapy, and show mildly 
abnormal red cell indices. There is no specific treatment for the carrier 
state, but genetic counseling should be considered later in the child's 
life as it is possible that offspring could develop Hemoglobin H or 
hydrops. Individuals from SE Asia will often have the genes deleted 
from the same chromosome (cis mutation) while those of African 
heritage will have genes deleted from both chromosomes (trans 
mutation). 
 
Hemoglobin H disease occurs when there is only one functional gene, 
and these individuals can have a mild to moderate thalassemia. Most 
patients are anemic and develop splenomegaly although the clinical 
manifestations can be variable. These children would require care at a 
pediatric hematology/oncology center for moderate to severe 
symptoms. 
Hemoglobin H Disease: Three Deleted Alpha Genes 
This is also known as alpha thalassemia major. This is rarely 
compatible with life unless detected early. Those patients would be 
transfusion dependent, but death usually occurs in utero or in early 
infancy unless detected prenatally.  
Fetal Hydrops: All Four Alpha Genes Deleted 
 At 2-3 months, examine infant for splenomegaly and do a CBC. If 
normal and hemoglobin electrophoresis did not report abnormal 
hemoglobin other than Bart’s then Hemoglobin H disease is unlikely 
and no further work-up is necessary until 9-2 months. If CBC or exam 
are abnormal, please consult a pediatric hematologist. 
Follow-Up Recommendations: 
 
Between 9-12 months check CBC and reticulocyte count. If this is 
normal, then the child likely is a silent carrier. No further work-up of 
the child is necessary. If infant is microcytic, do iron studies and treat 
with 3-6 months of iron if found to have iron deficiency. If the 
microcytosis resolves with iron therapy, then the child is likely a silent 
carrier and needs no further evaluation. If the patient has persistent 
microcytosis, then they likely have alpha thalassemia trait.  
The parents of a child with hemoglobin Bart’s should also have CBC’s 
performed, particularly if parents are of Asian ancestry. If the parents 
are microcytic, then further genetic testing and counseling should be 
done as there may be a risk of Hemoglobin H disease or hydrops in 
future children. 
 
A diagnosis of a silent carrier or alpha thalassemia does not 
necessarily constitute a reason to refer your patient to a pediatric 
hematology/oncology center. However, should questions or other 
circumstances arise in the lives of the affected children, for 
consultation contact Dr. Brenda Wittman or the pediatric 
hematologist on call at the University of Arizona School of 
Medicine at (520) 626-8278 or through Physician’s Resource 
Service at (520) 694-5868. Parents of this child may be directly 
referred for free counseling, screening, and educational services from 
the Sickle Cell Anemia Society of Arizona.  
 
 
 
